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SUMMARY 
Biopharmaceuticals are finding wide applications in the management of diverse disease 
conditions. Pulmonary delivery of proteins may constitute an effective and efficient non-
invasive alternative to parenteral delivery, which is currently the main route of 
administration of biopharmaceutical drugs. A particular area, in which pulmonary 
delivery of peptides and proteins may find ready application, is in the local delivery of 
antimicrobial peptides and proteins to the airway, a measure that could potentially bring 
about improvements to currently available antipseudomonal therapies.  
This thesis has therefore sought to develop inhalable antimicrobial proteins in 
combination with antibiotics that have particularly good antimicrobial activity against 
Pseudomonas aeruginosa infections in the respiratory tract of people with cystic fibrosis 
(CF). Through process optimisation, a suitable spray drying method was developed and 
used for the preparation of active, inhalable dry powder formulations of the antimicrobial 
protein, lactoferrin, and aminoglycosides (tobramycin and gentamicin). The 
physicochemical properties, aerosolisation performance and the antibacterial properties 
of the various spray-dried formulations were assessed. In addition, a relevant in vitro 
cellular model was employed to investigate the potential cytotoxic and pro-inflammatory 
effects of the various formulations on four bronchial human epithelial cells together with 
their effectiveness at reducing bacterial colonies when administered on to biofilm co-
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cultured on the epithelial cells. It was found that following spray drying the particles 
obtained were mostly spherical, amorphous and possessed suitable aerosolisation 
characteristics. The various spray-dried antimicrobial proteins (lactoferrin or apo 
lactoferrin) and co-spray dried combinations of the proteins and aminoglycosides were 
found to exhibit bactericidal activity against planktonic and biofilms of P. aeruginosa. In 
general, the spray drying process was found not to significantly affect the antimicrobial 
activities of the protein. Treatment of the different bronchial epithelial cell lines with the 
antimicrobial formulations showed that the various formulations were non-toxic and that 
the co-spray dried combinations significantly reduced established P. aeruginosa biofilms 
on the four bronchial epithelial cells. Overall, the results from this thesis demonstrates 
that spray drying could potentially be employed to prepare inhalable antimicrobial agents 
comprised of proteins and antibiotics. These new combinations of proteins and 
aminoglycosides has promising applications in the management of P. aeruginosa in the 
airway of cystic fibrosis patients. 
 
Keywords: Antimicrobial Protein, Spray drying, Pseudomonas aeruginosa, Cystic 
fibrosis, Inhalation  
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1.1     General introduction 
Proteins consist of a series of organic linear polypeptides (from a repertoire of nineteen 
α-amino acids and one imino acid ‘proline’) linked together through amide bonds. The 
amino acid building blocks of polypeptides are naturally occurring and play many vital 
roles in the body. Interestingly, the amino acid sequences usually vary in arrangement 
and determine the resultant protein’s unique 3-dimensional structure along with its 
specific function. Interactions of some protein molecules, in what is called the quaternary 
structure, may lead to the establishment of a larger and well defined structure (Manning 
et al., 1989). The order of arrangement of amino acids in a polypeptide chain is 
determined by genes which code for specific polypeptides. A composite analysis of 
available information in the public domain seems to identify proteins as having the most 
dynamic and diverse role of any macromolecule in the body, especially since their roles 
include catalysis of many biochemical reactions, receptor and channel formations, 
providing intracellular as well as extracellular scaffolding support, and participation in the 
transport of many molecules either within a cell or between cells. 
Today, with the recent advances in biotechnology, peptides and protein therapeutics 
now represent a promising class of pharmacologically active agents which can be 
employed in the management or treatment of many ailments (for example, those 
affecting the immune system) due to their high specificity and potency. Sadly, even 
though quite a large number of proteins have been found to have some clinical 
applications, the delivery of these proteins still poses a major challenge.  Since they are 
labile, have a high tendency to adhere to surfaces, are easily metabolised, cleared, and 
may elicit immunological responses. It is important to mention at this juncture that at 
present, intramuscular, intravenous and subcutaneous injections remain the method for 
administering these macromolecules. This is because oral administration which happens 
to be the most convenient and commonly utilised route for the administration of most 
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drugs, regardless of their molecular size or structure, is plagued with various challenges 
when employed in the delivery of proteins and peptides. Some of the challenges for oral 
delivery range from difficulties in overcoming the enzymatic degradation of proteins to 
insufficient permeation of the proteins through the gastrointestinal membrane. It has 
been suggested that the pulmonary route may well be best suited for the delivery of 
those macromolecules which are poorly absorbed from the gastrointestinal tract (Agu et 
al., 2001; Patton, 1996; Johnson, 1997). 
Notwithstanding polypeptide formulation challenges, proteins and peptides have 
continued to remain very attractive candidates in drug discovery applications, especially 
due to their unique functions as active regulators and components of the innate immune 
system (Leader et al., 2008). Available publication data suggest that there are specialist 
journals (like current protein and peptide science, the protein journal and protein and 
peptide letters) which only focuses on publishing breakthrough research in the areas of 
peptide and protein science. The torrent of information in these journals suggest that 
concept therapeutic approaches of the future will favour the employment of proteins in 
the treatment of many ailments (Edwards et al., 1998). 
It has been estimated that there are around 20,500 different genes in the human 
genome (Clamp et al., 2007; www.genome.gov, 2012) and taking into consideration 
alternative splicing of genes and post-translational modification of proteins (for example, 
cleavage, phosphorylation, acylation and glycosylation), the number of functionally 
distinct proteins is likely to be much higher (Pennisi, 2003; Lander et al., 2001; Venter et 
al., 2001). Viewed from the perspective of harnessing their therapeutic benefit, these 
proteins represent a tremendous opportunity since they can be employed in alleviating 
diseases. Currently, approximately 200 protein or peptide based active pharmaceutical 
agents (API’s) from various sources intended for use in the treatment of variety of 
human diseases and conditions have been approved by the US food and Drug 
Administration (FDA) (GBI, 2009). So far, much of the approvals have generally resulted 
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because some peptides and proteins are known to effectively treat a wide variety of 
specific ailments that are sometimes difficult to manage or are untreatable using other 
chemical-based agents due to their specific biologic activity. It is important to note that 
the potential of protein therapeutics seems to be at an early stage. An ever greater 
number of molecular targets which could be employed in the treatment of various 
diseases are still been discovered, but even then, formulation technologists have not 
been able to keep pace with the various discoveries that have been made with regard to 
the special nature of proteins.    
 
1.1.1     Advantages of employing proteins in therapeutics 
The advantages associated with the use of proteins and peptides in clinical therapeutics 
are vast. The table below summarises some of the many advantages, as well 
disadvantages, of employing proteins in therapeutics. Interestingly, while most of the 
advantages outlined are mostly pharmacologic, the disadvantages seem to deal with 
issues related to formulation design (which can be overcome).  
Table 1.1: Advantages and disadvantages of protein therapeutics 
Advantages Disadvantages 
High activity Low oral bioavailability 
High specificity Mostly administered by injection 
Reduced unspecific binding to 
molecular structure other than desired 
target 
Very unstable hence requires careful 
handling during processing and in use 
Minimization of drug-drug interaction Difficult to deliver across membranes 
Decreased accumulation in tissues Challenging and costly synthesis 
Low toxicity Solubility challenges 
Often very potent Risk of immunogenicity 
Biological and chemical diversity Usually cleared from the body very 
quickly 
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Over the last two decades, biotechnological advancements across the techniques of 
recombinant DNA technology and solid-phase peptide synthesis, which are generally 
employed in the production of pharmaceutically active proteins on a commercial scale, 
have been well refined (Agu et al., 2001). These advances have resulted in the 
following: (1) they effectively address the issue of scarcity, especially for proteins like 
interferons which are produced naturally in the body in minute quantities; (2) they have 
improved product safety since this technology effectively eliminates pathogens which 
may have been present in biological sources (e.g. human immunodeficiency virus (HIV), 
hepatitis B and C); (3) they also provide a ready alternative to direct extraction from 
potentially hazardous sources, for example, Follicle-stimulating hormone (FSH) and 
human chorionic gonadotrophin (hCG) used to be extracted from human urine (Walsh, 
2007). In addition, the use of biotechnology has permitted modifications to the molecular 
structure of these therapeutic proteins. The insertion, deletion or alteration of amino 
acids in the protein sequence can enhance site-directed interventions and improve 
activity (Walsh, 2007). It is pertinently obvious that the benefits of recombinant DNA 
technology, especially in the development of protein drugs, are quite enormous.  
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Table 1.2: Some therapeutic agents currently licensed for use in the UK, which are prepared 
through recombinant DNA technology, their therapeutic indications and the various sources from 
which they have been produced. Information was obtained from the electronic Medicines 
Compendium (electronic Medicines compendium – eMC). 
Product Therapeutic indication Source(s) 
Human insulin Treatment of diabetes mellitus Saccharomyces cerevisiae, E. coli 
Etanercept Rheumatoid arthritis, Juvenile 
idiopathic arthritis, Psoriatic arthritis, 
Ankylosing spondylitis, Plaque 
psoriasis 
Chinese hamster ovary (CHO) 
mammalian expression system 
Teriparatide Treatment of osteoporosis Chinese hamster ovary (CHO) 
mammalian expression system 
Somatropin Growth hormone deficiency Escherichia coli 
Interferon beta-1a Treatment of relapsing-remitting 
multiple sclerosis 
Chinese hamster ovary Cells (CHO-
K1) 
Interferon beta-1b Treatment of relapsing-remitting 
multiple sclerosis 
Escherichia coli 
Interferon gamma-1b Reduction of the frequency of serious 
infections in patients with chronic 
granulomatous disease (CGD) and 
severe, malignant osteopetrosis 
Escherichia coli 
Interferon alfa 2b Chronic hepatitis B, Chronic hepatitis 
C, Hairy cell leukaemia, Chronic 
myelogous leukaemia, multiple 
myeloma, carcinoid tumour 
Escherichia coli 
Dornase alpha 
(DNase I) 
Management of cystic fibrosis Chinese Hamster Ovary Cell Line 
CHO A14.16-1 MSB #757 
Glucagon Treatment of severe hypoglycaemia Saccharomyces Cerevisiae 
Follitropin alpha Female infertility 
Stimulation of spermatogenesis in men 
Chinese Hamster Ovary (CHO) 
cells 
Canakinumab Cryopyrin-associated periodic 
syndromes 
Gouty arthritis 
mouse hybridoma Sp2/0 cells 
Aldesleukin Treatment of metastatic renal 
carcinoma 
Escherichia coli 
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During the next decade, it has been suggested that as more molecular targets for the 
treatment of various diseases are identified, hundreds of bio-engineered proteins and 
peptides would be required in various forms of delivery. This chapter focuses on the 
discussion of current trends and potential challenges associated with the pulmonary 
delivery of peptides and proteins, with brief descriptions of the physiology of the lungs, 
the characteristics of formulations for pulmonary delivery, criteria for selecting 
pulmonary delivery devices, toxicity and in vivo efficacy studies.  
 
1.2     Pulmonary delivery of proteins and peptides 
Pulmonary drug delivery has been practiced for several centuries, especially in the 
widely common practice of ‘inhaling narcotics’ (Sanders, 2007). More recently, this 
delivery route has attracted much attention, not for its illegal applications, but for its 
suitability in delivering proteins and peptides whose characteristic large molecular size, 
high surface charge, hydrophobicity, lability and rapid ionisation over a wide pH range 
make their handling, processing into traditional dosage forms (for example, tablets and 
capsules) and therapeutic drug delivery applications most challenging. Pulmonary 
delivery of proteins has been suggested to be the most attractive alternative to both the 
subcutaneous and intravenous routes of protein administration (Selam, 2003), which 
have been the mainstay for systemic protein delivery. In addition to the desirable 
formulation characteristics of a pulmonary administered therapeutic agent (such as 
stability, ease of handling and dose administration), various physiological characteristics 
of the lungs also makes pulmonary administration an attractive choice in drug targeting 
and delivery. The large surface area, which, at approximately 140 m2 is nearly 40 times 
more than the external body surface area (Agu et al., 2001; Wearley, 1991; Gehr et al., 
1978), lower concentrations of metabolic enzymes compared to those of the 
gastrointestinal tract (Banga, 1995), a very thin epithelial lining (0.1 – 0.2 µm) in the 
deep lungs permitting relatively rapid equilibration of blood and alveolar fluid proteins 
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(Patton and Byron, 2007; Patton, 1996), and a highly vesiculated single layer of 
epithelial cells which permits effective gaseous exchange (Owens et al., 2003; Weibel, 
1973) and therefore allows rapid entry of inhaled therapeutics to the systemic 
circulation. 
Hundreds of proteins and peptides are currently undergoing clinical investigation for a 
wide range of clinical conditions including; cystic fibrosis, cancer, diabetes and multiple 
sclerosis. Although most of the proteins under investigation are formulated as injections, 
some of them have specifically been formulated for inhalation, by leveraging the various 
sites of action which have already been identified; airway surface (e.g. 
deoxyribonuclease) (Yang et al., 2010), airway cells (e.g. cyclosporin) (Waters et al., 
2005) and systemic targets (e.g. insulin) (Huang and Wang, 2006). It is important to note 
that despite the extensive research which has being carried out in the pulmonary 
delivery of peptides and proteins, very few therapeutic products have actually made it 
through clinical trials to full license.  
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Table 1.3: Some examples of proteins/peptides which are/have been considered for delivery to the airways for the management of various disease 
conditions. The various protein/peptides listed below are at various stages of clinical trial except for for DNase which has been approved.  
Clinical application Peptide/Protein 
drug 
Clinical status Sponsors Ref./Clinical trial 
registry number 
Cystic fibrosis (CF) Dornase alfa Approved Roche  
Respiratory Distress 
Syndrome in Premature 
Infant 
recombinant human 
CC10 (rhCC10) 
Phase 1 intratracheally (completed in nov, 
2011) 
Clarassance, Inc. And National 
Heart, Lung, and Blood Institute 
(NHLBI) 
NCT01473264 
Sarcoma 
Solid Tumors 
Pulmonary Metastases 
Lung Metastases 
Osteosarcomas 
Ewing Sarcoma 
Aerosol IL-2 Phase 1 (currently recruiting march 11 
2013) 
 
M.D. Anderson Cancer Center and 
Shannon Wilkes Foundation 
NCT01590069 
Asthma Recombinant human 
IL-4 receptor  
Phase 2 (completed in feb, 2000) National Institute of Allergy and 
Infectious Diseases (NIAID) and 
Immunex Corporation 
NCT00017693 
Pulmonary Fibrosis aerosol interferon-
gamma 
Phase 1 (currently ongoing) New York University School of 
Medicine and National Center for 
Research Resources (NCRR) 
NCT00563212 
Lung Transplantation 
Bronchiolitis Obliterans 
Chronic Rejection of Lung 
Transplant 
liposomal aerosol 
cyclosporine 
Phase 1 (currently recruiting march 11 
2013) 
University of Maryland NCT01650545 
Chronic Obstructive 
Pulmonary Disease 
Cyclosporine Phase 1 (completed in sept, 2009) University of Pittsburgh NCT00783107 
- 3
9
 - 
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Even today, as more and more biopharmaceuticals are gaining regulatory approval for 
general use, pharmaceutical companies and research institutions are still confronted 
with the challenges relating to inability to efficiently and effectively deliver aerosolised 
peptides and protein drugs to the airways. This is because there is a need to provide the 
drug as very small solid or liquid microparticles (usually between 1 and 5 µm) so as to 
reach the lungs (Carvalho et al., 2011). There is also the need to consider the use of 
deaggregation mechanisms to improve the delivery of solid microparticles to the airway 
by inhalation devices. It is also important to avoid in vivo biological degradation by 
proteases that are resident in the lungs, as well as overcome the various clearance 
mechanisms of the respiratory system (hoiby 2010). Section 1.7 below discusses these 
challenges in more detail. 
 
1.3     Anatomical features of the human airways 
In order to fully understand the therapeutic challenges facing drug delivery via the 
pulmonary route, it is important to discuss the anatomical organization of the respiratory 
tract and how this arrangement is structured to provide a very large surface area for 
efficient exchange of gases (carbon dioxide and oxygen) between the body and its 
surrounding environment – the main function of the respiratory system. The efficiency of 
gaseous exchange is highly visible since a healthy adult male inhales approximately 5 – 
10 L/min of air at rest, which increases to about 100 L/min during strenuous exercise 
(Kim and Folinsbee, 1997). 
Anatomically, the structures of the respiratory tract can be divided with respect to their 
position into two; the upper respiratory tract (the nasal cavity, mouth, pharynx and 
larynx) and the lower respiratory tract (including all airway structures from the trachea to 
the alveoli) (Suarez and Hickey, 2000). The upper respiratory tract is primarily a 
conducting passage way for air to reach the lungs. When air first enters through the 
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nose (which is lined with cilia, mucus membrane and blood capillaries) it is filtered by 
cilia, moistened by mucus membranes and warmed by blood, then the conditioned air 
moves on through the pharynx (a common passageway for both air and food) on to the 
larynx, (which contains the vocal folds). The lower respiratory tract which starts with the 
trachea at the lower border of the cricoid cartilage (level with the sixth cervical vertebrae 
C6) and connects the larynx to the bronchial tree. The trachea is made up of fibrous and 
elastic tissues and is prevented from collapsing due to the presence of about 20 rings of 
cartilage. The trachea bifurcates into right and left bronchi at the level of the sternal 
angle. The bronchi enter their corresponding right or left lungs where they subdivide into 
even smaller branches called bronchiole and at the end of each bronchiole are 
structures called the alveolar sacs. The alveolar sacs are surrounded by blood 
capillaries and contain single layer alveoli cells where the gas exchange takes place.  
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Figure 1 -1: The anatomy of the human airways. The diagram illustrates the locations of the 
respiratory structures in the body. a) shows both the upper and lower respiratory tract; b) shows 
an enlarged image of terminal bronchiole and alveoli; c)  shows the region where gaseous 
exchange takes place between the capillaries and the alveoli. 
 
The conducting airways possess mucus producing goblet cells, the mucus produced by 
the goblet cells, traps small airborne particles and with the aid of the ciliated epithelial 
cells moves the mucus to the pharynx, where it is swallowed and digested in the 
gastrointestinal tract. Individuals who suffer from cystic fibrosis where thick sticky mucus 
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adhere to the linings of their airways and interfere with airflow to the lung surface as well 
as providing a breeding ground for bacterial infection. 
In addition to this anatomical division of the respiratory tract, the respiratory system can 
be broadly divided into two functional units (Figure 1- 3);  
(a) The tracheo-bronchial airways  
(b) The bronchial circulation   
The tracheo-bronchial airways: The tracheo-bronchial airways enable the efficient 
distribution of inhaled air to areas where gaseous exchange takes place. Functionally, 
the structures of the tracheobronchial airway may be further classified into two;   
The conducting regions – includes all passageways, providing a fairly rigid 
conduit for the passage of inhaled air to the distal portions of the respiratory tract 
i.e. the bronchi, bronchioles and alveoli.  
The respiratory regions – these are the actual sites of gas exchange, 
comprised of all respiratory structures distal to the bronchioles (respiratory 
bronchioles, alveolar ducts, and alveoli).  
Weibel’s (1963) tracheobronchial anatomical classification of the human lung (Figure 1-
3) – is frequently used in computing pulmonary drug administration – the conducting 
region consists of the first 16 generations while generation 17 – 23 constitute the 
transitional and respiratory zones where rapid exchange of gases and solutes takes 
place.  
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Figure 1 -2: A schematic of airway branching of the human lung with approximate dimensions, 
number of branches and total cross sectional area of both the conducting and respiratory zone.  
(Weibel Dichotomous Lung Geometry) (Weibel, 1965).  
 
Bronchial circulation: The bronchial circulation plays a vital role in the efficient 
distribution of blood to the airway mucosa especially to the structures of the respiratory 
region. Mucosal blood supply, which is primarily derived from the bronchial artery, is at a 
relatively high flow rate (Nørgaard et al., 1999) and is responsible for the absorption, 
metabolism, redistribution and activation or inactivation of inhaled drugs as well as 
endogenous substances in the lung environment.  
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1.3.1     A description of the lung epithelium 
The lamina propia (comprised of collagen, elastin and proteoglycan) forms the basic 
scaffold to which the lung epithelium is attached (Bienkowski and Gotkin, 1995), rings of 
cartilage – which decreases both in size and frequency as the airways become smaller 
helps to maintain the rigidity of the luminal space from the trachea to the bronchi. 
Smooth muscles (also decreasing in size and frequency) surround the airway between 
the bronchioles and the respiratory bronchioles. The overall progressive reduction in 
rings of cartilage and smooth muscles, results in a smaller airway wall thickness closer 
to the alveoli. Interestingly, as the diameter of the respiratory tract decreases, the 
surface area available for gaseous exchange increases. For example, while the cross 
sectional area of the trachea is about 2.5 cm2 (Suarez and Hickey, 2000), the total cross 
sectional area of alveoli is about 104 cm2 (Okamoto et al., 2002). This means that the 
alveoli are more than 100 m2 larger than the small intestine (Okamoto et al., 2002).  
 
1.3.1     Cytology of the airway 
The cytology of the airway cells show that the cell population that make up both the 
nasal and tracheobronchial regions of the mammalian respiratory tract are very diverse 
(Breeze and Wheeldon, 1977). Generally, cells lining the nasal cavity up to the terminal 
bronchioles are pseudo stratified ciliated epithelium possessing mostly cilia and mucus 
secreting cells and primarily function to exclude debris from the airway by moving them 
up the mucociliary escalator where they may be expectorated or swallowed. Below the 
bronchioles, the pulmonary epithelium begins to thin, cell height begins to flatten and 
merge with the alveolar epithelial cells, thus, enabling exchange of gases (Harkema et 
al., 1991; Gruenert et al., 1995). 
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1.3.1.1     Airway epithelial cells 
1.3.1.1.1     Goblet and serous cells 
Goblet and serous cells are primarily secretory cells as they secrete mucin. While goblet 
cells are located on the surface of the lung epithelium and release vesicles directly into 
the luminal space, serous cells are present as a collection of cells that form the 
submucosal glands. Serous cells are normally found below the epithelial cell layer, 
although they may also be found as single cells within the epithelium surface. Both 
Goblet and serous cells are responsible for controlling the fluidity of mucus in the airway 
(Rogers, 1994; Rogers et al., 1993). They are able to do so by expressing high 
quantities of CFTR (which controls the fluid balance by moderating Cl- transport across 
the lung epithelium, which in turn is linked to water content). It is interesting to note that 
both goblet and serous cells are absent from regions of the lungs where gaseous 
exchange takes place.  
 
1.3.1.1.2     Ciliated cells 
Ciliated cells are usually found between the upper airways and the respiratory 
bronchioles where they usually make up about 50% of the epithelial cell population of 
the airways (Harkema et al., 1991). In humans, each ciliated cell usually possess about 
200 – 300 cilia that beat approximately 12 – 16 times per second to move mucus 
towards the larynx (where the mucus is either expectorated or swallowed). Hence, the 
mucus expelling actions of the ciliated cells make them important components of airway 
defence. 
1.3.1.1.3     Clara and basal cells 
Clara cells are commonly found in the bronchiolar epithelium where under normal 
conditions they have a very low turnover, however when stressed (for example, upon 
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exposure to NO2) they can be significantly increased by up to 20 fold (Evans et al., 
1978). When clara cells are stimulated, they act as precursors for secretory or ciliated 
epithelial cells by protruding above neighbouring ciliated cells (Breuer et al., 1990; 
Inayama et al., 1988). Basal cells on the other hand are attached to the basal 
membrane, they do not protrude into the lumen of the airway and may sometimes act as 
precursors for ciliated and/or goblet cells. With increasing airway generations, the 
number of basal cells decline dramatically with clara cells becoming the major secretory 
cell type. 
 
Figure 1 -3: An illustration of the structures of the airway epithelium. a) airway epithelial cells of 
the trachea and large bronchi where ciliated and goblet cells predominate with numerous basal 
cells b) airway epithelial cells of the bronchioles where ciliated and clara cells predominate. 
Goblet and serous cells decrease distally and are absent in the terminal bronchioles. Adapted 
from Forbes and Ehrhardt (2005). 
 
1.3.1.2     Alveolar epithelial cells 
The epithelium of the alveoli is quite thin and populated by two epithelial cell types: the 
terminally differentiated type I pneumocyte and its progenitor cell, the type II 
pneumocyte (Yang et al., 2000). Together both cells provide the boundary where 
gaseous exchange takes place. 
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1.3.1.2.1     Alveolar type I cells 
Alveolar type I cells are terminally differentiated, form the alveolar sacs, have a 
thickness of around 0.1 µm and typically possess a narrow elongated nuclei with very 
few other cell synthesis organelles. Alveolar epithelial cells type I  cells cover 
approximately 95% of the total internal alveolar surface area, therefore, primarily 
functioning as the pathway for gaseous exchange (Johnson et al., 2002). 
 
1.3.1.2.2     Alveolar type II cells 
Alveolar type II cells cover between 2-5% of the internal alveolar surface area. Type II 
cells are generally cuboidal in shape and play no role in gaseous exchange rather they 
produce, secrete and recycle pulmonary surfactant, pulmonary defence mechanisms 
and the trans-epithelial transport of ion. Type II cells are the progenitor cells for type I 
cells and increase their differentiation and turnover rate upon exposure to stressful 
conditions. 
 
Figure 1 -4: An illustration of the alveolar epithelium showing contrasting alveolar cell 
morphologies. Alveolar type I cells are extremely thin and accounts for 95% of the epithelial 
surface, while the type II cell are cuboidal in shape and cover between 2 and 5% of the epithelial 
surface. . Adapted from Forbes and Ehrhardt (2005). 
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1.4     Airway defence mechanisms 
At rest, the average human being breathes in about 20,000 litres of air every day, 
inevitably, a myriad of airborne particles including microbes, allergens, dusts and 
carcinogens are suspended in this inspired air, many of which will cause no harm. 
However, like all major points of contact with the external environment, the lung has 
intrinsic protective barriers which function to exclude (physical – e.g. movement of 
mucus by cilia; and chemical – e.g. pulmonary surfactants, α-defensins, cathelicidin) 
these undesired airborne particles from the body. (Cohen and Gold, 1975; Newhouse et 
al., 1976; Richardson and Peatfield, 1981).  
 
1.4.1     Physical defence mechanisms 
This defence mechanism, which appears to predominate, includes all the physical 
barriers that function to prevent the invasion of microbes. Firstly, mucus is produced by 
the goblet cells of the epithelium and the submucosal gland which functions to prevent 
the microorganism from adhering to the epithelium as well as expelling any microbe with 
the outward flow of mucus which is driven by the synchronous beating of the cilia 
towards the mouth (mucociliary transport or clearance). The beneficial contributions of 
this defence mechanism is evident in disease conditions like cystic fibrosis, which is 
characterised by thick mucus secretion or inhibition of ciliary movement (cilia 
dyskinesia), where the respiratory tract is colonised by bacteria. In addition to expelling 
microbes, the mucociliary transport also serves to clear insoluble particles depositing in 
the ciliated region of the airways usually within 24 – 48 hr (Lippmann and Albert, 1969; 
Svartengren et al., 1991). 
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1.4.2    Chemical defence mechanism 
The airway epithelium secretes several different types of antimicrobial proteins and 
peptides, which participates in microbial killing. These products are resident in the 
airway fluid and inducible upon invasion by microbes. The antimicrobial molecules 
produced can be small cationic molecules like β-defensins, LL-37 and CCL20, or larger 
proteins like lysozyme, lactoferrin and secretory leukocyte peptidase inhibitor (SLPI) all 
secreted by serous cells of the submucosal glands (Basbaum et al., 1990; Finkbeiner, 
1999) 
Other chemical components which contribute to airway defence include:  
a) Haematopoietic cells (polymorphonuclear leukocytes, platelets, eosinophils, 
macrophages) which have origins in the haematopoietic stem cells of the bone 
marrow and generally make up both the innate (non-specific) and adaptive 
(specific) immune systems;  
b) Lung immunoglobulins (IgA - predominantly in the form of secretory IgA, IgG, 
IgM and IgE) which are derived form both the vascular compartment (by diffusion 
through the lung tissue) and local production by cells of the epithelium or lamina 
propia (Burnett, 1986);  
c) Parts of the complement system (C3b, C3bi, C5a) which particularly is involved 
in the lysis of certain viruses and/or opsonize pathogens (e.g. C3b) thereby 
facilitating their uptake through the complement receptors on the phagocytic cells 
(Clarke, 1990; Kroegel and Costabel, 1994);  
d) Inflammatory mediators (prostaglandins, thromboxanes, leukotrienes, 
susbstance P, bradykinin, neurokinin A, platelet activating factor, histamine etc) 
which are produced by a number of cells in the airway epithelium (Clarke, 1990; 
Jordana et al., 1994; Raphael and Metcalfe, 1986);  
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e) Cytokines (interferons, tumour necrosis growth factor, interleukins, chemotaxins) 
which are produced in response to failure of cell differentiation (Barnes, 1994; 
Clarke, 1990; Jordana et al., 1994);  
f) Protease inhibitors ( secretory leukoprotease inhibitor, antichemotrypsin, α1 –
protease inhibitor, α1 – antichemotrypsin) which are secreted by both the 
respiratory epithelial cell (SLPI) and produced in the liver (α1 –protease inhibitor) 
to inhibit proteases – neutrophil elastase (Clarke, 1990) 
 
Overall, both physical and the chemical airway defence mechanisms operate in a 
complementary fashion to effectively remove or neutralise particulates with varying 
physicochemical properties from the respiratory tract. However, for the purpose of the 
body of work presented in this thesis, our focus will only be on antimicrobial proteins. 
 
1.4.2.1     Role of antimicrobial proteins in the defence against infections 
In the airways, several different types of antimicrobial proteins are produced and 
contribute to airway defence. However, since their contributions to airway defence is 
primarily dependent upon the concentration produced and the spectrum of activity of the 
individual antimicrobial protein, three major antimicrobial proteins have been identified to 
constitute airway defence and they include; lysozyme, lactoferrin and secretory 
leukoproteinase (SLPI). Interestingly, they are all produced by the serous cells of airway 
glands (Basbaum et al., 1990) 
1.4.2.1.1     Lysozyme 
Lysozyme is one of the most predominant antimicrobial factors in the airway surface 
liquid (ASL). Lysozyme is found at a concentration of approximately 10 μg/ml in airway 
lavage fluid (Fleming, 1922; Raphael et al., 1989; Thompson et al., 1990) and 1 mg/ml 
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in sputum (Brogan et al., 1975; Kotlar et al., 1980; Harbitz et al., 1984; Jacquot et al., 
1983). Human lysozyme is a 1,4-β-N-acetylmuramidase which selectively cleaves the 
β(1,4) glycosidic linkage between the C-1 of N-acetylmuramic acid (MurNAc) and the C-
4 of N-acetylglucosamine (GlcNAc) (both components of bacterial peptidoglycan) (Jollès 
and Jollès, 1984), however, since the peptidoglycan layer of Gram-positive bacteria are 
surface exposed (Fig 1 -4a), lysozyme is able to effectively cause damages to it there by 
exposing the lipid bilayer of the bacterial cell membrane (Fig 1 -4c). In contrast, since 
Gram-negative bacteria have an outer layer of lipopolysaccharide (LPS) covering their 
peptidoglycan layer (Fig 1 -4b), lysozyme is ineffective against Gram-negative 
organisms (Leive, 1974; Nikaido and Vaara, 1985; Nikaido, 2003). However, Singh et 
al., (2000) have been able to show that combinations of lysozyme with lactoferrin or 
lysozyme with secretory leukocyte protease inhibitor (SLPI) or a triple combination of 
lysozyme, lactoferrin and SLPI showed synergism in killing Escherichia coli (a gram 
negative bacteria), thereby, inferring that lysozyme does have secondary contributions 
in preventing the host defence system from invasion by Gram-negative microbes 
(Martinez and Carroll, 1980). 
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Figure 1 -5: An illustration of bacteria cell membrane showing the various structural components 
of the bacterial cell wall. N-acetylglucosamine is represented by the olive green hexagon, N-
acetylmuramic acid is represented by the orange circle and the cross linked peptide bridges is 
represented by the dark orange bars. a) Gram-positive bacterial cell wall is predominantly 
constituted of peptidoglycan and b) Gram-negative bacterial cell wall has a thin inner wall of 
peptidoglycan covered by an outer lipid membrane that contains proteins and lipopolysaccharide 
(LPS), c) a schematic showing lysozyme cleaving the β-(1,4) linkages between  MurNAc and 
GlcNAc thereby exposing the underlying cell membrane structures to other antimicrobial agents. 
 
1.4.2.1.2     Lactoferrin 
Lactoferrin is an iron binding glycoprotein that is active against a variety of Gram-
positive and Gram-negative microbes (Arnold et al., 1980; Flotte et al., 1993). 
Lactoferrin is relatively abundant at 1 to 10 μg/ml in airway lavage fluid (Raphael et al., 
1989; Thompson et al., 1990) and approximately 1 mg/ml in sputum (Brogan et al., 
1975; Harbitz et al., 1984; Jacquot et al., 1983). Although lactoferrin is found in 
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significant quantities in the airways, milk still remains the most abundant source of 
lactoferrin. 
The antimicrobial activity of lactoferrin has been related to its ability to deprive 
microorganisms of the essential nutrient of iron (Bullen, 1981; Griffiths, 1975; Norrod 
and Williams, 1978). However, lactoferrin has also been reported to have direct 
bacteriocidal activity on both Gram-negative and Gram-positive microorganisms, 
through interactions with the anionic portion (lipid A) of lipopolysaccharide (Ellison et al., 
1988). Lactoferrin is also known to disrupt the negatively charged lipid matrix of the 
Gram-positive bacterial by electrostatic interactions arising from its positively charged N-
terminal region. Lactoferrin is also reported to significantly enhance the activity of 
secretory IgA (sIgA) (Spik et al., 1978; Stephens et al., 1980; Arnold et al., 1977a; 
Boesman-Finkelstein and Finkelstein, 1985). All of these mechanisms highlighted above 
indicate the presence of other mechanisms of antimicrobial actions other than iron 
sequestration. Lactoferrin also enhances the antibacterial activity of other antimicrobial 
proteins towards Gram-negative and Gram-positive bacteria by interacting with 
lipoteichoic acid (present on Gram-positive bacterial cell wall) and lipopolysaccharide 
(present in Gram-negative bacteria cell membrane) leading to alterations in bacterial 
membrane permeability barriers which in turn contributes to microbial cell injury and 
death (Leitch and Willcox, 1999b; Arnold et al., 1982). Lactoferrin has also being found 
to prevent biofilm formation by P. aeruginosa (Singh et al., 2002) and because biofilms 
play an important role in the progression of lung infections in cystic fibrosis, efficient 
inhibitors like lactoferrin which prevent biofilm formation hold particular promise as a 
therapeutic agent. 
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1..4.2.1.3     Secretory leukocyte proteinase inhibitor (SLPI) 
Human secretory leukocyte proteinase inhibitor is a low molecular weight (11.7 kDa), 
high net negative charge (+11), non glycosylated protein (contains 107 amino acids) that 
is produced by the serous cells in the submucosal gland of the bronchi and by Clara and 
goblet cells of the bronchiolar and bronchial lining of the airway epithelium (De Water et 
al., 1986; Hiemstra et al., 1996), as well as by secretory cells in the genital and lacrimal 
glands and dermal keratinocytes (Wingens et al., 1998). SLPI provides an antiprotease 
shield against serine proteases (cathepsin G, trypsin, chymotrypsin but most importantly 
neutrophil elastase – a pro-inflammatory mediator which predominates in cystic fibrosis) 
secreted by activated neutrophils during phagocytosis (Williams et al., 2006; Balfour-
Lynn, 1999; Hutchison, 1987). SLPI is found at a concentration of 0.1 to 2 μg/ml in 
airway lavage fluid (Vogelmeier et al., 1991; Kouchi et al., 1993) and 2.5 μg/ ml in nasal 
secretions (Lee et al., 1993). 
SLPI has been shown to have in vitro antimicrobial activity against a variety of 
microorganisms including Staphylococcus aureus, Escherichia coli, P. aeruginosa, 
Klebsiella pneumoniae, Streptococcus pneumoniae, Mycobacterium tuberculosis, 
Aspergillus fumigates and Candida albicans (Hiemstra et al., 1996; Gomez et al., 2009; 
Travis et al., 1999; Wiedow et al., 1998; Fernie-King et al., 2002; Tomee et al., 1997) 
and HIV (Wahl et al., 1997; Mcneely et al., 1995; Mcneely et al., 1997). Although the 
biochemical mechanism by which SLPI is able to achieve these antimicrobial and 
antiviral activities have not been fully elucidated, it is thought that it may function in a 
similar way as other antimicrobial peptides (Hiemstra et al., 1996; Williams et al., 2006) 
through its N-terminal domain which may be involved in disruptions to the anionic cell 
membrane of bacterial cells . 
Recombinant SLPI (rSLPI) (identical to the native SLPI) produced by Escherichia coli  
has been considered as a potential therapeutic agent for cystic fibrosis ( a condition 
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characterised by excessive neutrophil elastase activity on the airway epithelium), studies 
by Gillissen et al., (1993) showed that inhalation of rSLPI resulted in increased 
gluthathione levels in the epithelial lining fluid, a clear indication that SLPI does augment 
anti-neutrophil elastase capacity and therefore well suited for therapy of lung diseases 
characterised by excessive production of serine proteases and oxidants on the 
respiratory epithelial surface. However, inefficient delivery of rSLPI to affected but poorly 
ventilated portions of the airway has been identified as a major setback of aerosolised 
rSLPI, thereby suggesting that rSLPI aerosol therapy may only be beneficial for 
prophylactic protection against neutrophil derived elastase (Stolk et al., 1995). 
 
1.5     Infections of the airways 
If inhaled microbes manage to evade all the host defences and colonise the respiratory 
tract, microbial infections of the airway result. Some of the organisms encountered 
include bacteria, viruses and airborne fungi. Since these organisms are deposited in 
different regions of the respiratory tract, a wide range of respiratory tract infections result 
and include pharyngitis, common cold, influenza, acute sinusitis, laryngitis, bronchitis, 
pneumonia, pulmonary tuberculosis, and bronchiolitis. Most of these respiratory tract 
infections are usually treatable with a course of antibiotic, but for people with respiratory 
diseases such as cystic fibrosis, repeated infections with opportunistic organisms 
usually result in death (Moreau-Marquis et al., 2009; Gibson et al., 2003; Lyczak et al., 
2000) 
 
1.6      Cystic Fibrosis 
Cystic fibrosis (CF) is an autosomal recessive lethal disease resulting from mutations in 
a single gene on the long arm of chromosome 7 that encodes cystic fibrosis 
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transmembrane conductance regulator (CFTR) protein (Riordan et al., 1989; Kerem et 
al., 1989; Rommens et al., 1989), a cyclic adenosine monophosphate (cAMP)-regulated 
Cl- channel (Dupont et al., 2007). The mutations of which more than 1,500 sequence 
variation have been identified (Döring et al., 2010), remains the most common life-
shortening genetic disorder amongst Caucasians with an estimated median survival age 
of 41.5 years in the United Kingdom in 2011 (Cystic Fibrosis Trust, 2013).  
The incidence of CF varies extensively across the globe, although available data 
suggests that it is more common among the Caucasian populations (Who, 2013). The 
Cystic Fibrosis Trust (2013) estimates that there are currently over 8500 people living 
with CF in the UK (an estimated incidence rate of 1 in every 2500 live births) (Waugh et 
al., 2012). Clinical presentations of CF vary among individuals and generally include; 
pancreatic insufficiency, infertility amongst most males (due to congenital bilateral 
absence of the vas deferens) and females (reduced fertility), bile duct obstruction, high 
sweat chloride, intestinal obstruction, nasal polyp formation, chronic sinusitis, liver 
disease, diabetes (Kubesch et al., 1993) progressive lung disease elicited by thick and 
dehydrated airway mucus frequently infected with Pseudomonas and Staphylococcus, 
which usually results in respiratory failure and CF mortality (Kubesch et al., 1993; 
Collins, 1992; Welsh et al., 1995). 
The biology of normal CFTR protein (composed of 1480 amino acids with a molecular 
weight of 170 kDa) expression and activation is a complex process involving; firstly DNA 
transcription to mRNA, translations of mRNA to a peptide, glycosylation of the peptide 
and finally insertion of the protein into the apical membrane (Jenni and Ban, 2003). 
However, whenever any step of this normal protein expression is impaired, an abnormal 
CFTR protein results, which in turn leads to defective electrolyte transport and defective 
chloride ion transport in the apical membrane of the epithelial cells of the sweat gland, 
airway, pancreas, and intestine. In the long term, therapeutics of cystic fibrosis aims to 
improve/correct the mutant CFTR protein through gene therapy although at the present 
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moment the therapy is yet to be successful in clinical trials. Interestingly, some exciting 
CFTR modulation therapies have began to appear; including Ivacaftor (currently 
licensed for the treatment of patients with G551D CFTR mutation) and Ataluren (phase 
3 clinical trials), which seeks to rescue particular mutations which only affect about 5 % 
of the UK population 
As a result of limitations in current CFTR modulation therapies, other therapeutic agents 
such as hypertonic saline (restoration of airway surface liquid), dornase alfa (mucus 
alteration), tobramycin (antimicrobial agent) and enzyme supplements also augment CF 
therapy until a time when a harmless virus, lipososome or adeno-associated virus can 
successfully deposit a normal CFTR gene into cells of both the lungs and the pancreas 
in a cost effective way. This thesis will however only focus on managing airway 
infections caused by P. aeruginosa in people with CF.   
 
1.6.1     Pathogenesis of pulmonary infections in cystic fibrosis 
The airway of people with CF are particularly susceptible to pulmonary infections due to 
the loss of innate immune functions, however, the pathogenesis of endobronchial lung 
infections in cystic fibrosis is still a topic of debate at present, with the exact role played 
by dysfunctional or absent CFTR in the whole sequence of events still unclear and 
embroiled in a controversial and incompletely understood mechanisms. The two major 
competing hypothesis that have been put forward to try and explain early and persistent 
endobronchial infections in CF include;  
The isotonic “low volume hypothesis” which suggests that mutant CFTR causes a 
decrease in chloride secretion into the lumen and increased sodium absorption, 
ultimately resulting in reduced flux of water into the lumen (Matsui et al., 1998a), hence, 
the mucus in the airways becomes dehydrated with the viscous air-surface liquid (ASL) 
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trapping inhaled bacteria and viruses. The cilia are unable to beat efficiently due to 
impaired mucociliary clearance consequently resulting in persistent airway infections.  
 
 
Figure 1 -6: Schematic representation of the mucocilliary escalator in the non-cystic fibrosis and 
cystic fibrosis airways. a) normal airway epithelia with; low viscosity periciliary layer, normal 
mucus volume and an efficient mucociliary clearance, b) cystic fibrosis airways where there is 
hypersecretion of viscous mucus which is plastered down upon the cilia thus inhibiting normal 
cilia beating. Microbes which are inhaled from the environment penetrate the mucus 
actively/passively (due to mucus turbulence) and are able to adapt to the local environment. In 
the  case of P. aeruginosa, these adaptations usually lead to the evolution of biofilms. 
 
The opposing theory, high salt theory, suggests that various mutation of CFTR protein 
leads to high levels of sodium chloride (salt) in the airway-surface liquid (Smith et al., 
1996) which is unsuitable for the activities of antimicrobial peptides involved in airway 
defence (for example lysozyme, lactoferrin and beta defensins) (Smith et al., 1996), 
contrary to this view, in vivo experiments by Knowles et al., (1997) have shown that ASL 
electrolyte levels in CF patients are not different from the electrolyte levels in the airway 
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of normal patients, also, the diversity and complexity and of the antimicrobial peptides 
found in ASL makes it difficult to understand how such a situation could be sufficiently 
compromised in CF to produce the phenotype of this disease (Travis et al., 1999; Travis 
et al., 2001). In general, the low volume hypothesis is considered the most plausible 
mechanism for CF airway infections although it does not explain the narrow range of 
pathogens characteristically encountered in CF. 
Notwithstanding, particular mechanisms by which airway infections result, it is clear that 
accumulations of viscid mucus in the airways makes the lungs of CF patients more 
vulnerable to colonisation by various micro-organisms such as Staphylococcus aureus 
in infancy, Haemophilus influenza in the early years and P. aeruginosa in early teens, 
Burkholderia cepacia and mycobacteria in the late teens (Govan and Nelson, 1992). 
Infections are usually localised in the major and minor airways with localised infections 
at other non- pulmonary sites or systemic infections being rare. In this study, attention 
will be focused on P. aeruginosa infection (which affects 36% of children and 69.2 % of 
adults) especially because it is difficult to treat with the currently available antibiotics and 
hence responsible for many of deaths in CF (Ramsey et al., 1999; Cystic Fibrosis Trust, 
2013). 
 
1.6.1.1     Mechanisms of P. aeruginosa persistence in the CF airway 
In a bid to have a better understanding of how P. aeruginosa is able to persist in the CF 
airways, since colonisation by P. aeruginosa is a poor prognostic indicator, several 
researchers have extensively investigated various adaptation mechanism available to 
the microbe in the CF airway including, increased binding of P. aeruginosa to the airway 
epithelium and the failure of non-specific immune systems to resolve bacterial infections. 
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1.6.1.1.1     Adaptions of P. aeruginosa in the CF airway 
P. aeruginosa is a highly adaptable, aerobic, Gram-negative bacillus that is motile by 
means of a single polar flagellum. Normally, P. aeruginosa is non-pathogenic, becoming 
pathogenic in individuals with weakened defences (Pitt, 1986). It possesses the ability to 
develop resistance to multiple antibiotics through a number of broadly specific multidrug 
efflux systems (Poole, 2001). In addition, hypermutable strains of P. aeruginosa which 
have an increased resistance to antibiotics have also been isolated from the airways of 
people with CF (Oliver et al., 2000). Initially, P. aeruginosa exists as a motile planktonic 
bacteria (the non-mucoid phenotype) in the airways of patients with CF. As bacterial 
infections progresses P. aeruginosa begins to produce mucoid exopolysaccharide 
(MEP) or an alginate. Alginate is a strongly anionic polysaccharide composed of linear 
1-4 linked β-D-mannuronic acid and its C5 epimer, α-L-guluronic acid (Linker and Jones, 
1966). The exopolysaccharide produces highly viscid aqueous solutions and has the 
capacity to bind water and divalent cations to form flexible gels. Due to the raised Ca2+ 
concentration found in the CF lung, alginate gel formation is induced leading to the 
formation of bacterial microcolonies. The emergence of mucoid strains usually 
correlates with a poor patient outlook (Pedersen et al., 1992). This is because the biofilm 
prevents the phagocytosis of bacteria since it masks the complement on the bacterial 
surface and the outer membrane of P. aeruginosa from antibodies of the host defence 
(Stiver et al., 1988) as well as from antimicrobial agents. In addition, P. aeruginosa also 
produces an alginate lyase enzyme which functions to cleave MEP and allow for further 
spread of the bacterial organism to contiguous sites (Boyd and Chakrabarty, 1994). 
Furthermore, P. aeruginosa may also synthesize specific lipid-A moieties containing 
palmitate and aminoarabinose which provoke increased host inflammatory responses 
and resistance to antimicrobial peptides (Ernst et al., 1999). The pyocyanin pigment 
possessed by P. aeruginosa has also been found to slow ciliary beat frequency, bind 
iron and inhibit the growth of other bacteria (Wilson et al., 1987) 
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1.6.1.1.2     Increased binding of P. aeruginosa to airway epithelium 
There is an increase in asialo-GM1 residues (a class of glycolipids which contain a 
GalNAcB14Gal sequence and enable P. aeruginosa attachment) on CF airway epithelial 
cells (Saiman and Prince, 1993), which has been found to be responsible for a two fold 
increase in bacterial binding (Saiman et al., 1992). The possession of adhesins (pilin 
and flagelin) by P. aeruginosa significantly contributes to development of chronic 
infections by the microbe since these structures contribute to the attachment of the 
microbe as well as the initiation of an exuberant inflammatory response (Scheid et al., 
2001). For example, the binding of pilin to asialo-GM1 activates the pro-inflammatory 
transcription factor NF-κB and induces production of the neutrophil chemoattractant, IL-8 
(Dimango et al., 1998; Dimango et al., 1995). On the otherhand, flagellin just like pilin 
also promotes P. aeruginosa retention in the airways of CF patients by binding to mucin 
oligosaccharides via flagellar cap protein FliD (Arora et al., 1998; Ramphal et al., 1996) 
and to epithelial cell oligosaccharides (in which case it stimulates the production of pro-
inflammatory cytokines) (Feldman et al., 1998). 
 
1.6.1.1.3     Failure of nonspecific airway defences to kill the bacteria 
From birth the human airway is repeatedly challenged by small doses of microbes. In 
the normal airway, nonspecific airway defences such as defensins, lysozyme, 
lactoferrin, SLPI and nitric oxide (NO) ordinarily resolve these small microbial 
challenges. In the airways of CF patients, the non-specific defences are compromised. 
For example, the major isoform of nitric oxide synthase (NOS) in airway epithelial cells, 
NOS-2, is reduced in CF airway epithelium (Kelley and Drumm, 1998). This reduction in 
local NO production (related to abnormal CFTR functioning) In combination with reduced 
amounts of or inactivated natural antimicrobial proteins and peptides (due to high salt 
content in the airway-surface liquid as earlier described) probably compromises the 
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host's ability to handle small bacterial challenges. A direct result of compromised 
nonspecific defences and reduced bacterial clearance is the recruitment of inflammatory 
cells and many other systems to fight bacterial invasion (which would otherwise have 
being resolved by nonspecific host defences) with mostly deleterious outcomes to the 
airway.  
 
1.6.2     Current treatment strategies of P. aeruginosa in the airway of 
CF patients 
Antibiotic therapy has been the corner stone for improvements to both life expectancy 
and quality of life of CF patients. Typically, antibiotic therapies are generally geared 
towards managing early, intermittent infections with particular focus on eradicating the 
pathogens or at least reducing the bacterial density as well as the inflammatory 
response that ultimately leads to lung injuries. However, once P. aeruginosa establishes 
itself in the airway of a person with CF, eradication is rarely achieved. Therefore, the 
most effective and efficient antimicrobial therapies have been those, which are able to 
supress this bacterial pathogen even though many other pathogens like Burkholderia 
cepacia complex and methicillin-resistant Staphylococcus aureus (MRSA) (which are 
associated to declining lung function) are also present in the airway of people with CF. 
Recently, clinicians have begun to evaluate eradication protocols for MRSA 
(www.clinicaltrials.gov identifier NCT01349192).  For the purpose of this thesis, mention 
would only be made about inhaled antibiotics employed for the treatment of P. 
aeruginosa infections in the airways of CF patients. 
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1.6.2.1     Currently approved aerosol antibiotics in the UK 
Commonly employed antibiotics include the aminoglycoside – tobramycin; the polymyxin 
E – colistin; the monobactam antibiotic – aztreonam; with the fluoroquinolones 
(ciprofloxacin and levofloxacin) and phosphonic acid-aminoglycoside combinations 
(fosfomycin-tobramycin combinations) still under clinical trials.  
 
1.6.2.1.1     Nebulised and inhaled tobramycin 
TOBI® (Tobramycin 300mg/5 mL nebuliser solution) and TOBI Podhaler (28 mg 
inhalation powder) both marketed by Norvatis Pharmaceutical UK Limited are currently 
indicated for the therapeutic management of chronic pulmonary infection resulting from 
P. aeruginosa in CF patients ≥ 6 years of age. The recommended dose for TOBI® in 
adults and children is 300 mg tobramycin twice daily for 28 days-on followed by 28 days-
off therapy while the recommended dose for TOBI Podhaler is 112 mg tobramycin (4 x 
28 mg capsules) administered twice daily for 28 days followed by 28 days off therapy. A 
multicentre, double-blind, placebo-controlled trial published by Ramsey et al., (1999) 
indicate an average increase in forced expiratory volume in one second (FEV1) of 10%, 
20 weeks after commencement of 300 mg inhaled tobramycin therapy compared with 
2% decline in FEV1 in the patients receiving the placebo. 
 
1.6.2.1.2     Colistimethate sodium 
Colistimethate sodium is a polymyxin antibiotic marketed as Promixin (1 million 
international unts of Colistimethate sodium powder for nebuliser solution) by Profile 
Pharma Limited for the treatment of P. aeruginosa lung infections sensitive to 
colistimethate sodium in CF patients ≥ 2 years of age. The recommended dose for both 
children and adult is 1-2 million IU for 8 to 12 hours daily. There has not been a large, 
randomized controlled study for colistimethate yet, but Jensen et al., (1987) have so far 
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shown that 90 day treatment with colistin is superior to treatment with a placebo.  
 
1.6.2.1.3     Aztreonam lysine for inhalation (AZLI) 
Aztreonam lysine is a monobactam antibiotic which has been used parentrally to treat 
infections caused by aerobic Gram-negative bacteria. It has however been reformulated 
as a lysine salt for inhalation. Cayston (75 mg aztreonam which forms aztreonam lysine 
in situ) is marketed by Gilead sciences Limited for suppressive therapy of chronic P. 
aeruginosa infections in CF patients’ ≥ 6 years of age. The recommended dose for 
children and adults is 75 mg every 8 hours for 28 days followed by 28 days off therapy. 
A double blind, randomized, placebo-controlled phase 2 study carried out by Retsch-
Bogart et al., (2008) showed that 75 and 225 mg of aztreonam lysine administered 12 
hourly for 14 days using eFlow electronic nebuliser (Pari Innovative Manufacturers, Inc., 
Midlothian, VA) significantly reduced bacterial density in sputum with the 75 mg dose 
being associated with fewer adverse events. 
 
1.6.2.1.4     Aerosol antibiotics in clinical development 
The continued improvement of the available therapies for managing P. aeruginosa 
infection as well as the fear that overuse of the same antimicrobials overtime may place 
selective pressure on CF microbiome has seen clinical explorations into the 
reformulation of some other already effective antibiotics for inhalation purposes 
including;  
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      Table 1.4: Some antipseudomonal antibiotics, which are currently at various stages of clinical development. 
Antibiotic class Antibiotic formulation Status Sponsors Ref./Clinical 
trial identifier 
Fluoroquinolones Inhaled ciprofloxacin Phase 2 clinical trial 
completed 
Bayer Healthcare AG, 
Germany 
NCT00645788 
liposomal ciprofloxacin Phase 3 clinical trials 
about to begin 
Aradigm corporation, 
USA 
NCT01515007 
Nebulised levofloxacin Phase 3 clinical trials 
is currently ongoing 
Mpex 
Pharmaceuticals USA 
NCT01180634 
Aminoglycoside Liposomal amikacin Phase 3 clinical 
studies about to begin 
Insmed Incorporated, 
USA 
NCT01315691 
Phosphonic acid Nebulised fosfomycin-
tobramycin combinations 
Phase 2 clinical trial 
completed 
Gilead Sciences, USA NCT00794586 
 
 
 
- 6
6
 - 
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1.6.3     Antibiotic resistance 
Unfortunately, one of the recurring problems with the currently available antimicrobial 
therapies employed in managing infections in CF patients is antibiotic resistance. 
Although many of the relevant antibiotics (aminoglycosides, β-lactams, fluroquinolones 
polymixin) employed for the treatment of P. aeruginosa infections in CF remain active 
against majority of respiratory isolates in the UK and Ireland 
(www.bsacurv.org/mrsweb/respiratory), resistance is still notable especially among 
patients with cystic fibrosis. An overview of some factors responsible for P. aeruginosa 
resistance have been previously reviewed by Lambert, (2002), Costerton et al.,(1999) 
and Gilbert et al., (1997) and they include; restricted penetration of antimicrobial agents 
into a biofilm, decreased growth rate of microbes in a biofilm and possible expression of 
resistance genes. 
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Table 1.5: Resistance among P. aeruginosa isolates in the United Kingdom and Ireland, 2008 – 2011. Data was obtained from the resistance 
surveillance website of the British Society for Antimicrobial Chemotherapy 
Antimicrobials Year No. of isolates 
tested 
Breakpoints Susceptible 
N (%) 
Intermediate 
N (%) 
Resistant N 
(%) 
S ≤ R > 
Ciprofloxacin 2008 - 2009 238 0.5 1 184 (82.1%) 15 (6.7%) 25 (11.2%) 
2009 - 2010 206 0.5 1 168 (81.6%) 9 (4.4%) 29 (14.1%) 
2010 - 2011 224 0.5 1 186 (78.2%) 20 (8.4%) 32 (13.4%) 
Gentamicin 
2008 - 2009 238 4 4 230 (96.6%) 0 (0%) 8 (3.4%) 
2009 - 2010 206 4 4 193 (93.7%) 0 (0%) 13 (6.3%) 
2010 - 2011 224 4 4 215 (96.0%) 0 (0%) 9 (4.0%) 
Colistin 2010 - 2011 224 4 4 224(100%) 0 (0%) 0 (0%) 
Imipenem 
2008 - 2009 238 4 8 197 (82.8) 20 (8.4) 21 (8.8%) 
2009 - 2010 206 4 8 168 (81.6%) 23 (11.2%) 15 (7.3%) 
2010 - 2011 224 4 8 184 (82%) 19 (8.5%) 21 (9.4%) 
 
 
- 6
8
 - 
Chapter one: Introduction  
- 69 - 
 
1.6.3.1     Restricted penetration of antimicrobial agents into a biofilm  
When P. aeruginosa forms biofilms, the exopolysaccharide matrix serves as a shield for 
the microbe by restricting the diffusion of an antibiotic through it (Nichols et al., 1988), 
unfortunately, all the major classes of antibiotic used to treat P. aeruginosa need to 
cross these biofilm to reach their target. For example, the mechanism of action of the 
aminoglycosides (tobramycin, gentamicin and amikacin) involves inhibition of protein 
synthesis through its binding to the 30S ribosomal subunit, the fluoroquinolones 
(ciprofloxacin, levofloxacin) inhibit DNA gyrase (an isozyme of topoisomerase found only 
in bacteria) through its binding to the subunit A of the enzyme, the β-lactams 
(aztreonam, ceftazidime, imipenem, meropenem and piperacillin) inhibit bacterial cell 
wall synthesis through its inhibition of peptidoglycan assembling transpeptidases and 
the polymyxins (colistin) which disrupt the outer cell membrane of Gram-negative 
bacteria by binding to lipopolysaccharides and phospholipids. Therefore the inability of 
the antibiotic agent to accumulate within the organism either due to restrictions 
presented by the outer membrane or the biofilms in which the bacteria exists, ensures 
the survival of the organism in a hostile environment   
 
1.6.3.2     Mutations and resistance 
All the antimicrobial agents currently being used to manage P. aeruginosa infections are 
all prone to compromise by mutational resistance. For example, mutations to 
topoisomerase II (gyrA) and topoisomerase IV (parC) in P. aeruginosa confer 
fluoroquinolone resistance (Jalal and Wretlind, 1998), depression of chromosomal 
AmpC β-lactamase confers cephalosporin and penicillin resistance (Livermore, 1995), 
up-regulation of MexAB-OprM, MexCD-OprJ, MexEF-OprN, MexXY-OprM compromises 
the fluoroquinolones, penicilins, cephalosporins and to some extent, meropenem (with 
only up-regulation of MexEF-OprN causes some reduced susceptibility to imipenem), 
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reduced aminoglycoside transport results in aminoglycoside resistance and changes to 
the membrane architecture of P. aeruginosa resulting in polymixin resistance. 
 
Overall, data from the European Antimicrobial Resistance Surveillance Network (EARS-
NET) indicate that there is growing Europe-wide increase in antimicrobial resistance of 
Gram-negative pathogens (including P. aeruginosa) to third generation cephalosporins, 
fluoroquinolones and aminoglycosides (Ecdc, 2012). It is an unfortunate situation that 
aminoglycosides which are the mainstay antibiotic component of most 
inhaled/aerosolised antipseudomonal therapies are gradually becoming less effective in 
combating P. aeruginosa infections in CF patients (Ecdc, 2012). While aminoglycoside 
toxicity (nephrotoxicity and ototoxicity) may be resolved by increasing dosing intervals 
(Turnidge, 2003), resistance of clinical isolates of P. aeruginosa are more difficult to 
manage.  
This thesis focuses on developing an inhalable antipseudomonal therapy (combination 
of aminoglycosides and antimicrobial protein) with the view of increasing the 
susceptibility of P. aeruginosa in the airways of CF patients. It is premised on the 
understanding that one of the major causes of reduced susceptibility of P. aeruginosa to 
antimicrobial agents is the formation of biofilms (free-living, independent planktonic 
bacteria attaching to surfaces and becoming sessile) which retard the diffusion 
antimicrobial agents or in which bacterial cells are non-growing (hence not very 
susceptible to many antimicrobial agents). A study by Singh et al., (2002) reported that 
depriving P. aeruginosa of iron, enhanced twitching motility and limited biofilm formation 
and development, an observation which suggests that an important feature of P. 
aeruginosa, antibiotic resistance, could be curtailed by combining an antimicrobial 
protein (lactoferrin) with other antibiotics. 
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1.7     Pulmonary delivery of antimicrobial peptides and proteins 
Inhaled medications have been available for many years and are widely accepted as the 
most effective first line therapy for local airway disorders: chronic obstructive pulmonary 
disorder, asthma and infections in people with cystic fibrosis.  Improvements in the 
understanding of inhalational science have now been employed to deliver peptide and 
protein based drugs as earlier mentioned (table 1 -3). Although, antimicrobial proteins 
have a lot of perceived benefits, there is so far no clinically available inhaled 
antimicrobial protein or peptide formulation. This is despite the fact that there is still a 
limited knowledge on the optimal lung deposition site for maximum therapeutic benefits 
of antibiotics. For example, we now know that chronic lung infection with P. aeruginosa 
in patients with CF resides in the airway lumen (beginning from the bronchioles and 
gradually proceeding to the larger airways) with limited invasion of the lung parenchyma 
(Baltimore et al., 1989; Potts et al., 1995). It is thought that the optimal site of deposition 
for inhaled antimicrobial therapy should therefore involve a uniform distribution on the 
conducting airways, however, this is not always feasible as the viscous mucus in the 
airway (bronchi and bronchioles) may prevent the deposition of inhaled antimicrobial 
particles distal to the airway obstruction thereby limiting the therapeutic effectiveness of 
the aerosolized antimicrobial agent (Alderson et al., 1974; Ilowite et al., 1987; Anderson 
et al., 1989). In order to gain insight into some of the challenges such an antimicrobial 
protein formulation may encounter, factors affecting the therapeutic delivery of proteins 
and peptides are briefly reviewed. 
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1.7.1     Factors affecting the effectiveness of aerosolised protein and 
peptide medications. 
1.7.1.1     Drug-associated factors 
1.7.1.1.1     Protein intergrity 
Many proteins are structurally unstable in solution, as a result they may undergo 
conformational changes during purification, formulation and storage with resultant 
physical damage (for example, protein aggregation) arising from exposures to stresses 
such as high temperatures, mechanical shear stress, extremes of pH or exposure to 
organic solvents (Wang, 2005; Ohtake et al., 2011) that affect their unique three-
dimensional structure (a key requirement for protein activity). In addition to physical 
degradation, therapeutic proteins are also subjected to degradation by lung peptidases 
and proteases, the extent of which is dependent on the unique protein characteristics.  
 
1.7.1.1.2     Macromolecular chemistry 
Knowledge of the concise chemistry of a protein/peptide to be employed in therapy 
could aid understanding and prediction of the therapeutic behaviour of the protein when 
administered to the respiratory tract. For example, understanding the hydrophilicity or 
hydrophobicity of administered proteins could serve in predicting how they may traverse 
across the airway epithelial membrane. It is known that most proteins are hydrophilic in 
nature thereby creating some difficulty in getting them across the lung epithelium (Patton 
and Byron, 2007), therefore strategies which increase hydrophobicity would be expected 
to improve their therapeutic effectiveness, if the aim is to deliver the proteins and 
peptides for systemic delivery. In other cases where local delivery is desired (especially 
in the delivery of antimicrobial proteins and peptides), strategies that enhance the 
hydrophilicity of the protein or peptide drug should be embarked upon. 
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Small hydrophobic chemical moieties are also known to be absorbed by simple passive 
diffusion throughout the lungs, while large hydrophilic moieties are thought to be 
absorbed via tight junctions or specific transporters (Patton, 1996). Unfortunately, the 
exact mechanism(s) by which protein drugs are absorbed through the lung/airways 
epithelium have not yet been fully understood. There still remains a considerable 
number of investigations that need to be carried out to fully ascertain the mechanism(s) 
by which protein drugs are absorbed. 
 
1.7.1.1.3     Mucociliary and macrophage clearance 
An important defence barrier factor which proteins need to overcome when they are 
administered to the respiratory tract is the mucociliary escalator, as it acts as a 
clearance mechanism for particles deposited in bronchi and bronchioles. As previously 
stated, the cilia drives the particles trapped in the mucus using coordinated ciliary 
beating to move mucus from the lower airways to the pharynx, where they can be either 
swallowed and degraded in the gastrointestinal tract, or ejected (Yu and Chien, 1997; 
Hoiby et al., 2010). On the other hand, even if the protein formulation is able to avoid 
mucociliary clearance, phagocytic cells like macrophages may degrade the protein 
particles. This is the major clearance mechanism of the lungs at the alveolar level and 
occurs when alveolar macrophages migrate to the particles and phagocytose them via 
chemotaxis involving opsonisation. The whole process of macrophage uptake is 
believed to be completed within 6–12 h after initial deposition of particles in the alveoli. 
Once internalised in the macrophages, the particles are either disintegrated (e.g. by 
enzymes in lysosomes) or accumulated in the lymphatic system, which drains the 
airways and alveoli. However, a minor fraction of the particle‐ carrying macrophages 
may eventually migrate to the ciliated airways, where they are removed by mucociliary 
clearance (Zhang et al., 2011). 
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1.7.1.1.4     Clearance by lung proteases 
Lung proteases specifically present a significant challenge to aerosolized/inhaled protein 
formulations. It has been suggested that addition of a protease inhibitor to the 
formulation may offer a way to protect the protein and consequently increase its local 
concentration in the lung (Siekmeier and Scheuch, 2009). However, the efficacy of this 
strategy will typically rely on what enzyme the protease inhibitor inhibits, for example 
while SLPI - inhibits serine proteases, α1 antitrypsin – inhibits neutrophil elastase 
(Greene and Mcelvaney, 2009). Some other protease inhibitor which have been 
investigated include nafamostat mesilate and bacitracin. 
 
1.7.1.2     Formulation-associated factors 
1.7.1.2.1     Aerosol particle size and site deposition 
The role of particle/droplet size in the formulation of aerosols intended for pulmonary 
application is of utmost importance, as particle size directly influences the mechanism of 
deposition (Weda et al., 2002; Usmani et al., 2003; Weda et al., 2004; Srichana et al., 
2007; Glover et al., 2008).  
Generally, it is thought that particles with aerodynamic diameter greater than 5 μm 
mainly deposit in the upper airways by the process of inertial impaction while particles 
with aerodynamic diameter between 1 and 5 μm mainly deposit in the bronchial tree and 
the alveoli by the process of sedimentation as a result of progressively decreasing air 
velocity. On the otherhand, particles within the size range of 1 and 3 μm are particularly 
suited for alveolar deposition while even smaller particles (i.e particles having an 
aerodynamic diameter of below 0.5 μm) usually undergo Brownian motion and in some 
instances are exhaled during the expiration process. 
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For effective drug delivery of antimicrobial protein to the respiratory tract, the 
recommended aerodynamic particle size has been suggested to be between 1 – 5 µm 
(Hinds, 1982; Gonda, 1992). Particle sizes within these ranges are quite susceptible to 
deposition in the conducting regions where infections usually occur. 
 
 
Figure 1 -7: Effect of particle size on the deposition of aerosol particles in the human respiratory 
tract following a slow inhalation and a 5-second breath hold. For optimal deposition in the 
alveolar region, aerosolised protein formulations must be within a particle size range of between 
1 and 3 µm. For maximum percent deposition in the airways especially for local delivery, the 
particle size of the formulation should be between 5 and 7 µm.   Adapted from Patton and Byron 
(2007).  
 
1.7.1.2.2     Aerosol mass density and aerodynamic diameter  
Since most aerosolised particles are not perfect spheres, the particle sizes of 
anisometric inhaled particles are commonly described in terms of their equivalent 
aerodynamic diameters (diameter of a unit density sphere having the same terminal 
settling velocity as the particle under laminar flow conditions). Summarily, aerodynamic 
diameter defines particle size, shape and density of inhaled particles. So far, therapeutic 
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dry powders for inhalation have been engineered to achieve a typical mass density (ρ) 
of approximately 1 ±0.5g/cm3 and a mean geometric diameter of <5 µm (Edwards et al., 
1997). Although, some researchers have generated large porous microparticles having 
a low mass density of <0.4 g/cm3 and aerodynamic diameter between 1 – 5 µm with 
actual geometric diameter of >5 – 10 µm for use in advanced delivery systems (Edwards 
et al., 1997; Lee et al., 2007; Kwon et al., 2007; Edwards et al., 1998). 
 
1.7.1.3     Device-associated factors 
The selection of an appropriate aerosol device that best suits the protein or peptide 
formulation is essential, since the role an aerosol device plays in the delivery of any 
protein or peptide formulation cannot be underestimated. For example, formulations 
presenting as solution will be well suited for nebulisers, while dry powders are generally 
delivered using DPI or pMDI devices. 
 
1.7.1.3.1     Devices for liquid protein formulations 
The device employed to generate aerosols from liquid protein formulations has a key 
role to play in ensuring a high degree of protein stability. Nebulisers are the device of 
choice to generate aerosol droplets; Briefly, a nebuliser can be best described as an 
aerosol device that atomises a drug containing solution into a mist of small fine droplets, 
either through the use of compressed gas (as in air jet nebulisers) or through piezo-
electric crystal transducer (as seen in ultrasonic nebuliser). Unfortunately, nebulisers 
have some serious drawback when used to aerosolise protein solutions or suspensions. 
These drawbacks will be discussed under the two types of nebulisers on the market. 
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1.7.1.3.1.1     Operational principles of a jet nebuliser 
A portable compressor delivers a jet of high velocity air stream through a nozzle which 
causes liquid to be drawn up from the reservoir due to the drop in partial pressure 
created at the orifice. An aerosol droplet is generated when the liquid formulation 
establishes contact with the air stream. Subsequently, larger droplets impact upon an 
appropriately placed baffle and are refluxed, i.e. returned to the reservoir, while 
sufficiently small aerosol droplets remain in the air stream and exit from the inhalation 
port of the nebuliser. Over the course of nebulisation, over 99% of the liquid protein 
formulation would be expected to be refluxed; this undoubtedly leads to repeated stress 
by the multiple exposures of the protein to the air-water surface, an experience that may 
essentially denature the protein formulation. For example, an investigation by Niven and 
Brain (1994) shows that there is an irreversible time-dependent loss of lactate 
dehydrogenase activity following jet nebulisation. This may have occurred due to 
physical disruptions to the protein structure resulting from shear stress and surface 
effects, which are dependent on the volume of fluid and rate of aspiration. However, 
Cipolla and co-workers (1994a) were able to maintain the activity and structural integrity 
of recombinant human deoxyribonuclease (i.e. the first protein approved for inhalational 
therapy amongst patients with cystic fibrosis) when a 2.5 mL of either 1 or 4 mg/mL 
aqueous protein solution was nebulised with the aid of four different variations of jet 
nebulisers. Interestingly, the activity of between 20 – 28% of the administered rhDNase 
dose having an aerosol droplet size of approximately 1 – 6 µm remained unchanged 
following jet nebulisation. Unfortunately, at the moment jet nebulisers are not being used 
to aerosolise recombinant proteins. 
 
1.7.1.3.1.2     Operational principles of the ultrasonic nebuliser 
The ultrasonic nebuliser is another suitable device which can be employed for the 
nebulisation of a liquid protein formulation. Basically, there two types of ultrasonic 
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nebuliser; (1) those which employ the use of vibrating screens and (2) those which use 
high frequency sound waves to cause the generation of aerosol droplets. However, in 
the latter, the transfer of the high energies generated as well as the potential build-up of 
heat energy in the protein formulation may well lead to the thermal degradation of the 
protein (Cipolla et al., 1994b; Phipps and Gonda, 1990; Taylor and Hoare, 1993). For 
example, recombinant consensus α-interferon (rConIFN) and lactate dehydrogenase 
have been reported to denature during nebulisation while employing commercially 
available ultrasonic nebulisers (Niven et al., 1995; Ip et al., 1995). Despite this, there are 
some advantages of ultrasonic nebulisers over jet nebulisers including; production of 
higher mass output, reduction in duration of nebulisation and it actually produces less 
noise in operation (Mccallion and Taylor, 1999). Additionally, the denaturation of 
proteins during ultrasonic nebulisation may be device dependent. Flament et al., (1999) 
reported that upon aerosolisation of an α1 protease inhibitor using an SAM LS ultrasonic 
nebuliser (Systeme AssistanceMedicale, Le Ledat, France), the anti-elastase activity 
was not reduced. 
Most recently, Boehringer Ingelheim have designed, tested and secured approval for 
Respimat®, a device which is able to generate small aerosol droplets by ultrasonic 
nebulisation of very small volumes of liquid formulations (15 µL) in one atomisation cycle 
lasting 1.2 seconds (Dalby et al., 2011). Although, the design features of Respimat® 
allows for circumvention of problems associated with degradation of the protein 
formulation upon aerosolisation, it will potentially have limited application for the delivery 
of antimicrobial peptides and proteins since it will necessitate administration of multiple 
doses and the use of high concentrations of liquid protein formulations hence making 
such a therapeutic applications relatively expensive. 
An alternative device that may be employed to improve the delivery efficiency and 
reproducibility of nebulised proteins and peptides is the AERx™ device developed by 
Aradigm Corporation. The device combines precise aerosol particle size and a control of 
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the patient’s inhalation to deliver a higher amount of drug to the lung with minimal loss of 
the drug in the mouth and throat.  In comparison to Respimat®, the AERx™ is able to 
deliver a higher volume of drug (50 µL) in about 1 second and also incorporates 
temperature controllers which minimise effects of ambient air conditions on the 
generation of small respirable droplets thereby optimising pulmonary deposition 
(Deshpande et al., 2002; Gonda et al., 1998; Schuster et al., 1997). 
 
a) 
 
b) 
 
Figure 1 -8: New generation of nebulisers. (a) AERx Essence
®
 device by Aradigm Coporation (b) 
Respimat device by Boehringer Ingelheim. Currently AERx is being used in phase 2 clinical trials 
to deliver liposomal ciprofloxacin for the treatment of infections in cystic fibrosis and Non-CF 
bronchiectasis patients and also for delivery of inhaled insulin. Respimat device is currently used 
in delivering a combination of ipratropium bromide and albuterol sulphate as Combivent respimat 
inhalation spray in the United States and tiotropium bromide monohydrate as Spiriva Respimat in 
the United Kingdom   
 
1.7.1.3.2     Devices for dry powder protein formulations 
Traditionally, small volume nebulisers (SVN) like Respimat and AERx are best suited for 
the pulmonary delivery of very potent proteins and peptides but in some special cases 
like the local delivery of antimicrobial peptides and proteins requiring the delivery of 
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much larger quantities of the therapeutic peptide, dry powder inhalers (DPI) are much 
more efficient in delivering high concentrations of protein or peptide agents to the 
airway.  In general, DPI devices are categorised as into two namely; multidose dry 
powder inhalers (mDPI: where the drug is stored as a bulk and metered inside the 
device prior to inhalation) and single-unit dose dry powder inhalers (DPI: where the drug 
is pre-metered into individual storage units). In addition, these two devices can be 
further sub-divided into two categories based on the inspiratory efforts required for the 
dispersion of the drug-powder formulation; passive devices (i.e. patient provides the 
energy required for dispersion) and active systems (i.e. an external source provides the 
energy required for dispersion) (Clark and Shire, 2000). 
 
1.7.1.3.2.1     Unit dose dry powder inhaler devices 
These groups of dry powder inhaler devices constitute the first generation DPIs and are 
the most commonly used devices for the aerosolisation of protein powders. In terms of 
device design, the unit dose dry powder inhalers have various forms of presentations, 
ranging from the early designs in which drug formulations are stored as single doses in 
hard gelatine capsules (e.g. the Spinhaler and the Rotahaler) to more recent complex 
variant in which individual doses are premetered into blisters, disks, tubes and dimples 
by the manufacturer. Overall, the blistered devices offer superior multidose convenience 
for patients and have become the device of choice for aerosolisation of dry powder 
formulations of proteins (Clark and Shire, 2000). However, among the many 
disadvantages of single dose devices is the requirement for dexterity to load each 
capsule means that a patient undergoing an asthma attack may find it difficult to use for 
immediate relief. Also, the contents of the capsules maybe vulnerable to extremes of 
temperature and humidity.  
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1.7.1.3.2.2   Multidose dry powder inhaler devices 
The multidose inhaler constitute the second generation of DPIs and represents an 
attempt to improve upon the DPI technology. It features a powder reservoir from which 
individual doses are metered. Unfortunately, these groups of DPI devices present some 
major challenges in terms of the delivery efficiency of protein powders. This is generally 
due to destabilization of the formulation, which is brought about by the tendency of the 
amorphous excipients employed as solid stabiliser to crystallise thereby leading to an 
increase in the moisture content of the powder and ultimately plasticized powder 
formulation. However, even though there is the possibility of developing protein 
formulations which are quite stable at ambient humidities, the instabilities commonly 
associated with amorphous solid will still severely limit the use of multidose dry powder 
inhaler devices for the delivery of protein powders. 
 
1.7.1.3.2.3   Passive and active dry powder inhaler devices 
Dry powder inhalers devices can be divided into two; passive and active devices 
(sometimes considered as third generation DPI devices). While passive devices rely on 
the patient’s inspiration flow to provide the energy required for dispersion, active devices 
rely on an external energy source to power dispersion. Currently, the majority of DPI 
devices in the market are patient-driven (passive) devices with relatively few active DPI 
devices. The very first approved active DPI device was the Exubera® device 
(manufactured by Pfizer) which has since been discontinued due the high cost of the 
inhaler and poor patronage by physicians and patients (Davila et al., 1990). The device 
relied on patient-generated compressed air as energy source to deliver insulin to the 
lung epithelium (White et al., 2005).  Other active DPI devices include; Aspirair® 
(Vectura) – a multidose device employing individual foil blisters to deliver systemic 
products to the deep lungs.  
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From a pulmonary delivery perspective, the choice between employing either a patient-
driven or a powered system is purely based on design attributes such as; delivery 
efficiency, stability and reproducibility of the device and patient based factors like; ease 
of use, compliance and cost of the device. Ideally, a device featuring unit dose 
packaging with some form of powered aerosol generation and an optimum control of 
inhalation flow rates may be deemed as a gold standard. However, since we live in an 
imperfect world, where all these attributes may well not be present in any one particular 
device design, some form of trade off may well be appropriate. It could also be the case 
that for some proteins and peptides, where cost and therapeutic effectiveness are less 
important, less efficient devices may be acceptable. For local delivery of therapeutic 
moieties like antimicrobial peptides, it is understandable that passive devices are 
sufficient while active devices may be better suited for systemic delivery of therapeutic 
moieties through the airways due to efficient and effective deep lung deposition.  
 
1.7.1.3.3      Pressurised metered dose inhaler devices for protein delivery 
Pressurised metered dose inhaler (pMDI) devices were first introduced in 1955 and at 
the time revolutionised the delivery of therapeutic agents to the airway. Since then, the 
pMDI devices have proven to be a convenient delivery system for targeting 
bronchodilators and corticosteroids to the airways of patients with asthma (Leach, 1998; 
Pauwels et al., 1997). The device is usually small, inexpensive and convenient to carry 
around and use providing reproducible dosing, hence they are usually considered the 
“gold standard” in many ways for the delivery of therapeutic agents to the airways. 
However, they have not been the preferred device of choice for the delivery of protein 
and peptide formulations. In a pMDI device, the drug is suspended or dissolved in 
liquefied gas such as hydrofluoroalkane propellants (HFA-227 and HFA-134a). pMDI 
devices are also not suitable for the delivery of antimicrobial peptides and protein as the 
metering valves can only deliver between 10 – 30 μL per actuation hence the quantities 
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of antimicrobial agents required to manage airway infections will require multiple 
actuations (an inconvenience to the patient) or very high concentration of the protein 
(making the therapy very expensive). 
 
1.7.1.4 Some other considerations 
Furthermore, the choice of excipient, interactions between the formulation and the 
device (e.g. adsorption), method and conditions of storage, target of drug activity (local 
or systemic), the nature of the aerosols to be delivered (droplets or particles) are some 
of the considerations which would inform the choice of any one aerosol delivery device. 
It is clearly understood that since efficient delivery of aerosols to the desired site of 
action is pertinent, it is of paramount importance to ensure that proteins/peptides for 
inhalation are of requisite aerodynamic size and possessing sufficient pharmacologic 
activity, since if it is otherwise, the inhaler/nebuliser device may only deliver a small 
percentage of the inhaled dose thereby making the cost of therapy prohibitive. 
Investigations are currently ongoing in order to determine the best way of circumventing 
formulation and operational challenges in the pulmonary delivery of peptides and 
proteins for example Li et al., (2010) have considered the use of sodium 
carboxymethylcellulose (NaCMC) to protect the activity of an active enzyme, alkaline 
phosphatase during processing (spray drying) and have found that 94.2 ±8.5% of the 
protein remained active when co-spray dried with NaCMC compared to 73.7 ±7.5% 
when spray-dried alone. 
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1.8     Aims and objectives 
The main aim of this study was to explore the benefit of co-formulating an antimicrobial 
protein and an aminoglycoside in order to increase the susceptibility of P. aeruginosa to 
antimicrobial agents. The specific aims were therefore: 
 To optimize a method of spray drying using alkaline phosphatase as a model 
protein in order to produce a functionally active micronized formulation suitable 
for inhalation 
 To determine the physicochemical and aerosolisation characteristics of a spray-
dried antimicrobial protein 
 To determine the efficacy of a spray-dried antimicrobial protein against 
planktonic cultures and biofilms of P. aeruginosa 
 To develop and characterise co-spray dried combinations of an antimicrobial 
protein and an antibiotic, as well as evaluate their efficacy against planktonic 
cultures and biofilms of P. aeruginosa 
 To determine the cytotoxicity and proinflammatory properties of various spray-
dried antimicrobial agents against submerged cultured human bronchial 
epithelial cells in vitro  
 To develop an in vitro static co-culture model of P. aeruginosa biofilm on human 
bronchial epithelial cell growing at air-liquid interface  
 
 
*****Not yet completed******* 
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2.1     Materials 
2.1.1     Chemicals 
The materials used and their sources are listed in Table 2-1 
Table 2.1: Materials sources 
Material* Source 
Sodium carboxymethylcelluose 
Diethanolamine 
Phosphatase alkaline from bovine intestinal 
mucosa 
Bromophenol blue indicator reagent 
Coomassie Brilliant blue R 
Sodium dodecyl sulphate 
Magnesium Chloride 
D-(+)-Glucose 
Luria broth 
Sodium acetate 
Sodium dihydrogen phosphate 
Ethylenediaminetetraacetic acid 
Kodak GBX developer 
Kodak GBX fixer 
Formaldehyde solution 
SIGMA-ALDRICH (Poole, UK) 
Spectrosol Ferric Nitrate (Standard solution 
for atomic spectroscopy) 
VWR  (Leicestershire, UK) 
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Fetal bovine serum (FBS) 
Dulbecco’s modified eagle medium: 
Nutrient mixture 12 – Ham (DMEM/F12) 
growth medium 
Phosphate buffer saline (1x, PBS) 
L-glutamine 
Penicillin/streptomycin 
Trypsin-ethylenediamineteraacetic acid 
PAA Laboratories Ltd (Somerset, UK) 
1-Step™ PNPP 
Pierce Silver stain kit 
BCA protein assay reagent 
Thermo Scientific (Rockford, IL USA) 
CellTiter-Blue™ Promega (Wisconsin, USA) 
Human IL-8 ELISA development kit Peprotech EC Ltd (London, UK) 
Casamino acids Becton Dickson (NJ, USA) 
Analytical grade, Absolute Ethanol Fisher Scientific. (Loughborough, UK) 
98% 4-Nitrophenol 
Glycine 
Acros organics. (New Jersey, USA) 
Mini-PROTEAN®TGX™ Precast gels Bio-Rad laboratories (Hercules USA) 
PageRuler™ Plus, prestained protein 
ladder 
Fermentas (York, UK) 
LIVE/DEAD kit Invitrogen Molecular Probes, Eugene, OR, 
USA 
Lactoferrin DMV Fonterra, Netherlands 
Gentamicin 
Tobramycin 
Fagron, (Newcastle upon Tyne, UK) 
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Primary antibodies (IG12, 4C6 and 4C3) Kindly provided by Dr Andrew Devitt of 
Aston University 
Mueller-Hinton Agar 
Antibiotic susceptibility disk 
Oxoid LTD (Basingstoke, UK) 
Immobilon® Western Enhanced 
Chemiluminescent substrate (ECL) 
Millipore (Watford, UK) 
*All chemicals are of analytical grade 
Distilled water was generated in-house using Fison’s Fi-streAm Water Still.  
 
  
2.1.2     General consumables and Equipment 
The general consumables used and their sources are listed in Table 2-2 
Table 2.2: General consumables 
Consumables Source 
Variable volume Micro pipettes  Appleton woods (Birmingham, UK) 
BD Falcon Transwell Inserts 
(polycarbonate with 0.4 µm pore size,) and 
companion plates 
VWR  (Leicestershire, UK) 
Nucleopore track-etched Membranes (13 
mm diameter and 25 mm diameter) with 
pore size 0.2 µm 
Whatman Int Ltd (Kent, UK) 
X-ray film  Amersham Biosciences (Buckinghamshire, 
UK) 
Nunc Maxisorp ELISA plates 
Microscope slides 
Fisher Scientific (Loughborough, UK) 
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Coverslips 
Filters for the biofilm assay 
Petri dishes Sarstedt Ltd (Leicester, UK) 
 
Table 2.3: Equipments 
Equipment Source 
Multiskan Spectrum - UV/Vis Microplate 
Spectrophotometer 
Thermo Scientific (Basingstoke, UK) 
G:BOX Syngene (Cambridge, UK) 
Mini Spray Dryer  Büchi Laboratoriums-Technik AG, Flawil, 
Switzerland 
Small scale crimper and propellant filler  Pamasol Willi Mäder AG, Pfäffikon, 
Switzerland 
Sympatec HELOS H1867 coupled to a 
RODOS dispersing unit and a VIBRI 
vibratory feeder used for particle sizing 
Helium-Neon Laser Optical System, 
Sympatec Inc. (Clausthal-Zellerfeld, 
Germany) 
Pyris 1 Thermogravimetric analyzer 
AAnalyst 100 
Perkin Elmer (Seer Green, UK) 
Vertical gel electrophoresis tanks and 
western blotting system 
Mini-PROTEAN®TGX™ tetra system Bio-
Rad laboratories (Hercules, USA) 
Confocal laser scanning microscope Leica TCS SP5 II Leica Microsystems 
(Milton Keynes, UK) 
UV light box UVP Inc (Cambridge, UK) 
TE22 mini transfer tank Hoefer Scientific (Newcastle-under-lyme, 
UK) 
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2.1.3     Bacterial strains 
Pseudomonas aeruginosa strain PAO1 and Escherichia coli NCTC 10418 (control 
strain) were identified and donated by Prof. Peter Lambert of Aston University. All 
bacterial strains were routinely grown on Mueller-Hinton agar (MHA) and liquid cultures 
were prepared in either 5mL of casamino acid media (P. aeruginosa) or 5mL of Luria 
Bertani media (E. coli) 
 
2.2     Methods 
2.2.1     Alkaline phosphatase enzyme assay 
2.2.1.1     Assay validation   
An assay procedure that ensures conformity to both Good Laboratory and current Good 
Manufacturing Practice standards, while maintaining a high degree of reliability and 
reproducibility in the various results obtained, was utilised for all investigations.  
 
2.2.1.1.1     Preparation of 4-nitrophenol standards 
Stock standard, p-nitrophenol, 1 mmol/litre 
139.1 mg of p-nitrophenol was dissolved in a 70 mL of deionised water, upon complete 
dissolution the final volume was made up to 100 mL with distilled water. Then the 
solution was diluted in a volumetric flask at 25 ± 1 °C to 1 litre. Then the entire solution 
was mixed thoroughly to produce a final concentration of 1 mmol/litre solution of 4-
nitrophenol. 
 
p-nitrophenol calibration  
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A standard calibration graph of p-nitrophenol (p-NP) in diethanolamine-HCl (1mM, pH 
9.8 at 25°C) was prepared by measuring the absorbance at 405 nm (Jenway 6305 
spectrophotometer) of serial dilutions ranging from 10µM to 50 µM of p-NP 
diethanolamine-HCl solution. 
A calibration graph of absorbance against concentration (µM) was plotted and a linear 
regression fitted using Microsoft Office Excel (2007). The equation of the line followed 
the equation below; 
            (Equation 2.1) 
 
where (y) is the absorbance value of the product formed, (m) is the slope of the line of 
best fit, (x) is the known concentration of the enzyme and (c) is the intercept on the y-
axis 
 
2.2.1.1.2     Calculating alkaline phosphatase activity in the various spray-dried 
powders 
The alkaline phosphatase activity of the of the various spray-dried powders were 
determined by adding 10µL portions of 100 μg/mL concentrations of the powders into 
1mL of p-NPP/Diethanolamine solution (1-Step™PNP) and allowed to react for 5 mins. 
The reaction was quenched by the addition of 500µL of 2 N NaOH and the absorbance 
values of the various solutions determined at a wavelength of 405 nm using a Jenway 
6305 spectrophotometer (Essex, UK).  
  
Principle of the enzyme activity assay. 
The equation for the reaction for the method described above in section 2.2.1.1.2 is 
shown in Figure 2 -1. 
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Figure 2 -1: Equation of reaction of alkaline phosphatase reacting with para-nitrophenol 
phosphate, producing the yellow product para-nitrophenolate 
 
2.2.1.1.3     Evaluating the specificity of the assay 
The specificity of the chosen assay method for the enzymatic activity of alkaline 
phosphatase was evaluated to confirm that the assay procedures were duly suited for 
the analytical procedure. This was done by spiking known concentrations of standard 
stock solutions of alkaline phosphatase with different amounts of sodium 
carboxymethylcellulose prior to measurement of alkaline phosphatase activity as 
described above. Potential interferences of the sodium carboxymethyl cellulose with the 
absorbance values of the activity of the enzymes were assessed by comparison with the 
enzyme activity results from unspiked standard solutions.  
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2.2.1.1.4     Limit of detection and quantitation of alkaline phosphatase 
The limit of detection (LOD) and limit of quantitation (LOQ) were determined for all the 
triplicate assessments of the alkaline phosphatase standard stock solutions using 
equations 2.2 and 2.3 (ICH, 1996).  
    
    
 
      (Equation 2.2) 
 
    
   
 
      (Equation 2.3) 
 
 
where; σ = standard deviation of the response 
  S = Slope of the calibration curve 
The slope S was estimated from a linear plot of the calibration curve while σ was 
determined from the standard deviation of the y-intercepts of the regression lines. 
 
The standard deviation of the response (σ) was calculated from the standard deviation 
of the y-intercepts on the various regression lines for all the triplicate assessments of the 
enzyme standard stock solutions. 
 
2.2.1.1.5     Linearity of the calibration plot of absorbance against standard 
concentrations of alkaline phosphatase 
A calibration curve of absorbance against concentration was plotted and for each set of 
calibration standards studied (20 - 100 µg/mL), the equation of the line as well as the 
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coefficient of determination (r2) was determined. A blank of (the 1 Step PNPP solution) 
was used in calibrating the instrument.  
 
2.2.1.1.6     Accuracy of the calibration plot of absorbance against standard 
concentrations of alkaline phosphatase 
Accuracy is defined as the degree of closeness between the “true” value and the 
observed value. It was determined by analysing the absorbance values of freshly made 
standard solutions of alkaline phosphatase at concentrations between 20 - 200 µg/mL. 
Each concentration was analysed in triplicate. For every concentration, each 
absorbance value obtained was then compared to the expected value (determined from 
the equation of the line) and the percent difference calculated to determine the intra-day 
accuracy. This procedure was repeated on 3 different days to establish the inter-day 
accuracy. 
 
2.2.1.1.7     Precision of the calibration plot of absorbance against standard 
concentrations of alkaline phosphatase 
Precision, defined as the degree of closeness among multiple independent observations 
was assessed from the percent relative standard deviation around the mean of all 
observations. Both inter- and intra-day precision was evaluated by determining the 
coefficient of variation for each set of calibration standards at the following 
concentrations 20, 40, 60, 80, 100µg/mL. 
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2.2.2     Preparation of powder formulations 
2.2.2.1     Alkaline phosphatase and alkaline phosphatase NaCMC 
combinations 
Aqueous formulations containing alkaline phosphatase alone and in combinations (0.4 
% w/v enzyme with 1.6 % w/v sodium carboxymethylcellulose) with NaCMC were 
prepared with a total powder mass of 2% w/v. Modified formulations containing two 
ethanol concentrations (10 and 30%) were also prepared. The viscosity of the 
formulations, % enzyme activity and pH were measured prior to spray drying. Viscosity 
was measured (in triplicate) using a Brookfield Engineering Laboratories (Stoughton, 
MA) Viscometer (Programmable DV-II) using spindle #2 at a shear rate of 12rpm. The 
spindle was rotated in the medium for 1 minute prior to taking a reading.  
 
Table 2.4: Formulation design for the investigation of the influence of co-solvent on co-spray 
dried carboxymethylcellulose (NaCMC) and alkaline phosphatase (AP) 
Formulation Feedstock solvent Formulation 
ID 
Viscosity 
(cP) 
pH % 
enzyme 
activity 
Excipient-free AP water SD-AP 3.1 ± 0.8 9.7 ±0.1 100.1 ±0.7 
AP/NaCMC (2:8) water SD-N-AP 33.4 ±0.4 9.5 ±0.1 102.3 ±2.0 
AP/NaCMC (2:8) Water-ethanol (9:1) SD-N-AP 1 36.7 ±1.2 8.7 ±0.1 99.6 ±1.2 
AP/NaCMC (2:8) Water-ethanol (7:3) SD-N-AP 2 40.1 ±0.8 8.5 ±0.1 97.2 ±0.8 
 
2.2.2.2     Spray drying 
All the various powder formulations employed in this investigation were obtained by 
spray drying using a Büchi 290 Mini Spray Dryer (Büchi Laboratoriums-Technik AG, 
Flawil, Switzerland) fitted with a standard 0.7mm two fluid nozzle. The spray drying 
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process was repeated in triplicates for each of the powders. The yields of the spray-
dried powders were quantified as a percentage of anticipated yields. The activity of the 
various spray-dried powders were measured in triplicates using validated assay 
methods described in previous sections and expressed as a percentage of nominal 
dose. 
 
2.2.2.2.1    Preparation of spray-dried alkaline phosphatase 
Alkaline phosphatase was spray-dried as a 2 % w/v aqueous solution. The spray drying 
parameters utilised in the micronisation of the enzyme were: Inlet temperature, 180 0C; 
spray flow rate, 606 L/hr; pump setting, 3.2 mL/min; aspirator setting, 85 % (34 m3/hr); to 
produce an outlet temperature of 99 – 101 0C.  
 
2.2.2.2.2    Preparation of spray-dried alkaline Phosphatase – Sodium 
carboxymethylcellulose combinations 
2 % w/v NaCMC:alkaline phosphatase (80:20) mixture was co-spray dried from water-
only and a water:ethanol (90:10 and 70:30) suspension feedstock using the following 
spray drying parameters; Inlet temperature, 180 0C; spray flow rate, 606 L/hr; pump 
setting, 3.2 mL/min; aspirator setting, 85 % (34 m3/hr); to produce varying outlet 
temperatures (Table 2-12) 
 
2.2.2.2.3     Preparation of spray-dried lactoferrin (SDLf) 
Lactoferrin was spray-dried as a 2 % (w/v) aqueous suspension. The spray drying 
parameters utilised include; inlet temperature – 180 °C, aspirator setting – 95 %, pump 
setting – 3.2 mL/min, to produce an outlet temperature of 99 – 101 °C. 
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2.2.2.2.4     Preparation of apo Lactoferrin (aLf) 
An iron deplete form of lactoferrin (aLf) was prepared from partially iron saturated 
lactoferrin as previously described by Newsome et al., (2007). Briefly, the partially iron 
saturated lactoferrin was resuspended at 1% (w/v) in deionzed water, transferred to 
dialysis membrane and dialyzed for 24h at 4 °C against 20 mmol/L sodium acetate, 
20mmol/L sodium dihydrogen phosphate and 40mmol/L EDTA (pH 3.5). The protein 
was then dialyzed against 900 mL of deionzed water with at least 2 changes and used 
immediately or quick frozen at -80 °C. Iron removal was confirmed by atomic absorption 
spectroscopic measurements. 
 
2.2.2.2.5     Preparation of spray-dried apo lactoferrin (SDaLf) 
Following dialysis, the resulting protein suspension was spray-dried with the following 
parameters; Inlet temperature, 180 °C; spray flow rate, 606 L/hr; pump setting, 3.2 
mL/min; aspirator rate, 95 %. These setting resulted in an outlet temperature ranging 
from 100 – 102 °C. This procedure was repeated two more times to produce a total of 
three batches of spray-dried apo lactoferrin powders. 
 
2.2.2.2.6     Preparation of co-spray dried lactoferrin with sodium 
carboxymethylcellulose (SDLf + NaCMC) 
A 2 % w/v suspension of lactoferrin  and sodium carboxymethylcellulose  was prepared 
by mixing 1 g of lactoferrin and 1 g of sodium carboxymethylcellulose and making the 
mixture up to a final volume of 100 mL of deionised water. The resulting slurry was then 
spray-dried with the following parameters; Inlet temperature, 180 °C; spray flow rate, 
606 L/hr; pump setting, 3.2 mL/min; aspirator rate, 95 %. These setting resulted in an 
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outlet temperature ranging from 97 – 99 °C. This procedure was repeated two more 
times to produce a total of three batches of co-spray dried lactoferrin with sodium 
carboxymethylcellulose dry powders. 
 
2.2.2.2.7     Preparation of co-spray dried apo lactoferrin with sodium 
carboxymethylcellulose (SDaLf-CMC) 
1g of lactoferrin was made up to a final volume of 100 mL with deionized water (1 % 
w/v) then transferred to dialysis membrane and dialyzed for 24h at 4 °C against 20 
mmol/L sodium acetate, 20mmol/L sodium dihydrogen phosphate and 40mmol/L EDTA 
(pH 3.5). The protein was then dialyzed against 900 mL of deionzed water with at least 2 
changes of the the deionised water. Then the entire content on the dialysis membrane 
was transferred into a beaker (usually the final volume was less than 100 mL), 1g of 
sodium carboxymethylcellulose was added to the dialysed protein and the final volume 
was then adjusted to 100 mL with distilled water (to produce a 2 % w/v suspension). The 
resulting slurry was spray-dried with the following parameters; Inlet temperature, 180 °C; 
spray flow rate, 606 L/hr; pump setting, 3.2 mL/min; aspirator rate, 95 %. These setting 
resulted in an outlet temperature ranging from 98 – 99 °C. This procedure was repeated 
two more times to produce a total of three batches of co-spray dried apo lactoferrin with 
sodium carboxymethylcellulose dry powders. 
 
2.2.2.2.8     Preparation of spray-dried tobramycin/gentamicin 
A 2 % w/v solution of tobramycin or gentamicin was prepared by dissolving 2 g of 
tobramycin or gentamicin in a 50 mL of deionised water, upon complete dissolution the 
final volume was made up to 100 mL. The resulting solution was then spray-dried with 
the following parameters; Inlet temperature, 180 °C; spray flow rate, 606 L/hr; pump 
setting, 3.2 mL/min; aspirator rate, 95 %. These setting resulted in an outlet temperature 
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of 102 – 104 °C (for spray-dried tobramycin) and 99 – 102 (for spray-dried gentamicin). 
This procedure was repeated two more times to produce a total of three different 
batches of spray-dried tobramycin/gentamicin powders. 
 
2.2.2.2.9     Preparation of co-spray dried lactoferrin with tobramycin/gentamicin 
A 2 % w/v suspension of lactoferrin  and tobramycin/gentamicin  was prepared by 
mixing 1 g of lactoferrin and 1 g of tobramycin/gentamicin  in 50 mL of deionised water, 
upon complete dissolution of the powders, the final volume was made up to 100 mL with 
deionised water. The resulting suspension was then spray-dried with the following 
parameters; Inlet temperature, 180 °C; spray flow rate, 606 L/hr; pump setting, 3.2 
mL/min; aspirator rate, 95 %. These setting resulted in an outlet temperature of 104 – 
106 °C (for co-spray dried lactoferrin with tobramycin) and 102 – 104 (for co-spray dried 
lactoferrin with gentamicin). This procedure was repeated two more times to produce a 
total of three batches of co-spray dried lactoferrin with tobramycin/gentamicin dry 
powders. 
 
2.2.2.2.10     Preparation of co-spray dried apo lactoferrin with 
tobramycin/gentamicin 
1g of lactoferrin was suspended in a final volume of 100 mL of deionized water (1 % 
w/v) then transferred to dialysis membrane and dialyzed for 24h at 4 °C against 20 
mmol/L sodium acetate, 20mmol/L sodium dihydrogen phosphate and 40mmol/L EDTA 
(pH 3.5). The protein was then dialyzed against 900 mL of deionzed water with at least 2 
changes of the deionised water. Then the entire content on the dialysis membrane was 
transferred into a beaker (usually this volume was less than 100 mL) and 1 g of 
tobramycin/gentamicin was added and the final volume made up to 100 mL (to produce 
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a 2 % w/v suspension). The resulting suspension was then spray-dried with the following 
parameters; Inlet temperature, 180 °C; spray flow rate, 606 L/hr; pump setting, 3.2 
mL/min; aspirator rate, 95 %. These setting resulted in an outlet temperature ranging 
from 103 – 104 °C (for co-spray dried apo lactoferrin with tobramycin) and 93 – 103 °C 
(for co-spray dried apo lactoferrin with gentamicin). This procedure was repeated two 
more times to produce a total of three batches of co-spray dried apo lactoferrin with 
sodium carboxymethylcellulose dry powders. 
 
2.2.3     Estimation of the iron content of Lf preparations 
A standard calibration graph of spectrosol ferric nitrate was prepared by measuring the 
absorbance of stock concentrations (0.05 – 5 ppm) using a Perkin Elmer AAnalyst 100 
atomic absorption spectrophotometer. The amount of iron bound to the various 
lactoferrin preparations was then estimated from the calibration curve following iron 
absorption measurements.  
 
2.2.4     Moisture content determination 
To determine the moisture content of the spray-dried powders, two methods were 
employed; gravimetric measurements and Karl Fischer titration.  
 
2.2.4.1     Gravimetric measurements:  
Thermogravimetric analysis was performed using Pyris 1 Thermogravimetric analyzer 
(Perkin elmer, Waltham, USA). Samples (weighing approximately 3 – 5mg) were placed 
into platinum pans and analysed under a nitrogen purge (20 mL/min) heated from 20 – 
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140°C at a heating rate of 10°C min−1 and the loss in mass as function of temperature 
were evaluated from triplicate assessments. 
2.2.4.2     Karl Fischer (KF) titration: 
Karl Fischer titration was carried out using a C20 Coulometric Karl Fischer titrator from 
Mettler Toledo (Leicester, UK). Analysis of samples weighing approximately 5mg was 
carried out using dried methanol KF Coulometric reagent CombiCoulomat fritless 
(Merck, Darmstadt, Germany). The polarising current for the KF coulometer was 5 µA 
and the endpoint (stop voltage) was 100mV. The absolute drift stop (end point criteria) 
value was 3 µg/min, relative drift stop was 2 – 5 µg/min and the maximum titration time 
was set to 10 minutes. The water content was calculated by predefined method function 
on the equipment. 
2.2.5     Particle size analysis 
Particle sizing of all the spray-dried powders utilised in the investigation were carried out 
in the dry state using the method of laser light diffraction within a Sympatec HELOS 
H1867 (Helium-Neon Laser Optical System, Sympatec Inc., Clausthal-Zellerfeld, 
Germany) with a measuring range of 0.1 – 87.5µm coupled to a RODOS dispersing unit 
and a VIBRI vibratory feeder. The powders were dispersed using compressed air while 
the RODOS dispersing unit was set at 2 bar. Dispersion pressures were carefully 
chosen following several titration experiments to determine the optimum pressure 
required for separation of the particles without causing their attrition. WINDOX 5.0 
sensor control program ‘HELOS Sensor control’ (Sympatec GmbH, Clausthal–Zellerfeld, 
Germany) was utilized in particle size analysis.The average Volume median diameter 
(VMD) of three consecutive measurements was calculated. 
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2.2.6     Thermal analysis 
The thermal behaviour of all the various powders was analysed using the Differential 
Scanning Calorimeter (DSC). DSC (Pyris Diamond DSC and Intracooler 2P: Perkin-
Elmer, Wellesley, USA) analysis of a 3mg quantity of the powder was carried out in 
hermetically sealed aluminum pan using nitrogen purge at 20 mL/min (range: 0 – 2500C, 
heating rate 10 0C/min). 
 
2.2.7     Angle of repose 
The angle of repose, which measures the inclination angle of the bulk powder to the free 
surface, was assessed as follows; 
A funnel was clamped to a retort stand at a fixed height from the base. A pan of 
diameter 4cm was centered at the base directly underneath the funnel. The various 
spray-dried powders were poured through the funnel and allowed to f low. Care was 
taken to prevent vibration or movement of the funnel. The procedure was repeated three 
consecutive times to ensure reproducibility of the results. 
The angle of repose was determined from the following equation; 
 
        
      
        
      (Equation 2.4) 
 
 
2.2.8     Colorimetric detection and quantification of total protein 
Quantitation of total protein was carried out according to the manufacturing instructions 
accompanying a bicinchoninic acid (BCA) assay kit. Briefly, bovine serum albumin 
standards were prepared by diluting the contents of a 1 mL ampoule containing 2 mg of 
Chapter two:  Materials and Methods 
- 103 - 
 
albumin (to prepare standard concentrations of 20 – 2000 µg/mL). The working reagent 
was prepared mixing 50 parts of BCA reagent A with 1 part of BCA reagent B. Then a 
200 µL aliquot of the working reagent was added into each of the wells already 
containing 25 µL of either standard or test protein. The plates were covered and 
incubated at 37 °C for 30 minutes, then cooled to room temperature and then the 
absorbance measured at 562 nm using a Multiskan Spectrum - UV/Vis Microplate 
Spectrophotometer.  
 
2.2.9     Sodium dodecylsulphate – Polyacrylamide Gel 
Electrophoresis 
The SDS-PAGE technique used in this investigation employed Laemmli sample buffer 
(prepared by mixing 4.4 ml of  0.5 M Tris (pH 6.8) with 4.4 mL of Glycerol, 2.2 mL of 
20% (w/v) SDS, 0.5 mL of 1% (w/v) Bromophenol Blue, 0.5 mL of Beta-
Mercaptoethanol) in the preparation of the protein samples. The β-mercaptoethanol in 
the sample buffer reduces protein disulphide bonds while the SDS denatures the 
proteins. The reduced and denatured proteins were heated at 70°C for 5 minutes  (to 
enhance the denaturation process) then a 15 µl aliquot of each of the protein sample 
was loaded into each of the wells of a 4 – 20 % precast polyacrylamide gels (Bio-Rad 
Laboratories, Hercules USA). 5 µL aliquot of prestained protein ladder was also loaded 
into one of the wells. The gels were run at a constant current of 60 mA (200V, 12W) for 
22 minutes in a Bio-Rad vertical electrophoresis tank until the dye had reached the 
lower edge of the gel.  Gels were run in 1 L of 1x running buffer diluted from a 10x stock 
(prepared by dissolving 30.3 g (0.25 M) Tris Base, 144 g (1.92 M) Glycine, 10 g (1%) 
SDS in distilled water to make a final volume of 1000 mL). 
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2.2.9.1     Detection of proteins 
2.2.9.1.1     Coomassie blue stain 
The various protein bands in the gels were detected by staining with the staining 
solution (0.1 % w/v Coomassie brilliant blue R-250 dye, 50 % v/v methanol and 10 % v/v 
glacial acetic acid) for 30 minutes followed by destaining (40 % v/v methanol and 10 % 
v/v  glacial acetic acid) for another 30 minutes. 
 
2.2.9.1.2     Silver stain 
Silver staining of the protein bands was performed on the SDS-PAGE using Pierce silver 
stain kit. This staining procedure is well suited for the detection of nanogram and 
subnanogram quantities of protein and hence makes this procedure a more sensitive 
technique than coomassie staining. The gel was washed with ultrapure water and fixed 
in a solution of 30% v/v ethanol: 10% v/v acetic acid solution for 15 mins. The fixative 
was decanted and the gel washed with a 10% ethanol solution for 5 mins, then with 
enough ultra pure water to just about cover the gel for another 5 mins. The gel was then 
incubated for 1 min at room temperature in the sensitising solution (prepared as directed 
by the manufacturer). After this, the gel was washed for 1 min with ultra pure water 
(twice). The gel was incubated for 30 minutes in the stain working solution (prepared as 
directed by the manufacturer). The working solution was decanted and the gel quickly 
washed with ultrapure water for 20 seconds and incubated with the developer working 
solution (prepared as directed by the manufacturer) until optimal protein bands are 
achieved (2 – 3 minutes). The developer working solution was decanted and replaced 
with stop solution (5 % v/v acetic acid) for 10 minutes. The gel images were captured 
using a G:BOX connected to a computer running GeneSnap version 7.07. 
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2.2.10   Western Blot 
Western blotting is an analytical technique whereby specific antibodies are used to 
detect specific proteins in a given sample of tissue homogenate or extract.  This was 
carried out to confirm the identity of the protein (lactoferrin) as supplied and following 
spray drying by using specific antibodies. Following protein quantification (section 2.2.8), 
1 mg/mL of the protein was diluted 1:5 in volume with laemmli sample buffer as 
described in section 2.2.9 and boiled for 5 minutes. 4 – 20 % polyacrylamide gels were 
loaded with the various protein preparations at 15 µL per lane; each gel also contained a 
lane of prestained molecular weight marker. Gels were run as described above in 
section 2.2.9. Separated proteins were then transferred from the gel to a nitrocellulose 
membrane using the wet transfer technique (Lin and Kasamatsu, 1983; Towbin et al., 
1979). Briefly, the gel and membrane were sandwiched between two sponges and filter 
paper and dampened with electrotransfer buffer (prepared and contained 100 mL of 10x 
running buffer, 200 mL of methanol and sufficient distilled water to make up to 1000 mL) 
making sure to roll out any air bubbles between the gel and the membrane. The 
assembly was submerged in transfer buffer, placed into a TE22 mini transfer tank to 
which an electric field is applied (400 mA) for 30 minutes. Following transfer of the 
proteins (confirmed by visual inspection of the gel to verify that the prestained markers 
have moved from the gel onto the membrane and also by staining the gel post-transfer), 
the nitrocellulose membrane was removed from the sandwich and covered with block 
buffer - 0.3 % (v/v) Tween 20 in PBS –for 1 hour at room temperature with agitation. The 
nitrocellulose membrane was then washed with wash buffer – 0.05 % (v/v) Tween 20 in 
PBS and incubated for 2 hours at room temperature (or stored at 4°C overnight) with a 
1:500 (v/v) dilution of the primary antibody (IG12, 4C6 and 4C3).The membranes were 
then washed with wash buffer - 0.05 % (v/v) Tween 20 in PBS –every 15 mins for 1 hour 
before incubating with a 1:5000 dilution of the secondary antibody (anti mouse)  for 2 
hours at room temperature. The membrane was once again washed with wash buffer 
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every 15 minutes for 1 hour and the antibody binding detected using Immobilon® 
Western Enhanced Chemiluminescent substrate (ECL) following the manufacturers 
instruction. Blots were drained and exposed to x-ray film for 2 minutes. x-ray films were 
developed using Kodak GBX developer and Kodak GBX fixer as per the manufacturer’s 
instruction in order to allow visualisation of the protein bands. 
 
2.2.11   Content uniformity determinations 
Following blending, the various powder formulations were assessed for content 
uniformity. Each formulation was spread on a clean petri dish surface. Ten samples 
each weighing 20 ± 2 mg were randomly taken from different areas within the spread-
out powder and dissolved in 10mL distilled water to give a concentration of 0.2 mg/mL. 
The enzyme activity of 500 µL was evaluated using methods described in section 
2.2.1.1.2 and absorbance values obtained were then compared to the standard 
calibration plot of absorbance against concentration (by extrapolation and intrapolation 
of the standard calibration curve) and their content uniformity expressed as relative 
standard deviation. 
 
2.2.12   Capsule filling for DPI device 
For spray-dried alkaline phosphatase: One empty size 3 gelatin capsule was weighed 
and 20 ± 2 mg of spray-dried alkaline phosphatase was measured and manually loaded 
into the capsule. This was repeated two more times to enable triplicate measurement of 
the aerosolisation performance of spray-dried alkaline phosphatase. 
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For spray-dried NaCMC modified formulations of alkaline phosphatase: For each 
of the formulations, five empty size 3 gelatin capsules were weighed and 20 ± 2mg of 
each formulation blend was measured and manually loaded into the 5 capsules.  
For spray-dried lactoferrin and combinations of lactoferrin with aminoglycosides: 
Empty size 3 gelatin capsules were weighed and 30 ±2 mg of the various formulations 
was measured and manually loaded into individual capsules.  
Following filling, each of the capsules was put into Cyclocaps™ Cyclohaler™ DPI device 
(Pharmachemie BV, The Netherlands) and aerosolised immediately. 
 
2.2.13   Preparation of pMDI canisters 
 
Calibration of the pamasol P2011 propellant filler: Empty aluminium MDI canisters 
with cap were weighed and crimped. The fill dial on the pamasol was set to deliver 6g of 
HFA-134a per fill was pressure filled into the canisters through the valve using a 
Pamasol P2011 propellant filler (Pamasol Willi Mäder AG, Pfäffikon, Switzerland). The 
mean actual fill weight of five MDI canisters was calculated. 
 
Preparing alkaline phosphatase pMDIs: Following calibration of the pamasol small 
scale crimper, empty aluminium MDI canisters with caps were weighed and 20mg of 
spray-dried alkaline phosphatase, 5 x 20 mg per canister of co-spray dried sodium 
carboxymethylcellulose and alkaline phosphatase were put into the aluminium canisters. 
All the canisters were crimped with a BK357 30 µL valve and approximately 6 g of HFA-
134a was pressure filled through the valve using a Pamasol P2011 propellant filler. 
Three pMDI canisters were prepared for each of the spray-dried formulations. All 
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formulations were vortex-mixed for 1 minute tested for in vitro aerosolisation properties 
using a next generation impactor for 2 x 5s and stored valves up at room temperature. 
2.2.14   In vitro aerosol characterisation 
An in vitro technique which is useful to some extent in the prediction of in vivo powder 
deposition was developed. Assessment of aerodynamic deposition was carried out 
using the Next Generation Impactor (NGI). The NGI (Model 170, Copley Scientific 
Limited, Nottingham, UK) had been calibrated by the manufacturers. A flow rate of 60 
L/min was maintained throughout the entire investigation.  
 
The detailed procedure for use of NGI in section 2.9.18 of supplement 5.1 of the 
European Pharmacopoeia (Ph. Eur.) was employed throughout the investigation.  
 
2.2.14.1     Assembly method for the NGI 
15mL of the collection solution (distilled water) was accurately measured and transferred 
into the pre-separator using a pipette. Care was taken to ensure that a good seal was 
obtained between the throat, the pre-separator and the vacuum during assembly of the 
NGI and by attaching a flow rate meter (Copley Scientific Limited, Nottingham, UK) to 
the induction port it was ensured that the flow rate was maintained at 60L/min.  
 
2.2.14.2     Operational method for the NGI 
The cyclohaler™ device fitted with the filled size 3 capsule, was attached to the 
induction port through a specially designed adaptor to provide a very good seal. The 
capsules were punctured by pressing the push buttons on the inhaler device. The 
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vacuum pump was started and the powder formulation was allowed to aerosolise for 2 x 
5 seconds. 
For the pMDI formulations, 20 actuations were aerosolised through a plastic actuator 
attached to the NGI via the USP throat. After each actuation the canister was removed 
and shaken to provide a homogenous mixture for the next actuation. Each deposition 
experiment was repeated in triplicate. 
 
2.2.14.3     Sample recovery method for the NGI 
Following aerosolisation of the dry powder inhaler (DPI) and pMDI formulations, the NGI 
was dissembled and deposits collected from all the different components using the 
collecting solution (distilled water). The powders which deposited in the throat were 
recovered by rinsing the throat with 20mL of distilled water; the pre-separator was 
properly washed with 15mL of collecting solution. 20mL volume of collecting solution 
was placed in stage 1 and MOC while 10mL volume of collecting solution was placed in 
stages 2 - 7, the resulting solutions were each swirled and transferred to 50mL beakers. 
Complete dissolution was facilitated in all solutions by placing the beakers containing 
the solutions on magnetic stirrers (Fisher Thermix Stirring Hot Plate, Model 201T). The 
resulting solutions were visually inspected to confirm the complete dissolution of the 
powders. A sample of the solution was then removed for UV analysis. 
 
  
Chapter two:  Materials and Methods 
- 110 - 
 
Table 2.5: Operating conditions and theoretical cut-off diameters of Next generation impactor 
Next generation impactor  
Flow rate (L/min) 60 
Time per actuation (s) 2 x 5 
Volume per actuation (L) 10 
Cut-off diameters (µm)  
Stage 1 8.1 
Stage 2 4.4 
Stage 3 2.8 
Stage 4 1.7 
Stage 5 0.94 
Stage 6 0.55 
Stage 7 0.34 
 
 
2.2.14.4     Validation of dry powder recovery from the NGI device 
The method employed in the collection of samples from the NGI was validated through 
the following procedure; 1mg each of both the commercially available alkaline 
phosphatase and the spray-dried alkaline phosphatase were each directly sprinkled on 
the cups, the pre-separator and the throat. The samples were recovered and quantified 
by rinsing the various impaction stages with the collecting solution (distilled water) and 
resulting solution analysed using the spectrophotometer.  
 
2.2.14.5     Determination of RD, ED, FPD, FPF, MMAD, GSD and 
Dispersibility 
The calibration curve was used to determine the concentration hence, the mass of the 
sample recovered from the throat, pre-separator and each of the cups. The recovered 
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dose (RD) denotes the sum total of all the impactor sections per aerosolised capsule. 
The emitted dose was taken as the amount of alkaline phosphatase that was emitted 
from the capsule. The fine particle dose (FPD) denotes the amount of alkaline 
phosphatase deposited in the lower stages of the NGI (cut-off diameter <5 µm). This 
was determined from a plot of cumulative mass against effective cut-off diameter and 
interpolating the activity of enzyme with a diameter of ≤5 µm. The fine particle fraction 
denotes the ratio of the FPD to total dose corrected for the actual amount of enzyme 
present in the formulation. Mass median aerodynamic diameter (MMAD) was 
determined by calculating the ECD at cumulative 50%. The dispersibility of the powders 
is the percentage of the FPD to ED. For the pMDI formulations, the pMDI vial was 
weighed before and after each run, to enable the computation of the total dose (TD) 
based on the proportion of alkaline phosphatase enzyme in each suspension. 
 
 
2.2.15   Bacterial viable counts 
All viable counts carried out in this study were based on the Miles and Misra method 
(surface viable count) with some modifications. Summarily, 10 µL aliquots of serially 
diluted bacterial suspensions taken from overnight cultures (10-fold, 100-fold, 1000-fold 
and in some cases 10,000-fold dilutions in sterile distilled water) were placed on the 
surface of ‘sufficiently dried Mueller-Hinton Agar plate’, evenly spread out and allowed to 
dry before incubating at 37 °C  for 18 – 24 hours. Each plate (or sector if divided) was 
observed for growth. Dilutions containing less than 300 discrete colonies were counted 
and the viable count determined by using the following equation 
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2.2.16   Bacterial Killing assays 
Minimum bactericidal concentration (MBC) determinations for the various antimicrobial 
test agents was performed as previously described by Xu et al., (2010) with some 
modifications. Briefly, 10 µL of overnight bacterial cell suspension was diluted to 
approximately 108 cfu/mL and incubated in a 96-well microtitre plate containing 90 µL of 
the various test agents in casamino acid (CAA) media for 1 hour. Bacterial growth was 
determined at 10 minutes intervals by plating out serially diluted aliquots from each well 
onto Mueller-Hinton agar which had been allowed to set in petri dishes.  Plates were 
incubated overnight at 37°C. The number of colony forming unit per millilitre was then 
determined as described above (in section 2.2.15.) 
 
2.2.17   Biofilm quantification assay 
The ability of P. aeruginosa PAO1 to form biofilms was investigated using methods 
previously described by Eckhart et al., (2007) and Merritt et al., (2005) with some 
modifications. Overall, the protocol involves growing bacterial cells in microtitre dishes 
for a desired period of time and then the wells are washed to remove planktonic 
bacterial cell. However, cells which remain adherent in the wells are stained with a dye 
(crystal violet in this case), washed again after a given period of time and the surface 
associated dye solubilised in an appropriate solvent (in this case 30 % v/v glacial acetic 
acid)  
 
2.2.17.1     Initiation of biofilm experiments 
100 µL aliquots of overnight cultures of planktonic bacteria culture were put into 
individual wells of a 96-well microtitre plate and then 100 µL of the test compounds; 
Lactoferrin (Lf), Spray-dried lactoferrin (SDLf), Apo Lactoferrin (aLf), Spray-dried apo 
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Lactoferrin (SDaLf), Tobramycin (Tobi), Spray-dried Tobramycin (SD Tobi), ), Spray-
dried Tobramycin + Lactoferrin (SD Tobi + Lf), Spray-dried Tobramycin + Apo 
Lactoferrin (SD Tobi + aLf), Gentamicin (Genta), Spray-dried Gentamicin (SD Genta), ), 
Spray-dried Gentamicin + Lactoferrin (SD Genta + Lf) and Spray-dried Gentamicin + 
Apo Lactoferrin (SD Genta + aLf),  were added at a concentration of 1mg/mL. Control 
wells were also setup with no antibacterial agents included (antibacterial agents were 
replaced with sterile distilled water). The microtitre plates were incubated at 37°C for 24 
hours after which biofilms grown by the bacteria were then quantified. 
 
2.2.17.2     Quantifying biofilms 
Bacterial suspensions were removed and the wells washed twice with 250 µL of distilled 
water. Bacterial biofilms (usually consisting of microcolonies encased in extracellular 
polysaccharide material (Costerton et al., 1999)) adhering to the walls of the 96-well 
plate were stained with 200 µL of 0.1 % w/v crystal violet (CV) solution in water for 15 
mins. Excess CV was removed and the wells rinsed with distilled water. The dye (CV) 
which was still adherent to the biofilm was eluted with 200 µL of a 30 % v/v solution of 
glacial acetic acid. The quantity of biofilms in each well was then quantified by 
measuring the optical density of the eluate at 550 nm. The absorbance values of control 
wells containing only 30 % acetic acid was subtracted from the test wells in order to 
minimise background interference. All experiments were repeated in triplicates using 
new 96-well microtitre plates every time. The absorbance values obtained at 550 nm 
(A550) are proportional to the amount of biofilm present. 
2.2.17.3     Persistence of biofilms experiments 
In order to assess the effects of the test compounds on the  persistence of bacterial 
biofilms, 100 µL aliquots of overnight planktonic bacteria cultures were put in wells of a 
96-well microtitre plate and incubated at 37°C for 24 hours. Then all the various 
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antibacterial agents listed in section 2.2.17.1 was then added at the same 
concentrations (1mg/mL). Control wells were setup as well which contained only sterile 
distilled water and the plates incubated at 37°C for 24 hours. The biofilms were 
quantified using the procedure described above in section 2.2.17.2. 
 
2.2.18   Growing biofilms on cover glass 
A 1 mL aliquot of overnight bacterial cell suspension (~ 107 cfu/mL) of P.aeruginosa 
PAO1 grown at 37°C in a media containing 0.5 % w/v casamino acids and 1 mM MgCl2 
(casamino acid rich media) was put into each chamber of an 8-well chamber glass slide 
and incubated at 37°C for 72 hours. The bacterial cell suspension was removed and 
replaced with 0.5 mL of fresh casamino acid rich medium every 16 hours. Following 72 
hours growth of bacterial biofilms on the glass slide, the wells were carefully washed 
with phosphate-buffered saline (PBS) to remove any remaining planktonic bacteria that 
may be surface attached to the biofilms, without detaching the biofilm from the glass. 
The surface attached biofilms were exposed to 200 µg of the various test agents in 
solution and incubated at 37°C for 24 hours. Both positive and negative controls were 
setup. While the positive controls contained 200 µL of the CAA rich media without any 
antibiotic included, the negative control contained 200 µL of Isopropanol (to ensure the 
complete destruction of bacterial micro-colonies in the biofilms). 
 
2.2.18.1     Staining of biofilms to enable visualisation of live/dead biofilms 
Following treatment with the antimicrobial agents, the glass slides were washed again 
with 0.5 mL of PBS and stained with a LIVE/DEAD kit (Invitrogen Molecular Probes, 
Eugene, OR, USA) using a mixture of 3 μL of syto 9 (green fluorescent) with 3 μL of 
propidium iodide (red fluorescent) per mL of saline. Both syto 9 and propidium iodide are 
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nucleic acid stains. While syto 9 stains all nuclei acid in a population (both those with 
intact and damaged membranes), propidium iodide on the other hand stains only 
bacteria with damaged membranes. It is important to note that when used together, 
propidium iodide causes a reduction in the green fluorescence of syto 9. 
2.2.18.2     Visualisation of biofilms 
 Visualisation of both the treated and untreated biofilms was carried out using Leica TCS 
SP5 II (Leica Microsystems, Milton Keynes, UK) confocal laser scanning microscope 
(CLSM). Images were obtained using 20x HC PL APO20x/0.70 CS lens. For detection of 
SYTO 9 (green channel), 488 nm line of the argon laser was used and a detection 
bandwidth of 495 – 515 nm. For detection of propidium iodide (red channel), 561 nm line 
was used and a detection bandwidth of 615 – 600 nm. Image analysis was carried out 
using a Leica LAS AF Version 2.2.1 build 4842. 
 
2.2.19   Antibiotic permeability assay 
The penetration of tobramycin, gentamicin and their various combinations through 
P.aeruginosa biofilms was investigated using the method previously described by Singh 
et al., (2010) with some modifications.  
 
2.2.19.1     Antibiotic disc preparation 
Antibiotic susceptibility disks containing; tobramycin, gentamicin and combinations of 
both antibiotics and the different preparations of lactoferrin were all prepared locally by 
impregnating a sterile blank paper disk cut-out with a diameter of 6.3 mm with 0.02 mL 
of 1mg/mL standard antibiotic solutions (to prepare a 20 µg antibiotic disc). The 
procedure employed was as follows; using an ordinary two-hole puncher, paper disk 
with approximate diameter of 6.3 mm were cut out. Then the curled surfaces were 
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flattened by spreading the discs on a clean smooth surface and then pressing them by 
rolling a bottle repeated over them. The disk were then sterilised by autoclaving. To load 
various concentrations of the antibiotics onto the disks, antibiotic solutions containing 
the required mass of the antibiotic agent in 0.02 mL was prepared (since 0.02 mL is the 
optimum volume that a paper disk that size could absorb). For example, for the 
preparation of tobramycin disk with a potency of 10 µg, the antibiotic solution prepared 
contained 500 µg of tobramycin per mL. Using a micropipette, 0.02 mL aliquots were 
delivered onto the sterile disks place on a dry petri dish making sure to allow the tip 
pipette to make light contact with the disk. The petri dishes were then placed in a clean 
incubator set at 37 °C for 2 hours. Upon drying the locally made antibiotic disks were 
used immediately or stored at -20 °C. Escherichia coli NCTC 10418 was used as the 
organism for quality control of the antibiotic discs as well as in preparing a calibration 
curve of the diameter of the zone of inhibition (mm) against log concentration. 
 
2.2.19.2     Growing the biofilms on track-etched polycarbonate membranes 
Sterile track-etched ploycarbonate membranes were inoculated with 5 µL of 
P.aeruginosa bacterial suspensions and incubated on Muller-Hinton agar plates at 37 °C 
for 48 hours with the membrane-supported biofilms transferred to a new agar plate 
every 18 hours.  
The quality control organism Escherichia coli NCTC 10418 was cultured overnight in 
Luria broth. The growth of the control organism was adjusted to the density of a 0.5 
McFarland standard (prepared by adding 0.5 mL of 0.048 M BaCl2 to 99.5 mL of 0.18 M 
H2SO4 with constant stirring, absorbance range; 0.08 – 0.13) by adding sterile distilled 
water while visually inspecting both the test and the standard suspension against a 
white background with a contrasting black line. A sterile cotton swab was dipped into the 
culture medium containing the E. coli and spread on Mueller-Hinton agar plate in order 
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to permit the growth of a confluent lawn of bacteria following 18 hours of incubation at 
37 °C. 
 
2.2.19.3     Penetration of antibiotics through biofilms 
The control organism (Escherichia coli NCTC 10418) which was applied on the surface 
of the agar was allowed to dry and nitrocellulose membranes supporting biofilm growth 
were then placed on top of the agar already impregnated with the control organism. A 6 
mm nitrocellulose membrane was then placed on top of each biofilm and the antibiotic 
disc placed on the top of this.   
 
 
 
Figure 2 -2: Schematic depiction of experimental setup used to track the penetration of 
antibiotics through Pseudomonas aeruginosa biofilms. The Mueller-Hinton agar plate is covered 
with a confluent lawn of the control strain (E. coli NCTC 10418). A sterile track-etched 
polycarbonate membrane (0.2 µm pore size) that supports biofilm growth is placed on MHA with 
a smaller diameter polycarbonate membrane and a moistened paper disk containing the test 
compound place on the biofilm. 
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Both locally prepared and commercially supplied antibiotic disks were moistened with 20 
µL of sterile distilled water to prevent capillary action of the antibiotics (as it may 
adversely affect the zone diameter). Controls, which comprised of sterile polycarbonate 
membranes and antibiotic disc without biofilms were also set up. All plates were 
incubated at 37°C for 24 hrs and the clear zones visible on the plates indicating the 
inhibition of growth by the antibiotic (tobramycin or gentamicin) were measured.  A 
calibration plot of the zone diameter measurements against log concentration (for 
antibiotic discs containing 1 – 10,000 µg) was constructed and used to estimate the 
concentration of the antibiotic that passed through the biofilms. The diameter of the 
zones of inhibition in the controls were taken to signify 100% penetration and used to 
determine the percent penetration and percent retardation of the antibiotics through the 
Pseudomonas biofilms. All experiments were performed in triplicates and a two-tailed, 
paired t-test was used for statistical analysis. In order to avoid false negative results 
arising from side diffusion of the antibiotic around the biofilm rather than through the 
biofilm, biofilms were only used if they were <13 mm in diameter and were therefore 
contained within the larger membrane. 
 
2.2.20   Testing the compounds on airways epithelial cells in vitro  
2.2.20.1     Culturing cells from frozen stock 
As all cell stocks were stored in liquid nitrogen prior to commencement of experiments, 
there was a need to properly thaw all cell types to ensure that they maintain their 
viability.  
Frozen cells (BEAS-2B, C38 and IB3) were removed from liquid nitrogen and put into a 
water bath set to 37 °C and allowed to thaw. Once the cells had thawed, the 1 mL 
content of the vials was put into a tube containing 5 mL of cell culture medium (DMEM 
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supplemented with 10% v/v fetal bovine serum, 2mM L-glutamine and antibiotics) and 
centrifuged at 2000 rpm for 5 minutes. Following centrifugation, the supernatant was 
discarded while the cell pellet was resuspended in 10 mL of cell culture medium. The 
entire contents of the tube was then transferred into a tissue culture flask, the flask was 
appropriately labelled (cell type, passage number and date) and flasks were incubated 
at 37 °C, 5 % CO2 in a humidified incubator. 
 
2.2.20.2     Subculturing cells 
The cell culture medium was warmed to 37 °C in a water bath. The cells were washed 
with phosphate buffered saline (PBS) to remove the FBS which would have inhibited the 
activity of trypsin. The PBS was discarded and 2 mL of trypsin-EDTA (0.25%) was 
added to lift adherent cells off the tissue culture flask. Following the addition of trypsin, 
the tissue culture flask was incubated at 37 °C for 10 mins as this is the optimum 
condition required for trypsin’s enzymatic activity. Following detachment of the cells from 
the tissue culture flask, 3 mL of the cell culture medium was added to the tissue culture 
flask to neutralize the trypsin. All the cells contained in the tissue culture flask were then 
collected into a falcon tube and centrifuged at 2000 rpm for 5 mins. The supernatant 
was discarded and the bottom of the falcon tube flicked to loosen the cells. Enough cell 
culture medium was added to make 1 mL for each of the tissue culture flask to be used- 
flasks were usually subcultured at a 1:3 ratio. Finally 9 mL of cell culture medium was 
added to each tissue culture flask and incubated 37 °C, 5 % CO2.  For setting up plates 
of cells for experiments, cells were resuspended in 1ml and counted using a 
haemocytometer.   
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2.2.20.4     Counting of cells 
Cell counts were carried out to ensure consistency in the number of cells seeded in 
every experiment. After the cells have been trypsinized, centrifuged and resuspended in 
1ml fresh cell culture medium as described previously, 10 µL of a homogenously mixed 
cell suspension was withdrawn from the falcon tube and put into an eppendorf tube 
containing 10 µL of trypan blue and mixed properly (1:1 dilution). 10 µL of the mixture 
was then added to opposite sides of an improved Neubauers haemocytometer and a 
cover slip placed over the counting chamber. Cells in the four quadrants and the middle 
of each of the grids of the haemocytometer were counted and the average calculated 
number of cells multiplied by the dilution factor and then by 104 to obtain the number of 
cells per mL. 
 
2.2.20.3     Submerged cell culture 
Airway epithelial cells were counted and seeded at a density of 100,000 cells per well in 
a 24-well plate. The cells were grown under submerged conditions (i.e. airway epithelial 
medium inundates the epithelial cells) maintained in DMEM/F12 medium supplemented 
with (5 % v/v FBS, and 0.1 U/mL penicillin and 0.1 mg/mL streptomycin) and incubated 
in tissue culture flasks at 37 °C, 5 % CO2 until they had attained approximately 90 % 
confluency. A light microscope was used to monitor cell confluency, and to make sure 
that there was no bacterial or fungal contamination. 
 
2.2.20.5     Culturing cells on Transwell® (TW) Inserts 
Culturing epithelial cells on either Transwell or inserts permits growth at the air-liquid 
interface and allows for in vitro simulation of airway epithelial cells from either the apical 
(lumen-facing) or basal (blood-facing) aspect of the cultures.  The Transwell insert used 
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comprised a 24-well translucent PET membrane with the following specifications; 
membrane diameter – 6.4 mm, pore size – 0.4 µm,  an effective growth area of 0.3 cm2.  
Airway epithelial cells were seeded at a density of 100,000 cells per 300 µL of airway 
epithelial cell growth medium into the apical portion of the insert. 600 µL of epithelial cell 
growth medium was ten added to the basal compartment of the Transwell®. 
The whole setup was incubated at 37 °C, 5 % CO2 for four days. On the fourth day, the 
epithelial growth medium on the apical portions of the Transwell® was removed and the 
epithelial cells were now said to be at air-liquid interface (ALI – this has been shown to 
permit the induction of mucociliary differentiation). The epithelial cell growth medium in 
the basolateral compartment was also replaced concurrently. Subsequently, all the liquid 
permeating to the apical portion of the inserts (apical liquid) was removed and the 
basolateral medium replaced every other 4 or 5 days until the cells have assumed the 
required tight junction. This had been previously reported by Willets, (2012) and 
Bielemeier (2012) to be around 11 to 14 days post apical medium removal. 
 
2.2.20.6     Measurement of transepithelial electrical resistance (TEER)  
Trans epithelial electrical resistance (TEER), which is a measure of the resistance of 
electrical current across an epithelial cell layer, informs on the confluence of a cellular 
monolayer as well as the presence of tight junctions. To measure the TEER of cell 
cultures growing at ALI, 300 µL of airway epithelial medium was added to the apical 
compartment of the inserts containing the various epithelial cells growing at ALI. The 
trans epithelial electrical resistance was then measured using Epithelial Voltohmmeter 
with STX2 chopstick electrodes (World precision instruments, Sarasota FL, USA).  The 
shorter portion of the chopstick electrode was introduced into the apical compartment 
while the longer portion was put into the basolateral compartment. Three independent 
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measurements were made for each well including a blank (empty) well containing no 
cells. The resistance of the empty well was subtracted from the mean resistance of the 
wells containing epithelial cells and reported as ohm (Ω) • cm2.  
 
2.2.20.7     In vitro toxicity assessments 
Airway epithelial cells were seeded at a density of 100,000 cells per 1 mL of airway 
epithelial cell growth medium per well and left for 24 hours. Following achievement of 90 
% confluency of submerged cells (BEAS-2B, C38, IB3 and CALU) in the 24 well plates 
the cell culture media in the various wells were replaced with 0.5 mL per well of a serum 
(FBS) and antibiotic free media and incubated at 37 °C, 5 % CO2 for 24 hours. The wells 
were visually inspected for bacterial or fungal growth under the light microscope, in the 
absence of which 500 µL aliquot of insulin transferring and selenium (ITS) cell culture 
medium containing 5 mg of the individual agents (either alone or in combination) 
undergoing test was added and incubated for a further 24 hours at 37 °C, 5 % CO2. 
 
2.2.20.7.1     Cell viability assay using Cell Titer Blue™ (CTB) 
Cell viability assessments whose primary goal was to determine if the metabolic 
processes of submerged cells (previously exposed to the various antimicrobial agents) 
was still active. 
Cell Titer-Blue™ assay is an endpoint assay that provides a homogenous, fluorometric 
method for monitoring cell viability. The assay is based on the ability of living cells to 
convert resazurin (a redox dye) into resorufin (a fluorescent product) 
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Figure 2 -3: Conversion of resazurin to resorufin by metabolically active cells.  
Following exposure of submerged cells to the various agents for 24 hours as described 
in section 2.2.20.7,100 µL of CTB was added to each well and cells were incubated at 
37 °C for 3 hours. A 200 µL aliquot from each well was transferred to a black 96 well 
plate and the fluorescent intensity measured using a standard multi-well fluorescent 
plate reader (Spectramax Gemini XS, Molecular Devices, Berkshire UK) with 560 nm 
excitation and 590 nm emission wavelength. 
 
2.2.20.7.2     Quantification of IL-8 using Enzyme-linked immunosorbent assay 
For ELISA studies, after 24 hour incubation, the supernatant was harvested, put into 1.5 
mL eppendorf tubes, labelled and centrifuged at 2000 rpm for 5 min to remove any dead 
cells or cellular debris from the supernatant so as to prevent interference with the ELISA 
results. The resulting supernatant was put into a 1.5 mL eppendorf and used 
immediately for cell viability or IL-8 investigations or stored at -80 °C. 
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The ELISA was carried out according to the manufacturer’s instructions, with some 
minor modifications. Briefly, high affinity binding microtitre plates (Nunc MaxiSorp™) 
were coated with capture antibody in coating buffer.  This was prepared by adding 50 µL 
of reconstituted capture antibody (100 µg/mL) in 10 mL of carbonate bicarbonate buffer 
(reconstituted by dissolving one capsule of buffer (Sigma) in 70 mL of deionised water, 
upon complete dissolution the final volume was made up to 100 mL with distilled water 
to produce 0.05 M carbonate-bicarbonate buffer (pH 9.6). 50 µL of capture antibody was 
dispensed into each well, plates were covered with adhesive seals and incubated 
overnight at a temperature of 4 °C. Following incubation, the contents of the plates were 
discarded and the microtitre plates washed three times with the wash buffer – PBS with 
0.05 % v/v Tween-20 and vigorously tapped to dry. 200 µL of block buffer – wash buffer 
with 1% w/v BSA was added into each well and plates were re-sealed and incubated for 
1 hour at room temperature. The microtitre plates were once again washed with the 
wash buffer and tapped dry, then, 50 µL of standard dilutions of IL-8 (0 – 1000 pg /mL) 
and test samples were added into individual wells in triplicates and incubated at 37 °C 
for 1 hour. Following incubation, the microtitre plates were once again washed three 
times and slapped dry, 50 µL of detection antibody (anti-human IL-8) was then put into 
each well and incubated at 37 °C for 1 hour (2 hours at room temperature). Excess 
antibody was removed and the wells washed again. 50 µL of reconstituted Avidin-HRP 
enzyme (6 µL stock diluted in 12 mL of the diluent) was put into each well and the 
microtiter plate incubated at room for 30 minutes. The microtitre plate was again washed 
and 50 µL of SigmaFAST™ OPD substrate (prepared according to manufacturers 
direction) was put into each well and the absorbance measured after 10 minutes. The 
IL-8 content of each of the test samples were determined from a calibration plot of 
absorbance against log concentration of standard IL-8.    
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2.2.21   Statistical analysis 
Statistical analyses were performed on the data obtained. Data is presented as the 
mean ± standard deviation of the mean. GraphPad InStat version 3.06 software was 
used in analyzing data. One way ANOVA with Tukey multiple comparison and post test 
was employed. 
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3.1     Summary 
The purpose of this study was to investigate the effects that different excipients and 
solvents have during the process of spray drying proteins. Alkaline phosphatase was 
chosen as the model protein because it is readily available, economical to use and 
spray-drying induced damage can be assayed using a straight forward enzyme activity 
assay.  Specifically, the suitability of using the excipient, sodium carboxymethylcellulose, 
as a thermoprotectant with or without employing different concentrations of cosolvent 
during spray drying were examined. This investigation also sought to assess the in vitro 
suitability of utilising either pressurised metered dose inhaler (pMDI) or dry powder 
inhaler (DPI) in the delivery of the various spray-dried powders to the airways. Four 
spray-dried powders were investigated: a control comprising of 2% w/v spray-dried 
enzyme alone, and three test formulations comprising of  combinations of 4:1 (w/w) 
sodium carboxymethylcellulose/enzyme spray-dried from a water based suspension 
feedstock and two water:ethanol (70:30 and 90:10) co-solvent system, with suitably 
optimised spray drying parameters. The alkaline phosphatase activity, molecular weight, 
particle size, moisture content, crystallinity and yield of the spray-dried formulations 
were assessed. Both DPI and pMDI formulations were prepared. In vitro deposition 
studies using the next generation impactor (NGI) indicates that higher units of alkaline 
phosphatase were delivered using the DPI (130 – 242 units/mL compared to 20 shots of 
pMDI delivering 19 – 124 units/mL) with the co-solvent,  sodium carboxymethylcellulose 
modified formulations delivering a significantly higher fine particle fraction (< 5 µm) (p < 
0.001) than the excipient-free spray-dried formulations. In vitro deposition studies of the 
various spray-dried powders using the pMDI device showed that a high percent 
respirable fraction of the enzyme was consistently delivered, although the water-ethanol 
(90:10) cosolvent and sodium carboxymethylcellulose modified formulation delivered 
significantly (p < 0.01) higher respirable fraction. While the selection of appropriate 
excipients and solvent systems may offer the ability to prepare spray-dried powders 
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suitable for the pulmonary delivery of peptides and proteins (since they possess very 
low inter-particulate cohesion and the requisite particle size needed for deposition in the 
lower respiratory tract), they can also have negative effects. The data shows that 
proteins which are spray-dried without excipients may also retain >70% enzymatic 
activity compared to the native activity, while also producing respirable particles which 
can be delivered to the lower airways. 
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3.2     Introduction 
The inhaled route has been widely used to deliver low molecular weight active 
pharmaceutical ingredients (APIs), which aids the management of local airway diseases 
such as asthma, chronic obstructive pulmonary diseases and infection. However, recent 
developments in biotechnology means that therapeutic protein drugs are now more 
readily used in the management of various diverse diseases including; anaemia 
(erythropoietin and analogues) , chronic hepatitis B or C (interferon alfa), prostate 
cancer (Luteinizing Hormone Releasing Hormone; LHRH), rheumatoid arthritis and 
Crohn’s disease (infliximab) (Li et al., 2002; Fukuda et al., 1989). Even though protein 
formulations are now commonplace amongst the repertoire of medicines available to 
medical practitioners, it is still the case that the parenteral route remains the major route 
utilised in the delivery of these therapeutic peptides. This is due to formulation 
challenges commonly encountered with protein APIs including; inactivation of the protein 
during or after processing and poor long term stability. The two most common 
stabilisaton methods employed to stabilise proteins are; 1) the use of excipients and 2) 
dehydration of the protein formulation to produce dry protein powders (Ameri and Maa, 
2006).  
While, the inclusion of excipients enhances the physical and chemical stability of the 
active pharmaceutical ingredient and improves the aerosolisation characteristics 
(Lechuga-Ballesteros et al., 2008; Ohtake et al., 2011), the removal of water 
(dehydration or drying) from protein formulations that are insufficiently stable in aqueous 
environments and greatly increases protein stability due to reduced mobility of the 
protein and the absence of certain degradation pathways facilitated by water (Maltesen 
and Van De Weert, 2008). 
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3.2.1     The use of stabilising excipients in pulmonary delivery of 
proteins 
Pharmaceutical excipients tend to be inert substances that are added to protein 
formulations for various reasons including; stabilisation of protein formulations, assisting 
the manufacture of the dosage form, controlled or targeted drug delivery and as 
preservatives within the protein formulation. Some of these excipients categories include 
– Polymers (e.g., polyethylene glycol, dextran, hydroxyl ethyl starch), salts (e.g., sodium 
chloride, potassium chloride, sodium sulphate), sugars (e.g., lactose, sucrose, trehalose, 
glucose, sorbitol), buffering agents (e.g., citrate, acetate,Tris, phosphate), amino acids 
(e.g., histidine, arginine,  lysine, methionine), surfactants (e.g., polysorbate 20 and 80) 
and preservatives (e.g, benzyl alcohol, m-cresol, phenols). It is important to note that, 
even though there are a lot of excipients under study for liquid protein formulations, only 
a few are currently approved by the FDA for inclusion in dry protein formulations due to 
a lack of toxicity studies that are yet to be conducted with inhaled excipients. Currently, 
the only accepted excipients used for inhalation are the sugars: glucose, lactose and 
mannitol, with lactose being the most commonly employed in currently marketed DPIs, 
as they are good carriers (i.e. facilitate deaggregation of micronized powders), have an 
established safety and stability profile, are inexpensive and easily available at different 
grades (Pilcer et al., 2012).  
In particular, the use of polymers as excipients in pulmonary drug delivery systems has 
also been gaining a lot of interest among researchers (Amidi et al., 2010; Charman et 
al., 1993; Manning et al., 1995; Li et al., 2010). This is because they are good at 
stabilising proteins during processing (Tiwari et al., 2010; Pisal et al., 2010) as well as 
for controlling the release of protein drugs (Zeng et al., 1995). Polymers have also been 
reported to preserve biological activities of proteins (Liao et al., 2005; Tawfeek et al., 
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2013; Tewes et al., 2010) as well as improve and maintain fine particle fraction of 
encapsulated protein above 50% (Liao et al., 2005).   
3.2.2     Mechanism of polymer protection of proteins 
In solution, polymers stabilize proteins through specific and non specific mechanisms. 
While hydrophilic polymers (e.g. polyethylene glycols, polysaccharides and inert 
proteins) stabilize proteins independent of their chemical nature, charged polymers 
particularly function in a protein-specific manner. Several mechanisms have been 
reported by various aurthors to explain how hydrophilic polymers are able to stabilize 
proteins (Vrkljan et al., 1994; Arakawa and Timasheff, 1985; Gombotz et al., 1994; 
Cleland et al., 1992) but what stands out amongst them is the ‘crowding effect’ which 
plays a role in stabilizing proteins (Laurent, 1963). The ‘crowding effect’ is the ability of 
the included polymers to cause a spatial reduction in the radius of the native protein 
structure, a phenomenon that is more thermodynamically favourable to maintain, as 
confined protein possess a smaller surface area for exclusion (Zhou, 2004b; Zhou, 
2004a). As polymer exclusion increases with polymer size, large polymers have been 
reported to be more effective at stablising proteins in solution (Minton, 2005). A second 
mechanism by which polymers can stabilize proteins is though specific binding, for 
example, the binding of acid fibroblast growth factor (aFGF) to heparin stabilizes it 
(Volkin et al., 1993). In addition, polymers have also been shown to prevent instabilities 
that may lead to protein aggregation, for example, dextran, a high molecular weight 
polysaccharide inhibits metal-ion catalyzed oxidation through metal ion complexation (Li 
et al., 1996).  
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3.2.3     The use of sodium carboxymethylcellulose as a 
thermoprotectant for proteins during spray drying 
Excipients such as sodium carboxymethylcellulose – an anionic water soluble polymer – 
have been successfully employed in the development of non-invasive systems for 
delivery of proteins to the lungs. Particularly, Li and Seville (2009)  and Li et al., (2010) 
have co-spray dried formulations of proteins and sodium carboxymethylcellulose with 
the view of developing respirable pMDI and DPI formulations with improved stability. 
From these pilot investigations, sodium carboxymethylcellulose was shown to be 
especially suited as an excipient in the formulation of respirable spray-dried proteins due 
to its ability to significantly (p < 0.05) increase the FPF compared to NaCMC free spray-
dried protein formulations (Li and Seville, 2009), provide significant (p < 0.01) protection 
to the enzymatic activity of spray-dried alkaline phosphatase, it is also non toxic (Greig, 
1999), high soluble and possess colloidal properties (Hooton, 2009). However, their non 
degradability and irritating nature may present a problem during routine use in 
formulations intended for pulmonary delivery. The use of sodium carboxymethylcellulose 
in formulations intended for lung delivery has yet to be fully characterised therefore, this 
chapter will investigate the potential application and limitations of the excipient in the 
formulation of inhalable protein particles. 
 
3.2.4     Drying techniques used for the production of protein 
particulates 
Drying is a very important unit operation within the pharmaceutical industry this is 
because a dry product is generally more stable than a liquid preparation. In view of this, 
various drying techniques are currently being used to produce protein powders with 
desirable stability properties. The most commonly used drying technique for producing 
dry protein pharmaceuticals is freeze drying, followed by spray drying with supercritical 
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fluid (SCF) and spray freeze drying still emerging as a viable alternatives. The different 
techniques utilise different physical principles; sublimation (freeze drying), evaporation 
(spray drying), precipitation (SCF) and a combination of evaporation and sublimation 
(spray freeze drying) to produce protein powders with significantly different powder 
characteristics (Vehring, 2008; Abdul-Fattah et al., 2007; Shoyele and Cawthorne, 2006; 
Amorij et al., 2008). While freeze drying is widely employed for the production of 
parentral formulations (Carpenter et al., 1997), spray drying is better suited for the 
production of pulmonary formulations (Maa and Prestrelski, 2000). Regardless of the 
drying method employed to produce powdered proteins the outcome is usually the 
production of an amorphous material with a somewhat better stability than the liquid 
preparation   
 
3.2.5     Spray drying technique 
Spray drying is a widely employed technique in industrial chemistry and food science 
due to its ability to rapidly dry aqueous or organic solutions, emulsions and suspensions 
producing dry powders. In the pharmaceutical industry, spray drying is being used as a 
micronisation technique for the development of highly respirable powders whose release 
properties and morphological characteristics can be varied by incorporating suitable 
excipients into the spray drying feedstock (Seville et al., 2007). The spray drying 
technique has remained popular especially due to the increasing demand for the design 
of sophisticated particles such as: large porous particles (i.e. polymer particles made by 
double- and single emulsification solvent evaporation or consisting of 
dipalmitoylphosphatidylcholine (DPPC) albumin and saccharides spray-dried from 
ethanol water co-solvent systems) (Vanbever et al., 1999a; Vanbever et al., 1999b; Ben-
Jebria et al., 1999; Wang et al., 1999); particles with foam-like morphology (e.g. 
PulmoSpheres™) (Dellamary et al., 2000; Weers, 2000a); encapsulated particles 
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including proteins (Quaglia et al., 2003; Bittner et al., 1998; Burke et al., 2004); hollow, 
low density particles with controllable surface characteristics (Edwards et al., 2003; Kuo 
and Lechuga-Ballesteros, 2003; Platz et al., 2002; Weers et al., 2009); particles with 
single or multiple functional layers (Learoyd et al., 2009) and nano sized particles (Pilcer 
et al., 2009; Sham et al., 2004). 
The basic principle of operation behind spray drying involves the atomisation of the 
liquid feedstock leading to the creation of high frictional forces over the liquid surfaces 
with a large contact surface area, subsequent injection of the liquid feedstock into a 
drying chamber containing hot gaseous medium (typically air or nitrogen), leads to 
instant drying of the spray droplets into solid droplets (Cal and Sollohub, 2010). It is 
important to mention that the temperature of the material being dried never reaches the 
inlet temperature of the drying gas due to the short period (10-4 – 10-3 s) of drying and 
the short residence time of the particle in the drying chamber (Elversson and Millqvist-
Fureby, 2005), making spray drying a very useful method for drying heat sensitive 
substances such as proteins (Cal and Sollohub, 2010). However, there is a need to 
optimise the spray drying parameters for each individual protein as thermal stability of 
proteins vary (Maltesen and Van De Weert, 2008).  
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Figure 3 -1: Buchi B290 laboratory spray dryer. (a) laboratory scale equipment (b) schematic 
diagram of the dry airflow: (1) air intake (2) heater (3) flow stabiliser intake into the drying 
chamber (4) cyclone separator (5) product collector (6) Aspirator (7) outlet temperature sensor 
(8) inlet temperature sensor. 
 
The newly-formed particles are separated from the gas by means of a cyclone separator 
(fig 3 -1), bag filter or electrostatic precipitator (Sou et al., 2011). Amongst the many 
potential advantages offered by spray drying, the ability to effectively control the particle 
size of the resultant powder by modifying spray-drying parameters seems to be the most 
obvious. The typical particle diameter usually produced following spray drying, range 
between 0.5 – 50 μm (Vehring, 2008).  
Nothwithstanding all the advantages of spray drying already outlined, the use of the 
spray drying technique to produce protein-microparticulates has not been without 
challenges. Spray drying is associated with various stresses including; pressure effects, 
exposure to air-liquid interfaces during atomisation and dehydration. Together, this 
stressess may result in disruptions to the native structure of proteins thereby decreasing 
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protein activity considerably (Tzannis and Prestrelski, 1999a; Prestrelski et al., 1993; 
Mumenthaler et al., 1994; Broadhead et al., 1994). 
 
3.2.6     Alkaline phosphatase as a model protein  
Alkaline phosphatases (EC 3.1.3.1) (APs), are dimeric enzymes present in most 
organisms. They are non specific phosphomonoesterases that catalyze the hydrolysis of 
monoesters of phosphoric acid as well as facilitate the transphosphorylation reactions 
that occur in the presence of large concentrations of phosphate acceptors (Millan, 
2006). In humans, four distinct variants of alkaline phosphatase exist, three isoenzymes 
are tissue specific (i.e intestinal AP, placental AP and germ cell AP) while the fourth 
isoezyme is tissue-nonspecific (expressed in a variety of tissues including liver, bone 
and kidney). The tissue specific isoenzymes are 90 – 98% homologous between 
themselves and 50% homologous with the tissue-nonspecific isoenzymes. Functional 
properties of mammalian alkaline phosphatase indicate that while the tissue-nonspecific 
alkaline phosphatases have bone mineralisation functions, intestinal alkaline 
phosphatase likely facilitate intestinal absorption (Millan, 2006), the biological function of 
placental AP has not yet been unravelled but it has been suggested that it may have a 
role to play in the transfer of maternal IgG to the foetus (Makiya and Stigbrand, 1992a; 
Makiya and Stigbrand, 1992b; Stefaner et al., 1997).  
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Figure 3 -2: Schematic representation of the three-dimensional structure of alkaline 
phosphatase. Monomer A is shown in ribbon representation and in cyan, while monomer B is 
shown in surface representation in yellow. Also indicated are the active site metals, Zn1, Zn2 and 
Mg, the novel fourth metal site occupied by Ca, the crown domain and the amino terminal arm. 
The image is adapted from Millan (2006) 
 
For the purposes of this pilot study, bovine intestinal alkaline phosphatase was used and 
it comprised of two identical subunits with a molecular weight of 160,000 kDa (Neumann 
and Lustig, 1980). Each unit contains two (one loosely bound and one tightly bound) 
Zn2+ molecules, one magnesium binding site and one calcium binding site which aids 
the structural stability of the protein. The enzyme has a broad specificity for phosphate 
esters of alcohols, amines, pyrophosphate and phenols. However in research 
laboratories, the enzyme is commonly used to dephosphorylate proteins and nucleic 
acids (Morton, 1955b; Morton, 1955a) 
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The optimal pH range for alkaline phosphatases activity is between 8 – 10.5, and is 
dependent on the substrate, substrate concentration and ionic concentration. For the 
purpose of this study, the enzyme activity was determined at pH 9.8 (i.e. diethanolamine 
assay).  The choice of alkaline phosphatase as the model protein for this study is based 
on the availability of the purified protein, the existence of a suitable assay method for 
assessing the activity of the enzyme and its relatively cheap cost compared to most 
commercially available proteins. 
 
3.3     Aims and objectives 
The aim of this study was to investigate the feasibility of developing spray-dried protein 
particles, which are suitable for delivery to the lower respiratory tract without loss of 
biological activity either by using optimised spray drying parameters alone, or by 
modifying the protein formulation by the inclusion of sodium carboxymethyl cellulose. In 
order to improve the percentage fine particle fraction of the sodium carboxymethyl 
cellulose modified protein formulation, the use of water-ethanol (90:10 and 70:30) co-
solvent system in the preparing the NaCMC modified formulation will be investigated. 
Alkaline phosphatase was selected as a model protein for assessing the biological 
activity of the various formulations following spray drying. 
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3.4     Materials  
Phosphatase alkaline from calf intestinal mucosa (1.46 U/mg), bromophenol blue 
indicator reagent, Coomassie Brilliant blue R, sodium dodecyl sulphate all purchased 
from sigma-aldrich (Poole, UK), 1-Step™ PNPP and BCA protein assay reagent both 
purchased from Thermo Scientific (Rockford, IL USA), analytical grade, absolute ethanol 
was purchased from Fisher Scientific (Loughborough, UK), 98% 4-Nitrophenol from 
Acros organics (New Jersey, USA), Mini-PROTEAN®TGX™ Precast gels  was 
purchased from Bio-Rad laboratories (Hercules USA), PageRuler™ Plus and pre-
stained protein ladder  was purchased from Fermentas (York, UK), Hydrofluoroalkane 
(HFA)-134a (pharmaceutical grade) was purchased from INEOS Fluor (Cheshire, UK). 
 
3.5     Methods 
 
3.5.1     Preparation of spray-dried alkaline phosphatase 
Alkaline phosphatase was spray-dried as a 2 % w/v aqueous solution. The spray drying 
parameters utilised in the micronisation of the enzyme were: Inlet temperature, 180 0C; 
spray flow rate, 606 L/hr; pump setting, 3.2 mL/min; aspirator setting, 85 % (34 m3/hr); to 
produce an outlet temperature of 99 – 101 0C. 
 
3.5.2     Preparation of spray-dried alkaline Phosphatase – Sodium 
carboxymethylcellulose combinations 
2 % w/v NaCMC:alkaline phosphatase (80:20) mixture was co-spray dried from water-
only and a water:ethanol (90:10 and 70:30) suspension feedstocks using the following 
spray drying parameters; Inlet temperature, 180 0C; spray flow rate, 606 L/hr; pump 
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setting, 3.2 mL/min; aspirator setting, 85 % (34 m3/hr); to produce varying outlet 
temperatures 
 
3.5.3     Characterisation of the enzymatic activity of alkaline 
phosphatase  
The alkaline phosphatase content of the spray-dried powders was determined using a 
quantitative assay described in section 2.2.1.1.2. Briefly, 100 μg/mL of the various 
spray-dried powders (SD-AP, SD-N-AP, SD-N-AP 1, SD-N-AP 2) was prepared and 10 
μL aliquot of the sample solution was subsequently added into 1mL of 1-Step PNPP and 
incubated at room temperature for 5 minutes, during which time the PNPP was 
converted to PNP through the action of alkaline phosphatase. Following completion of 
the incubation period, the reaction was quenched by the addition of 500 μL of 2 N NaOH 
and the absorbance values of the solution determined by UV–vis spectrometry at 405 
nm. The activity of alkaline phosphatase was defined as follows: one unit of alkaline 
phosphatase generates 1 μmol PNP in 1min at 37 °C. The amount of PNP generated 
was calculated by reference to a PNP calibration curve, prepared using a series of 
standard solutions of PNP (10–50 μM) in diethanolamine–HCl solution (section 
2.2.1.1.1) 
 
3.5.4     Determination of moisture content 
The moisture content of the spray-dried powders was determined using 
thermogravimetric analysis. Samples (approximately 5 mg) were placed into platinum 
pans and analysed under a nitrogen purge (20 mL min−1 ), heated from 20 to 140°C at a 
heating rate of 10°C min−1.  
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3.5.5     Particle size distribution (PSD) 
Particle size distributions of the various spray-dried powders were determined using a 
Helos H 2178 laser diffraction instrument in combination with a Rodos dry dispersing 
unit and a Vibri vibratory feeding unit. Approximately 5 – 10 mg of each sample was 
dispersed at 2.0 bars using an R2 lens which covered sample size range between 0.45 
– 87.5 μm. Triplicate measurement was carried out on all the sample batches and data 
are expressed as the percentage of particles sized in the lower 10, middle 50, upper 10 th 
percentile (d[v,10], d[v,50] and d[v,90] respectively) and the volume mean diameter 
(VMD). The span of the volume distribution, a measure of the width of the distribution 
relative to the median diameter (d[v,50]), was also calculated using equation 3.1. A large 
span is indicative of a heterogenous size distribution 
     
                
       
 
(Equation 3.1) 
 
3.5.6     Scanning Electron Microscopy (SEM) 
The morphology of the micro-particles making up the bulk of the various spray-dried 
alkaline phosphatase powders were investigated using scanning electron microscopy 
(SEM, STEREOSCAN 90, Cambridge instruments). Samples were mounted on 
adhesive black carbon tabs (premounted on aluminium stubs) and sputter-coated 
(Polaron SC500, Polaron Equipment) with a thin layer of gold for 3 mins at 20 mA prior 
to analysis. The samples were studied under high magnification. This analysis was 
repeated three times, once for each of the spray-dried powder batches. 
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3.5.7     Preparation of DPI formulations 
For spray-dried alkaline phosphatase: One empty size 3 gelatin capsule was weighed 
and 20 ± 2 mg of spray-dried alkaline phosphatase (theoretically equivalent to 196 units 
of the alkaline phosphatse enzyme) was manually measured into the capsule and 
subsequently loaded into a cyclohaler™. This was repeated two more times to enable 
triplicate measurement of the aerosolisation performance of spray-dried alkaline 
phosphatase. 
For spray-dried NaCMC modified formulations of alkaline phosphatase: For each 
of the formulations, five empty size 3 gelatin capsules were weighed and 20 ± 2mg 
(theoretically equivalent to 240 units of the enzyme for the SD AP, 155 units of the 
enzyme for the SD-N-AP 1 and 135 units of the enzyme for the SD-N-AP 2 and 
contained in the 5 capsules) of each formulation blend was measured and manually 
loaded into the 5 capsules.  
Preparing alkaline phosphatase pMDIs: pMDI formulations of the spray-dried 
powders were prepared by adding either 100mg of spray-dried powder (theoretically 
equivalent to 995 units enzyme for the SD AP, 235 units of the enzyme for SD-N-AP, 
170 units of the enzyme for SD-N-AP 1 and 148 units of the enzyme for SD-N-AP 2) into 
pre-weighed 15 mL polyethylene terephthalate (PET) uncoated pMDI vials. A BK357 30 
µL valve was crimped onto the vials using a Pamasol P2002 small-scale crimper and 
approximately 6 g HFA- 134a was pressure-filled through the valve using a Pamasol 
P2011 propellant filler to form suspensions with an approximate concentration of 1.6% 
(w/w) powder in propellant. The formulations were vortex-mixed for 1 minute and tested 
for in vitro aerosolisation properties using a next generation impactor for 2 x 5s. The 
theoretical dose contained in 20 shots from each formulation was calculated to be ~125 
units of enzyme for the SD AP pMDI formulation, ~30 units of enzyme for the SD-N-AP 
pMDI formulation, ~22 units of enzyme for the SD-N-AP 1 pMDI formulation and ~19 
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units of enzyme for the SD-N-AP 2 pMDI formulation. The actual dose released per test 
was calculated from the mass loss following actuation. A total of three pMDI 
formulations were prepared for each batch of spray-dried powder (n = 3). 
 
3.5.8     In vitro aerosolisation testing of the various DPI and pMDI 
formulations 
The aerosolisation properties of the different DPI and pMDI formulations were 
investigated using Next Generation Impactor (NGI). The flow rate through the NGI was 
adjusted to 60 L/min using an electronic digital flow meter (Model DFM2: Copley 
Scientific). The cyclohaler™ device fitted with size 3 capsule, was attached to the 
induction port of the NGI using an adapter, the vacuum pump was switched on and the 
powder formulation was allowed to aerosolise for 2 x 5 seconds. Following 
aerosolisation of the dry powder formulations, the NGI was dissembled and deposits 
collected from all the different components using the collecting solution (diethanolamine-
HCl solution). A flow rate of 60 L/min was maintained throughout the entire investigation. 
The powders which deposited in the throat were recovered by rinsing the throat with 
20mL of distilled water; the pre-separator had 15mL of collecting solution in it during 
aerosolisation. 20mL volume of collecting solution was placed in stage 1 and MOC while 
10mL volume of collecting solution was placed in stages 2 - 7, the resulting solutions 
were each swirled and transferred to 50mL beakers. Complete dissolution was 
facilitated in all solutions by placing the beakers containing the solutions on magnetic 
stirrers (Fisher Thermix Stirring Hot Plate, Model 201T). The resulting solutions were 
visually inspected to confirm the complete dissolution of the powders. A sample of the 
solution was then removed for UV analysis making sure to dilute even further when 
necessary. For the pMDI formulations, 20 actuations were aerosolised through a plastic 
actuator attached to the NGI via the USP throat. After each actuation the canister was 
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removed and shaken to provide a homogenous mixture for the next actuation. Each 
deposition experiment was repeated in triplicate 
 
 
3.5.9     Determination of RD, ED, FPD, FPF, MMAD, GSD and 
Dispersibility 
The method for determining RD, ED, FPD, FPF, MMAD, GSD are outlined in section 
2.2.14.5. For the pMDI formulations, the pMDI vial was weighed before and after each 
run, to enable the total dose (TD) to be calculated, based on the proportion of alkaline 
phosphatase in each suspension. For the DPI formulations, the TD was defined as the 
activity of alkaline phosphatase present in the powder loaded into the capsule. In each 
case, the TD was corrected for the alkaline phosphatase activity in each powder. The 
recovered dose (RD) was defined as the total activity of alkaline phosphatase detected 
(i.e. device + throat + Stages 1–8), expressed as the percentage of TD. The fine particle 
dose (FPD) was defined as the activity of alkaline phosphatase recovered from Stage 3 
to stage 8 of the NGI (effective cut-off diameter 4.4 µm). The fine particle fraction (FPF) 
was calculated as the ratio of FPD to RD, expressed as a percentage. A total of four 
pMDI and four DPI formulations were prepared for each batch of spray-dried powder (n 
= 3) to enable the aerosolisation performance of the formulations to be determined. 
 
3.5.10   SDS-PAGE analysis of the various alkaline phosphatase 
formulations 
Analysis of samples by SDS-PAGE was carried out using a 4 – 20 % precast 
polyacrylamide gel following the procedure described by Laemmli (1970) and detailed in 
section 2.2.9. A lane of prestained molecular weight marker was included in each gel to 
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allow determination of the apparent molecular weight of the lactoferrin in each 
preparation. Following electrophoresis, gel protein staining was performed using 
Coomassie brilliant blue R-250, following the procedure detailed in section 2.2.9.1.1. 
 
3.5.11   Statistical analysis 
Statistical analysis were performed on the data obtained. Data is presented as mean ± 
standard deviation (n = 3). GraphPad InStat version 3.06 software was used in 
analyzing data. One way ANOVA with Tukey multiple comparison and post test was 
employed. 
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3.6     Results  
3.6.1     Determining the unit of alkaline phosphatase through 
diethanolamine 
One unit of AP was defined as the amount of AP required to generate 1 μM PNP per 
minute at 37 °C. Based on this, three calibration curves of PNP were prepared on three 
different days (as described in section 2.2.1.1.1). A calibration plot of absorbance at 405 
nm against molar concentration of PNP (10 – 50 µM) yielded a linear relationship (y= 
0.0189x 0.0026, r2 > 0.999). Using Beer-Lambert’s law, A = ε c l (where A – absorbance, 
ε – molar absorbtivity, c – concentration and l – path lenght) the molar absorbtivity for 
PNP was calculated to be 18.9 mM–1 cm–1 for this study. This value was then used to 
determine the units of AP in throughout this study. 
 
Figure 3 -3: Calibration curve showing a plot of absorbance versus concentration for p-
nitrophenol. The mean absorbance of triplicate measurements obtained on 3 different days are 
plotted against nominal concentration values (n = 9). Error bars representing standard deviation 
is displayed for each point although they are within the limits of the symbols. 
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All calibration curves obtained on different days and constructed for 4-nitrophenol were 
linear within the measured concentration range of 10 – 50 µM (Day 1: y= 0.0188x + 
0.0069, r2 = 0.999; Day 2: y= 0.019x + 0.0008, r2 > 0.999; Day 3: y= 0.019x + 0.0001, r2 
> 0.999). The assay method generally showed good reproducibility with similar inter-day 
results.  
 
3.6.2     Validating the p-nitrophenol assay 
In order to ensure the validity of the assay method and the calibration graph produced, 
especially since it was going to be used to estimate the units of alkaline phosphatase in 
the entire study, some validation parameters were determined including; specificity, 
precision, detection limit, quantitation limit and linearity. The specificity of the assay 
method in estimating the absorbance of PNP in the presence of sodium 
carboxymethylcellulose was assessed and found not to be different from calibration plot 
in figure 3 -3, the linearity of the assay method was found to be > 0.999 on all three 
days, the precision of the assay which is the degree of scatter between absorbance 
measurements obtained on three differenet days was determined by evaluating the 
standard deviation (SD) and relative standard deviation  (RSD) (table 3 -1). The 
detection limit, which is the lowest amount of the analyte in a sample that can be 
detected but not necessarily quantified using the calibration plot was determined (table 3 
-1) and finally, the quantitation of the graphical plot of absorbance against, micromolar 
concentration of PNP. All results obtained showed that the assay method was 
appropriate for use. 
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Table 3.1: Calculated and measured mean absorbance, standard deviation, % RSD, r
2
, LOD. 
LOQ and nominal concentration of p-nitrophenol. Values were calculated or measured on three 
separate days and nominal concentrations, absorbances and calculations are shown for each 
day.  
 
Standard 
conc. 
(µmol/L) 
Mean 
absorbance 
Standard 
deviation 
Relative 
standard 
deviation (%) 
Linear 
regression 
(r
2
) 
Limit of 
detection 
(µmol/L) 
Limit of 
quantitation 
(µmol/L) 
D
a
y
 1
 
10 0.187 0.003 1.34 
0.9988 0.7021 2.1277 
20 0.383 0.006 1.68 
30 0.587 0.007 1.23 
40 0.765 0.004 0.53 
50 0.938 0.003 0.28 
D
a
y
 2
 
10 0.188 0.004 1.92 
0.9994 1.0421 3.1579 
20 0.378 0.006 1.55 
30 0.579 0.012 2.00 
40 0.766 0.009 1.17 
50 0.940 0.002 0.22 
D
a
y
 3
 
10 0.188 0.002 1.11 
0.9996 0.5211 1.5789 
20 0.377 0.005 1.22 
30 0.572 0.010 1.79 
40 0.767 0.006 0.73 
50 0.941 0.005 0.48 
 
The highest %RSD for inter-day precision was determined to be 2 % at nominal 
concentration of 30 µmol/L on day 2 (Table 3.1) indicating good inter-day precision. 
Analysis also showed that the lower limits of detection and quantification were 
approximately 0.52 µmol/L and 1.58 µmol/L respectively. Both were obtained on day 3. 
 
Chapter Three: Developing a method for spray drying a model protein 
- 149 - 
 
3.6.3     Determination of the unit of alkaline phosphatase in the 
various spray-dried formulations 
In order to determine the effect of spray drying on the activity of alkaline phosphatase 
the units per millilitre of the enzyme was calculated using the equation 3.2; 
                      
 
          
   
           
            
 
 
(Equation 3.2) 
 
where; 1.01 = Volume (in millilitres) of assay; DF = Dilution factor; 18.9 = millimolar extinction 
coefficient of p-Nitrophenol at 405 nm; 0.01 = volume (in millilitres) of enzyme used. 
 
Table 3.2: The calculated units per millilitre and percent relative activity of various alkaline 
phosphatase powders. The percent relative activity was calculated by assuming the activity of the 
supplied alkaline phosphatase enzyme to be 100%. The values are mean ± SD of triplicate 
measurments. 
 Before spray drying  After spray drying 
Formulations Units/mL 
enzyme 
% relative 
activity 
 Units/mL 
enzyme 
% relative 
activity 
SD-AP 135.71 ±0.8 100 ±0.6  99.50 ±5.3 73.3 ±3.9 
SD-N-AP  138.83 ±2.7 102.3 ±2.0  117.89 ±4.8 86.9 ±3.5 
SD-N-AP 1 135.20 ±1.6 99.6 ±1.2  85.22 ±2.8 62.8 ±2.1 
SD-N-AP 2 131.89 ±1.1 97.2 ±0.8  73.96 ±4.1 54.5 ±3.0 
 
The enzymatic activity of the preparations were measured before and after spray drying 
in order to assess the impact of the spray drying technique on the activity of the protein. 
Prior to spray drying, SD-N-AP 2 had the lowest mean enzymatic activity of 97.2 ±0.8% 
of nominal alkaline phosphatase activity and also the lowest mean pH value of 8.5 
(Table 2.4). Following spray drying, the alkaline phosphatase activity of the spray-dried 
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powders: SD-AP, SD-N-AP, SD-N-AP 1 and SD-N-AP 2 were found to be 73.3 ±3.9%, 
86.9 ±3.5%, 62.8 ±2.1% and 54.5 ±3.0% respectively of the original activity of the non-
spray-dried enzyme which was arbitrarily assigned as 100%. 
  
3.6.4     Spray-dried powder characteristics 
3.6.4.1     Spray drying parameters 
A total of 4 different spray-dried powders of alkaline phosphatase were generated by 
using the spray drying parameters outlined in table 3.3. 
Table 3.3: Spray drying parameters employed to produce the four different alkaline phosphatase 
powders. Three batches of powders were produced using these parameters.  
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SD-AP 2 Water 180 99 - 101 606 3.2 34 67.2 ±2.7 
SD-N-AP 2 Water 180 99 - 101 606 3.2 34 76.1 ±1.0 
SD-N-AP 
1 
2 
Water-Ethanol 
(9:1) 
180 102 - 106 606 3.2 34 71.3 ±3.2 
SD-N-AP 
2 
2 
Water-Ethanol 
(7:3) 
180 101 - 104 606 3.2 34 71.1 ±2.8 
 
The data shown in table 3.3 illustrates that spray drying alkaline phosphatase alone 
resulted in a yield of 67.2 ±2.7 % of the initial starting mass while the inclusion of 
NaCMC in the water-only feedstock resulted in a significantly greater yield of 76.1 ±1% 
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(p < 0.01). However,  no statistical difference was found between yield of the co-solvent 
modified NaCMC-AP and the excipient-free spray-dried alkaline phosphatase. 
 
3.6.4.2     Moisture content and particle size distribution of the various 
spray-dried formulations 
The residual moisture content of the various formulations are shown in table 3.4. 
Excipient-free spray-dried alkaline phosphatase contained a residual moisture level of 
5%, whereas the residual moisture content of NaCMC modified was 6.5 % when spray-
dried from water and 3.0 % when spray-dried from a water-ethanol cosolvent. The 
particle size distribution of the various spray-dried formulation shows that SD-N-AP had 
highest VMD, while the excipient free spray-dried alkaline phosphatase produced the 
least VMD (Table 3.4).  
 
 
 
 
 
 
 
 
Table 3.4: Moisture content and particle size distribution of spray-dried alkaline phosphatase 
powders and sodium carboxymethylcellulose modified formulations. The values are mean ± SD. 
Statistical analysis of the various formulations were carried out by one-way analysis of variance 
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(ANOVA) using GraphPad prism 5. † denotes p < 0.05 statistical difference compared to the 
spray-dried alkaline phosphatase only formulation, and  ‡ denotes p < 0.01 statistical difference 
compared to the spray-dried alkaline phosphatase only formulation 
  Particle size distribution (µm) 
Formulations Moisture 
content (%) 
d[v,10] 
(µm) 
d[v,50] 
(µm) 
d[v,90] 
(µm) 
Span Volume mean 
diameter (µm) 
SD AP 5.0 ±1.8 1.10 ±0.3 4.04 ±0.6 8.86 ±1.0 1.97 ±0.5 4.56 ±0.8 
SD-N-AP 6.5 ±1.1 1.23 ±0.4 5.39 ±0.5 20.86 ±0.8 3.67 ±0.4
‡
 8.54 ±1.0
‡
 
SD-N-AP 1 3.3 ±0.3 1.14 ±0.2 5.06 ±0.4 17.18 ±0.5 3.19 ±0.3
†
 7.48 ±0.3
‡
 
SD-N-AP 2 3.0 ±0.8 1.31 ±0.3 5.51 ±0.5 19.74 ±0.5 3.38 ±0.4
‡
 8.33 ±0.5
‡
 
 
The spray drying parameters utilised in producing the various dry powders shows that 
powders generated by spray drying from co-solvents exhibited lower moisture content 
(analysed by thermogravimetric analysis) although possessed a higher particle size 
compared with excipient free spray-dried alkaline phosphatase powders (Table 3-11). 
The NaCMC-modified formulations showed greater heterogenicity  with significantly 
higher span than excipient-free spray-dried alkaline phosphatase.  
3.6.5     Aerodynamic assessment of powder blends 
A total of eight products were evaluated for their aerodynamic properties using the next 
generation impactor. Four of the products were dry powders delivered from a cyclohaler 
and the other four products were delivered from a pressurised metered dose inhaler. 
3.6.5.1     In vitro deposition data 
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Figure 3 -4: In vitro deposition profile of four DPI formulations following aerosolisation into the 
NGI. Following preparation of the spray-dried powders, 20 mg of SD AP and 5 x 20  mg of SD-N-
AP, SD-N-AP 1 and SD-N-AP 2 were placed into size 3 gelatin capsules and aerosolised from a 
cyclohaler device. Values are mean ± SD, n = 3 of percent nominalised units per mL of alkaline 
phosphatase.  
 
Following aerosolisation of 20 mg of SD AP (theoretically equivalent to 188 ±3.5  units of 
the enzyme of spray-dried alkaline phosphatase) from the cyclohaler, about 47±3.8 units 
of alkaline phosphatase (25.3%) was retained in the device with a further 36 ±0.4 units 
alkaline phosphatase (19.23%) depositing in the throat of the NGI. However, 49.14 ±4.8 
units of alkaline phosphatase (26%) deposited on stages 3 – 8.  
Upon aerosolisation of 100 mg of SD-N-AP (theoretically equivalent to 242 ±5.9  units of 
the enzyme of NaCMC modified alkaline phosphatase) from the cyclohaler, about 37 
±0.3 units of alkaline phosphatase (15.1%) was retained in the device with a further 36 
±0.4 units alkaline phosphatase (14.83%) depositing in the throat of the NGI. However, 
105.9 ±3.1 units of alkaline phosphatase (43%) deposited on stages 3 – 8.  
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Upon aerosolisation of 100 mg of SD-N-AP 1 (theoretically equivalent to 159 ±3.1  units 
of the enzyme of NaCMC modified alkaline phosphatase prepared for 90:10 water-
ethanol co-solvent) from the cyclohaler, about 14 ±0.8 units of alkaline phosphatase 
(8.6%) was retained in the device with a further 14 ±0.8 units alkaline phosphatase 
(8.94%) depositing in the throat of the NGI. However, 79.6 ±1.6 units of alkaline 
phosphatase (50%) deposited on stages 3 – 8. 
Upon aerosolisation of 100 mg of SD-N-AP 2 (theoretically equivalent to 130 ±1.5  units 
of the enzyme of NaCMC modified alkaline phosphatase prepared for 70:30 water-
ethanol co-solvent) from the cyclohaler, about 11 ±1.0 units of alkaline phosphatase 
(8.6%) was retained in the device with a further 11 ±0.8 units alkaline phosphatase 
(8.6%) depositing in the throat of the NGI. However, 73 ±4.6 units of alkaline 
phosphatase (56%) deposited on stages 3 – 8. 
 
Figure 3 -5: In vitro deposition profile of four pMDI formulations following aerosolisation into the 
NGI. Following preparation of the spray-dried powders, 20 actuations of SD AP, SD-N-AP, SD-N-
AP 1 and SD-N-AP 2 were aerosolised from the pMDI device into the NGI. Values are mean ± 
SD, n = 3 of percent nominalised units per mL of alkaline phosphatase.  
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Following aerosolisation of 20 actuations of SD AP (theoretically equivalent to 124 ±0.3  
units of the enzyme of spray-dried alkaline phosphatase) from the cyclohaler with about 
27 ±0.7 units of alkaline phosphatase (21.92%) depositing in the throat of the NGI while 
47.58 ±3.4 units of alkaline phosphatase (38%) deposited on stages 3 – 8.  
Upon aerosolisation of 20 actuations of SD-N-AP (theoretically equivalent to 30 ±0.2  
units of the enzyme of NaCMC modified alkaline phosphatase) from the cyclohaler with 
about 6 ±0.1 units of alkaline phosphatase (21%) depositing in the throat of the NGI 
while 14 ±0.7 units of alkaline phosphatase (47%) deposited on stages 3 – 8.  
Upon aerosolisation of 20 actuations of SD-N-AP 1 (theoretically equivalent to 21 ±0.6  
units of the enzyme of NaCMC modified alkaline phosphatase prepared for 90:10 water-
ethanol co-solvent) from the cyclohaler with about 3.84 ±0.3 units of alkaline 
phosphatase (18.3%) depositing in the throat of the NGI while 12 ±1 units of alkaline 
phosphatase (57%) deposited on stages 3 – 8. 
Upon aerosolisation of 100 mg of SD-N-AP 2 (theoretically equivalent to 19 ±0.5  units 
of the enzyme of NaCMC modified alkaline phosphatase prepared for 70:30 water-
ethanol co-solvent) from the cyclohaler, about 3.8 ±0.1 units of alkaline phosphatase 
(20%) depositing in the throat of the NGI while 10 ±0.7 units of alkaline phosphatase 
(53%) deposited on stages 3 – 8. 
 
3.6.5.2     The fine particle fractions of the aerosolised powder formulations 
The total dose of particles with aerodynamic diameters smaller than 5 µm was 
calculated by interpolation from the cumulative mass against the cut-off diameter of 
respective stages and considered as the fine particle dose (FPD), with a ratio of FPD to 
the recovered dose representing the fine particle fraction (FPF). 
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Figure 3 -6: Fine particle fraction < 5 µm of spray-dried alkaline phosphatase and sodium 
carboxymethylcellulose and co-solvent modified DPI and pMDI formulations evaluated using the 
NGI. Values are mean ±SD, n = 3. Comparisons of groups were made by one-way analysis of 
variance (ANOVA) using graphpad prism 5 (GraphPad Prism Software Inc., Version 5.0) followed 
by Dunnett post-test; p values were considered significant and the *** represents p value < 0.001 
between SD AP and the sodium carboxymethylcellulose modified DPI formulations; †, p < 0.01 
between SD AP and the sodium carboxymethylcellulose modified pMDI formulations. ns indicates 
no significance between SD AP and the sodium carboxymethylcellulose modified pMDI 
formulations. 
 
The FPF of the DPI formulations ranged from 29% to 44% of the recovered dose, while 
the FPF of the pMDI formulations ranged from 47% to 51% (figure 3 -6). Sodium 
carboxymethylcellulose modified DPI formulations generally had significantly improved 
FPF while the FPF of the various pMDI formulations were found to be independent of 
sodium carboxymethyl cellulose content or the solvent used for preparation. However, 
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SD AP, SD-N-AP and SD-N-AP 2 were found to deliver statistically the same FPF, while 
SD-N-AP 1 delivered a significantly (p < 0.01) higher FPF.  
 
3.6.5.3     Powder emission from the DPI device 
The percent of powder emitting from the DPI increased with incorporation of sodium 
carboxymethylcellulose into the formulations as well as by spray drying from a co-
solvent (Figure 3 -7) 
 
 
Figure 3 -7: Total powder emission of spray-dried alkaline phosphatase and sodium 
carboxymethylcellulose and co-solvent modified DPI at 60 L/min. Comparisons of groups were 
made by one-way analysis of variance (ANOVA) using graphpad prism 5 (GraphPad Prism 
Software Inc., Version 5.0) followed by Dunnett post-test; p values were considered significant 
and *** represents p value < 0.001 between SD AP and the sodium carboxymethylcellulose 
modified formulations; * represents p value < 0.05 between SD AP and the sodium 
carboxymethylcellulose modified formulations. 
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Impaction studies from the DPI device shows that the highest average % emission of 
105.4 ±4.6% was measured for SD-N-AP 2. The lowest average % emission of 75.6 
±1.8% was measured for the SD AP dry powder inhaler. No statistical difference was 
measured between the %emission of SD AP and SD-N-AP, also between SD-N-AP 1 
and SD-N-AP 2 (ANOVA, p value is >0.05). However, the %emission of SD-N-AP 1 and 
SD-N-AP 2 compared to SD-AP were found to be significantly different (ANOVA, p value 
is < 0.001). 
 
3.6.5.4     Dispersibility of the powder formulations from both DPI and pMDI 
The dispersibility of the formulation is the ratio of the fine particle dose to the emitted 
dose. Dispersibility measures the adherence of the dispersed powders (released from 
the capsule or pMDI device) to the air stream.  
 
Figure 3 -8: Dispersibility of the spray-dried alkaline phosphatase and sodium 
carboxymethylcellulose and co-solvent modified DPI and pMDI formulations. Values are mean 
±SD, n = 3. Comparisons of groups were made by one-way analysis of variance (ANOVA) using 
graphpad prism 5 (GraphPad Prism Software Inc., Version 5.0) followed by Dunnett post-test; p 
values were considered significant and the *** represents p value < 0.001 between SD AP and 
the sodium carboxymethylcellulose modified DPI formulations; ** represents p value < 0.01 
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between SD AP and the sodium carboxymethylcellulose modified formulations; †, p < 0.01 
between SD AP and the sodium carboxymethylcellulose modified pMDI formulations. ns indicates 
no significance between SD AP and the sodium carboxymethylcellulose modified pMDI 
formulations. 
 
The dispersibility of the various spray-dried powders aerosolised from DPIs were found 
to significantly (p < 0.01) increase with inclusion of sodium carboxymethyl cellulose as 
well as spray drying the sodium carboxymethylcellulose modified formulation from an 
increasing concentration of ethanol in the suspension feedstock. However, this was not 
found to be the same for the pMDI formulations as only the SD-N-AP 1 had a 
significantly (p <0.05) increased dispersibility compared to the SD AP formulation. 
 
3.6.5.5     Mass median aerodynamic diameter of the various spray-dried 
powders  
The mass median aerodynamic diameter (MMAD) of the powders which is the 50% 
mark of a plot of percent cumulative enzyme deposition versus the effective cut-off 
diameter of the NGI. The smaller the diameter, the better are the chances that the 
particle deposition would occur in the lower airways. 
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Figure 3 -9: Mass median aerodynamic diameter (MMAD) of excipient-free and sodium 
carboxymethylcellulose modified spray-dried alkaline phosphatase. Values are mean ±SD, n = 3. 
Comparisons of groups were made by one-way analysis of variance (ANOVA) using graphpad 
prism 5 (GraphPad Prism Software Inc., Version 5.0) followed by Dunnett post-test; p values 
were considered significant and the *** represents p value < 0.001 between SD AP and the 
sodium carboxymethylcellulose modified DPI formulations; †, p < 0.01 between SD AP and the 
sodium carboxymethylcellulose modified pMDI formulations. ns indicates no significance between 
SD AP and the sodium carboxymethylcellulose modified pMDI formulations; ‡, p < 0.001 
between SD AP and the sodium carboxymethylcellulose modified pMDI formulations. ns indicates 
no significance between SD AP and the sodium carboxymethylcellulose modified pMDI 
formulations 
 
The MMAD ranged between 3.72 µm and 4.79 µm for the aerosols generated by the 
DPI devices and between 4 µm and 4.3 µm for the aerosols generated by the pMDI 
devices. Statistically, the MMAD of particles formulated with sodium 
carboxymethylcellulose were significantly lower than for those which were excipient free. 
 
S
D
-A
P
S
D
-N
-A
P
S
D
-N
-A
P
 1
S
D
-N
-A
P
 2
S
D
-A
P
S
D
-N
-A
P
S
D
-N
-A
P
 1
S
D
-N
-A
P
 2
0
2
4
6
DPI
pMDI
 
*** † ‡ †
A
e
ro
d
y
n
a
m
ic
 d
ia
m
e
te
r 
( 
m
)
Chapter Three: Developing a method for spray drying a model protein 
- 161 - 
 
3.6.6     Powder properties: Angle of repose 
In order to predict the flowability characteristic of the various spray-dried powders, the 
angle of repose of the powders were determined. It is a characteristic measure of 
interparticulate friction, or resistance to movements between particles.The British 
pharmacopoeia (2013) proposes the following classification of flowing properties to the 
angle of repose: excellent (25 o< θ<30 o), good (31 o< θ<35 o), fair (36 o< θ<40 o), 
passable (41 o< θ<45 o), poor (46 o< θ<55 o), very poor (56 o< θ<65 o), and very, very poor 
(θ<66 o). 
 
Table 3.5: Angle of repose values for the various formulations. Values are mean ± SD; (n = 3)   
Formulation Angle of repose (θ)  Comment 
SD-AP ** ** 
SD-N-AP 47  ±0.3 o True cohesiveness 
SD-N-AP 1 34 ±0.1 o Some cohesiveness 
SD-N-AP 2 28 ±0.2 o Some cohesiveness 
** not enough powder for investigation 
 
The descending rank of powder flowability is SD-N-AP 2 (angle of repose, 28o) > SD-N-
AP 1 (34o) > SD-N-AP (47o). Significant differences were observed between all the 
formulations (ANOVA; p < 0.001),  
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3.6.7     The effects of spray drying on the molecular size of Alkaline 
phosphatase  
A comparative assessment between the commercially available enzyme (positive 
control), a thermally destroyed enzyme (negative control) and the four spray-dried 
formulations were carried out samples. Polyacrylamide gel electrophoresis, which 
seperates proteins on the basis of charge, and size was used to estimate the molecular 
mass of the polypeptides that make-up the enzyme.  
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a) 
 
b) 
 
Figure 3- 10: SDS-PAGE profile of alkaline phosphatase. a) Comparison of alkaline phosphatase 
preparations following separation on SDS-PAGE. Positive control; 2% w/v alkaline phosphatase, 
SD AP; 2% w/v spray-dried alkaline phosphatase, Water only; 2% w/v (20% alkaline 
phosphatase and 80% sodium carboxymethylcellulose) spray-dried from water only feedstock, 
W/E 90:10; 2% w/v (20% alkaline phosphatase and 80% sodium carboxymethylcellulose) spray-
dried from a mixture of 90% water and 10% ethanol feedstock, W/E 70:30; 2% w/v (20% alkaline 
phosphatase and 80% sodium carboxymethylcellulose) spray-dried from a mixture of 70% water 
and 30% ethanol feedstock, W/E 50:50; 2% w/v (20% alkaline phosphatase and 80% sodium 
carboxymethylcellulose) spray-dried from a mixture of 50% water and 50% ethanol feedstock, 
Negative control; 2% w/v alkaline phosphatase heated at 70°C for 5 minutes. The gel was run at 
a constant current of 60 mA for 22 minutes in a Bio-Rad vertical electrophoresis tank following 
which the gels were stained with Coomassie brilliant blue R-250 dye. (b) calibration curve of the 
protein standard showing  log molecular weight versus mobility. 
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In order to enable determination of the molecular weights of the various polypeptides 
shown as bands on the gel, a calibration plot of log of molecular weight (daltons) against 
mobility (Rf) of the protein band (figure 3- 10b) was ploted and it yielded a linear 
relationship (y= -1.7716x + 5.5562, r2 > 0.9964). Using the equation of the line, the 
molecular weights of various polypeptides was estimated to be 124,477.6, 79,604.5, 
43,050.4, 26,034.8, 20,819.8, 14,888.9, 13314.5 and 9004.1 daltons. Upon heat 
treatment, the molecular weights of the various breakdown polypeptide products were 
71,186.8, 60199.3, 34427.1, 10647.5 and 9004.1 daltons 
 
3.6.8     Morphology of the various spray-dried formulations 
Scanning electron micrographs of the various spray-dried alkaline phosphatase powders 
are presented in Figure 3- 11. Fig. 3- 11a shows the commercially supplied sodium 
carboxymethylcellulose as long cylindrical particles whilst the commercially supplied 
alkaline phosphatase (Fig. 3- 11b) was light and flake-like in appearance.  Spray-dried 
alkaline phosphatase (Fig. 3- 11c) appeared spherical and heterogenous in size. 
Similary, co-spray dried alkaline phosphatase and sodium carboxymethylcellulose (Fig. 
3-11d) also appeared spherical but with greater heterogenicity between particle sizes. 
Spray drying alkaline phosphatase and sodium carboxymethylcellulose from water-
ethanol cosolvents (90:10 and 70:30) also produced spherical particles with 
heterogenous particle sizes.  
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Figure 3- 11: Scanning electron micrographs of (a) commercial sodium carboxymethylcellulose 
(b) commercial alkaline phosphatase (c) spray-dried alkaline phosphatase (d) spray-dried sodium 
carboxymethylcellulose and alkaline phosphatase from water-only suspension feedstock at a 
mass ratio of 4:1 (e) spray-dried sodium carboxymethylcellulose and alkaline phosphatase from 
water (90%) and ethanol (10%) suspension feedstock at a mass ratio of 4:1 (f) spray-dried 
sodium carboxymethylcellulose and alkaline phosphatase from water (70%) and ethanol (30%) 
suspension feedstock at a mass ratio of 4:1. Magnifications are shown on the top of each 
micrograph along with scale bar in µm. 
 
(a) (b) 
(c) (d) 
(e
) 
(f) 
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3.7     Discussion 
Results from this study reveal that it is possible to spray dry a protein and produce 
respirable, more regularly shaped, spherical particles while maintaining substantial 
enzymatic activity of the protein. This can be achieved with or without solvents or 
excipients. It was also observed that the inclusion of ethanol in the suspension 
feedstock can be damaging to the activity of the protein even before the spray drying 
process (table 3.2), although water-ethanol co-solvents may help to improve the % 
emission and dispersibility of various spray-dried powders delivered by a Cyclohaler™ 
DPI device (figure 3- 7, figure 3 -8). Also, the inclusion of sodium 
carboxymethylcellulose were found to be useful in altering the FPF of alkaline 
phosphatase DPI, and spray drying the modified protein from a water-ethanol co-solvent 
system resulted in an even greater improvement of the FPF of the protein (figure 3-6). 
On the other hand, there was no major difference in the deposition profiles of excipient-
free and NaCMC modified alkaline phosphatase powders delivered through a pMDI 
device (figure 3- 5, 3- 6 and 3- 8). The findings in this study are in agreement with a 
previous study by Li and Seville (2009), who found that formulating pMDI suspension 
containing a model protein, bovine serum albumin and NaCMC resulted in powders with 
statistically better aerosolisation performanace compared with NaCMC-free pMDI 
formulation. Li et al., (2010) also found that NaCMC-modified spray-dried powders 
provided improved protection to the enzymatic activity of alkaline phosphatase as well 
as maintaining the aerosolisation performance of the powders, when formulated as a 
pMDI, over a 16 week storage period. This study extends their findings by providing 
information on the use of co-solvents when preparing these inhalable NaCMC-modified 
protein formulations, and in addition, this study also demonstrated that 80% NaCMC 
sufficiently protected the enzymatic activity of the protein (alkaline phosphatase) from 
the harsh spray drying conditions (table 3.2). 
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Assessment of the powder flow properties of various spray-dried powders showed that 
spray-dried powders prepared from water-ethanol co-solvents generally had good flow 
properties (classified under the  the British Pharmacopoeia) as the angle of repose 
ranged between 28° and 34° (table 3.5). The flow properties of NaCMC-modified 
powders spray-dried from a water only suspension feedstock were classified to be fair, 
however, spray-dried powders of alkaline phosphatase alone generally had poor flow 
properties as powder greatly adhered to the walls of storage vials (unfortunately, not 
enough powder was generated to enable the determination of the angle of repose). 
More of the SD-AP powders were retained in the DPI device as well as on the throat of 
the NGI. This related to powder adhesion of the various spray-dried alkaline 
phosphatase formulation. In summary, increases in the percent ethanol composition 
leads to improvement in the flow properties of spray-dried protein powders. This 
observation is in agreement with Rabbani and Seville (2005) who found that inclusion of 
ethanol as a formulation component enhanced the aerosolisation properties of β-
estradiol dry powders. 
With the particle size of dry powders being a cruicial factor in the prediction of DPI 
deposition profile, two particle sizing measurements were carried out; particle sizing by 
laser diffraction and MMAD determined from the 50% mark on a plot of cumulative 
percent deposition versus the effective cut-off diameter (table 2.5). It was found that 
laser diffraction measurement of between 5 mg and 10 mg of the spray-dried powder 
samples had a d [v,50] range of between 4 μm and 6 μm (table 3.4). However, the span 
of the NaCMC-modified powders indicated a significantly higher heterogenicity 
compared with the excipient-free alkaline phosphatase formulation. The volume mean 
diameter (VMD) of the formulations was found not to correlate with the MMAD, which 
was found to range between 3.7 μm and 4.8 μm. This maybe accounted for by the 
failure of the MMAD to take into consideration particles depositing on the throat of the 
NGI, while laser diffraction measures light scattering of an entire mass of powder.  
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The statistical analysis of the MMAD values (Fig. 3 -9) measured upon aerosolisation of 
the spray-dried powders from the different devices (DPI and pMDI) shows that there are 
significant (p <0.001) differences between the aerodynamic diameters of the excipient-
free alkaline phosphatase powders and the NaCMC-modified (SD-N-AP, SD-N-AP 1, 
and SD-N-AP 2) powders, however, there is no statistical difference between both co-
solvent modified formulations.  
The scanning electron micrographs of the various spray-dried powders show a 
heterogenous particle size distribution especially among the NaCMC-modified powder 
formulations. This observation further supported the large span calculated from the 
volume distribution of the laser diffraction measurements (table 3.4). Overall, there were 
observable changes in the morphology of the spray-dried powders compared with the 
commercially supplied enzyme and excipients.  
SDS-PAGE analysis of the various spray-dried powder preparation show the presence 
of various polypeptides which were particularly different from the heat treated alkaline 
phosphatase samples. Takeuchi (1990) reported the isolation of the polypeptide 
between 120 and 130 kDa to be responsible for the phosphatase activity of the enzyme. 
Similar analysis in this study showed that less of the polypeptide was visible upon spray 
drying NaCMC-modified preparations with co-solvents, even though the same amount of 
protein was loaded. This observation may account for the decreased activity of the 
phosphatase which was measured by the diethanolamine assay.  
 
3.8     Conclusion 
This study demonstrated that while the selection of appropriate excipients and solvent 
systems may enable the preparation of co-spray dried powders of model proteins and 
NaCMC with the requisite size, possessing low interparticulate cohesion which results in 
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improvements to fine particle fraction, there are challenges that may also arise from 
such formulations. These include heterogenous particle sizes and a significant loss in 
activity of the protein (i.e for protein powders prepared from co-solvent systems). On the 
otherhand, excipient-free spray-dried powders prepared from water only suspensions 
however posses the requisite size, are more homogenous (very small span) and also 
have the advantage of one less processing step when compared with NaCMC-modified 
formulations. Since the methods developed in this study will inform the subsequent 
development of a pulmonary delivered antimicrobial protein, dry powder inhaler devices 
were found to be better suited at delivering the masses of powder that would be required 
for the proposed therapies in one or two divided doses.  
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4.1     Summary 
Having designed a plausible method of micronising and delivering active proteins to the 
airway through co-spray drying them with the excipient sodium carboxymethylcellulose 
(NaCMC) in the previous chapter, the next logical step was to advance the application of 
the method to potentially therapeutic proteins. In this chapter, we investigated the 
possibility of formulating the antimicrobial protein, lactoferrin, with suitable aerodynamic 
properties to enable its delivery directly to the airways. The fundamental aerodynamic 
properties required for the design of a successful inhaled therapy included; particle size, 
morphology, density, moisture content, and its aerosolisation performance. This chapter 
also examines the preparation and spray drying of iron-free lactoferrin since this 
compound may possess more biological activity than the iron-rich form.  Micro-particles 
of the iron-free and iron-rich lactoferrin preparations were prepared from a suspension 
feedstock of 2% w/v using a small scale laboratory spray dryer. The particles generated 
were characterized by differential scanning calorimetry (DSC), helium gas pycnometry, 
scanning electron microscopy and Karl Fischer titration and in vitro aerosolisation 
properties of the micro-particles produced evaluated using the multi-stage liquid 
impinger. Overall, the data indicate that the spray drying parameters employed were 
able to generate micro-particles with requisite size, residual moisture content and 
suitable aerosolisation properties  
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4.2     Introduction 
 Delivering biopharmaceuticals directly to the airways as aerosols has continued to be 
an attractive, convenient and effective way of directly employing macromolecules as 
therapeutic agents for a variety of airway disorders. In particular, the direct delivery of 
high concentrations of antimicrobial agents (formulated as aerosols) to the various sites 
of infection in the airway of people with respiratory infections is advantageous over 
macromolecular drug delivery through other conventional routes. This delivery strategy 
can be employed to effectively treat respiratory infections, such as pneumonia or 
specific airway infections as commonly seen in diseases such as cystic fibrosis and 
tuberculosis (Gelperina et al., 2005). It is also the case that aerosolized antimicrobial 
therapies seem to offer an appealing and logical approach for the treatment of airway 
infections.  This is not just because they ameliorate lung function, reduce systemic long 
term toxicity (due to the lower therapeutic doses required) (Adi et al., 2008), represent a 
non-invasive means of drug administration (thereby increasing patient compliance) as 
well as decrease hospitalizations, but also because they offer significant improvement in 
diseases like cystic fibrosis where their efficacy possibly should possibly make them a 
mainstay therapeutic concept. The efficiency of utilizing aerosolized antimicrobial 
particles in therapy depends on several characteristics. Of these, particle size, density, 
morphology, surface energy and surface roughness play a key role in determining where 
an aerosolized particle would most likely deposit.  
 
In chapter three, the spray drying technique was highlighted as a popular dry powder 
production technique for pulmonary formulations, this is especially because it is able to 
produce micron sized powders suitable for inhalation in combination with a parallel 
optimisation of density and morphology. Spray drying could potentially be a more 
attractive technique for producing dry powders of therapeutic proteins suitable for 
Chapter Four: Characterisation of lactoferrin 
- 173 - 
 
inhalation although it is however still fraught with various challenges ranging from 
thermal degradation of spray-dried products (Broadhead et al., 1994) to the production 
of unstable amorphous materials (Chan and Chew, 2003) (although this may also be an 
advantage).The drawbacks of spray drying are marked for proteins in particular, 
especially among those containing cysteine and methionine residues (as they are easily 
oxidized to sulphoxides). 
 
4.2.1     Reasons for selecting lactoferrin as our protein of choice 
Lactoferrin (formerly known as lactotransferrin) is a glycoprotein with a capacity to bind 
Fe3+ ion – and is a member of the transferrin family (Metz-Boutigue et al., 1984a). 
Lactoferrin is the main iron-binding protein in human milk (Johanson, 1960; Montreuil et 
al., 1960) although it is also found in specific granules of neutrophils and in most 
mucosal secretions including; tears, saliva, bile, vaginal secretions, seminal fluid, 
pancreatic juice and small intestinal secretions  (Levay and Viljoen, 1995; Lönnerdal and 
Iyer, 1995; Baker and Baker, 2005a; Masson et al., 1966; Iyer and Lonnerdal, 1993; 
Thompson et al., 1990). Various biological functions have been ascribed to lactoferrin 
including antibacterial, antiviral and anti-inflammatory activities. Lactoferrin is a part of 
the innate immune system along with other antimicrobial peptides which makes it a 
potentially useful protein in the treatment of various airway infections. In this respect, 
aerosolized delivery of this important protein to the airway should present a suitable 
means of harnessing its activity against susceptible microbes present in the infectious 
airways. In secretions from the normal airways, lactoferrin found at between 1 to 10 
µg/mL (Thompson et al., 1990). 
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4.2.2     Delivering lactoferrin to the airways 
The challenges of delivering lactoferrin to the airways are enormous, therefore, a careful 
selection of the formulation characteristics and a method of delivering it is crucial for 
achieving a successful lactoferrin therapy. Furthermore, it is thought that in order to 
efficiently and effectively deliver lactoferrin to the airways, it is pertinent that the 
formulation is delivered as a dry powder (since dry powder formulations are more stable 
than liquid formulations). There are only two aerosol devices that can deliver dry powder 
formulations; the pressurized metered dose inhaler (pMDI) or the dry powder inhaler 
(DPI). While pMDI’s can only deliver small masses of therapeutic agent, DPI’s can 
deliver very high doses. In order to achieve the high therapeutic concentrations that are 
likely to be required for effective therapy, the DPI devices seem more attractive. 
 
The DPI provides a technique for efficiently delivering proteins to the airways by utilizing 
the inspiratory energy of the patient. Today there are a variety of DPI devices available 
for clinical use. All currently available DPI systems feature several attractions including; 
ability to deliver high doses, they do not require a propellant to aerosolise incorporated 
API’s and they usually do not interact with the formulations which they deliver. 
 
Since the performance of a DPI system is not only dependent on the device employed 
but also on the powders aerosolized, both aspects must be considered in order to 
produce powders (with API’s included) with favourable aerodynamic properties. This 
challenge is especially made difficult if the therapeutic agent is either a protein or 
peptide (due to their labile nature) as not many processing conditions are suited to these 
groups. Nevertheless, since the percentage of the emitted dose deposited in the airways 
is dependent on the powder’s dispersibility (a determinant of the micronisation process 
Chapter Four: Characterisation of lactoferrin 
- 175 - 
 
to be employed), the need to produce powders with suitable characteristics and which 
can be easily dispersed cannot be overemphasized (as efficient dispersion is key to 
achieving patient-reproducible delivery) (Weers, 2000b).  
 
4.3     Aims and objectives 
This chapter aims to exploit the methods used in the previous studies (which involved 
spray drying a model protein alkaline phosphatase) to develop microparticulate 
formulations of Lactoferrin. The suitability of these spray-dried formulations for inhaled 
therapy will then be assessed by investigating the physical aspects of various spray-
dried lactoferrin formulations.  
Two different lactoferrin powders will be prepared through spray drying of commercially 
available bovine milk lactoferrin, and a iron depleted form of this lactoferrin. These will 
be spray-dried in the presence and absence of sodium carboxymethylcellulose, before 
characterisation to determine particle size, particle density, residual moisture, thermal 
properties and in vitro aerosolisation properties. The data was then be analysed to 
determine the most optimal formulation for pulmonary delivery. 
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4.4     Materials 
Lactoferrin from bovine milk was obtained as a kind donation from DMV Fonterra. 
sodium carboxymethylcellulose, sodium acetate, sodium dihydrogen phosphate were all 
of analytical grade and were purchased from Sigma aldrich (Poole, UK). Spectrosol 
ferric nitrate was purchased from VWR (Leicestershire, UK), BCA protein assay reagent 
was purchsed from Thermo Scientific (Rockford, IL USA). 
 
4.5     Methods 
4.5.1     Preparation of micro-particulate lactoferrin powders 
Two grams of lactoferrin powder was dispersed in 70 mL of distilled water, stirred until a 
homogenous suspension resulted and then made up to a final volume of 100 mL to 
produce a 2 % w/v suspension at room temperature, the mixture was stirred until a fine 
mixture was obtained. This was spray-dried using a Buchi B290 spray dryer with the 
following conditions: feed rate  - 3 mL/min, aspiration rate 95 %; air flow rate 606 L/hr, 
inlet temperature 180°C, to produce an outlet temperature of 99 – 101 °C. This 
procedure was repeated two more times to produce three batches of spray-dried 
lactoferrin powders. 
 
4.5.2     Preparation of apo-lactoferrin 
An iron deplete form of lactoferrin (aLf) was prepared from partially iron saturated 
lactoferrin as previously described by Newsome et al., (2007). Briefly, the partially iron 
saturated lactoferrin was resuspended at a final concentration of 2% (w/v) in deionzed 
water, transferred to dialysis membrane and dialyzed for 24h at 4 °C against 20 mmol/L 
sodium acetate, 20mmol/L sodium dihydrogen phosphate and 40mmol/L EDTA (pH 3.5). 
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The protein was then dialyzed against 900 mL of deionzed water with at least 2 changes 
and used immediately or quickly frozen at -80 °C. 
4.5.3     Preparation of spray-dried apo lactoferrin 
Following dialysis, the resulting protein suspension was spray-dried with the following 
parameters; Inlet temperature, 180 °C; spray flow rate, 606 L/hr; feed rate  - 3 mL/min; 
aspirator rate, 95 %. These setting resulted in an outlet temperature ranging from 100 – 
102 °C. 
 
4.5.4     Estimation of the iron content of lactoferrin preparations 
A standard calibration graph of spectrosol ferric nitrate was prepared by measuring the 
absorbance of stock concentrations (0.05 – 5 ppm) using a Perkin Elmer AAnalyst 100 
atomic absorption spectrophotometer. The amount of iron bound to the various 
lactoferrin preparations (Lf, SDLf, aLf and SDaLf) was then estimated from the 
calibration curve following iron absorption measurements. 
 
4.5.5     Preparation of co-spray dried lactoferrin with sodium 
carboxymethylcellulose  
A 2 % w/v suspension of lactoferrin and sodium carboxymethylcellulose  was prepared 
by dispersing 1 g of sodium carboxymethylcellulose in 70 mL of deionised water and 
then stirred until a slurry resulted, before 1 g of lactoferrin was added to the slurry, 
stirred  and the final volume made up to 100 mL with deionised water. The resulting 
slurry was then spray-dried with the following parameters; Inlet temperature, 180 °C; 
spray flow rate, 606 L/hr; feed rate  - 3 mL/min; aspirator rate, 95 %. These setting 
resulted in an outlet temperature ranging from 97 – 99 °C. This procedure was repeated 
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two more times to produce three batches of co-spray dried lactoferrin with sodium 
carboxymethylcellulose dry powders. 
 
4.5.6     Preparation of co-spray dried apo lactoferrin with sodium 
carboxymethylcellulose  
One gram of sodium carboxymethylcellulose was made up to a final volume of 100 mL 
with apo lactoferrin (prepared as outlined in section 2.2.2.2.4) to produce a 2 % w/v 
suspension feedstock containing 1:1 apo lactoferrin-sodium carboxymethylcellulose 
suspension feedstock. The resulting slurry was then spray-dried with the following 
parameters; Inlet temperature, 180 °C; spray flow rate, 606 L/hr; feed rate  - 3 mL/min; 
aspirator rate, 95 %. These setting resulted in an outlet temperature ranging from 98 – 
99 °C. 
 
4.5.7     Karl-Fischer titration analysis 
Residual moisture of the various spray-dried powders were determined (immediately 
following spray drying) by Karl-Fischer titration at 25 ±1°C using a C20 Coulometric Karl 
Fischer titrator (Mettler Toledo).   Triplicate measurements of approximately 5 mg of the 
various powders were analysed and the percent moisture content (mean ±SD) 
computed for each of the powder preparations. 
 
4.5.8     Particle size Distribution 
Particle size distributions of the various spray-dried powders were determined using the 
same method outlined in section 3.5.5. Briefly, about 5 – 10 mg of each powder sample 
was analysed with a Helos H 2178 laser diffraction instrument coupled to a Rodos dry 
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dispersing unit at 2.0 bars using an R2 lens. The data obtained are reported as the 
percent of particles sized in the lower 10, middle 50, upper 10 th percentile (d[v,10], 
d[v,50] and d[v,90] respectively) and the volume mean diameter (VMD). Also the span of 
the volume distribution, a measure of the width of the distribution relative to the median 
diameter (d[v,50]), was also calculated using equation 3.1 also detailed in section 3.5.5  
 
4.5.9     Scanning Electron Microscopy of the various lactoferrin 
powders 
Scanning electron micrographs of the various lactoferrin powder formulation were 
obtained using the same method outlined in section 3.5.6. Briefly, samples were 
mounted on adhesive black carbon tabs (premounted on aluminium stubs) and sputter-
coated (Polaron SC500, Polaron Equipment) with a thin layer of gold for 3 mins at 20 
mA. The samples were subsequently studied under high magnification (which is shown 
on each micrograph along with a scale bar in µm). 
 
4.5.10   Density of the various spray-dried lactoferrin powders 
The true density of the various powders was determined using a helium pycnometer 
(Multipycnometer, Quantachrome Instruments) with a 3 cm³ sample cup at 22 °C. Prior 
to analysis, the helium pycnometer was calibrated against a standard steel ball. For 
each analytical determination the reference volume was pressurized to approximately 17 
pounds per square inch (1.195 Kg/cm2) above the ambient pressure. Measurements 
were performed in triplicate for each preparation. 
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4.5.11   X-ray powder diffraction 
The crystal structure of both the single and co-spray dried powders were characterized 
using an x-ray powder diffractometer (Bruker D2 Phaser, UK). The system comprised of 
a scintillation counter and a 1-dimensional LYNXEYE detector with a CU Kα radiation 
source, an accelerating voltage of 30 kV and an emission current of 10 mA. Diffraction 
patterns were recorded between 2° and 70° of 2θ with an increment of 0.02° and a step 
time of 0.1 s. 
 
4.5.12   Differential scanning calorimetry  
Differential scanning calorimetry (Pyris Diamond DSC and Intracooler 2P: Perkin Elmer, 
Wellessey, USA) was employed to characterise the thermal behaviour of the various 
powder formulations. Prior to the start of the assessments, the DSC was calibrated for 
temperature and heat flow using standard samples of indium (melting point: 156.6 °C, 
∆Hm: 28.42 J/g) and Zinc (melting point: 419.5 °C, ∆Hm: 108.26 J/g).  Following 
calibration, 4 mg of each of the powders was loaded into an aluminium pan, cooled to -
30 °C and then heated to 200 °C at 10 °C/min with a nitrogen purge of 10mL/min. An 
empty aluminium pan was used as reference for all measurements. The resulting data 
were analysed using a Pyris manager software. Triplicate measurements of all 
independently prepared sample batches were assessed.  
 
4.5.13   Preparation of DPI formulations  
Doses of 30 mg of either lactoferrin, apo lactoferrin (aLf) or spray-dried lactoferrin 
(SDaLf) were manually loaded into size 3 gelatin capsules. The dose loaded into the 
gelatin capsule was determined to be the optimum dose which can be effectively loaded 
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into the capsule without packing it too tightly as to impede aerosolisation as well as 
ensuring sufficient material to calculate a fine particle fraction. 
 
4.5.14   Quantification of total protein in the formulations 
Protein quantitation was carried out as previously described in section 2.2.8.  
 
4.5.15   In vitro aerodynamic assessment 
The pulmonary deposition of the dry powders were estimated in vitro using a Multi-stage 
liquid impinge (MSLI). Twenty millilitres of water was poured into each of the four stages 
of the impinger to wet the collection surface. A vacuum pump was attached to the MSLI 
and the inspiratory flow rate was calibrated (by adjusting the vacuum pump settings) and 
set at a flow rate of 60 L/min. Approximately 30 ±2 mg of each of the dry powders was 
manually weighed into a size 3 hard gelatin capsules. A capsule was placed into the 
capsule compartment of a Cyclocaps™ Cyclohaler™ DPI device (Pharmachemie BV, 
The Netherlands), pierced and actuated for 5 s. Powders depositing in the four impinger 
levels were recovered by agitating the apparatus to ensure complete dissolution. The 
powder which deposited in the throat and the back filter were also collected and the 
amount of protein depositing in each of these stages determined by carrying out BCA 
assay which is described in section 2.2.8. The assessment was carried out on three 
batches of dry powder with triplicate measurement for each of the protein suspensions. 
From these protein measurements, the recovered dose (RD, the sum of protein 
collected from all stages, filter and throat), the Fine Particle dose (FPD, mg of protein 
possessing less than 5 μm aerodynamic diameter) and the Fine Particle Fraction (FPF: 
the ratio between FPD and RD) were calculated. The Mass Median Aerodynamic 
Diameter (MMAD) was determined from a graphical plot of % cumulative undersize 
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against effective cut-off diameter (i.e 13.0, 6.8, 3.1 and 1.7 µm for stages 1 to 4) at a 
flow rate of 60 L/min. The MMAD was defined from this graph as the particle size at 
which the line crossed the 50 % mark. 
 
4.5.16   Statistical analysis 
Data was subjected to statistical analysis using one-way ANOVA to examine for 
significant difference (defined as p > 0.05). Significant differences between the various 
formulations were analysed using Dunnett post test with p values of < 0.05 being 
considered to be significant.  
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4.6     Results 
4.6.1    Calibration plot of absorbance against ferric ion concentration 
A calibration curve of absorbance against ferric ion (Fe3+) concentration (0.05 – 5 ppm) 
was plotted (figure 4 -1) and it yielded a linear relationship (y = 0.361x + 0.0013, r2 > 
0.999). The equation of the line of best fit was used to estimate the ferric ion content in 
various lactoferrin preparations in subsequent analyses. 
 
 
 
Figure 4 -1: Calibration plot of mean absorbance against standard ferric ion concentrations. The 
mean absorbance calculated from calibrations obtained on 3 different days are plotted against 
nominal ferric ion concentration values (n = 3). Error bars representing standard deviation are 
displayed for each point but are within the limits of the symbols.  
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All calibration curves obtained on different days were linear within the measured 
concentration range of 0.05 – 5 ppm ( Day 1: y= 0.036x + 0.0012, r2 = 0.999; Day 2: y= 
0.0362x + 0.0009, r2 > 0.999; Day 3: y= 0.036x + 0.0019, r2 > 0.999). The assay method 
generally showed good reproducibility with similar inter-day results. 
 
4.6.2     Validating the ferric ion quantitation assay 
As with majority of compounds quantified using atomic absorption spectrophotometer 
(AAS), there is a need to validate the analytical method employed. Intra- and inter-day 
precisions were determined by computing the % RSD (otherwise known as coefficient of 
variation CV) obtained from three individual absorbance values of nominal 
concentrations 0.05 – 5 ppm obtained on the same day (intra-day precision) and over a 
three day period (inter-day precision). The lower the value, the better the assay 
performance. Data analysis showed that the highest intra-day % RSD calculated (an 
indicator of precision) was 24.74 % at ferric ion concentration of 0.05 ppm on days 1 and 
2 (Table 4.1). The high % RSD is due to limitations in the sensitivity of the equipment. 
The inter-day assay variability was found to range between 0.28 – 14.32. 
 
According to the assay method employed, the limit of detection (LOD) which is the 
lowest concentration of ferric ion that can be detected but not quantified and the limit of 
quantitation (LOQ) which is the lowest concentration of ferric ion that can be measured 
with acceptable precision by the assay method were calculated from the mean of the 
slope and the SD of the intercept of three calibration curves. The mathematical method 
for calculating LOD and LOQ are outlined in equation 2.2 and 2.3 respectively (section 
2.2.1.1.4, page 80) and the values obtained are shown in table 4.1. 
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Table 4.1: Calculated mean absorbance, standard deviation, % RSD, R
2
, LOD, LOQ and 
Nominal concentration of ferric ion. Linear regression measurement provided the necessary 
information to estimate the LODs and LOQs. Except for nominal concentrations 0.1 ppm and 
below, the small standard deviations of the absorbance values indicate good intra-day precision. 
  
Fe
3+
 
Conc. 
(ppm) 
Mean 
Absorbanc
e 
Standard 
deviatio
n 
Relative 
standard 
deviation (%) 
Linear 
regression 
(R
2
) 
Limit of 
detectio
n (ppm) 
Limit of 
quantitation 
(ppm) 
D
a
y
 1
 
0.05 0.002 0.0006 24.74 
0.9996 0.0007 0.0022 
0.1 0.004 0.0006 15.75 
0.5 0.019 0.0006 2.99 
1 0.038 0.0006 1.51 
3 0.111 0.0015 1.37 
5 0.180 0.0015 0.85 
D
a
y
 2
 
0.05 0.002 0.0006 24.74 
0.9995 0.0018 0.0054 
0.1 0.003 0.0010 17.32 
0.5 0.019 0.0010 5.26 
1 0.038 0.0010 2.63 
3 0.112 0.0010 0.89 
5 0.180 0.0010 0.56 
D
a
y
 3
 
0.05 0.003 0.0006 21.65 
0.9995 0.0024 0.0073 
0.1 0.004 0.0010 15.75 
0.5 0.021 0.0015 7.16 
1 0.038 0.0015 3.98 
3 0.112 0.0010 0.89 
5 0.181 0.0015 0.85 
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4.6.3     Ferric ion concentration in lactoferrin  
The mean ferric ion concentration in the commercially supplied lactoferrin was found to 
be 2.81 ± 0.05 ppm (values were estimated from the calibration curve of absorbance vs 
ferric ion concentration), after spray drying, the ferric ion content was 2.77 ±0.04 and 
this did not represent any significant difference from the starting material.  However 
dialysis of Lf against sodium acetate, sodium dihydrogen phosphate and EDTA to 
produce iron-free aLf resulted in a ferric ion content of 1.0 ±0.11 ppm.  This was 
measured to be 0.92 ±0.03 ppm after spray drying.  
 
 
Figure 4 -2: Ferric ion concentration in parts per million of various lactoferrin preparations. The 
mean and standard deviation of each of the lactoferrin preparation is shown (n = 3). Error bars 
represent standard deviation around the mean. Comparisons of groups were made by one-way 
analysis of variance (ANOVA) using graphpad prism 5 (GraphPad Software Inc., Version 5.0) 
followed by Dunnett post-test; *** indicates p <0.001 compared to iron content in the 
commercially supplied lactoferrin (Lf). 
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4.6.4     Spray drying conditions, yield and moisture content 
The spray drying parameters employed, yield of the dried powders and moisture content 
of the various lactoferrin powder formulations are summarized in table 4.2. All the 
formulations were spray-dried with an inlet temperature of 180 °C and airflow rate of 606 
L/hr to produce various outlet temperatures ranging from 99 – 102 °C. The residual 
moisture in all the various spray-dried formulations was measured by Karl fischer and 
found to between 5 and 9 % (Table 4.2).  The mean yield for the spray-dried protein only 
formulations were between 45 and 58 %, however, upon inclusion of NaCMC into the 
spray drying feedstock the percent yield improved (74 – 76 %) (Table 4.2). 
 
Table 4.2: Spray drying parameters, yield and moisture content of spray-dried lactoferrin and 
spray-dried apo lactoferrin. Three different batches of the various lactoferrin powders were 
prepared and the mean ±SD of the yield and moisture content are shown below. Statistical 
analysis of the various formulations were carried out by one-way analysis of variance (ANOVA) 
using GraphPad prism 5. ‡ denotes p < 0.01 statistical difference compared to the spray-dried 
lactoferrin only formulation. 
 
Formulations Inlet temp 
(°C) 
Outlet 
temp (°C) 
Airflow 
rate (L/hr) 
Mean 
yield (%) 
Moisture 
content (%) 
SDLf 180 99 - 101 606 45.2 ±2.7 5.9 ±0.4 
SDaLf 180 100 - 102 606 57.8 ±1.8‡ 5.7 ±0.2 
SDLf + NaCMC 180 97 - 99 606 76.1 ±2.2‡ 8.2 ±0.6‡ 
SDaLf + NaCMC 180 99 - 101 606 74.3 ±1.8‡ 7.6 ±0.7‡ 
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4.6.5     Particle size distribution 
The volume mean particle size of lactoferrin was measured before spray drying and 
found to be 27.89 µm. After spray drying, the volume mean particle size decreased to 
5.9 µm for SDLf and 5.7 for SDaLf. The particle size distribution (PSD) for Lf, aLf SDLf 
and SDaLf is summarized in table 4.3. The data is expressed in terms of the particle 
diameter at 10, 50 and 90% of the volume distribution (d[v,10], d[v,50] and d[v,90] 
respectively).  The span of the volume distribution, a measure of the width of the volume 
distribution relative to the median diameter (d[v,50]), was derived from (d[v,90] - d[v,10]/ 
d[v,50]) and varied between 1.5 ±0.1 (Lf) and 3.5 ±0.4 (SDaLf + NaCMC) (Table 4.3). 
 
Table 4.3: Particle size distribution of the various lactoferrin powder formulations determined 
through laser diffraction measurements. Addition of NaCMC increased the span the of the 
particle size distribution. The values are mean ± SD of triplicate measurements.   
 
 Particle size distribution (µm) 
Formulations d[v,10] 
(µm) 
d[v,50] 
(µm) 
d[v,90] 
(µm) 
Span Volume mean 
diameter (µm) 
Lf 8.80 ±0.3 26.24 ±0.3 48.59 ±0.5 1.52 ±0.1 27.89 ±0.4 
SDLf 1.38 ±0.2 4.91 ±0.3 11.08 ±0.4 1.98 ±0.2 5.85 ±0.4 
SDaLf 1.28 ±0.3 4.79 ±0.2 11.01 ±0.5 2.03 ±0.1 5.67 ±0.5 
SDLf + NaCMC 1.16 ±0.6 5.23 ±0.6 14.78 ±0.8 2.63 ±0.4 7.51 ±0.5 
SDaLf + NaCMC 1.29 ±0.4 5.48 ±0.6 20.56 ±0.8 3.55 ±0.4 8.55 ±0.5 
 
 
The d[v,50] of the spray-dried protein particles were below 5 µm however, upon 
including NaCMC into the suspension feed stock, the d[v,50] increased to 5.5 ±0.6 µm 
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while the VMD increased from < 6 µm (for the spray-dried proteins) to between 8 and 9 
µm. The span of the co-spray dried formulations were also increased from about 2 
(SDaLf) to 3.6 (SDaLf + NaCMC). 
 
4.6.6     Morphology of the various spray-dried formulations 
Scanning electron micrographs of native, iron-rich lactoferrin as supplied revealed that 
the protein was composed of spherical particles and ranged up to 40 µm (Fig 4 -3a). 
Upon spray drying the proteins, the particles became less smooth, less regular, formed 
smaller agglomerates ranging up to 10 µm (Fig 4 -3b and c). On the other hand, the co-
spray dried lactoferrin-NaCMC formulations yielded particles of a heterogenous size 
distribution of big, compact aggromerates that ranged up to 10 µm and small irregular 
shaped particles of < 5 µm (Fig. 4 -3d and e) 
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a) Lf b) SDLf 
 
 
c) SDaLf d) SDLf + NaCMC 
 
 
e) SDaLf + NaCMC  
 
 
Figure 4 -3: Representative scanning electron micrographs of various lactoferrin powders (a) 
commercially supplied lactoferrin (b) spray-dried lactoferrin (c) spray-dried apo lactoferrin (d) co-
spray dried lactoferrin and sodium carboxymethylcellulose (e) co-spray dried apo lactoferrin and 
sodium carboxymethylcellulose. Mostly the morphology of the protein particles were retained 
although there was an increase in the number of deformed particles. Magnifications are shown 
on the top of each micrograph. The images are a representative of three batches of powders. 
SE micrographs (Fig. 4 -3) showed that the Lf (Fig. 4 -3a) powders comprised of 
spherical particles generally resembling broken beads. SDLf (Fig. 4 -3b) comprised of 
particles of an irregular shape with indentations on the surface, suggesting the 
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appearance of a collapsed sphere. SDaLf (Fig. 4 -3c) comprised of aggregates of 
irregular shaped particles with a rough surface morphology. It also comprised of very 
small amount of spherical particles with a hollow morphology. SDLf + NaCMC (Fig. 4 –
3d) and SDaLf + NaCMC (Fig. 4 -3e) comprised of particles with varied surface 
morphologies, while some particles were more rounded in appearance, others had a 
rough surface morphology. The addition of NaCMC to the spray drying feedstock also 
resulted in an apparent increase in particle size.   
 
4.6.7     True density  
The true densities of the powders were evaluated using a gas pycnometer and found to 
have very small inter-batch variation. However, the true densities of the various spray-
dried powders were significantly higher than the true density of the commercially 
supplied lactoferrin powder (Lf) (Figure 4 -4). In addition, while the true density of the 
spray-dried iron deplete lactoferrin was significantly higher than the spray-dried protein, 
there were no significant difference between the particle densities of both NaCMC 
modified proteins.   
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Figure 4 -4: True density of the various lactoferrin powders measured by helium gas 
pycnometer. The various spray-dried lactoferrin particles possessed a significantly higher true 
density compared to the commercially supplied lactoferrin particles, also, SDaLf possessed 
possessed significantly higher true density compared to SDLf. However, the particle size 
densities of SDLf, SDLf + NaCMC and SDaLf + NaCMC. Values are mean ±SD of triplicate 
measurements from three batches of powders. Comparisons of groups were made by one-way 
analysis of variance (ANOVA) using graphpad prism 5 (GraphPad Prism Software Inc., Version 
5.0) followed by Dunnett post-test; p values were considered significant and the *** represents p 
value < 0.001 between the various spray-dried lactoferrin powders and the commercially supplied 
lactoferrin powders (Lf); ‡, p < 0.001 between SDLf and SDaLf formulations. 
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4.6.7     X-ray powder diffraction (XRPD) 
The X-ray powder diffraction patterns (figure 4 -5a and 4 -5b), shows that the various 
spray-dried powders lacked any sharp distinct peaks. An indication that all the powders 
were amorphous. 
 
a) 
 
  
b) 
 
Figure 4 -5: X-ray powder diffraction patterns of various lactoferrin powder formulations. (a) 
shows representative XRPD patterns of the commercially supplied lactoferrin powders compared 
to spray-dried lactoferrin (SDLf) and spray-dried apo lactoferrin powders, (b) shows 
representative XRPD patterns of the commercially supplied lactoferrin powders compared to co-
spray dried lactoferrin-NaCMC and co-spray dried apo lactoferrin-NaCMC powders. All the spray-
dried powders have a broad halo and lack resolved reflections indicating that they are all 
amorphous. The results presented are a representation of repeats from three batches of powder. 
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All the diffractograms illustrated in Figure 4 -5 were all characterised of two broad 
humps between 4° 2θ and 50° 2θ and had no resolved reflection.  
 
4.6.8     Thermal analysis 
The thermal properties of the various lactoferrin formulations are shown in figure 4 -6. 
The DSC scans of the various spray-dried drug was characterised by abnormal heat 
transitions indicative of the presence of some amorphous content 
 
 
Figure 4 -6: DSC thermograms of the various protein formulations. The scans show the thermal 
events of the various powder samples when heated from -30 °C to 200 °C, while the 
thermograms were mostly uneventful, Lf, SDLf, SDaLf and SDLf + NaCMC had single or multiple 
broad peaks generally between -5 °C and 10 °C, SDaLf + NaCMC had no peaks at all. The 
absence of melting point peaks indicated that the powders were amorphous. 
 
The thermograms obtained from DSC analysis of Lf showed that protein had no peaks 
except for broad peaks between 5 °C and 10 °C. Similarly, the thermograms obtained 
from DSC analysis of SDLf showed no melting point peaks except for three broad peaks 
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between 0 °C and 10 °C and the thermograms obtained from DSC analysis of SDaLf 
also showed no melting point peaks but had two broad superimposed peaks between 0 
°C and 10 °C. Furthermore, while the thermograms obtained from DSC analysis of SDLf 
+ NaCMC showed no melting point peaks but had three broad peaks between -5 °C and 
10 °C, the thermograms obtained from DSC analysis of SDaLf + NaCMC showed no 
peaks at all. 
 
4.6.10   In vitro aerodynamic assessment 
Besides particle size, density and morphology of a drug powder, the de-agglomeration 
characteristics of the powder in the air stream is also a very important performance 
characteristic for effective aerosol deposition in the airways. This is because in order to 
separate particles, specific forces of interaction (for example, mechanical interlocking, 
capillary forces, electrostatic forces and van der Waals forces) must be overcome. 
Therefore it is pertinent to assess the performance of the powder formulations in order 
to enable the prediction of the aerodynamic properties of the various powder 
formulations. Results for the aerodynamic behaviour of various lactoferrin powder 
formulations as analyzed with the MSLI are presented in the following sub-sections.  
 
4.6.11   Validating the protein quantitation assay 
In order to ensure the validity of the assay method and the calibration graph employed in 
estimating protein deposition on the various stages of the MSLI following aerosolisation, 
some validation parameters were determined including; linearity, precision, limit of 
detection and limit of quantitation. The specificity of the assay to quantify proteins in the 
presence of sodium carboxymethylcellulose was assessed and found not to be any 
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different from the calibration plot in figure 4 -7. In other words, the presence of NaCMC 
in the formulations did not produce any significant change in the absorbance values  
 
The calibration curves prepared on different days were linear (> 0.99) within the 
measured range of 5 – 2000 µg/mL. The assay method showed good reproducibility with 
similar inter-day results (day 1: y = 0.0011x + 0.0248; day 2: y = 0.0011x + 0.0269; day 
3: y = 0.0011x + 0.0071). Figure 4 -7 shows the mean calibration plot of absorbance 
against concentration of triplicate values obtained on three different days. The equation 
of the line of best fit (y = 0.0011x + 0.0194) was used to estimate the protein 
concentration of the various lactoferrin formulations as well as the nominal dose 
depositing on each of the MSLI stages. 
 
 
Figure 4 -7: Linear regression plot of absorbance against standard BSA concentrations. The 
mean absorbance calculated from calibrations obtained on 3 different days are plotted against 
nominal protein concentration values (n = 3). Error bars representing standard deviation are 
displayed for each point but are mostly within the limit of the symbols. 
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4.6.11.1     In vitro deposition properties of the various lactoferrin powders 
The various powders were formulated as DPI and aerosolized at a flow rate of 60 L/min 
into the MSLI for 2 x 5s. The deposition profile of the various protein powders in all the 
stages of the MSLI is shown in figure 4 -8.  
 
 
Figure 4 -8: Influence of spray drying on the aerodynamic characteristic of various lactoferrin 
formulations; Lf – commercially supplied lactoferrin, SD Lf – spray-dried lactoferrin, SD Apo Lf – 
spray-dried apo lactoferrin and co-spray dried lactoferrin with sodium carboxymethylcellulose. 
The nominal dose of protein depositing on each stage was assessed using a BCA protein assay. 
The data shown is a mean ± SD of three individual batches measured three times each. 
 
Following aerosolisation of 30 mg of Lf from the cyclohaler, about 13 % of the protein 
was retained in both the capsule and the DPI device (mouth piece), ~ 27 % deposited in 
the throat of the MSLI, 34 % deposited on stage 1, 14 % deposited on stage 2 and about 
10 % deposited on stages 3 through to the filter (particle sizes < 6.8 µm). In comparison, 
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Upon aerosolisation of 30 mg of SDLf, about 11 % of the protein was retained in both 
the capsule and the DPI device, 11 % of the protein deposited in the throat, 12 % of the 
protein deposited in stage 1, 16 % of the protein deposited on stages 2 and 47 % 
deposited on stages 3 through to the filter. Aerosolisation of 30 mg of SDaLf resulted in 
the retention of about 8 % of the protein in the device, while 10 % of the SDaLf protein 
deposited in the throat of the MSLI, 14 % deposited on stage 1, 18 % deposited on 
stages 2 and 48 % deposited on stages 3 through to the filter. Aerosolisation of 30 mg of 
the NaCMC spray-dried powders resulted in the retention of about 8% (SDLf + NaCMC) 
and 6 % (SDaLf + NaCMC) of the protein in both the capsule and the DPI device (mouth 
piece), while 14 % of the protein deposited in the throat, 12 % of the protein deposited 
on stage 1, about 17% of the protein deposited on stage 2 and ~ 48 % of the NaCMC 
modified protein deposited on stage 3 through to the filter.   
 
4.6.11.2     Fine particle fractions of the various aerosolized powder 
formulations 
The amount of lactoferrin depositing on all the stages of the MSLI varied for the different 
formulations. The commercially supplied lactoferrin powders showed poor protein mass 
deposition below stage 3 (effective cut-off of 6.8 µm) of the MSLI making the % 
FPF<6.8µm ~ 9.8 %.  However, the FPF<6.8µm of the various spray-dried lactoferrin 
formulations (Fig 4 -9) was greater than 48 % of the total recovered protein dose. 
NaCMC-free formulations compared to NaCMC-modified formulations were found to 
possess statistically equivalent FPF. 
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Figure 4 -9: Fine particle fraction < 6.8 µm of the various lactoferrin powders. Assessments were 
carried out using the MSLI and the protein content of each powder was corrected for each of the 
formulation and reported as a % of the nominal dose. Values are mean ± SD, n = 3. 
Comparisons of groups were made by one way analysis of variance using graphpad prism 5 
(GraphPad Prism Software Inc., version 5.0) followed by Dunnett post-test; p values were 
considered significant and the *** represents p value < 0.001 between the various spray-dried 
formulations and the commercially supplied protein. All the spray-dried lactoferrin formulations 
demonstrated equivalent FPF values.  
 
4.6.11.3     Mass median aerodynamic diameter of the various aerosolized 
powder formulations 
The MMAD of the commercially supplied lactoferrin was found to be 33.6 µm, however 
upon spray drying, the MMAD of the various spray-dried powders was found to range 
between 4 µm and 6 µm. Statistically, while the MMAD of the spray dried formulations 
were significantly (p < 0.001) less than that of the commercially supplied lactoferrin, 
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there were no significant differences between the MMAD of the excipient free dry 
powder formulations and the sodium carboxymethylcellulose modified formulations. 
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Figure 4 -10: Mass median aerodynamic diameter (MMAD) of commercially supplied (Lf), 
excipient-free (SDLf and SDaLf) and sodium carboxymethylcellulose modified (SDLf + NaCMC 
and SDaLf + NaCMC) spray-dried lactoferrin. Values are mean ±SD, n = 3. Comparisons of 
groups were made by one-way analysis of variance (ANOVA) using graphpad prism 5 (GraphPad 
Prism Software Inc., Version 5.0) followed by Dunnett post-test; p values were considered 
significant and the *** represents p value < 0.001 between Lf and the various spray dried DPI 
formulations. There are no significant differences between the excipient-free and the sodium 
carboxymethylcellulose modified spray-dried lactoferrin formulations.  
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4.7     Discussion 
Research into employing inhaled therapeutics to manage respiratory infections usually 
begin with evaluating the physical characteristics of the powder formulations, not just 
because of the inherent advantages associated with a better understanding of the in-use 
performance of the formulations but also because it affords the opportunity to optimise 
inhaled formulations thereby increasing the delivery efficiency of the right amounts of 
active ingredient to the regions of the respiratory tract where they are most needed. In 
the present study, it was clearly demonstrated that spray drying could be a useful 
method that could be employed to produce powders with relatively good aerosolisation 
properties. To begin with, it was found that the iron content of bovine lactoferrin was 
significantly (p < 0.001) depleted by dialysis of the protein an observation that had been 
previously reported by Wakabayashi et al., (2009) although using a different dialysis 
method.  
 
In comparison to the Wakabayashi et al., (2009) dialysis method (where apo lactoferrin 
was prepared through incubation of native bovine lactoferrin with in 0.1 M citric acid 
solution, followed by dialysis against distilled water) which was only able to reduce the 
iron saturation rate of native bovine lactoferrin from 8.1 % to 3.5%, atomic absorption 
measurements showed that the dialysis method employed in this study reduced the Fe3+ 
content from 2.8 ppm to 1 ppm (i.e. > 64% reduction). In addition, it was also found that 
following spray drying, the iron content of spray-dried apo lactoferrin powder formulation 
were not significantly different from the iron content of the apo lactoferrin preparations 
(Fig. 4 -3). To the best of our knowledge, this is the first time the iron content of spray-
dried apo lactoferrin is being reported hence the values obtained could not be effectively 
compared in order to inform on the effect of the processing method employed.  
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Spray drying as one of the many micronisation techniques available, has proven to be a 
very useful method of generating micro-particles of proteins and peptides. In the present 
investigation, the spray drying parameters utilised were carefully chosen based on 
favourable results from previous pre-formulation studies (chapter three – developing a 
method for spray drying proteins). The yields of the process varied for the different 
protein formulations with NaCMC-free powders performing poorly (between 45 to 58 % 
yields) compared to the NaCMC-modified powders which provided much better yields of 
about 74%. In general incorporating NaCMC into the suspension feedstock, increased 
the yield of the resultant powder, this observation is in agreement with previous studies 
by Li and Seville, (2010) who found that co-spray dried BSA and NaCMC resulted in 
higher yield compared to spray drying BSA alone. The moisture content of the powders 
obtained from Karl Fischer showed that there was a significant (p < 0.01) increase in the 
moisture content of the spray-dried powders upon inclusion of NaCMC, this was also 
found to be in agreement with previous reports by Li and Seville, (2010) who reported 
that co-spray dried BSA powders containing 50 % (w/w) NaCMC had a moisture content 
of 7.8 ±0.8 %.  
 
The particle size distributions of the various formulations obtained through laser 
diffraction measurements showed that the d[v,50] of the powders were successfully 
reduced from 26 μm (commercially supplied lactoferrin powders) to < 5.5 μm, indicating 
that the spray drying parameters employed were duly suited for producing powders that 
avoid inertial impaction in the oropharyngeal cavity. Since larger particles would be 
expected to deposit in the upper airways due to the impaction of particles which are not 
able to follow the changes in the air stream, and excessively small particles are known 
to have a terminal velocity that is so low that they hardly deposit, the particle size of the 
powders produced through spray drying in this study would be expected to deposit in the 
lower regions of the airway due to sedimentation (i.e. over time, the velocity of the 
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particles would reduce to a point where they deposit under the influence of gravity). This 
prediction is premised upon previous reviews by Newman and Clarke (1983), Gonda 
(1990) and studies by Zanen et al.,(1994), Zanen et al., (1995) Zanen et al., (1996) who 
reported that optimal particle size of aerosols intended for lower airway deposition to be 
between 1 and 5 μm (specifically, particles with a MMAD of < 2.8 μm possessed 
significantly much lower airway deposition).  
 
The span of the particle size distribution (calculated using equation 3.1) was found to be 
significantly higher upon co-spray drying the protein with NaCMC, this indicates that the 
inclusion of NaCMC must have facilitated the formation of widely heterogenous 
particles. This observation was found to be in agreement with previous reports by Li et 
al., (2010) who found that NaCMC-modified powders generated through spray drying 
exhibited a broad particle size distribution upon measuring the particle sizes of the 
formulations in both wet and dry environments. In addition, investigations into the 
morphology of the powders using scanning electron micrographs also revealed that 
while the various protein powders consisted of spherical particles, these particles were 
of a heterogenous size distribution (Fig. 4 -3b). The particle morphology which have 
been known to affect particle packing in an agglomerate as well as in determining inter-
particulate forces (i.e. the flowability and powder emptying from the powder inhaler) 
were observed to vary in the different powder formulations. In terms of roughness, the 
following order describes the roughness of the particles; SDaLf > SDLf > SDLf + 
NaCMC >> Lf. 
 
Following aerosolisation of dry powders, out of the five possible mechanisms (inertial 
impaction, sedimentation, brownian diffusion, interception and electrostatic precipitation) 
by which particles deposit, inertial impaction and sedimentation were more likely found 
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to influence the deposition profile of the various protein formulations on to the different 
MSLI stages (this is evidence by the significantly high deposition of the powders 
(especially the commercially supplied Lf powders) on the throat, first and second stages 
of the MSLI). While impaction means that the particles are not able to follow changes of 
the air stream and therefore deposit on the upper stages of the MSLI (i.e. the throat, 
stage 1 and stage 2), sedimentation is a time dependent variable related to velocity 
which influenced by gravity causes particles to fall. In order words, these two variables 
cause large, irregular shaped particles to deposit on the upper MSLI stages representing 
the upper airways, whereas, smaller more spherical particles escape impaction and 
deposit in the lower MSLI stages representing the lower regions of the airway. FPF 
values that are significantly higher than 30% indicates that the powder has good 
aerosolisation behaviour (Heng et al., 2012). 
 
In this study, in vitro deposition and aerosolisation studies of the various protein 
formulations showed that DPI formulations of the commercially supplied lactoferrin (Lf) 
had very poor aerodynamic properties with FPF of 9.8 % at 60L/min (an airflow rate 
considered to be achievable with minimal inhalation effort). In comparison, all the 
various spray-dried DPI formulations possessed a fairly good delivery efficiency with a 
FPF of approximately 50 % (Fig. 4 -9) indicating that the powders were not particularly 
cohesive, this observations also further validated the particle sizing data (Table 4.3, 
Figure 4.6.11.3) which showed the commercially supplied lactoferrin powders to 
possess a VMD of 27.89 ±0.4 μm and a MMAD of 33.61 ±6 μm while the spray-dried 
proteins had a VMD of between 5 and 9 μm and a MMAD of between 4 and 6 μm. 
Therefore, this study has demonstrated that spray drying using the B290 spray dryer is a 
useful formulation platform for facilitating the delivery of antimicrobial protein like 
lactoferrin to specific regions of the airway for therapeutic applications. In addition the 
Chapter Four: Characterisation of lactoferrin 
- 205 - 
 
approach also showed the simplicity of preparing inhalable particles with a controlled 
size distribution.  
An important drawback of current aerosol antibiotic treatments in their inability to 
penetrate into the deep lung, thereby setting up a concentration gradient (i.e. higher 
concentrations in the proximal airway but extremely low levels in the distal airway), 
which might lead to antibiotic resistance (Rubin, 2006). There is considerable evidence 
to suggest that antibiotic concentrations below the MIC, at sub-inhibitory levels, select 
and enrich for resistant bacteria (Gullberg et al., 2011). Therefore, combination 
therapies of antimicrobial protein like lactoferrin (which have an antibiofilm activity) and 
potent antibiotics produced through co-spray drying should provide a more robust 
antimicrobial therapy with adequate penetration potential. The FPF in this work 
represents a single cut-off (mass percent of particles with aerodynamic diameter < 6.8 
μm) and is represented by the total amount of particles depositing from stage 3 down to 
the filter in the in vitro deposition graphs (Fig 4 -7). The FPF of a co-formulated DPI 
therapy prepared using the same spray drying parameters should also produce 
aerodynamic particle size distribution and respirable fractions similar to those observed 
in the present study. 
 
4.8     Conclusion 
Dry powder formulations of lactoferrin were prepared through spray drying and 
consisted of respirable-sized particles (d[v,50]  of between 4.8 and 5.5 μm) capable of 
achieving a FPF of approximately 50 %. In addition, a concomitant and uniform in vitro 
deposition profile could be achieved across all impaction stages when dispersed at 60 
L/min. Spray-dried powders of lactoferrin may therefore offer an alternative antimicrobial 
therapy for control of airway infections. The next logical step to advance the current 
study would be to assess the in vitro antimicrobial activities of the spray-dried lactoferrin 
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formulations in order to determine the protein remained active on microorganisms 
following processing.  
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5.1     Summary 
The data presented in the previous chapter showed that spray drying lactoferrin 
produces microparticulates with good aerosolisation characteristics. In this chapter, we 
investigate the antimicrobial functionality of the various spray-dried powders with the 
view of determining the influence of the processing conditions (particularly heating and 
excipient - NaCMC) on the activity of the protein. The ability of lactoferrin to inhibit the 
growth of P. aeruginosa strain PAO1 was used as a measure of antimicrobial 
functionality.  Using the same dry powder production techniques as in the previous 
result chapters, the antimicrobial activities of various lactoferrin dry powder formulations 
were studied.  In particular their bactericidal activity on the planktonic cells and their 
ability to modify biofilm formation and depletion were the primary indicators used in 
establishing their antimicrobial functionality. Also, to better understand the mechanism 
by which apo-lactoferrin is able to inhibit bacterial cell growth, the effect of chemical iron 
chelators on the growth of both planktonic and biofilm cultures of P. aeruginosa was 
assessed. Results obtained showed that significantly (p < 0.01) more planktonic 
bacterial cells were killed by apo lactoferrin than with the commercially supplied 
lactoferrin. Also the various lactoferrin preparations were found to inhibit the formation of 
P. aeruginosa biofilms, although, interestingly, this property was lost upon co-spray 
drying the protein with sodium carboxymethylcellulose. Overall, the spray drying process 
was found not to significantly affect the antimicrobial activity of the proteins. The anti-
biofilm activities observed with the lactoferrin preparations was thought to be related to 
their iron chelating abilities, however, it was not possible to replicate this using some 
known synthetic iron chelators, suggesting that there may be more than one mechanism 
of action that confers anti-biofilm activity to lactoferrin.  Taken together, these data 
indicate that aerosolized lactoferrin and apo-lactoferrin, prepared by the spray drying 
method, retains antimicrobial activity against either planktonic or biofilm cultures of P. 
aeruginosa. However, this was not observed when synthetic iron chelators were 
Chapter Five: Antimicrobial activity of SDLf, SDaLf on P. aeruginosa  
- 209 - 
 
employed, indicating that this anti-biofilm activity is not purely due to the iron-chelating 
abilities of the protein. 
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5.2     Introduction 
Iron binding proteins play crucial roles in the maintenance of iron homeostasis in the 
lung by limiting the availability of free iron in the extracellular tissue fluid (Mateos et al., 
1998; Reid et al., 2007a). One of the many consequences of limiting the available iron in 
the airways is that it serves to limit the growth of microbes that rely on iron for replication 
and respiration under both aerobic and anaerobic conditions (Bals, 2000). Iron 
restriction is also known to play a crucial role in moderating phenotypic changes, such 
as those responsible for multiplication and pathogenicity of many bacteria.  In the 
absence of iron restriction, unregulated growth and infectivity of these bacteria may 
eventually overwhelm the host’s immune defence systems (Van Asbeck and Verhoef, 
1983; Ward et al., 1996; Griffiths and Williams, 1999; Griffiths and Chart, 1999; Crosa, 
1999)  
Lactoferrin is an antimicrobial polypeptide and a very important component of the innate 
immunity.  One of the many roles of lactoferrin is to sequester essential iron from 
microbes thereby limiting their growth. Lactoferrin, just like the other transferrin family 
members (including serotransferrin or siderophilin and membrane-associated 
melanotransferrin) are primarily iron binding proteins found in exocrine secretions such 
as; tears, saliva, intestinal and cervical mucus, mucosal surfaces and within the specific 
granules of polymorphonuclear leukocytes (Klein et al., 1988; Koch and Hoiby, 1993; 
Andersen et al., 2001; Travis et al., 2001; Adlerova et al., 2008). Milk is the most 
abundant source of lactoferrin, especially colostrum (the early milk) which contains 
about 7 g/L (Masson and Heremans, 1971). There is however a great variation in the 
concentration of lactoferrin in various human body fluids; 1μg/mL in blood, ~10 µg/mL in 
airway lavage fluid and 2 mg/mL in tears (Masson and Heremans, 1971; Brogan et al., 
1975; Raphael et al., 1989; Thompson et al., 1990).  
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5.2.1     Structure of lactoferrin 
Lactoferrin is a monomeric, bilobal glycoprotein with a molecular weight of about 78 and 
80 kDa for bovine milk and human breast milk, respectively. Human and bovine 
lactoferrin consist of 692 and 689 amino acids, respectively, with both homologues 
having two sections that share over 70 % similarity in overall amino acid sequence with 
100 % identity in several stretches of 10 – 15 amino acids at the C terminus (Teng, 
2002). The N- and C-lobe of human and bovine lactoferrin share 66 and 73 % sequence 
homology (Teng, 2002). Both bovine and human lactoferrin molecules have two metal-
binding sites, each of which can reversibly bind two iron atoms (as Fe3+), concomitantly 
with two bicarbonate anions (Williams, 1982; Metz-Boutigue et al., 1984b; Anderson et 
al., 1987). Some notable features of lactoferrin include synergism between cationic and 
anionic binding which greatly enhances its antimicrobial actions.  Its ability to tightly bind 
to iron (Fe3+), with a binding constant of approx. 1022 M, means that iron is not freely 
available for microbial utilization.  However, the lactoferrin-bound iron is still available to 
the host in vivo, through binding to specific receptors such as intelectin-1, low density 
lipoprotein receptor-related protein 1 and low density lipoprotein receptor-related protein 
2 (Cox et al., 1979; Anderson et al., 1987). Furthermore, despite the striking 
physicochemical similarities between lactoferrin and the transferrins, lactoferrin 
remarkably has a higher metal binding constant (K1) compared to the transferrins – for 
example, the K1 of bovine and human lactoferrin is approximately 35 and 260 times 
respectively greater than human transferrin (Aisen and Leibman, 1972). Another 
distinguishing feature of lactoferrin from transferrin is the ability of lactoferrin to retain 
iron at very low pH (pH 3-4, compared with pH 5-6 for transferrins) (Mazurier and Spik, 
1980; Shimazaki et al., 1993). 
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Figure 5 -1: The three dimensional structure of human lactoferrin. The two homologous lobes of 
the protein are shown within the dotted lines. The N-lobe is on the left, with its bound Fe
3+
 and 
bicarbonate anions (represented by the spherical-red coloured atoms) in the cleft between the 
two domains, N1 (dark blue) and N2 (teal). The C-lobe is on the right with similarly bound Fe
3+
 
and bicarbonate anions depicted in between the two C domains; C1 (dark blue) and C2 (teal). 
The two lobes are joined by a three turn helix (magenta, top) with another helix making a final 
contact between the lobes at the C terminus (magenta, below). Adapted from Baker and Baker 
(2005b).  
 
5.2.2     Antimicrobial activity of lactoferrin 
The antimicrobial activity of lactoferrin is well established, the discovery that this activity 
is linked to the ability of the protein to sequester iron, thereby depriving potential 
pathogens of this essential nutrient, has generated a lot of interest amongst researchers 
(Singh et al., 2002; Wakabayashi et al., 2009; O'may et al., 2009). Interestingly, 
lactoferrin has also been found to possess a secondary antimicrobial activity that is 
independent of iron-binding.  This followed the discovery that areas of high positive 
charge on the N-terminal surface of lactoferrin permit binding to negatively charged 
bacterial membranes of bacteria (Ellison and Giehl, 1991; Leitch and Willcox, 1999a).  
The interaction with bacteria is favoured over the more neutral-charged host eukaryotic 
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membranes.  Lactoferrin binding to bacterial membranes can disrupt and destabilise the 
regular membrane bilayer structure, thereby stopping the microbe from adhering to host 
cells (Vogel et al., 2002; Ward et al., 2002). 
The ability of lactoferrin to inhibit bacterial growth in vitro was indeed one of the earliest 
functions described for the protein. The antimicrobial activity of lactoferrin has so far 
been demonstrated on a number of microbes. Apolactoferrin (i.e. the iron deplete form 
of lactoferrin) has been shown to be bactericidal against several different species of both 
gram-positive and gram negative bacteria including Staphylococcus aureus, 
Porphyromonas gingivalis, Prerotella intermedia, P. aeruginosa, Streptococcus mutans 
and Vibrio cholerae, but not for Escherichia coli (Arnold et al., 1977b; Clarke and Foster, 
2008; Musk and Hergenrother, 2008; Wakabayashi et al., 2009). Studies have also 
shown that whilst lactoferrin is bactericidal in its iron-free, apolactoferrin state, iron-
saturated lactoferrin also has reduced antimicrobial activity (Arnold et al., 1980; Kalmar 
and Arnold, 1988; Yamauchi et al., 1993), further implying a role for iron sequestration in 
the antimicrobial actions of the protein. However, apart from being able to deprive 
microorganisms of essential nutrient iron (Finkelstein et al., 1983), many studies have 
also suggested that lactoferrin binds to the isolated lipid A portion of lipopolysaccharide 
(LPS) (Appelmelk et al., 1994).  LPS is a component of the outer membrane of Gram-
negative bacteria and interactions between lactoferrin and lipid A damage the bacterial 
membrane and alters its permeability (Rossi et al., 2002).  Lactoferrin has been shown 
to modulate the activity of known antibacterial agents such as lysozyme and antibiotics, 
so may work synergistically (Ellison Iii et al., 1988; Ellison Iii and Giehl, 1991). 
Lactoferrin is also known to prevent P. aeruginosa biofilm formation by enhancing 
‘twitching motility’; a process made possible by the protein’s iron chelation ability which 
prevents bacterial cells from forming the sessile structures that are a prerequisitie to 
biofilm formation (Rogan et al., 2004). 
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5.3     Aims and objectives 
The aim of the current study was to better understand the value of lactoferrin as an 
antimicrobial agent following pharmaceutical processing (in this instance spray drying). 
The antimicrobial activities of lactoferrin against planktonic growth and biofilms of P. 
aeruginosa will be evaluated. In addition, in order to improve our understanding of the 
possible mechanism of action of lactoferrin (i.e. through iron chelation), we investigated 
the antimicrobial activities of a range of chemical iron chelators. The data from this study 
is likely to inform future searches for potent, inhalable antimicrobials that are effective 
against chronic P. aeruginosa infections and importantly that prevent or reduce biofilm 
formation in the airways.  
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5.4     Materials  
Lactoferrin was kindly donated by DMV Fonterra (Netherlands), Mueller-Hinton Agar 
was supplied by Oxoid LTD (Basingstoke, UK), casamino acids were supplied by Becton 
Dickson (NJ, USA), Ferric chloride, 2,2’ –dipyridyl (2DP), diethylenetriaminepentacetic 
acid (DTPA), ethylenediamine tetraacetic acid (EDTA), deferoxamine mesylate (DM),  
magnesium chloride, Kodak GBX developer, Kodak GBX fixer and Coomassie Brilliant 
blue R were all supplied by SIGMA-ALDRICH (Poole, UK). Immobilon® Western 
Enhanced Chemiluminescent substrate (ECL)  were supplied by Millipore (Watford, UK), 
Pierce Silver stain kit were supplied by Thermo Scientific (Rockford, IL USA), 
PageRuler™ Plus, prestained protein ladder were supplied by Fermentas (York, UK) 
and primary antibodies (IG12, 4C6 and 4C3)  were a Kind gift by Dr Andrew Devitt of 
Aston University. 
Bacterial strain: P. aeruginosa PAO1 was kindly provided by Prof. Peter Lambert of 
Aston University, Birmingham, UK. 
5.5     Methods 
5.5.1     Medium and bacterial strains 
P. aeruginosa strain PAO1 was routinely grown in 0.5% w/v casamino acid medium 
supplemented with 1 mM MgCl2, and where specified 3 µM FeCl3 and/or 0.2 % w/v 
glucose were also included. The various growth media were autoclaved and stored at 
room temperature until required. All incubations were carried out at 37 °C. Casamino 
acid medium with and without bacteria served as positive and negative controls, 
respectively. 
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5.5.2     Preparation of apo lactoferrin 
Apo lactoferrin was prepared as previously described in section 2.2.2.2.4. 
 
5.5.3     Spray-dried powder formulations 
All batches of spray-dried lactoferrin used in this investigation were prepared as 
previously described in section 2.2.2.2.3 (for spray-dried lactoferrin), section 2.2.2.2.5 
(for spray-dried apo lactoferrin), section 2.2.2.2.6 (for co-spray dried lactoferrin with 
sodium carboxymethltcellulose) and section 2.2.2.2.7 (for co-spray dried apo lactoferrin 
with sodium carboxymethltcellulose) 
 
5.5.4     Minimum inhibitory concentration (MIC) determination 
Susceptibility tests for each of the formulations was carried out on overnight planktonic 
cultures of P. aeruginosa according to the National Committee for Clinical Laboratory 
Standards (NCCLS) guidelines for antimicrobial susceptibility testing. Briefly, the 
turbidity of an overnight bacterial suspension of P. aeruginosa was adjusted to that of a 
0.5 McFarland standard (this should correspond to between 1 and 2 x 108 cfu/mL) then 
the suspension was diluted 1:10 in sterile distilled water. 10 µL of this inoculum was put 
into each well of a 96 well plate, making sure to set up positive (broth plus inoculum) 
and negative (broth only) control wells.  10 – 250 µg/mL of the various lactoferrin 
formulations were added into the appropriate wells and plates were incubated at 37°C 
for 18 hours. Following incubation, the MIC for each of the agents was determined as 
the lowest concentration that inhibited growth of the organism, this growth inhibition was 
apparent as a clear broth.   
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5.5.5     Minimum bacteriostatic concentration (MBC) determination 
Whilst the MIC determines the lowest concentration of an antimicrobial that will inhibit 
visible growth of a microorganism, the MBC determines the lowest concentration of an 
antimicrobial that will prevent the growth of a microorganism (i.e. bactericidal 
concentration). To test for bactericidal activity of the various lactoferrin formulations 
against planktonic P. aeruginosa, a planktonic bacterial cell viability assay was 
performed based on the method of Xu et al. (2010). Briefly, 20 μL of 1:10 dilution of an 
overnight P. aeruginosa bacterial suspension was incubated at 37 °C with 180 μL of 100 
μg/mL stock preparations of the various lactoferrin formulations or 180 µL of sterile 
distilled water (this served as a positive control).  At intervals of 10 mins for up to 1 hour, 
10 µL aliquots were plated out neat and serially diluted from 1:10 to 1:108 in sterile, 
deionized water. Each dilution was plated on Mueller-Hinton agar and incubated at 37 
°C for 24 hours. Following incubation, the number of colonies from each of the serial 
dilutions were counted and the dilutions having a colony count of < 300 colonies were 
used to estimate the colony forming unit per mL surviving at that time the sample was 
collected. The formula in section 2.2.15 was used for this determination.  
 
5.5.6     Assessment of bacterial biofilm formation and reduction by 
various lactoferrin formulations 
To test the ability of various lactoferrin dry powder formulations to modify biofilm 
formation by P. aeruginosa strain PAO1, a modification from methods previously 
described by Eckhart et al., (2002) and Merrit et al., (1998) was employed. Briefly, 
overnight cultures of P. aeruginosa were diluted 1:10 (v/v) in fresh medium containing 
0.5 % w/v casamino acids, 0.2 % glucose and 1 mM MgCl2 (casamino acid rich 
medium). 10 µL aliquots of the dilution were dispensed into a 96 well plate and 90 µL of 
a 1 mg/mL stock suspension of the various lactoferrin formulations were then added to 
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the bacterial suspension in the 96 well plate (to produce a final antimicrobial 
concentration of 900 µg/mL). The 96 well microplate was then covered and incubated at 
37°C for 24 h, after which excess broth was removed. The biofilm, which remains 
adherent to the 96 well plate, was then washed and stained with 0.1% (w/v) crystal violet 
for 15 mins at room temperature. Following vigorous washing with water, the stained 
biofilms were solubilized in 30 % (v/v) acetic acid and the absorbance at 550 nm was 
determined using a Multiskan spectrum plate reader and 30% acetic acid in water as the 
blank. 
To assess the effects of the various lactoferrin formulations on already formed biofilms 
(i.e. biofilm persistence) a slight modification was made to the above method. Briefly, 
100 µL of a 1 in 10 dilution of an overnight bacterial suspension of P. aeruginosa was 
put into 96 well plates, covered with a lid and incubated at 37°C for 24 hours. Then the 
bacterial suspension was removed, leaving the preformed biofilm adherent to the plate, 
and 90 µL of a 1 mg/mL (i.e. antimicrobial concentration of 900 µg/mL) stock suspension 
of the various lactoferrin formulations were added and plates were incubated for a 
further 24 hours at 37 °C. The antimicrobial suspensions were then removed and the 
wells washed twice with distilled water before staining with 0.1 % w/v crystal violet 
solution. Detailed description of method employed in staining and quantifying biofilms is 
as previously described in section 2.2.17.2. 
 
5.5.7     Assessment of bacterial biofilm formation and reduction by 
various synthetic chelators  
Overnight cultures of P. aeruginosa bacterial suspension were diluted 1:10 in casamino 
acid rich medium supplemented with 0 or 3 µM FeCl3. 10 µL aliquots of the bacterial 
dilution were put into 96 well micro-plate wells and 90 µL of 2 mM stock preparation of 
various iron chelators was added to the wells to give a final chelator concentration of 1.8 
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mM. The 96 well microplates were then covered and incubated at 37 °C for either 6 or 
24 hours. Following incubation, the bacterial and chelator suspension were removed 
and the plate washed twice (to ensure complete removal of planktonic bacterial cells). 
Detailed description of the method employed in staining and quantifying biofilms is 
previously described in section 2.2.17.2. 
 
To determine the effects of the various chelators on already formed biofilms (persistent 
biofilms), a slight modification was made to the method by growing the biofilm first then 
exposing it to the various chelators. Briefly, the biofilms were grown by incubating 100 
µL of a 1:10 dilution of an overnight grown bacterial cell suspension at 37 °C for 24 
hours. Then the bacterial cell suspension was removed and 90 µL of a 2 mM stock 
preparation of the various chelators were put into each of the wells and incubated at 37 
°C for 24 hours. The method previously described in section 2.2.17.2 was employed in 
staining and quantifying biofilms. 
 
5.5.8     SDS-PAGE analysis of the various lactoferrin formulations 
SDS-PAGE was carried out using a 4 – 20 % precast polyacrylamide gel following the 
procedure described by Laemmli (1970) and detailed in section 2.2.9. The 
electrophoresis procedure was repeated 3 times using the Mini-Protean® TGX™ (Bio-
Rad, Hercules, CA, USA). Two of the gels were used to investigate the molecular weight 
of the various protein preparations, while one of the detection methods used Coomassie 
brilliant blue R-250 (detailed method is described in section 2.2.9.1.1), the other applied 
the more accurate technique of silver staining (detailed method is described in section 
2.2.9.1.2). The third gel was used to perform western blot analysis. A lane of prestained 
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molecular weight marker was included in each gel to allow determination of the apparent 
molecular weight of the lactoferrin in each preparation. 
 
5.5.9     Western blot analysis of the various lactoferrin formulations 
Western blot was performed as previously described in section 2.2.10. Briefly, after 
separation by SDS-PAGE, proteins were transferred to nitrocellulose membrane. 
Membranes were blocked for 1 hour using a solution of 0.3 % (v/v) Tween 20 in PBS. 
The blots were washed twice for 1 min with wash buffer – 0.05 % (v/v) Tween 20 in 
PBS, and incubated for 2 h at room temperature with a 1:500 (v/v) dilution of the primary 
antibody (IG12 and 4C6). After the incubation with the primary antibody, membranes 
were washed every 15 mins for 1 hour with 0.05 % (v/v) Tween 20 and then incubated 
for 2 hours at room temperature with 1:5000 dilution of secondary antibody (HRP-
labelled rabbit anti-mouse). After incubation with the secondary antibody, membranes 
were washed again every 15 mins for 1 hour with the wash buffer. Finally, developing 
and detection of bound antibody was achieved with chemiluminescence (Kricka, 1996). 
Briefly, the membranes were incubated with Immobilon® Western enhanced 
chemiluminescent substrate according to the manufacturer’s instructions (Millipore, 
Watford, UK) and exposed to Kodak film (Sigma-Aldrich, Poole, UK) for 1 minute. The 
films were then developed with Kodak GBX developer and fixed in Kodak GBX fixer. 
 
5.5.10   Statistical analysis 
Means and standard deviation were calculated using GraphPad prism 5. A Dunnett 
post-test analysis was used to examine the significant differences between the various 
formulations and the relevant controls.  
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5.6     Results  
5.6.1     Minimum inhibitory concentration (MIC) of lactoferrin 
preparations on planktonic P. aeruginosa 
The MIC’s of Lf, aLf, SDLf, SDaLf, SDLf + NaCMC and SDaLf + NaCMC against P. 
aeruginosa were determined via the microdilution method. MIC values are summarized 
in Table 5.1. SDLf + NaCMC and SDaLf + NaCMC were found to have little antimicrobial 
effect on the bacteria at concentrations up to 2 mg/mL. 
Table 5.1: Minimum inhibitory concentration (MIC) of the various lactoferrin formulations. The 
MIC of each drug was assessed by a microdilution method derived from clinical and laboratory 
standard institute (CLSI) for broth microdilution antimicrobial susceptibility testing. The MIC of the 
protein ranged from 1 to 2000 µg/mL. The minimum inhibitory concentration (MIC) was defined 
as lowest concentration which inhibited visible growth. While the the MIC of Lf and SDLf were the 
same, SDaLF had a reduced MIC compared to aLf.   
Formulation MIC (µg/mL) 
Lf 50 
SDLf 50 
aLf 10 
SDaLf 25 
SDLf + NaCMC >2000 
SDaLf + NaCMC >2000 
NaCMC >2000 
 
 
5.6.2     Effects of Lf, aLf, SDLf, SDaLf, SDLf + NaCMC and SDaLf + 
NaCMC on planktonic P. aeruginosa 
In order to determine the activity of the various lactoferrin preparations against 
planktonic P. aeruginosa, bacterial cultures were grown in the presence or absence of 
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the various lactoferrin dry powders. Approximately 108 cfu/mL of P. aeruginosa was 
incubated with 100 µg/mL of various lactoferrin preparations (prepared in casamino acid 
media) for 1 h, the bacterial growth was monitored by plating out a 10 µL aliquot every 
10 mins.  Bacterial growth in the control (no antimicrobial added) was not significant at 
the end of the 1 h assessment period. In contrast, incubation of the bacteria with Lf or 
SDLf resulted in a 2 log reduction of bacterial colonies compared to the number of 
colonies present at the start of the investigation. However, aLf and SDaLf reduced the P. 
aeruginosa bacterial colonies present at the beginning of the investigation by 5 log units 
(Fig. 5 -2).  
 
Since the inclusion of sodium carboxymethylcellulose demonstrated an appreciable 
thermoprotective function on the activity of alkaline phosphatase in an earlier study 
(Table 3.2), we decided to co-spray dry the water soluble polymer with lactoferrin to see 
if this effect can be replicated with a more therapeutically relevant protein. Incubation of 
sodium carboxymethylcellulose with planktonic P. aeruginosa cells resulted in ca. 2 log 
unit growth in number of P. aeruginosa colonies after 1 h incubation compared to the 
number of colonies present at the start of the investigation. However, upon incubation of 
P. aeruginosa with SDaLf + NaCMC and SDLf + NaCMC, the number of bacterial 
colonies was suppressed by 1 log unit but this was still less efficacious compared to Lf, 
SDLf, aLf and SDaLF (Fig. 5 -2). A ranking order of efficacy of the of the powders 
against P. aeruginosa planktonic growth was  – aLf > SDaLf > Lf> SDLf > SDLf+CMC = 
SDaLF+CMC > Control >> CMC. 
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Figure 5 -2: Time-kill curves for various lactoferrin formulations. Logarithmic plot of the changes 
in bacterial cell viability in the presence of different lactoferrin preparations and sodium 
carboxymethylcellulose. The bacteria were seeded in polystyrene 96-well plates with the various 
antimicrobial protein preparation present at a concentration of 100 μg/mL  and incubated at 37 
°C. Aliquots were plated out onto MHA agar plates at 10, 20, 30, 40, 50, 60 mins. Bacterial 
colonies were counted after 24 hours incubation of the MHA agar plates at 37 °C and data are 
presented as mean ± SD; n = 3 independent evaluations of triplicate wells. While the log colony 
forming unit per mL of the control wells remained relatively unchanged, after 1 hour incubation, 
the number of viable cells began to reduce in the presence of the various antimicrobial agents. 
Iron depletion (aLf) increased the rate of viable cell reduction although spray drying iron deplete 
forms of lactoferrin (SDaLf) slightly reduces the impact of the antimicrobial protein on viable cells, 
in agreement with MIC data (Table 5.1). However, the inclusion of NaCMC into the various 
lactoferrin formulations significantly reduced the efficacy of the antimicrobial protein with bacterial 
colonies increasing significantly in the presence of NaCMC alone compared to the control.  
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Overall, these data suggests that the iron-depleted form of the protein, aLf, was the 
most effective antimicrobial form of lactoferrin (even after spray drying), displaying both 
growth inhibitory and bactericidal activity against P. aeruginosa. We therefore sought to 
examine the effects of chemical iron depletion on bacterial growth. We tested the effects 
of four synthetic iron chelators on the viability of planktonic bacterial cells of P. 
aeruginosa in an iron deplete environment to maximize iron sequestration from the 
organism. Approximately 108 cfu/mL of P. aeruginosa were incubated with the different 
chemical iron chelators (2 mM) in CAA media for 1 hour. Samples were plated out every 
10 minutes and the cfu/mL determined following 24 hrs incubation of the plates (f igure 5 
-2).  While the number of bacterial cells in the control (CAA media with no chelating 
agent added) remained fairly constant, incubation of the bacterial colonies in CAA media 
supplemented with EDTA resulted in a slight reduction (< 1 log unit) in the cfu/mL 
compared to the initial number of colonies. Incubating the bacterial cells in CAA 
supplemented with 2DP or DM resulted in less than 1 log reduction of the cfu/mL. 
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Figure 5 -3: Logarithmic plot of changes in bacterial cell viability following incubation with 
different synthetic iron chelators. Planktonic P. aeruginosa was seeded in polystyrene 96-well 
plates with an equal volume of the iron chelators at a final concentration of 2 mM and incubated 
at 37 °C for the times indicated. Aliquots were plated out onto MHA agar plates at 10, 20, 30, 40, 
50, 60 mins. Bacterial colonies were counted after 24 hours at 37 °C and data are presented as 
mean ± SD; n = 3 independent evaluations of triplicate wells. There were no bacterial colonies to 
count following incubation with DTPA. 
 
  
5.6.3     Inhibition of biofilm formation by Lf, SDLf, aLf, SDaLf, 
NaCMC, SDLF + NaCMC and SDaLf + NaCMC 
We investigated whether Lf or aLf could modify the biofilm formation of P. aeruginosa 
and also, importantly, whether spray-drying the lactoferrin-related agents affected their 
biofilm-modifying abilities. P. aeruginosa cultures were incubated, in the presence or 
absence of 3M Fe3+, with the various Lf preparations for 24 hours then the planktonic 
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cells were removed and the quantity of adherent biofilm estimated by measuring the 
absorbance at 550 nm after crystal violet staining . Control experiments indicated the 
importance of free iron in the formation of the biofilm, as, significantly (p < 0.001) more 
bacterial biofilm was produced in iron-rich media, compared to iron-depleted media. This 
was expected as iron is known to be essential for P. aeruginosa biofilm formation 
(O'may et al., 2009; Banin et al., 2005; Yang et al., 2007; Patriquin et al., 2008). Lf 
significantly (p < 0.001) inhibited P. aeruginosa from forming biofilms in both the iron-rich 
and iron depleted environments. It is noteworthy to mention that there were no 
significant differences between the biofilm-inhibitory activities between Lf, aLf, SDLf and 
SDaLf. However, upon incubating P. aeruginosa with SDLf + NaCMC, there was a 
significant (p < 0.05) increase in the number of bacterial colonies in the iron-depleted 
media compared to the numbers seen with the control (where no agent was added). 
Upon incubating P. aeruginosa in CAA media supplemented with iron and SDLf + 
NaCMC, there was no significant change in the number of bacteria colonies compared 
with the control at the end of the 24 hr incubation period.  Furthermore, there was no 
significant change in the number of bacterial colonies compared to the control when P. 
aeruginosa was incubated with SDaLf + NaCMC in either iron supplemented or iron free 
media. To better understand the reason for the reduced effectiveness of Lf in the 
presence of NaCMC, P. aeruginosa was incubated with sodium carboxymethylcellulose. 
Under these conditions, significantly (p < 0.001) more biofilm intensity was apparent in 
either the iron rich or iron-deplete environments compared with their respective controls 
(where no agent was added). 
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Figure 5 -4: Crystal violet staining of P. aeruginosa biofilms following 24 hr incubation with various 
lactoferrin-containing formulations, in the absence or presence of 3m Fe
3+
. The control had no 
antimicrobial agents included and indicates that Fe
3+ 
significantly enhanced biofilm formation. Lf, 
SDLf, aLf and SDaLf retarded the formation of biofilm by the organism while the co-spray dried 
lactoferrin/apo lactoferrin-sodium carboxymethylcellulose formulation failed to prevent biofilm 
formation.  Sodium carboxymethylcellulose alone encouraged more biofilm growth. Values are 
mean ±SD, n=3. Comparisons of groups were made by one-way analysis of variance (ANOVA) 
using graphpad prism 5 (GraphPad Prism Software Inc., Version 5.0) followed by Dunnett post-
test; P values were considered significant and the *** represents p value < 0.01 between the iron-
free and iron-supplemented media; **, P < 0.001 compared with the result for the iron-free 
control; *, P < 0.05 compared with the result for the iron-free control; ‡, P < 0.001 compared with 
the result for the iron-supplemented control; ns indicates no significance compared to the iron-
free control (no antibiotic added) and # indicates no significance compared to the iron-
supplemented control. 
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5.6.4     Reduction of preformed biofilms by Lf, SDLf, aLf, SDaLf, 
NaCMC, SDLF + NaCMC and SDaLf + NaCMC 
We estimated the abilities of the different Lf preparations to deplete the quantities of 
preformed P. aeruginosa biofilms. These were grown in either iron-free or iron-
supplemented media for 24 hours to allow development prior to the addition of the Lf 
compounds. Following a further 24 hour incubation with the Lf preparations, planktonic 
bacteria were washed away and the adherent biofilm assessed with crystal violet 
staining. There was no significant difference between the preformed biofilm masses in 
both environments.  Treatment with Lf and aLf reduced the intensity of preformed P. 
aeruginosa biofilm significantly (p < 0.05) in both the iron rich and iron free media. 
Incubation of the preformed P. aeruginosa biofilm with SDLf resulted in a significant (p < 
0.001 for the iron free and p < 0.005) reduction of the biofilm intensity. Treatment with 
SDaLf resulted in a significant reduction (p < 0.05 for the iron free and p < 0.001) of the 
biofilm intensity. However, incubation of preformed biofilms of P. aeruginosa with SDLf + 
NaCMC and SDaLf + NaCMC failed to reduce biofilm intensity in either the iron-deplete 
or iron-rich media but rather resulted in significantly (p < 0.001) increased biofilm 
intensity. Incubation with sodium carboxymethyl cellulose alone resulted in significant (p 
< 0.001) increases in preformed biofilm intensity in both iron rich and iron free medium.  
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Figure 5 -5: Crystal violet staining of preformed P. aeruginosa biofilms following exposure of to 
various lactoferrin formulations. The control well had no agent added and served as a positive 
control. Commercially supplied lactoferrin (Lf) and spray-dried lactoferrin (SDLf), apo lactoferrin 
(aLf) and spray-dried apo lactoferrin (SDaLf) significantly reduced the intensity of staining of 
biofilm while the co-spray dried lactoferrin/apo lactoferrin-sodium carboxymethylcellulose 
formulation failed to reduce the intensity of preformed biofilms of P. aeruginosa.  Sodium 
carboxymethylcellulose alone encouraged more biofilm growth when compared to the control. 
Values are mean ±SD, n=3. Comparisons of groups were made by one-way analysis of variance 
(ANOVA) using graphpad prism 5 (GraphPad Prism Software Inc., Version 5.0) followed by 
Dunnett post-test;  ‘ns’ indicates no significant difference in the preformed biofilm masses under 
either iron-free or iron-supplemented media; **, P < 0.001 compared with the result for the growth 
of P. aeruginosa in the iron-free control; *, P < 0.05 compared with the result for the Iron-free 
control; and ‡, P < 0.001 compared with the result for the iron-supplemented control; †, P < 0.05 
compared with the result for the iron-supplemented control. 
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5.6.5     Biofilm formation in the presence of iron chelators 
In order to examine the contributions of iron chelation in preventing biofilm formation by 
P.aeruginosa, we incubated the organism with various iron chelators (at a chelator 
concentration of 2 mM) in an iron free media. Crystal violet staining was used to 
measure the intensity of biofilm formed in the presence of the various chelators after 6 
hrs and 24 hrs (Figure 5 -6). Upon incubation of P. aeruginosa with either 2DP, DTPA or 
EDTA, there were no significant changes in terms of biofilm intensity compared with the 
control (no agent added) by 6 h post incubation, however, deferoxamine caused a 
significant (p < 0.001) increase in P. aeruginosa biofilm intensity. Although, at the end of 
the assay (24 h post incubation with P. aeruginosa), all the chelators had reduced 
biofilm formation to levels that were significantly (p < 0.001) less than the control, they 
were still not as effective as Lf, aLf, SDLf and SDaLf in reducing biofilm intensity (fig 5 -
5). 
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 Figure 5 –6: Crystal violet staining of biofilms of PAO1 following 6 and 24 hr incubation with 
various synthetic iron chelators (chelator concentration of 2 mM prepared in iron-free CAA 
media). The control contained bacteria in the absence of any chelator. 2,2’ –dipyridyl (2DP), 
diethylenetriaminepentacetic acid (DTPA), ethylenediamine tetraacetic acid (EDTA), and failed to 
retard biofilm formation following 6 hrs of incubation whilst deferoxamine mesylate DM 
significantly (P < 0.001) increased the biofilm mass following 6 hrs incubation. However, there 
was significant reduction in biofilm intensity after 2h compared with the control.  This was true for 
all the iron chelators. Values are mean ±SD, n=3. Comparisons of groups were made by one-way 
analysis of variance (ANOVA) using graphpad prism 5 (GraphPad Prism Software Inc., Version 
5.0) followed by Dunnett post-test; **, P < 0.001 compared with the result for the control 6 h post 
incubation; †, P < 0.05 compared with the result for the control 24 h post incubation and ‡, P < 
0.001 compared with the result for the control 24 h post incubation. 
 
Since the iron chelators were able to alter biofilm formation after 24 hours incubation in 
iron-deplete medium, we sought to investigate whether this effect could be mirrored in 
iron-supplemented medium. P. aeruginosa was incubated with various iron chelators (at 
a chelator concentration of 2 mM) in an iron supplemented media containing 3 µM 
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FeCl3. The extent of biofilm formation was determined by measuring crystal violet 
staining intensity after 24 h. The values for the growth of P. aeruginosa in the iron-free 
media are the same as the 24 h data in the previous experiment and has only been 
duplicated in figure 5 -6 for comparison purposes. Incubation of P. aeruginosa in CAA 
medium supplemented with 3 µM FeCl3 and 2DP resulted in a significant (p < 0.001) 
decrease in biofilm mass compared to the iron supplemented control. Additionally, 
incubation of the gram negative bacteria with iron-supplemented medium and either 
DTPA or EDTA still resulted in a significant (p < 0.05) decrease in biofilm mass 
compared to the iron supplemented control. There was however no significant change in 
the biofilm mass post incubation of P. aeruginosa with CAA medium supplemented with 
3 µM FeCl3 and DM. 
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Figure 5 -7: P. aeruginosa biofilm formation in CAA medium supplemented with 3 µM FeCl3 and 
2 mM of various chemical iron chelators. The A550 values for growth of P. aeruginosa in iron-free 
medium are the same as the A550 values for the 24 h data in figure 5 -6. Whilst CAA medium 
supplemented with 3 µM FeCl3 and 2DP showed the most significant reduction in biofilm 
intensity, DTPA and EDTA also significantly (p < 0.05), reduced biofilm intensity, whereas CAA 
medium supplemented with 3 µM FeCl3 treated with DM resulted in no significant change in 
biofilm intensity compared to the control. Values are mean ±SD, n=3. Comparisons of groups 
were made by one-way analysis of variance (ANOVA) using graphpad prism 5 (GraphPad Prism 
Software Inc., Version 5.0) followed by Dunnett post-test; **, P < 0.001 compared with the result 
for P. aeruginosa growth in the iron-free control, †, P < 0.05 compared to the result for the iron-
supplemented control; and ‡, P < 0.001 compared with the result for the iron-supplemented 
control. 
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5.6.6     Effect of chemical iron chelators on preformed P. aeruginosa 
biofilms in the presence of Fe3+ 
 
The ability of four chemical chelators to disrupt preformed P. aeruginosa biofilms formed 
in iron-supplemented medium was investigated. These studies were carried out in order 
to better understand the contribution of iron sequestration in the ability of apo-lactoferrin 
(aLf) to disrupt preformed biofilms. To directly measure the contributions of chemical 
iron chelation on preformed P. aeruginosa biofilms, bacterial biofilms were grown in 96 
well microtitre plates under iron restricted and iron supplemented conditions. There was 
no significant difference between the quantities of biofilms pre-formed in the iron-free 
media (CAA alone) and quantities of biofilms pre-formed in iron supplemented media (3 
µM). When preformed biofilms produced under iron-supplementation, were exposed to 
the various chemical iron chelators, only EDTA produced a significant (p < 0.05) 
reduction in the quantity of biofilm compared to the control (i.e. where no chelator agent 
was added), DTPA and DM both produced significant (p < 0.05 and p < 0.01 
respectively) increases in the amount of biofilm quantified when compared to the control 
while 2DP produced no significant change compared to the amount of pre-formed 
biofilms that were produced in the control wells. None of the iron chelators had any 
significant effects on preformed biofilms formed in iron-supplemented media compared 
to the relevant iron-supplemented control. 
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Figure 5 -8: Crystal violet staining of P. aeruginosa biofilms following exposure of preformed 
biofilms, produced in the presence or absence of Fe
3+
, to various chemical chelators. The control 
wells had no agent added and served as a positive control. EDTA was the only chelator to 
significantly reduce the quantities of preformed biofilms grown from the iron-free media while 
there was no change in biofilm quantities when preformed P. aeruginosa biofilms were incubated 
with 2DP. DTPA and DM significantly increased biofilm quantities. When preformed biofilms 
grown from iron supplemented media were exposed to the various chemical iron chelators, there 
were no significant changes in the quantities of the preformed biofilms compared to the control. 
Values are mean ±SD, n=3. Comparisons of groups were made by one-way analysis of variance 
(ANOVA) using graphpad prism 5 (GraphPad Prism Software Inc., Version 5.0) followed by 
Dunnett post-test; P values were considered significant and the symbol; **, P < 0.001 compared 
to preformed biofilm quantities obtained in the control wells of the iron-free media; and *, P < 0. 
compared to preformed biofilm quantities obtained in the control wells of the iron-free media. 
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5.6.7     SDS-PAGE and Western blot analysis for confirmation of the 
identity of Lf, SDLf, aLf and SDaLf. 
Fig 5 -9a shows the SDS-PAGE patterns of Lf, SDLf, aLf and SDaLf when the gels were 
stained with Coomassie Brilliant Blue. One major band was observed for all four 
preparations, and the molecular weight which was estimated from a linear plot of log of 
molecular weight against mobility of the protein band (y = -0.1812x + 5.6499, r2 > 
0.9968) was found to be 80 kDa - equivalent to the reported molecular weight of bovine 
lactoferrin (Wakabayashi et al., 2006). Fig 5 -9b shows the SDS-PAGE patterns of Lf, 
SDLf, aLf and SDaLf when the gels were silver stained. The molecular weight bands on 
the silver stained gels were more sensitive and were generally characterized by three 
molecular weight bands which were mostly observable in all four preparations; the first 
band which is the most intensive staining was estimated from a linear plot of log 
molecular weight against mobility (y = -0.1822x + 5.6166, r2 > 0.9979) to be 78 ±4 kDa 
(n = 3), the second band which was less broad is estimated to be 52 ±4 kDa (n = 3) and 
the third band which is even less broad (and almost absent in apo lactoferrin) is 
estimated to be 28 ±1 kDa. 
Fig 5 -9c shows a representative example of Western blot analysis of Lf, SDLf, aLf and 
SDaLf. Lactoferrin bands correspond to the 80 kDa bands on the gel and are recognized 
by 4C6 and IG12 anti-bovine lactoferrin antibody.  
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a) 
 
b) 
 
    
c) 
 
Figure 5 -9: Analysis of the apparent molecular weight of various lactoferrin formulations, before 
and after spray drying using SDS-PAGE (a and b) and Western blotting (c). 5 -9a- shows a 
representative image of a Coomassie-blue stained SDS gel.  prestained protein ladder (lane 1), 
lactoferrin (lane 2), spray-dried lactoferrin (lane 3), apo lactoferrin (lane 4) and spray-dried apo 
lactoferrin (lane 5). 5 -9b shows a representative image of a Silver stained SDS gel.  prestained 
protein ladder (lane 1), lactoferrin (lane 2), spray-dried lactoferrin (lane 3), apo lactoferrin (lane 4) 
and spray-dried apo lactoferrin (lane 5). For both gels, approximately 375 ng of each of 
denatured protein was loaded into each well and a constant current of 60 mA applied for 22 
minutes. The molecular weight of the different proteins in the marker are shown in the left of the 
images. 5.9c shows a representative image of the specific detection of lactoferrin through 
Western blot analysis Lf (1), aLf (2), SDLf (3) and SDaLf (4). 
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5.7     Discussion 
This study is the first analysis to demonstrate that spray-dried lactoferrin retains its 
antimicrobial activity against planktonic and biofilms of P. aeruginosa. It was found that 
following spray drying of the protein, the MIC remained unchanged, however, following 
spray drying of the iron-deplete form of the protein (aLf) the MICs of the protein was 
increased from 10 µg/mL to 25 µg/mL (Table 5.1). This indicates that spray drying the 
protein in its iron-free form (apo lactoferrin), reported by Anderson et al., (1990) to exist 
in an open conformation compared to the closed conformation of the iron-bound form, 
may account for the observed detrimental effects to the antimicrobial activities of the 
protein. This observation however requires further investigation as there is currently no 
other evidence that shows that the three-dimensional structure of spray-dried apo 
lactoferrin is in any way different to the three-dimensional structure of apo lactoferrin.  
 
The different time-kill studies showed that 100 μg/mL of Lf and aLf suppressed the 
growth of planktonic cultures of P. aeruginosa. However, findings in this study suggest 
that iron depletion of lactoferrin is essential to achieve high efficacy in bacterial killing. 
This observation was found to correspond with previous reports by Arnold et al., (1980) 
who previously reported that while 2.2 x 107 cfu/mL of P. aeruginosa survived incubation 
with 83 μM iron saturated lactoferrin, only 8.6 x 103 cfu/mL of P. aeruginosa survived 
incubation with 4.2 μM apo lactoferrin with no detectable growth at 42 μM and 83 μM. 
Most importantly, regardless of the iron content of the proteins, it was observed that the 
proteins remained active to a considerable degree following spray drying; a clear 
indication that the particle production technique was well suited for producing micronized 
antimicrobial proteins. 
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Furthermore, although lactoferrin and spray-dried lactoferrin elicited bactericidal activity 
against P. aeruginosa at MICs of between 10 – 50 µg/mL, upon co-spray lactoferrin/apo 
lactoferrin with NaCMC, the MICs were found to be > 2 mg/mL, therefore indicating that 
the antimicrobial activities of the protein on planktonic cultures of P. aeruginosa were 
subdued in the combination. This may probably have occurred due to protein-polymer 
interactions which although functioning to stabilize the protein, resulted in the significant 
reduction in the efficacy of the protein. Another important antimicrobial property of 
lactoferrin which was investigated is its antibiofilm activity against P. aeruginosa. Since 
the protein had been previously reported by Singh et al., (2002) to prevent P. 
aeruginosa biofilm formation by increasing the twitching motility of the bacteria, we 
therefore sought to assess the antibiofilm activity of the spray-dried proteins compared 
to the non spray-dried proteins. Results obtained indicate that the antibiofilm activities of 
SDLf and SDaLf were comparable to the antibiofilm activities of Lf and aLf respectively.  
 
Furthermore, upon incubating the co-spray dried lactoferrin/apo lactoferrin with NaCMC 
formulations with P. aeruginosa, more biofilms were formed in both the iron-free and iron 
supplemented media, indicating that the antibiofilm effects of lactoferrin were lost. A 
possible explanation for this observation is that sodium carboxymethylcellulose provided 
an enabling environment for bacterial growth. A similar observation was also reported by 
Valappil et al., (2013) who found that following 24hrs of incubation P. aeruginosa and 
NaCMC had increased numbers of colony forming units (1.5 log units), but upon 
substituting the Na+ for Ga3+ in carboxymethylcellulose salts (of various molecular 
weights) there was a reduction in P. aeruginosa biofilm growth by 0.85 log units 
compared to the growth of the bacteria in NaCMC over the same 24 hour period.  
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Another antimicrobial property of the various lactoferrin formulations which was also 
assessed was the ability of the proteins to deplete already established biofilms. Tests 
were carried out on two different types of biofilms; structured biofilms (iron replete 
media) and flat biofilm (iron limited media) as previously shown by Banin et al., (2005) 
and Klausen et al., (2003). The results in this study showed that Lf, SDLf, aLf and SDaLf 
were more efficient than co-spray dried lactoferrin/apo lactoferrin with sodium 
carboxymethylcellulose and the various synthetic iron chelators at depleting both types 
of biofilms (figure 5 -5). The relevance of this finding is that biofilms developed by P. 
aeruginosa can be particulary susceptible to Lf and more importantly in this case spray-
dried lactoferrin which have been optimized for lower airway delivery, where the 
presence of P. aeruginosa biofilms usually result in recurrent infections.  
 
SDS-PAGE analysis which is a useful tool for identifying and differentiating proteins, 
showed that there was a very prominent band at about 80 kDa (Fig. 5 -11a and b, 
values were estimated from a calibration plot of log molecular weight against mobility of 
the individual protein bands), this was a verification that the spray drying process did not 
have detrimental effects on the molecular structure of the protein, therefore, making 
spray drying a viable option for preparing lactoferrin dry powders which are well suited 
for inhalation. Furthermore, the various staining procedures (Coomassie and silver 
staining) employed during SDS-PAGE analysis allowed for detailed comparisons of the 
molecular integrity of the different lactoferrin preparations (Lf and aLf) following spray 
drying. It was observed that the protein bands from the various lactoferrin formulations 
presented similar patterns before and after spray drying, therefore, indicating that the 
protein (lactoferrin) was not destroyed during spray drying.  Western blot analysis 
confirmed the identity of the protein band at 80 kDa to be lactoferrin as this particular 
band was recognized by IG12 and 4C6 anti-bovine lactoferrin antibody for both spray-
dried and non-spray-dried sources. 
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5.8     Conclusions 
In this study, assessments of the antimicrobial activity of the various protein formulations 
revealed that spray-dried lactoferrin/apo lactoferrin formulations remained active 
against; planktonic P. aeruginosa, preventing formation of biofilms as well as reducing 
the quantities of matured (preformed) biofilms by P. aeruginosa. The antimicrobial 
activity of spray-dried protein was also found to possess greater efficacy when 
compared to synthetic iron chelators.  Although the lactoferrin employed in this pilot 
study was from a bovine source (as human lactoferrin is strategically more difficult and 
expensive to obtain) and may elicit some immunological responses if delivered into 
humans, it basically should be seen as a proof of concept study and with prospect of 
delivering recombinant human lactoferrin-derived peptide (hLF1-11) which has a similar 
antimicrobial activity to lactoferrin. It has also been observed in this study that although 
NaCMC may have been a good thermoprotectant for the enzyme (alkaline 
phosphatase), it was however not the appropriate excipient of choice for formulating 
lactoferrin dry powders which are required to retain their antimicrobial activities following 
processing. Consequently, NaCMC would be excluded from subsequent studies and 
relevant antibiotics which improve the antimicrobial activities of the protein on P. 
aeruginosa through a combination therapy would be pursued. In the end, this study 
generally suggest that the delivery of active antimicrobial proteins to the airway of CF 
patients is possible and may potentially constitute a new strategy for managing P. 
aeruginosa infections of the airways.  
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6.1     Summary 
In the previous chapter the antimicrobial activities of various lactoferrin formulations 
against P. aeruginosa were studied. One of the key findings in that chapter was that, SD 
lactoferrin and apo lactoferrin gave a 2 log reduction in the number of surviving bacterial 
colonies after 60 minutes, despite a tendency for spray drying to reduce the activity of 
the antimicrobial proteins. In addition, the spray-dried preparations were effective at 
reducing the intensity of bacterial biofilms and the effects of iron-free apolactoferrin 
could not be mimicked by iron chelation alone. These data demonstrated that lactoferrin 
exhibits antimicrobial effects on P. aeruginosa. In this chapter, the effects of formulating 
a combination therapy of lactoferrin with currently prescribed antibiotics were studied. 
The selected antibiotics of choice for this assessment were tobramycin and gentamicin.  
These are both members of the aminoglycoside class of antibiotics and have activity 
against P. aeruginosa. Although the antimicrobial action of these two antibiotics have 
been extensively studied, to our knowledge, no study has investigated the potential of 
delivering a combination therapy of lactoferrin or the iron depleted lactoferrin (apo 
lactoferrin) with tobramycin/gentamicin to the airways for the purpose of preventing or 
eradicating P. aeruginosa especially in the context of managing this pathogen in cystic 
fibrosis. This chapter therefore focuses on co-spray drying each antibiotic with lactoferrin 
or apo-lactoferrin, investigating the physical characteristic of the spray-dried powders, 
assessing the antibacterial properties of the combinations on both planktonic cultures 
and biofilms of P. aeruginosa and measuring the penetration of spray-dried formulations 
through PAO1 biofilms. Results obtained indicate that antibacterial potency of 
tobramycin was significantly (p < 0.01) increased by co-formulating with lactoferrin or 
apo lactoferrin, and also the synergy obtained on combining apo lactoferrin with 
tobramycin was not replicable by co-formulating tobramycin with known chemical iron 
chelators. In conclusion, the spray drying process process produced amorphous, micron 
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sized dry powders suitable for lower airway deposition, as well as an active antimicrobial 
powder containing combinations of lactoferrin and aminoglycosides 
(tobramycin/gentamicin) which were observed to have a better activity than that of either 
lactoferrin or tobramycin/gentamicin alone on both planktonic and biofilm cultures of P. 
aeruginosa.  
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6.2     Introduction 
Bacterial biofilms result when sessile unicellular organisms coalesce to form a surface 
attached community usually surrounded by an exopolysaccharide matrix – a major 
distinguishing feature between planktonic cells and biofilms (Costerton et al., 1994). This 
sessile mode of growth is also called the biofilm mode of growth. Studies have found 
that the biofilm mode of growth is responsible for the exceptional ability of most bacteria 
to resist destruction by their host immune cells and antimicrobial. Cystic fibrosis is a 
classic example where the persistence of bacterial biofilms leads to respiratory failure, 
lung transplantation or death (Høiby and Pressler, 2006; Govan and Deretic, 1996).  
 
In the United Kingdom, P. aeruginosa is the most frequent cause of chronic pulmonary 
infections – accounting for about 69 % of all bacterial infections in people with CF. The 
age specific prevalence of P. aeruginosa in pre-school children is 2.9 %, rising to 65.3 % 
for 28 to 31 year olds. Overall, available data suggests that chronic P. aeruginosa 
infections are more prevalent among adults (55.8 %) compared to children (10.9 %) due 
to improved paediatric care (Cystic Fibrosis Trust, 2013). In contrast, the United States 
has a higher incident rate of P. aerugionsa infections across all age groups (Cystic 
Fibrosis Foundation Patient Registry, 2011) 
 
When P. aeruginosa exist in biofilms they not only become resistant to both innate and 
adaptive immune responses but also to antimicrobial therapy. In fact, several studies 
have suggested that mucoid bacterial cells of P. aeruginosa are 10 – 1000 times more 
resistant to the effects of antimicrobial agents than their nonattached (non mucoid) 
individual planktonic counterparts (Rogan et al., 2004; Smith, 2005; Stewart and William 
Costerton, 2001; Mehrotra, 2007; Nickel et al., 1985).  
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To date, aggressive antibiotic therapy continues to be one of the most important 
components of cystic fibrosis management especially since this successively increases 
the median survival age, improves the quality of life and determines the overall cost of 
care of the cystic fibrosis patient (Langton Hewer and Smyth, 2009). However, the 
overall outcome of antimicrobial therapies is controversial, with some studies suggesting 
that the currently available antimicrobial agents are virtually ineffective at eradicating 
chronic P. aeruginosa infections (Doring et al., 2000; Hoiby, 2000; Koch, 2002; The Uk 
Cystic Fibrosis Trust Infection Control Group, 2004; Frederiksen et al., 1997).  This is 
thought generally to be due to the difficulty of achieving effective concentrations of 
antimicrobials in the CF airways, partly as a consequence of the viscous nature of 
desiccated mucus lining the CF airway as well as the production of an mucoid 
exopolysaccharide matrix (biofilm) or alginate which surrounds P. aeruginosa 
(Costerton, 1977; Govan and Fyfe, 1978; Slack and Nichols, 1981; Tannenbaum et al., 
1984) . However, other studies like the ones by Li et al., (2005) and McPherson et al., 
(2010) suggest otherwise, generally positing that it is possible to eradicate or suppress 
early mucoid P. aeruginosa by aggressive anti-P. aeruginosa treatment. 
 
Several antibiotic strategies currently exist to treat early P. aeruginosa lung infections in 
CF patients. Some of these strategies are based in part on a variety of factors including 
patient’s age, disease severity, patient history and P. aeruginosa susceptibility tests. 
However, the UK cystic fibrosis trust antibiotic working group (2009) standard of care 
guidelines recommends three approaches to effectively manage infections in patient 
with CF: the first approach is prophylactic antibiotic therapy which serves to reduce 
infection and inflammation in the developing lung (hence reduced prevalence) as well as 
prevent secondary bacterial infection and colonization, however, prophylactic antibiotics 
use are not without consequences as they may sometimes present other challenges 
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following administration such as adverse effects like oral candidiasis and diarrhea 
(Smyth and Walters, 2012); the second approach generally deals with treating acute 
pulmonary infectious exacerbations by the use of various combinations of oral 
quinolones such as ciprofloxacin (Taccetti et al., 2005), inhaled antibiotics such as 
colistin and tobramycin (Ratjen et al., 2001) and intravenous antibiotics usually 
consisting of combination of tobramycin and a beta-lactam  (Douglas et al., 2009); the 
third approach generally deals with inhaled and intravenous antibiotic administration to 
control infections as well as to slow the progression of chronic lung disease (Ryan et al., 
2011; Ballmann et al., 2011) 
 
Unfortunately, notwithstanding all the strategies currently in place to delay or prevent 
chronic P. aeruginosa infections, the infection still persists, becoming progressively 
resistant to conventional antibiotic therapy especially those involving the 
aminoglycosides in particular (Emerson et al., 2010). There is a clear need for new 
antimicrobial agents and novel approaches including combination of currently existing 
antimicrobial agents that possess activity against the increasingly resistant respiratory 
pathogen; P. aeruginosa. 
 
Antimicrobial peptides/proteins which are components of the innate defence system are 
known to possess an unusually broad activity spectra against microorganisms resistant 
to conventional antibiotics as well as being relatively nonimmunogenic.  These are a 
particularly attractive candidate for pharmaceutical development. One of such 
antimicrobial peptide which does have applications in the pharmacotherapy of airway 
infections is Lactoferrin. Lactoferrin and apo lactoferrin have been shown to kill or inhibit 
bacterial growth of a variety of organisms; Porphyromonas gingivalis (Dashper et al., 
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2012); V. cholera, E. coli and S. thyphimurium (Ellison and Giehl, 1991); Streptococcus 
mutans, Streptococcus pneumonia, P. aeruginosa and Candida albicans (Arnold et al., 
1980). Additionally, the presence of lactoferrin has been shown to enhance the 
susceptibility of various bacteria to a range of different antibiotics (Alkawash et al., 1999; 
Qamruddin et al., 2005; Ellison et al., 1990; Naidu and Arnold, 1994; Singh et al., 2000). 
More importantly, lactoferrin has been shown to inhibit the formation of P. aeruginosa 
biofilms (Singh et al., 2002). 
 
Tobramycin, an aminoglycoside, is currently one of the most commonly used 
aerosolized antibiotics in the management of airway infections resulting from P. 
aeruginosa. It is one of several components of nebramycin – a complex of antibiotic 
substances produced by Streptomyces tenebrarius (Higgins and Kastner, 1967; Preston 
and Wick, 1970). It is currently recommended for use in patients with CF who are six 
years of age and older with moderate to severe lung disease and persistent P. 
aeruginosa infection (Flume et al., 2007).  
Tobramycin and gentamicin both have similar spectra of activity and both antibiotics 
function by irreversibly inhibiting protein synthesis in susceptible bacteria by binding to 
the 30S ribosomal subunit (Lambert, 2002). They however have a poor lipid solubility 
and so do not readily cross biologic membranes. To improve upon the activity of the 
aminoglycoside in treating airway infections it has become a common practice to 
combine an aminoglycoside with a second agent to achieve a synergistic effect as well 
as to minimize the risk of developing bacterial resistance to the aminoglycosides 
(Hodson et al., 1981; Hodson et al., 1983; Downs et al., 1986; Tré-Hardy et al., 2008; 
Moreau-Marquis et al., 2009; Cai et al., 2009; Macleod et al., 2009; Mccaughey et al., 
2012). Tobramycin and gentamicin both show a concentration dependent tendency in 
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causing nephrotoxicity and ototoxicity. The risks of these side effects developing is 
based on the duration of therapy. A delivery system that reduces the drugs’ drug toxicity 
while increasing their therapeutic index is of great interest and a dry powder formulation 
containing combinations of aminoglycosides and an antimicrobial protein (lactoferrin/apo 
lactoferrin) would be expected to provide these benefits. 
6.3     Aims and objectives 
The purpose of this study was threefold: (i) to develop dry powder co-formulations of an 
antimicrobial peptide and aminoglycoside antibiotics (tobramycin/gentamicin) and 
evaluate their physicochemical properties in order to establish that the dry powders 
produced were well suited for delivery to the lower regions of the respiratory tract. (ii) to 
determine the activity of the co-formulations against both planktonic and biofilm cultures 
of P. aeruginosa and also determine whether synergism was present between the 
various co-formulations against P. aeruginosa, and (iii) to determine the ability of the co-
formulations to penetrate bacterial biofilms.  
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6.4     Materials 
 
Tobramycin and gentamicin were supplied by Fagron (Newcastle upon Tyne, UK), 
Mueller-Hinton Agar, 30 µg tobramycin and 200 µg gentamicin antibiotic disks were 
supplied by Oxoid LTD (Basingstoke, UK), LIVE/DEAD cell viability assay kit was 
supplied by Invitrogen Molecular Probes (Life Technologies Ltd, Paisley, UK), 
Formaldehyde solution 37% by weight in water was supplied by Sigma-Aldrich (Poole, 
UK), Nucleopore track-etched Membranes (13 mm diameter and 25 mm diameter) with 
pore size 0.2 µm were supplied by Whatman Int. Ltd (Kent, UK) 
 
6.5     Methods 
6.5.1     Preparation of spray-dried tobramycin/gentamicin 
Spray-dried tobramycin or gentamicin were prepared according to the method previously 
outlined in section 2.2.2.2.8. Briefly, 2 g of either tobramycin or gentamicin were 
dissolved in 50 mL of deionised water, upon complete dissolution of the antibiotic, the 
final volume of the solution were made up to 100 mL. The resulting solution were then 
spray-dried with the following parameters; Inlet temperature, 180 °C; spray flow rate, 
606 L/hr; pump setting, 10 %; aspirator rate, 95 %. These settings resulted in an outlet 
temperature of 102 – 104 °C (for spray-dried tobramycin) and 99 – 102 (for spray-dried 
gentamicin). This procedure was repeated two more times to produce three different 
batches of spray-dried antibiotic powders. 
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6.5.2     Preparation of co-spray dried lactoferrin/apo lactoferrin with 
tobramycin/gentamicin 
Co-spray dried powder formulations of lactoferrin/apo lactoferrin and 
tobramycin/gentamicin were prepared according to the method describe in sections 
2.2.2.2.9 and 2.2.2.2.10. Briefly, to prepare co-spray dried lactoferrin and 
tobramycin/gentamicin powder formulations, 1 g of lactoferrin was mixed with 1 g of 
either tobramycin or gentamicin in 50 mL deionised water, upon complete dissolution of 
the powders, the final volume was made up to 100 mL with deionised water. The 
resulting suspension was spray-dried with the following parameters; Inlet temperature, 
180 °C; spray flow rate, 606 L/hr; pump setting, 10 %; aspirator rate, 95 %. These 
setting resulted in an outlet temperature of 104 – 106 °C (for co-spray dried lactoferrin 
with tobramycin) and 102 – 104 (for co-spray dried lactoferrin with gentamicin). This 
procedure was repeated two more times to produce a total of three batches of co-spray 
dried lactoferrin with tobramycin/gentamicin dry powders 
To prepare co-spray dried apo lactoferrin and tobramycin/gentamicin dry powders, 1g of 
either tobramycin or gentamicin were dissolved in 50 mL of apo lactoferrin prepared 
according to the method outlined in section 2.2.2.2.4. Upon complete dissolution of the 
antibiotic, the final volume of the solution was made up to 100 mL with apo lactoferrin 
solution. The resulting solution was then spray-dried with the following parameters; Inlet 
temperature, 180 °C; spray flow rate, 606 L/hr; pump setting, 10 %; aspirator rate, 95 %. 
These setting resulted in an outlet temperature ranging from 103 – 104 °C (for co-spray 
dried apo lactoferrin with tobramycin) and 93 – 103 °C (for co-spray dried apo lactoferrin 
with gentamicin). This procedure was repeated two more times to produce a total of 
three batches of co-spray dried apo lactoferrin with sodium carboxymethylcellulose dry 
powders. 
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6.5.3     Measurement of moisture content 
Moisture content was determined using the method previously described in section 2.4.2 
 
6.5.4     Measurement of spray-dried yield 
Spray-dried yield was calculated using the following equation: 
 
      
                                
                                    
       
(Equation 6.1) 
 
6.5.5     Zeta potential analysis 
The zeta potential of suspensions of the various tobramycin/gentamicin preparations 
was determined using a Zetaplus (Brookhaven Instruments) at 25 °C. Deionised water 
was used as dispersion medium and 2 mL volumes were assessed. Triplicate 
measurements were conducted on each of the three batches of tobramycin, spray-dried 
tobramycin, co-spray dried lactoferrin-tobramycin, co-spray dried apolactoferrin-
tobramycin, co-spray dried lactoferrin-gentamicin, co-spray dried lactoferrin-gentamicin.  
 
6.5.6     Density of the various spray-dried powders 
The true densities of the various powders were determined as previously outlined in 
section 4.5.10. Briefly, 3 cm3 volume of dry powders were put into the sample cup and 
pressurised to approximately 17 pounds per square inch (1.195 Kg/cm2) above the 
ambient pressure. Recordings were made and the true density of the powders 
calculated in MS Excel by determining the the pore volume (i.e. the difference between 
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the total volume and the solid volume as determined by the helium pycnometer) and 
dividing the weight of the powder sample by the total sample volume.  
 
6.5.7     Particle size analysis 
Particle size distribution of the various spray-dried tobramycin/gentamicin and co-spray 
dried powders were determined as previously described in section 2.2.5  
 
6.5.8     Differential scanning calorimetry  
Differential scanning calorimetric determinations were carried out as previously 
described in section 4.5.12. Briefly, 4 mg of the powder was loaded into an aluminium 
pan, cooled to -30 °C and then heated to 200 °C at 10 °C/min with a nitrogen purge of 
10 mL/min. An empty aluminium pan was used as reference for all measurements. The 
resulting data were analysed by Pyris manager software. Triplicate measurements of all 
independently prepared sample batches were assessed. 
 
6.5.9     X-ray powder diffraction 
X-ray powder diffraction measurements were carried out as previously described in 
section 4.5.11. Briefly, the sample holder was filled with the spray-dried powders, and 
diffraction patterns of the powders recorded between 2° and 70° of 2θ with an increment 
of 0.02° and a step time of 0.1 s. 
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6.5.10   Determination of minimal Inhibitory concentration and 
minimal bactericidal concentration (MBC) 
The MIC of each antimicrobial agent against P. aeruginosa was determined by the 
microdilution technique (100 µL volume) as described by NCCLS guidelines for 
antimicrobial susceptibility testing. The inoculum was prepared from an overnight culture 
of P. aeruginosa and diluted to yield 1x106 CFU/ml. Plate counts were performed to 
determine the exact count. The MIC was the lowest concentration of drug allowing no 
visible growth after 18 hr of incubation at 37°C. From each well where there was no 
visible growth, 10 µL was plated on a Mueller-Hinton agar plate, incubated at 37 °C for 
24, and counted. The MBC was defined as the lowest concentration of drug that killed 
99.9% of the original inoculum. 
 
6.5.11   Determination of fractional inhibitory concentration 
The fractional inhibitory concentration were calculated by the formula of Berenbaum 
(1978) as follows: 
 
    
                                
                        
 
(Equation 6.2) 
An FIC index of ≤ 0.5 was considered synergism, 0.5 to < 1 was considered weak 
synergism, 1 was considered additive, and >1 was considered antagonism. 
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6.5.12   Time-kill curve of the various protein-antibiotic co-
formulations 
20 μL of ~ 6.6 x 107 CFU/ml P. aeruginosa PAO1 was incubated at 37 °C with 180 μL of 
a 100 μg/mL stock preparations of the various protein/antibiotic co-formulations or 180 
µL of sterile distilled water (as positive control) or 180 µL of 500 µg/mL gentamicin (as 
negative control). At intervals of 10 mins for up to 1 hour, 10 µL aliquots were plated out 
neat as well as serially diluted with deionized water before plating out on Mueller-Hinton 
agar. The Muller-Hinton agar plates were then incubated at 37 °C for 24 hours. 
Following incubation, the number of colonies from each of the serial dilutions plated out 
was counted and the dilution having a colony count of < 300 colonies was used to 
estimate the colony forming unit per mL surviving at that time the sample was collected. 
The colony forming unit per mL was estimated by the equation previously stated in 
section 2.2.15 
 
6.5.13   Assessment of the ability of tobramycin/gentamicin alone or 
in combination with lactoferrin/apo lactoferrin to inhibit 
biofilm formation  
To test the ability of P. aeruginosa to form biofilms (on the surface of microtitre dishes) 
in the presence of the various tobramycin/gentamicin dry powder formulations, a method 
previously described by Eckhart et al., (2002) and Merrit et al., (1998) was employed. 
Briefly, overnight cultures of P. aeruginosa were diluted 1:10 (v/v) in fresh medium 
containing 0.5 % w/v casamino acids, 0.2 % glucose and 1 mM MgCl2 (casamino acid 
rich medium). 10 µL aliquots of the dilution were dispensed into a 96 well plate and 90 
µL of a 1 mg/mL (i.e. 900 µg/mL of the antimicrobial agent) stock suspension of the 
various antimicrobial formulations were then added to the bacterial suspension in the 96 
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well plate. The 96 well micro-plate was then covered and incubated at 37°C for 24 h, 
after which, excess broth was removed and the adherent biofilms to the microtitre plates 
stained. Detailed description of the method employed in staining and quantifying biofilms 
is as previously described in section 2.2.17.2. 
 
6.5.14   Assessment of the ability of tobramycin/gentamicin alone or 
in combination with lactoferrin/apo lactoferrin to reduce 
preformed biofilms   
To assess the effects of the various tobramycin/gentamicin formulations on already 
formed biofilms (i.e. biofilm persistence) a slight modification was made to the above 
method. Briefly, 100 µL of a 1 in 10 dilution of an overnight grown bacterial suspension 
of P. aeruginosa was put into 96 well plate, covered with a lid and incubated at 37°C for 
24 hours. Then the bacterial suspension was removed, leaving the adherent biofilm in 
the well, then, 100 µL of a 1 mg/mL (i.e. 100 µg/mL of the antimicrobial agent) stock 
suspension of the various tobramycin/gentamicin formulations was added and incubated 
for a further 24 hours at 37 °C. The various formulations were removed and the wells 
washed twice before staining with the method previously described in section  2.2.17.2 
 
6.5.15   Assessment of the ability of combinations of 
tobramycin/gentamicin with iron chelators to inhibit biofilm 
formation 
Overnight cultures of bacterial suspension were diluted 1:10 in casamino acid rich 
medium supplemented with 3 µM FeCl3. Then, 2 mM of various iron chelators (2DP, 
DTPA, EDTA and DM) was prepared using a 1 mg/mL solution of tobramycin/gentamicin 
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to produce various combinations of tobramycin/gentamicin with the iron chelators. 10 µL 
aliquots of the bacterial dilution were put into 96 well microplate and 90 µL of the stock 
preparation of the combinations of tobramycin/gentamicin with iron chelators was added 
to the wells. The 96 well microplates were then covered and incubated at 37 °C for 
either 6 or 24 hours. Following incubation, the procedure previously described in section 
2.2.17.2 was employed to stain and quantify the biofilms that formed.  
 
6.5.16   Preparation of antibiotic disks 
Antibiotic susceptibility disks containing combinations of tobramycin/gentamicin with 
lactoferrin/apo lactoferrin were all prepared locally by impregnating a sterile blank filter 
paper disk (diameter 6.3 mm) with 0.02 mL of 1mg/mL standard antibiotic solutions (to 
prepare a 20 µg antibiotic disc). The procedure previously described in section 2.2.19.1 
was employed to prepare the antibiotic disks.  
 
6.5.17   Antibiotic penetration through P. aeruginosa biofilms 
The penetration of the tobramycin and gentamicin either alone or in combination with 
lactoferrin preparations through the biofilms was determined using a method previously 
described by Singh et al., (2010) with some modifications. Sterile track-etched 
ploycarbonate membranes were inoculated with 5 µL of P.aeruginosa bacterial 
suspensions and incubated on Muller-Hinton agar plates at 37 °C for 48 hours with the 
membrane-supported biofilms transferred to a new agar plate every 18 hours. The 
polycarbonate membranes supporting biofilms growth were transferred to MHA plates 
inoculated with a quality control organism Escherichia coli NCTC 10418 whose growth 
was adjusted to the density of a 0.5 McFarland standard to give a confluent lawn of 
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grown. A 6 mm nitrocellulose membrane was then placed on top of each biofilm together 
with the antibiotic disc and moistened with 20 µL of sterile distilled water so as to 
prevent capillary action in the movement of the antibiotics. Controls, which comprised of 
sterile polycarbonate membranes and antibiotic disc without biofilms were also setup. All 
plates were incubated at 37°C for 24 hrs and the clear zones visible on the plates 
indicating the zone of inhibition of growth by the antibiotic (tobramycin or gentamicin) in 
both the control and test were measured.  A calibration plot of standard zone diameter 
measurements against log concentration (for antibiotic discs containing 1 – 10,000 µg) 
was used to estimate the concentration of the antibiotic that passed through the biofilms. 
The diameter of the zones of inhibition in the controls were taken to signify 100% 
penetration and used to determine the percent penetration and percent retardation of 
the antibiotics through the Pseudomonas biofilms. All experiments were performed in 
triplicates and a two-tailed, paired t-test was used for statistical analysis. In other to 
avoid false negative results arising from side diffusion from the antibiotic disc 
precautions were taken to ensure that the biofilms obtained after incubation was <13 
mm in diameter so as to prevent overgrowth of the biofilms unto the control organism. 
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Figure 6 -1: Schematic depiction of experimental setup used to track the penetration of 
antibiotics through Pseudomonas aeruginosa biofilms. The Mueller-Hinton agar plate is covered 
with a confluent lawn of the control strain (E. coli NCTC 10418). A sterile track-etched 
polycarbonate membrane (0.2 µm pore size) that supports biofilm growth is placed on MHA with 
a smaller diameter polycarbonate membrane and a moistened paper disk containing the test 
compound place on the biofilm. 
 
6.5.18   Confocal microscopy to investigate co-formulation-
dependent changes in the viability of biofilms of P. 
aeruginosa grown on glass 
Bacterial colonies of P. aeruginosa grown on Mueller-Hinton agar were suspended in a 
media rich in casamino acids and incubated for 24 hours at 37°C. An aliquot of 1mL of 
bacterial cell suspension (~ 107 cfu/mL) was added into each of the chambers created 
on a glass slide using a silicon gasket and incubated at 37°C. The media was removed 
and replaced every 16 hours. Following 72 hours growth of the biofilms on the coverslip, 
were carefully washed twice with phosphate-buffered saline (PBS) to remove planktonic 
bacteria while leaving behind the biofilm adherent to the glass.  
The biofilms were then treated for 24 hours with 100 µL per chamber of a 1mg/mL 
solution of the various antimicrobial formulations. Positive controls contained 100 µL of 
the CAA rich media without any antibiotic included, whilst the negative control contained 
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100 µL of 100 % isopropanol. The entire chamber containing the antimicrobial agents 
were incubated at 37°C. 
Following treatment, the slides were washed again with PBS and stained with a 
LIVE/DEAD bacterial viability kit using a mixture of 3 μL of syto 9 (green fluorescent) + 
3 μL of propidium iodide (red fluorescent) per mL of saline. Both syto 9 and propidium 
iodide are nucleic acid stains. While, syto 9 stains all nuclei acid in a population (both 
those with intact and damaged membranes), propidium iode on the other hand stains 
only bacteria with damaged membranes and when used together with syto 9 causes a 
reduction in the green fluorescence of the latter. 
Visualisation of biofilms was carried out using a Leica TCS SP5 II (Leica Microsystems, 
Milton Keynes, UK) confocal laser scanning microscope (CLSM). For detection of Syto 9 
(green channel), the 488 nm line of the argon laser with a detection bandwith of 495 – 
515 nm was used, while, for detection of propidium iodide (red channel), the 561 nm line 
with a detection bandwidth of 615 – 600 nm was used. Image analysis was carried out 
using the Leica software (LAS AF Version 2.2.1 build 4842). 
 
6.5.19   Statistical analysis 
Data was subjected to statistical analysis using one-way ANOVA to examine for 
significant differences (defined as p > 0.05). Significant differences between the various 
formulations were analysed using Dunnett post test with p values of < 0.05 being 
considered to be significant. 
 
 - 261 - 
 
6.6     Results 
6.6.1     Physical characteristics of various spray-dried powders 
The spray drying yield and moisture content of 2 % (w/v) tobramycin/gentamicin 
formulations are summarized in table 6.1. All the formulations were spray-dried with an 
inlet temperature of 180 °C and airflow rate of 606 L/hr to produce various outlet 
temperatures ranging from 99 – 102 °C. The lactoferrin-tobramycin/gentamicin 
formulations had the highest mean percent spray drying yield while the apo lactoferrin-
tobramycin/gentamicin formulations had the lowest mean spray drying yield. The 
moisture content, as determined by Karl Fischer titration of all the various spray-dried 
formulations, was generally below 5 %. Zeta potential measurements indicate that both 
tobramycin and gentamicin had a net negative charge while the combinations of 
protein:aminoglycoside had a net positive charge although the lactoferrin-
tobramycin/gentamicin combinations were slightly more positive than the apo lactoferrin-
tobramycin/gentamicin. The average true density measurements of the various powders 
was found to be 1.7 g/cm3 for the co-spray dried formulations while it was less for the 
spray-dried tobramycin and gentamicin only powder formulations. 
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Table 6.1: Percent spray drying yield, percent moisture content, zeta potential and true density of 
spray-dried tobramycin/gentamicin and co-spray dried tobramycin/gentamicin with lactoferrin. 
Three different batches of the various tobramycin/gentamicin powders were prepared and the 
mean values for the measurements are shown below.  
 
Formulation Mean yield 
(%) 
Moisture 
content (%) 
Zeta Potential 
(mV) 
True Density 
(g/cm3) 
SD Tobi 82.1 ±2.2 3.2 ±0.4 -3.34 ±3.1 1.52 ±0.01 
SDLf + Tobi 87.5 ±1.4 3.7 ±0.2 2.67 ±0.4 1.68 ±0.01 
SDaLf + Tobi 76.3 ±2.4 3.3 ±0.5 1.14 ±0.9 1.66 ±0.01 
SD Genta 85.4 ±1.3 4.0 ±0.2 -2.99 ±2.0 1.61 ±0.01 
SDLf + Genta 87.3 ±2.1 3.9 ±0.3 2.29 ±0.7 1.67 ±0.01 
SDaLf + Genta 80.1±1.9 3.4 ±0.4 0.97 ±0.8 1.67 ±0.01 
 
6.6.2     Particle size analysis of spray-dried tobramycin/gentamicin 
and co-spray dried lactoferrin-tobramycin/gentamicin 
The particle size distribution of the various co-spray dried formulations is summarized in 
table 6.2. Particle size analysis reveals that all the spray-dried powders were within the 
respirable size range, with a d[v,50] from 4.90 ±0.54 to 6.23 ±0.30 μm. 
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Table 6.2: Particle size distribution represented as volume fractions 10 % d[v,10], 50 % d[v,10], 
90 % d[v,10], their respective span and volume mean diameter (VMD). The values are mean ± 
SD. 
Formulations d[v,10] (μm) d[v,50]  (μm) d[v,90]  (μm) Span VMD (μm) 
SD Tobi 1.25 ±0.45 4.90 ±0.54 11.29 ±0.70 2.07 ±0.28 6.00 ±0.6 
SDLf + Tobi 1.17 ±0.20 5.27 ±0.30 15.23 ±0.51 2.68 ±0.21 7.51 ±0.4 
SDaLf + Tobi 1.02 ±0.39 5.06 ±0.40 14.31 ±0.45 2.63 ±0.22 7.07 ±0.5 
SD Genta 1.40 ±0.55 6.06 ±0.65 14.38 ±0.83 2.16 ±0.28 7.61 ±0.5 
SDLf + Genta 1.47 ±0.23 6.23 ±0.30 14.41 ±0.57 2.08 ±0.16 7.72 ±0.4 
SDaLf + Genta 1.47 ±0.32 5.15 ±0.33 11.53 ±0.55 1.96 ±0.17 6.11 ±0.3 
 
 
6.6.3     Thermal properties of spray-dried tobramycin/gentamicin and 
co-spray dried lactoferrin-tobramycin/gentamicin 
The thermal properties of six spray-dried powders are shown in Figure 6 -2. The 
absence of endothermic peaks on the DSC scans for spray-dried tobramycin and 
gentamicin powder formulation is indicative that the powders were amorphous. The DSC 
scan for the various co-spray dried powder formulations was characterized by broad 
endothermic peaks usually between 2 and 7 °C.  
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Figure 6 -2: DSC scans showing a comparison of the thermal behaviour of spray-dried 
tobramycin (SD Tobi), spray-dried gentamicin (SD Genta), co-spray dried lactoferrin + tobramycin 
(SDLf + Tobi), co-spray dried apo lactoferrin + tobramycin (SDaLf + Tobi), co-spray dried 
lactoferrin + gentamicin (SDLf + Genta) and co-spray dried apo lactoferrin + gentamicin (SDLf + 
Genta) 
 
6.6.4     X-ray powder diffraction (XRPD) 
X-ray diffraction analysis of the various spray-dried powder formulations revealed that 
the were no distinct peaks for any of the different formulations indicating that most of the 
formulations were amorphous following spray drying (Figure 6- 3a and 6- 3b) 
 
 
a) 
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b) 
 
Figure 6 -3: X-ray powder diffraction patterns of various lactoferrin-tobramycin/gentamicin spray-
dried powder formulations. (a) shows the XRPD patterns for the tobramycin containing 
formulations; spray-dried tobramycin (SD Tobi), co-spray dried lactoferrin-tobramycin  (SDLf + 
Tobi) and co-spray dried apo lactoferrin-tobramycin  (SDaLf + Tobi), (b) shows the XRPD 
patterns for the gentamicin containing formulations; spray-dried gentamicin (SD Genta), co-spray 
dried lactoferrin- gentamicin (SDLf + Genta) and co-spray dried apo lactoferrin- gentamicin  
(SDaLf + Genta). All the spray-dried powders have a broad halo and lack resolved reflections 
indicating that they are all amorphous. The results presented are a representation of three 
repeats.  
 
6.6.5     MIC, MBC and FIC of the various antimicrobials 
The MIC’s and MBC’s and the FIC index (compared to the single therapy) of SD Tobi, 
SDLf + Tobi, SDaLf + Tobi, SD Genta, SDLf + Genta and SDaLf + Genta against P. 
aeruginosa are summarized in Table 6.3. FIC calculations were made using equation 
6.2 and show SDaLf + Tobi, SDLf + Genta and SDaLf + Genta to be synergistic while 
SDLf + Tobi was weakly synergistic.  
 
Table 6.3: MIC, MBC and FIC of the various lactoferrin formulations. The MIC of each 
antimicrobial was assessed by a microdilution method derived from clinical and laboratory 
standard institute (CLSI) for broth microdilution antimicrobial susceptibility testing and defined as 
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the lowest concentration which inhibited visible growth. The MBC of the various antimicrobial was 
determined by plating out the wells with no visible growth on Mueller-Hinton agar. The FIC were 
calculated by dividing the MIC of the various combinations by the MIC of the antibiotic component 
of the combination  
 
Formulation MIC (µg/mL) MBC (µg/mL) FIC Index 
SD Tobi 1.17 ±0.1 2.08 ±0.1  
SDLf + Tobi 0.67 ±0.1 1.17 ±0.1 0.57 ±0.06 
SDaLf + Tobi 0.58 ±0.1 1.08 ±0.1 0.50 ±0.10 
SD Genta 2.33 ±0.1 4.00 ±0.0  
SDLf + Genta 1.17 ±0.1 2.00 ±0.3 0.50 ±0.06 
SDaLf + Genta 0.83 ±0.1 1.83 ±0.1 0.36 ±0.08 
 
6.6.6     Antimicrobial activity of the various powder formulations 
against planktonic bacteria 
The antimicrobial activity of the various spray-dried powders against planktonic P. 
aeruginosa was determined quantitatively through time-kill studies. P. aeruginosa 
cultures were grown in the presence or absence (control) of the various protein-antibiotic 
dry powders. Over a 1 hr period the number of colonies in the control remained fairly 
constant, spray-dried tobramycin reduced bacteria count by 2- log units within 1 hour, 
this was enhanced to 3- log units when tobramycin was spray-dried with lactoferrin. 
However, combinations of apo lactoferrin and tobramycin were even more effective, 
reducing viable counts to 5- log units within the same 1 hour period 
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Figure 6 -4: Logarithmic plot of bacterial cell viability in the presence of different combinations of 
lactoferrin:tobramycin preparations. The bacteria were seeded in polystyrene 96-well plates with 
equal volume of the antimicrobial preparation present at a concentration of 1 μg/mL of the 
antibiotics (tobramycin) and incubated at 37 °C for the times indicated. Aliquots were plated out 
onto MHA agar plates at 10, 20, 30, 40, 50, 60 mins. Bacterial colonies were counted after 24 
hours at 37 °C and data are presented as mean ± SD; n = 3 independent evaluations of triplicate 
wells. While the log colony forming unit per mL of the control wells remained relatively 
unchanged, after 1 hour incubation, the number of viable cells began to reduce in the presence of 
the various antimicrobial agents. 1 µg/mL of SD tobramycin-only showed the least impact on the 
population of viable cells. Iron depletion increased viable cell reduction. 
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For the gentamicin containing formulations, the number of colonies in the control (no 
antibiotic added) were fairly constant at about 108 colonies over a 1 hr period (figure 6 -
5). Spray-dried gentamicin only formulations decreased the bacterial colonies by 2 log 
units compared to the control. Co-spray dried lactoferrin-gentamicin (SDLf + Genta) 
combinations were more effective than gentamicin alone in eliminating bacteria colonies 
by a 4 log unit reduction within 1 hr. However, co-spray dried apo lactoferrin-gentamicin 
(SDaLf + Genta) were able to completely eliminate all the bacterial colonies within 40 
minutes.  
 
 
 
Figure 6 -5: Logarithmic plot of bacterial cell viability in the presence of different combinations of 
lactoferrin:gentamicin preparations. The bacteria were seeded in polystyrene 96-well plates with 
equal volumes of the antimicrobial preparation present at a concentration of 1 μg/mL of the 
antibiotics (gentamicin) and incubated at 37 °C for the times indicated. Aliquots were plated out 
onto MHA agar plates at 10, 20, 30, 40, 50, 60 mins. Bacterial colonies were counted after 24 
hours at 37 °C and data are presented as mean ± SD; n = 3 independent evaluations of triplicate 
wells. While the log colony forming unit per mL of the control wells remained relatively 
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unchanged, after 10 min incubation, the number of viable cells began to reduce in the presence 
of the various antimicrobial agents. 1 µg/mL of SD gentamicin showed the least impact on the 
population of the viable cell.  
 
 
 
6.4.6    Combination activity against biofilms  
In order to assess the effect of the various formulations on P. aeruginosa biofilm 
formation, a control (i.e. no antibiotic added) was setup which involved incubating the 
bacteria in two media; casamino acid only (CAA; iron free) and casamino acid 
supplemented with 3 μM FeCl3 medium. Absorbance values show that more P. 
aeruginosa biofilm formed in the iron rich medium within a 24 hr period (figure 6 -6). 
Spray-dried tobramycin only formulations were able to reduce biofilm formation in both 
the iron free and iron rich medium (figure 6 -6). However, co-spray dried lactoferrin-
tobramycin (SDLf + Tobi) and co-spray dried apo lactoferrin-tobramycin (SDaLf + Tobi) 
further significantly (p value < 0.001) reduced biofilm formation compared to the spray-
dried tobramycin only formulations. Similarly spray-dried gentamicin was also able to 
reduce biofilm formation in both the iron free and iron rich medium figure 6 -6 with co-
spray dried lactoferrin-gentamicin (SDLf + Genta) and co-spray dried apo lactoferrin-
gentamicin (SDaLf + Genta) further significantly reducing biofilm formation. 
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Figure 6 -6: P. aeruginosa biofilm formation in the presence and absence of various antimicrobial 
agents. Biofilm formation was assessed in both an iron free medium (CAA alone) and iron 
supplemented medium (with 3 µM FeCl3). The concentration of all the antibiotics was 1 mg/mL. 
Co-spray dried protein:antibiotic combinations were more effective at preventing biofilm formation 
than aminoglycosides alone. The values are mean ±SD of triplicate measurements. Comparisons 
of groups were made by one-way analysis of variance (ANOVA) using graphpad prism 5 
(GraphPad Prism Software Inc., Version 5.0) followed by Dunnett post-test; P values were 
considered significant and the symbol *** is used to represent p < 0.001 of the lactoferrin/apo 
lactoferrin – tobramycin combinations compared with spray-dried tobramycin; ‡ is used to 
represent p < 0.001 of the lactoferrin/apo lactoferrin – gentamicin combinations compared with 
spray-dried gentamicin 
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The ability of the various antimicrobial formulations to reduce or modify pre-formed 
biofilms were also assessed.  Here, a control (i.e. no antibiotic added) was setup in the 
iron-free and iron-supplemented media and P. aeruginosa was allowed to form biofilms 
over a 24-hour period. The various antimicrobial agents were added to 96 well microtitre 
plate (bacterial growth medium was added to the control wells) and incubated at 37°C 
for a further 24 hours. The absorbance values show that more P. aeruginosa biofilm was 
formed in the iron-rich medium within the 48 hr period growth compared with the iron 
free media. There was however no significant difference between the quantity of biofilm 
measured when a 24-hr biofilm was exposed to spray-dried tobramycin only 
formulations (SD Tobi) in both the iron free (CAA alone) and iron rich (casamino acid 
supplemented with 3 μM FeCl3) media following a further 24-hr incubation. In 
comparison, the quantity of biofilm measured when pre-formed biofilms were exposed to 
SDLf + Tobi and SDaLf + Tobi formulations for a further 24-hrs were significant (p < 0.05 
and p < 0.001 respectively) in both the iron free or iron rich media (figure 6 -7).  
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Figure 6 -7: Effect of antimicrobial agents on pre-formed P. aeruginosa biofilms. Antimicrobial 
effect was assessed in both in an iron free medium (CAA alone) and iron supplemented medium 
(with 3 µM FeCl3). The concentration of all the antibiotics was 1 mg/mL. Co-spray dried apo 
lactoferrin-antibiotic combination showed the most pronounced antimicrobial effect on pre-formed 
biofilms of P. aeruginosa, this is evidenced by the low absorbance units. The values are mean ± 
SD of triplicate measurements. Comparisons of groups were made by one-way analysis of 
variance (ANOVA) using graphpad prism 5 (GraphPad Software Inc., Version 5.0) followed by 
Dunnett post-test; ns indicates no significance compared to the CAA alone control (no antibiotic 
added), # indicates no significance compared to the 3 µM FeCl3 supplemented control, *** 
indicates p < 0.01 compared to the CAA alone control, * indicates p < 0.05 compared to the CAA 
alone control, ‡ indicates p < 0.01 compared to the 3 µM FeCl3 supplemented control and † 
indicates p < 0.05 compared to the 3 µM FeCl3 supplemented control. 
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While spray-dried gentamicin did not have any effect on the quantity of biofilm measured 
in the iron rich medium (p > 0.05), in the iron free medium it slightly reduced the quantity 
of biofilm measured compared to the respective controls (figure 6 -7). Upon incubating 
the 24 hr pre-formed biofilms with co-spray dried lactoferrin-gentamicin formulations 
there was no significant reduction in the pre-formed biofilm quantified in the iron free 
medium although there were significant (p < 0.05) reduction in the amount of biofilm 
quantified in the iron rich medium compared to the respective controls (figure 6 -7). The 
co-spray dried apo lactoferrin-gentamicin formulations significantly (p < 0.01) reduced 
the pre-formed biofilm quantified in both the iron free and iron rich media compared to 
the respective controls (figure 6 -7). 
 
6.6.7     Activity of combinations of iron chelators with 
aminoglycoside against biofilms of P. aeruginosa 
 
The activities of combinations of tobramycin and iron chelators on P. aeruginosa biofilms 
were evaluated at 6 and 24 hr post incubation in iron supplemented media. Results 
obtained shows that there was significantly more biofilm formed 6hrs post incubation of 
the control compared to 24 hr post incubation (figure 6 -8). Tobramycin was also found 
to significantly (p < 0.01) prevent biofilm formation for up to 24 hrs post incubation with 
this inhibition being more pronounced 6 hrs post incubation, however the combination of 
tobramycin and 2DP was most effective combination at preventing biofilm formation at 
both 6 and 24 hr post incubation. Combinations of tobramycin and DTPA and 
tobramycin and EDTA had similar biofilm prevention profiles; both being very effective at 
preventing biofilm formation 6 hrs after incubation and less effective at 24 hr post 
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incubation. The tobramycin-deferoxamine combination also significantly prevented 
biofilm formation up to 24 hrs post incubation. 
 
Figure 6 -8: P. aeruginosa biofilm formation following 6 and 24 hr incubation with 1 mg/mL 
tobramycin in the absence and presence of various iron chelators at 2mM. The entire experiment 
was carried out in casamino acid (iron free) medium. Values are mean ±SD of triplicate 
measurements for three batches of the combinations. Comparisons of groups were made by one-
way analysis of variance (ANOVA) using graphpad prism 5 (GraphPad Software Inc., Version 
5.0) followed by Dunnett post-test; *** indicates p < 0.01 compared to the 6 hr biofilm growth 
control (no antibiotic or iron chelator added) and ‡ indicates p < 0.01 compared to the 24 hr 
biofilm growth control 
 
Similarly, the activity of gentamicin and combinations of gentamicin and various iron 
chelators on biofilm formation was assessed at 6 and 24 hrs after incubation with P. 
aeruginosa. While gentamicin alone was able to significantly prevent biofilm formation 
up to 24 hrs post incubation, the gentamicin-2DP combination had the best anti-biofilm 
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activity of all the combinations following 6 or 24 hr incubation with P. aeruginosa. 
Gentamicin-DTPA combination was no different than gentamicin alone, again being 
more effective at 6 hrs post incubation compared to 24 hrs post incubation. Finally, even 
though Gentamicin-EDTA and gentamicin-DM combinations were able to significantly (p 
< 0.01) prevent biofilm formation in the first 6 hrs post incubation they failed to sustain 
this activity 24 hr post incubation. 
 
 
Figure 6 -9: P. aeruginosa biofilm formation following 6 and 24 hr incubation with gentamicin 
(Genta) in the absence and presence of various different iron chelators at 2mM. The entire 
experiment was carried out in casamino acid (iron free) medium. Values are mean ±SD of 
triplicate measurements for three batches of the combinations. Comparisons of groups were 
made by one-way analysis of variance (ANOVA) using graphpad prism 5 (GraphPad Software 
Inc., Version 5.0) followed by Dunnett post-test; *** indicates p < 0.01 compared to the 6 hr 
biofilm growth control (no antibiotic or iron chelator added), ‡ indicates p < 0.01 compared to the 
24 hr biofilm growth control and † indicates p < 0.05 compared to the 24 hr biofilm growth control. 
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6.6.8     Penetration of antibiotics only and protein-antibiotic co-
formulations through P. aeruginosa biofilms 
Antibiotic penetration through biofilms is commonly used to determine how much 
antibiotic is able to pass through a biofilm.  The penetration of the various antimicrobials 
through P. aeruginosa biofilms was evaluated to determine their suitability for treating 
chronic P. aeruginosa infections. The results presented here provide some mechanistic 
insight into the effectiveness of the various antimicrobial formulations during use.  
 
6.6.8.1     Calibration curves 
A calibration curve was set-up to allow the conversion of the zone of inhibition obtained, 
to effective concentration of drug that got through the biofilm. The penetration of 
tobramycin or gentamicin through P. aeruginosa biofilms was assessed from a 
calibration plot of zone diameter against log concentration of aminoglycoside. 
Representative images from three separate repeats showing changing zone diameter 
with increasing concentrations of tobramycin or gentamicin are shown in Figure 6- 10. 
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Figure 6 -10: Representative photographs showing the zone of inhibition apparent following the 
placement of antibiotic disc containing the various concentrations of tobramycin/gentamicin on an 
agar plate seeded with E. coli.  These zones were measured and used to prepare a standard 
calibration curve relating aminoglycoside concentration to zone of inhibition. Subsequently, the 
calibration curve was used to evaluate antibiotics penetration through P. aeruginosa strain PAO1 
biofilms grown on track-etched polycarbonate membranes. The images show agar plates seeded 
with the control organism – Escherichia coli NCTC 10418. A sterile polycarbonate membrane and 
an antibiotic disk containing 10, 100, 1000, and 10,000 µg of tobramycin (for the top row) and 10, 
100, 1000, and 10,000 µg of gentamicin (for the bottom row) were place at the centre of each 
plate and incubated at 37 °C for 24 h. Following incubation, the zone of inhibition was measured 
and used in the preparation of a calibration plot of mean zone diameter against log concentration. 
The calibration plot was subsequently used to assess the concentration of combinations 
formulations penetrating through the biofilms.  
 
All calibration curves obtained on different days for zone of inhibition of tobramycin on 
the control organism were linear within the assessed concentration range of 10 – 10,000 
µg (y = 5.0667x + 17.6, R2 > 0.99) Figure 6 -11 shows the mean calibration curve for 
mean zone diameter against log concentration of tobramycin. 
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Figure 6 -11: Calibration curve showing a plot of mean diameter versus log concentration for 
tobramycin. The mean diameter calculated from calibrations obtained on three different days are 
plotted against log10 of concentration values (n = 3). Error bars representing standard deviation 
are displayed for each point. 
All calibration curves obtained on different days for zone of inhibition of gentamicin on 
the control organism were linear within the assessed concentration range of 10 – 10,000 
µg (y = 5.0667x + 17.6, R2 > 0.99) Figure 6 -12 shows the mean calibration curve for 
mean zone diameter against log concentration of gentamicin. 
 
 
Figure 6 -12: Calibration curve showing a plot of mean diameter versus log concentration for 
gentamicin. The mean diameter calculated from calibrations obtained on three different days are 
plotted against log10 of concentration values (n = 3). Error bars representing standard deviation 
are displayed for each point. 
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6.6.8.2     Penetration of antimicrobial agents through P.  aeruginosa 
biofilms 
The assembly was set up as shown in figure 6 -1. A control assembly was set-up and 
contained no biofilm. An antimicrobial disc containing ~30 µg either tobramycin was 
placed on the nitrocellulose membrane and 20 µL of distilled water added and the entire 
assembly was incubated at 37°C for 24 hours.  
 
Figure 6- 13: Penetration of various tobramycin formulations through P. aeruginosa biofilms. 
While the control assembly contained no biofilm, the test assembly contained a biofilm. The 
concentration of tobramycin penetrating through the biofilm was estimated from a calibration plot 
of zone diameter against log of concentration. No significant difference was found between the 
concentration penetrating through the control assembly compared with the concentration 
penetrating through the test assembly. Values are mean ± SD.  
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The penetration of various antimicrobials formulations through P. aeruginosa biofilm 
showed that while 48.7 ±21.6, 30.9 ±13.7 and 34.4 ±9.6 µg of Tobi, SDLf + Tobi and 
SDaLf + Tobi were able to penetrate through the control assembly (i.e. no biofilm 
present) respectively, only 13.1 ±13.9, 21.8 ±6.1 and 30.9 ±13.7 µg of Tobi, SDLf + Tobi 
and SDaLf + Tobi were able to penetrate through the test assembly (i.e. in the presence 
of P. aeruginosa biofilm) thereby indicating that the mean percent penetration of 
tobramycin alone through the biofilm was 24.14 ±16.9 %. In comparison, 80.1 ±34.5 and 
87.8 ±21.1 of co-spray dried lactoferrin-tobramycin and co-spray dried apo lactoferrin-
tobramycin penetrated through the P. aeruginosa biofilm.  
 
A similar setup was also used to determine the penetration of gentamicin through P. 
aeruginosa biofilms. The amount of gentamicin, co-spray dried lactoferrin-gentamicin 
and co-spray dried apo lactoferrin-gentamicin passing through the control assembly (i.e. 
no biofilm present) were determined to be 172.4 ±75.4 µg as estimated from the 
calibration curve.  
 
 
 
 
Chapter six: Co-formulation of lactoferrin with antibiotics 
 
- 281 - 
 
 
Figure 6- 14: Penetration of various gentamicin formulations through P. aeruginosa biofilms. 
While the control assembly contained no biofilm, the test assembly contained a biofilm. The 
concentration of gentamicin penetrating through the biofilm was estimated from a calibration plot 
of zone diameter against log of concentration. Values are mean ± SD. Comparisons of groups 
were made by one-way analysis of variance (ANOVA) using graphpad prism 5 (GraphPad 
Software Inc., Version 5.0) followed by Dunnett post-test; ** indicates p < 0.01 compared to the 
control assembly of gentamicin and † indicates p < 0.05 compared to the control assembly of the 
SDLf + Genta. 
 
In the test assembly, i.e in the presence of P. aeruginosa biofilms 23.6 ±5.6, 70.3 ±30.8 
and 90.6 ±21.5 µg of gentamicin, co-spray dried lactoferrin-gentamicin and co-spray 
dried apo lactoferrin-gentamicin respectively was able to penetrate through the biofilm. 
Indicating that about 14.6 ±3.5, 40.8 ±0 and 56.2 ±13.3% of gentamicin were able to 
penetrate through the biofilm matrix. Statistical analysis showed that significant amounts 
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of gentamicin (p < 0.01) and SDLf + Genta (p < 0.05) were retarded by the P. 
aeruginosa biofilms. 
 
 
 
 
 
Figure 6 -15: Zone of inhibition studies showing antibiotic penetration through P. aeruginosa 
strain PAO1 biofilms grown on track-etched polycarbonate membranes. All plates were seeded 
with the control organism – Escherichia coli NCTC 10418. A track-etched polycarbonate 
membrane on which a 48 hr biofilm of P. aeruginosa was grown or a sterile track-etched 
polycarbonate membrane without biofilm (serving as a control) were placed on the seeded agar 
plates and the various tobramycin and gentamicin antibiotic disk containing a 30 µg of tobramycin 
or 200 µg of gentamicin or combinations were placed at the centre of each plate and incubated at 
37 °C for 24 h. The zone of inhibition was measured and the concentration of antibiotic 
penetrating through the biofilm matrix estimated from a calibration curve. 
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6.6.9     Confocal laser scanning microscopy of biofilms exposed to 
various antimicrobial agents. 
To further characterize the penetration of the formulations through P. aeruginosa 
biofilms grown on cover slip. The biofilms were exposed to the various agents or in the 
case of the control, remained untreated for 24 hours following which propidium iodide 
was used to stain dead cells and syto-9 was used to stain bacteria on the coverslip. 
Confocal microscopy of untreated P. aeruginosa biofilms shows very little propidium 
iodide stain (red fluorescence, indicating dead cells) although more syto-9 (green 
fluorescence, indicating live cells) was observed (fig. 6 -14a). Confocal microscopy of 
biofilms of P. aeruginosa treated with tobramycin alone shows the relatively low 
penetration (indicated by the low intensity of the red fluorescence- propidium iodide 
showing limited cell death) of the antibiotic into the biofilm (Figure 6 -14b). Upon treating 
the biofilm with SDLf + Tobi and SDaLf + Tobi, there was deeper penetration (indicated 
by the high intensity of the red fluorescence that indicates propidium iodide uptake into 
dead bacterial cells) (Figure 6 -14c -d). The penetration of gentamicin into the biofilms 
was also very low (Figure 6 -14e) while the penetration of the combinations of lactoferrin 
and gentamicin shows relatively deeper penetration of the antimicrobial agents (Figure 6 
-14f -g). Overall, the co-spray dried apo lactoferrin-tobramycin/gentamicin formulations 
reduced viability the most, evidenced by the intense yellow colouration of the composite 
image.  
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(a) 
 
(b) 
 
    
(c) 
 
(d) 
 
    
(e) 
 
(f) 
 
    
(g) 
 
  
Figure 6 -16: Confocal microscopic images of P. aeruginosa biofilms formed after 72 h growth on 
glass slide. The biofilms were stained using the LIVE/DEAD staining assay and visualised using 
confocal laser scanning microscopy. The green-fluorescent SYTO 9 staining (left-most images) is 
indicative of live cells while the red-fluorescent propidium iodide staining (middle image) is 
indicative of dead cells.  The yellow image on the right shows the overlay to indicate increased 
number of dead cells which are stained by propidium iodide (a) untreated biofilms; (b) biofilms 
treated with 1mg/mL spray-dried tobramycin for 24 h; (c) biofilms treated with 1mg/mL co-spray 
dried lactoferrin-tobramycin for 24 h; (d) biofilms treated with 1mg/mL co-spray dried apo 
lactoferrin-tobramycin for 24 h; (e) biofilms treated with 1mg/mL spray-dried gentamicin for 24 h; 
(f) biofilms treated with 1mg/mL co-spray dried lactoferrin-gentamicin for 24 h; (g) biofilms treated 
with 1mg/mL co-spray dried apo lactoferrin-gentamicin for 24 h. Control shows little cell death 
(very low red fluorescence), while biofilms treated with the various antibiotics showed different 
degrees of cell death (increased red fluorescence compared with the control). The images are 
representative of two independent experiments.   
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6.7     Discussion 
The idea of combining various antibiotics to increase their efficacy has been around for 
decades. In the present study, both the powder properties and antibacterial activities of 
a novel inhaled antibiotic combination consisting of a 1:1 spray-dried combinations of 
lactoferrin and tobramycin/gentamicin were investigated.  
 
It was found that upon spray drying the various preparations, the spray-dried yield of the 
various powders varied, depending on aminoglycoside composition. Co-spray drying 
lactoferrin with tobramycin/gentamicin was found to produce a high percent yield of over 
87.3 ±2.1% compared to co-spray drying apo lactoferrin with tobramycin/gentamicin or 
even spray drying tobramycin or gentamicin alone (Table 6.1). As this was the first time 
such a combination has been prepared, there were no prior data to compare the results 
with, however compared with the typical yield of spray-dried powders which is usually 
between 20% and 50% (Labrude et al., 1989) the percent yield of the spray-dried 
powders obtained in this study were well above average.   
 
A residual moisture content of between 3.2 ±0.4% and 4.0 ±0.2% was obtained 
indicating that the drying process was efficient in evaporating most of the moisture. The 
residual moisture content of spray-dried powders have been shown to be a particular 
important factor in determining the long term stability of dry powders especially those 
containing proteins. Typically, residual moisture contents of between 2% and 8% 
(Tzannis and Prestrelski, 1999b; Maa et al., 1998) have been previously reported upon 
spray drying proteins alone or in combination with excipients.  In this study however, a 
residual moisture content of between 3 and 4 % was obtained and consequently, the dry 
powders produced would be expected to exhibit better long term protein biochemical 
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stability. 
 
The zeta potential measurement of the various formulations showed that the net charge 
of spray-dried tobramycin was -3.34 ±3.1 while the net charge of gentamicin was -2.99 
±2.0 (table 6.1). Upon co-spray drying lactoferrin with the tobramycin/gentamicin, a net 
positive charge of 2.67 ±0.4 (SDLf + Tobi), 1.14 ±0.9 (SDaLf + Tobi), 2.29 ±0.7 (SDLf + 
Genta) and 0.97 ±0.8 (SDaLf + Genta) were obtained indicating that the co-spray dried 
formulations were cationic and would therefore have greater antimicrobial effect on 
Gram-negative bacteria (like P. aeruginosa which have anionic membranes) (Gottenbos 
et al., 2003) compared to spray-dried tobramycin or spray-dried gentamicin only 
formulations. Probably, the net positive charge of the co-formulation may account for the 
greater antimicrobial activity of the various combinations on both planktonic and biofilms 
of P. aeruginosa compared to the monotherapies. 
 
Analysis of the particle size distribution of the various spray-dried powders show that the 
d[v,50] of the powders ranged between 4.90 ±0.54 and 6.23 ±0.30 µm. Particles within 
this size range will be expected to deposit in the lower regions of the airway according to 
the prediction models by Martonen and Yang, (1996) and will therefore provide 
distinctive benefits such as; the required amount of drug at the site where it is most 
needed and a cost effective medication due to minimization of waste. The span of 
particles (table 6.2), which was found to range between 1.96 ±0.17 and 2.68 ±0.21 only 
further, corroborate deposition of the drug at the desired location. The similarity in 
particle size distribution was expected, as all the powders were prepared under similar 
particle engineering condition. 
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XRPD studies showed that all the spray-dried formulations had a broad halo and lacked 
resolved reflections (figure 6 -3a and 6 -3b) this is clearly indicative that all the spray-
dried powders were predominantly amorphous as the powders showed no evidence of 
crystallinity. Hence indicating that while the powder formulations would be expected to 
have a good solubility in biological fluids they may however present with stability issues 
during long-term storage. DSC scans for the various co-spray dried powders revealed a 
broad endothermic peaks usually between 2 and 7 °C, indicative of moisture loss and no 
crystalline melting temperature a further indication of the amorphous nature of the spray-
dried powders.  
 
The activity of the various antimicrobial agents against planktonic and biofilms of P. 
aeruginosa were evaluated. SDaLf + Tobi was found to be the most potent with MIC 
values of 0.58 ±0.1 µg/mL and MBC values of 1.08 ±0.1 µg/mL (Table 6.3). The FIC 
index shows that all the various protein-antibiotic combinations showed synergism (i.e. 
the combined effect of the combinations were larger than the effect predicted from the 
sum of each agent alone). The highest degree of synergy was obtained with the SDaLf + 
Genta formulations (Table 6.3). The indications of this finding is that by combining 
tobramycin/gentamicin with apo lactoferrin, the minimum bactericidal concentration of 
tobramycin and gentamicin against a, P. aeruginosa can be significantly reduced. To our 
knowledge, this is the first study to show that the activity of an antibiotic currently 
indicated for the management of infections in cystic fibrosis has increased activity 
against P. aeruginosa when combined with lactoferrin. Previously, Singh et al., (2000) 
reported that combined actions of lysozyme and tobramycin as assessed by a 
checkerboard assay produced an additive interaction (FIC index 1.04) in the killing of 
Escherichia coli DH5α whereas lysozyme in combination with lactoferrin showed 
synergistic interaction (FIC index 0.23) in the killing of the same E. coli strain. As their 
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choice of test organism is not relevant CF and the stability of the combinations were not 
considered, the antimicrobial activities of the powder formulations in this study was 
deemed to be relatively good and fit for purpose.  
 
Time-kill experiments were also carried out to evaluate the effects of the individual 
agents as well as the combinations over time. The time-kill curves are presented in 
Figures 6 -4 and 6 -5. A bactericidal effect as defined by the Clinical and Laboratory 
Standards Institute (1999) is a 3 log10 reduction in cfu/mL or a 99.9 % kill over a 
specified time period (in this case it was 1 hr).   
 
Results show that while spray-dried tobramycin and gentamicin were poorly active 
against planktonic P. aeruginosa at 1 µg/mL within 60 mins, co-spray dried combinations 
of lactoferrin and tobramycin/gentamicin produced significant and amplified bactericidal 
effect at the same concentration within the same time period. This amplified bactericidal 
effect resulted in the overall reduction of the cfu/mL by 3 log10 units. The co-spray died 
apo lactoferrin-tobramycin/gentamicin combinations performed even better than other 
formulations (since it reduced the cfu/mL by over 5 log10 units) presumably this was due 
to synergy.  The significance of this is that by combining lactoferrin with aminoglycoside 
antibiotic, less of the aminoglycoside combination would be required to kill more P. 
aeruginosa bacterial cells, hence there is a chance that such a combination may 
probably improve compliance (due to possible reduction in the adverse effects of 
aminoglycoside). 
 
Given that chronic P. aeruginosa infection in the airway usually results from biofilm 
Chapter six: Co-formulation of lactoferrin with antibiotics 
 
- 289 - 
 
formation, we sought to assess the antimicrobial activity of the various formulations on 
P. aeruginosa biofilms grown on abiotic (polystyrene) surfaces. This evaluation was 
carried out in both iron free (i.e. casamino acid only) and iron rich environments so as to 
determine the efficacy of the various formulations on biofilms of P. aeruginosa in both 
extremes of iron concentrations especially since increased levels of iron in the airway 
surface liquid has been cited as the possible reason for increased persistence of P. 
aeruginosa (Stites et al., 1998; Reid et al., 2007b). Results obtained in this study 
indicate that by supplementing the growth media with low levels of iron, the amount of 
biofilm quantified increased significantly (figures 6 -6, and 6 -7) this observation is in 
agreement with previous studies by Yang et al., (2007) and Banin et al., (2005) who 
have all reported low  iron concentrations to be essential for P. aeruginosa biofilm 
formation. While Yang et al., relate this increased biofilm development to the up-
regulation of pqs genes (a quorum sensing system) and the increased formation of 
extracellular DNA, Banin et al., relate this occurrence to the ability of the ferric uptake 
regulator, Fur, (a protein which controls expression of iron responsive genes in many 
bacteria including P. aeruginosa) of the bacteria to promote biofilm formation. Any or all 
of these reasons may probably account for the high amount of biofilm quantified when P. 
aeruginosa was grown in the iron supplemented media, however, upon incubating the 
bacteria with the various formulations, spray-dried tobramycin and spray-dried 
gentamicin exhibited some biofilm prevention activity in both iron rich and iron free 
environments, the inclusion of lactoferrin into the various formulations (especially apo 
lactoferrin) significantly restricted the development of P. aeruginosa biofilms even in the 
iron supplemented environment (Figure 6 -6). A possible explanation for this observation 
may reside in a previous report by Singh et al (2002) who found that exposing P. 
aeruginosa to lactoferrin resulted in increased incessant twitching motility of the 
bacteria, a phenomenon which usually means that the P. aeruginosa cells do no attach 
to a surface (a necessary step involved in the formation of microcolonies). 
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Upon exposing already existing biofilms to the various formulations, spray-dried 
tobramycin and gentamicin were found not to have any significant effect on biofilms 
formed in both iron free and iron supplemented environments. These observations were 
found to be in agreement with those of Tré-Hardy et al., (2008) and Moreau-Marquis et 
al.,  (2009) who have previously reported that tobramycin failed to disrupt established 
biofilms. The reason for these occurrences may reside in the mechanism of action of the 
aminoglycoside. Aminoglycosides generally inhibit the growth of bacteria cells, but to 
achieve this they need to be in contact with the bacteria cell, however, as they have 
poor penetration through bacterial biofilms due to the high degree to which they bind to 
the alginate matrix (Gordon et al., 1988) which is related to their overall charge (found to 
be net negative, table 6.1), thereby rendering their antimicrobial activity ineffective. On 
the other hand, co-spray dried apo lactoferrin and tobramycin/gentamicin powder 
formulations were found to significantly (p < 0.01) disrupt preformed biofilms (Figure 6 -
7) this may also have some relationship with their overall charge which was found to be 
net positive (table 6.1) and hence would mean that the negatively charged biofilm 
membrane formed by the bacteria are more readily disrupted. The effects of co-spray 
dried apo lactoferrin-tobramycin/gentamicin powder formulations on preformed biofilms 
have not been previously reported. But unlike the previous report by McCaughey et al., 
(2012) which found that 5.120 mg/mL of a 4:1 (w/w) combination of 
fosfomycin:tobramycin was required to effectively disrupt preformed biofilms, results 
from our study showed that 1 mg/mL of a co-spray dried apo lactoferrin-
tobramycin/gentamicin was enough to significantly disrupt preformed P. aeruginosa 
biofilms.  
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The increased susceptibility of P. aeruginosa to antibiotics in the presence of lactoferrin 
was thought to be as a result of iron chelation as previously indicated (Singh et al., 
2002; Banin et al., 2005; Banin et al., 2006; Singh, 2004). We decided to investigate the 
degree to which iron chelation contributes to observed activities of our lactoferrin-
tobramycin/gentamicin combinations in preventing or disrupting P. aeruginosa biofilms. 
Four iron chelators were chosen and combined with tobramycin. The combinations of 
tobramycin and the various iron chelators were exposed to P. aeruginosa growing in an 
iron free medium and it was observed that the iron chelators were not as effective as the 
co-spray dried apo lactoferrin-tobramycin preparation in preventing biofilm formation. 
Iron deprivation however, is not the sole mechanism by which lactoferrin/apo lactoferrin 
is able to increase the susceptibility of P. aeruginosa to antibiotics. Some other 
additional mechanism of action have been described by  Ellison et al., (1990) who 
showed that lactoferrin and transferrin alter the outer membrane of Gram-negative 
bacteria thereby sensitizing the bacteria to both a hydrophobic antibiotic and a surface-
active agent. A study by Leitch and Wilcox (1999a) have also similarly reported that the 
antibacterial synergy of lactoferrin and lysozyme against Gram-negative bacteria is 
dependent on the ability of the protein to disrupt the outer-membrane of the bacteria or 
the biofilm. Particularly, they found that incubating Staphylococcus epidermidis with 
artificial tear fluid containing serum (ATFS) and 1.8 mg/mL of lactoferrin for 6 hours at 
37°C and then adding 5.4 mg/mL of lysozyme and incubating for a further 6 hours 
resulted in a significant reduction of the number of colonies per mL due to disruptions to 
the outer membrane of the bacteria.  
 
Understanding that one of the underlying factors of antibiotic resistance is the inability of 
the antibiotic to penetrate to all areas of a biofilm and effect killing of bacterial cells 
within the biofilm elicited investigations into how a co-spray dried powder formulation of 
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lactoferrin and aminoglycoside would perform. A method previously described by Singh 
et al., (2010) was employed albeit with some modifications. Briefly, antibiotic discs 
containing either tobramycin or gentamicin with/without lactoferrin or apo lactoferrin 
were placed on P. aeruginosa biofilms grown on track-etched polycarbonate 
membranes (the setup for the experiment is shown in figure 6- 1). The zone of inhibition 
of E. coli growing on Mueller-Hinton agar plates were measured and the quantities of 
tobramycin or gentamicin penetrating through the biofilms assessed (fig 6- 13 and 6- 
14). Results obtained showed that > 80% of tobramycin and > 40 % of gentamicin 
penetrated through the P. aeruginosa biofilms when the antibiotics were combined with 
either lactoferrin or apo lactoferrin compared to the approximately, 24% penetration of 
tobramycin or  approximately, 15% penetration of gentamicin when the antibiotic disk 
contained one agent alone. While our results extend previous reports that 
aminoglycosides have reduced penetration through P. aeruginosa biofilms, a 
phenomenon typically referred to as impermeability resistance (Bryan et al., 1976; 
Maloney et al., 1989; Turnidge, 2003), it also informs on a probable mechanism that 
explains why the various combinations significantly reduced preformed biofilms as 
quantified by the crystal violet assay. The reason for this occurrence is probably linked 
to the net cationic charge of the combination which destabilizes the negatively charged 
biofilm membrane thereby enabling the penetration of the antibiotic into the biofilm to 
effect its antimicrobial actions. 
Confocal microscopy images of the P. aeruginosa biofilms grown on cover slip and 
treated with/without various antimicrobial agents shows varying degrees of dead cells 
(indicated by the red fluorescence of propidium iodide). While the untreated biofilm 
showed very little propidium iodided stain (fig 6 -16a), SDaLf + Tobi, SDLf + Genta and 
SDaLf + Genta caused the most damage to the biofilms and indicates that the 
antimicrobial agents were able to penetrate into the biofilm visually confirming previous 
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observations in the antimicrobial penetration experiments. As this is the first time these 
images are being made reported, there are no data to compare them against. 
 
6.8     Conclusion 
The present study is novel as it is the first to report the physical characteristics and 
antimicrobial activities (in both iron supplemented and iron deplete environments) of 
lactoferrin and tobramycin/gentamicin combinations. Overall, results from the present 
study show that the spray-dried combinations of aminoglycosides and lactoferrin appear 
to have a superior antimicrobial activity on P. aeruginosa PAO1 biofilms compared to 
monotherapy. The delivery of spray-dried tobramycin-apo lactoferrin combination to 
lower airway structures could be a potentially new therapeutic strategy for combating 
biofilm associated infections. However, before the various combinations can be used for 
such a therapeutic application, there is a need to investigate their in vitro activities.   
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7.1     Summary 
Several potential antimicrobial formulations have been evaluated for physicochemical 
properties and their activity against planktonic and biofilm cultures of P. aeruginosa 
evaluated. For an inhaled therapy to be accepted by the “host”, it was important to 
confirm that there were no deleterious effects on the host. The work presented in this 
chapter used an in vitro cellular model to investigate the potential cytotoxic and pro-
inflammatory effects of individual formulations on human bronchial epithelial cells. This 
work has assessed the effectiveness of the antimicrobial formulations at reducing 
bacterial cell viability when administered through biofilms cultured at the air-liquid 
interface. Four immortalised human bronchial epithelial cell lines were employed; CALU-
3 (expressing high levels of wild-type CFTR), BEAS-2B (expressing wild-type CFTR), 
IB3-1 (cystic fibrosis cell line possessing mutant CFTR) and C38 (mutation corrected 
IB3-1 cells transfected with wild-type CFTR).  All cell lines were grown in submerged cell 
culture at an air-liquid interface (ALI; a condition which promotes cellular differentiation). 
Confluent submerged cells were exposed to formulations for 24 hours prior to 
determination of cell viability (using CellTiter-Blue (CTB)) and quantification of 
chemokine interleukin-8 (IL-8) (measured using an enzyme linked immunosorbent 
assay) this would allow discussion of the metabolic activity of the epithelial cells. A co-
culture model whereby a P. aeruginosa biofilm was grown on bronchial epithelial cells 
was employed to determine the effectiveness of formulations on bacterial biofilm 
growing in a relevant physiological environment. Results obtained show that the 
exposure of any of the epithelial cell lines to the various formulations produced no 
reduction in cell viability as determined by CTB assay. The amounts of IL-8 produced 
varied across the different epithelial cells with BEAS-2B cells releasing the most 
amounts. Co-spray dried combinations of lactoferrin or apo lactoferrin with tobramycin or 
gentamicin reduced the established biofilm mass by 4- to 5-log units across all epithelial 
cell types. Neither the lactoferrin/apo lactoferrin nor tobramycin/gentamicin formulations 
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had such an effect. This data suggests that lactoferrin or the aminoglycosides are non 
toxic to epithelial cells and that the combined use should be effective in the treatment of 
patients with resistant P. aeruginosa lung infections.  
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7.2     Introduction 
There is an ever increasing pressure on the pharmaceutical industry to ensure that 
pharmaceutical products meet prescribed claims, are devoid of side effects or adverse 
effects and are effective irrespective of a patient’s genetic predispositions. It therefore 
means that, the more we know about the physicochemical properties of a drug 
candidate during the pre-screening stages, the more likely it is that the drug candidate 
will progress to be used as a medicine. Consequently, the last step of drug development 
usually involves in vivo studies in animals to assess the toxicity, absorption, metabolism 
and clearance of the drug compound. However, ethical arguments against the use of 
animals in research have been made for well over two decades (Rowan and Andrutis, 
1990) and continue to be made at the present time by various humane societies all over 
the world.  
 
7.2.1     The growing case for the use of non-animal alternatives for 
toxicity testing  
In the UK, the growing public criticism against the use of animals in research has driven 
the evolution of relevant legislation and regulatory policies such as the Animals 
(scientific procedures) act of 1986 (a replacement for cruelty to animals act of 1876) 
which guides the use of animals in research. In fact, the regulatory policy (governing the 
use of animals in research) in the UK is considered to be one of the tightest regulations 
in the world. This is due to the strict requirements needed for personal, project and 
institutional licenses and also the requirement of explicit cost benefit assessment that 
has to be put forward for every application requesting the use animals in research (The 
Animal Procedures Committee, 1986).  
 
Chapter seven: Characterisation of in vitro activity of co-formulations 
- 298 - 
 
Hence, the use of alternative methods based on the 3Rs approach (Replacement, 
Reduction and Refinement) during toxicity studies is now becoming a popular approach 
among the scientific community. Independent scientific agencies like the National Centre 
for the Replacement, Refinement and Reduction of animals in Research (NC3Rs) and 
the Fund for the Replacement of Animals in Medical Experiments (FRAME) are typical 
examples of institutions which currently exist to drive the development and validation of 
alternatives to animal toxicity testing (www.nc3rs.org.uk; www.frame.org.uk). It is 
arguably the case that in vitro assessments do not always correspond to in vivo 
responses, there is still a need for better non animal alternatives specifically for toxicity 
testing. This is because, the development of in vitro models that predict starting doses 
for in vivo drug study would save considerable animal numbers.   
 
The scientific interest to develop non-animal experiments as alternative approaches to 
toxicity testing has gradually increased, international laboratories including the European 
Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) are fully 
dedicated to the work of developing and validating these non-animal alternatives. For 
example, the slug mucosal irritation assay (Adriaens, 2006), BCOP assay (Gautheron et 
al., 1992) and the Isolated Chicken Eye tests (Prinsen and Koëter, 1993) have both 
been developed and validated to replace the Draize rabbit eye test (Draize et al., 1944), 
which was the most widely used toxicity test for substances applied to the skin or 
mucosal surfaces (Oecd, 2012).  
 
7.2.2     The use of in vitro cell culture techniques in cytotoxicity 
assessments 
In vitro cell/tissue culture techniques are techniques currently being used by biomedical 
researchers for non-animal based toxicity testing as they provide physiologically-
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relevant response and are cheaper alternatives for carrying out preliminary biological 
tests on lead compounds. Tests are simpler, robust, fast and provide good experimental 
control, saving time when compared to animal studies (Hertzfeld and Myers, 1987; 
Eisenbrand et al., 2002).  
 
Various in vitro and ex vivo cell/tissue models are currently being used to study lung 
related diseases (Choe et al., 2003; Choe et al., 2006b; Choe et al., 2006a). In vitro and 
ex vivo cell culture models have also proved to be good predictors of in vivo toxicities of 
new drugs since they provide the ability to focus on the effects of the drug on one 
particular cell type and in so doing are more likely to reflect what happens in the human 
body to that particular cell type compared to animal models (Bérubé et al., 2010). 
However, a disadvantage of in vitro cell culture models maybe that in animal models, 
many cells types exist in synergy. So, cells cultured in vitro are not truly representative 
of all the epithelial cell types that exist in vivo. In addition, the cell culture system lacks 
all the hormones, nervous system and immunity which are present in animal models. 
However, In vitro models are good predictors of toxicities of new drugs to be employed 
for managing respiratory diseases, as during development, the drugs can be examined 
for inflammatory cytokine production, mucus hyper secretion, goblet cell hyperplasia 
(GCH), and epithelial hyperplasia and metaplasia (Rogers, 2003). The need to carefully 
select the most suitable model that is appropriate for determining the possible effects of 
inhaled therapies in terms of how they cause injury or hinder repair in the respiratory 
tract is crucial for improving the rate of bench-to-bedside progression of potentially new 
therapies. 
 
For the purpose of investigating the cytotoxicity and pro-inflammatory effects of the 
presented formulations and co-formulations, four immortalised human bronchial 
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epithelial cell lines (CALU-3, BEAS-2B, IB3-1 and C38) were selected as models for the 
response of human bronchial epithelial cells to these novel formulations.  
7.2.2.1     CALU-3 cells 
CALU-3 cells are derived from a bronchial adenocarcinoma, they form tight junctions 
and express a high level of functional CFTR, they therefore secrete Cl− in response to 
cAMP-elevating agents via apical CFTR (Haws et al., 1994). CALU-3 cells are routinely 
used to model in vitro airway epithelial cell responses because they produce features 
consistent with differentiated and functional cells (Zhu et al., 2010). The CALU-3 cell line 
was chosen because they are an adequate model of the bronchial epithelium with 
respect to morphology and simple solute barrier functions. It is however important to 
mention that the cancerous origins of CALU-3 cells may interfer with cellular responses 
when employed as in vitro models hence raising concerns over how representative of 
the “normal airways” they are.  
 
7.2.2.2     BEAS-2B cells 
BEAS-2B cells were originally derived from normal human bronchial epithelial cells 
obtained during autopsy. To produce an immortalised cell line, the epithelial cells were 
infected with replication-defective simian virus 40 (SV40 virus) or an Adenovirus 12-
simian virus 40 hybrid (Ad 12-SV40 hybrid virus), and then subsequently cloned (Reddel 
et al., 1988). BEAS-2B cells have been very useful in studies involving airway structure 
and function, including phenotyping and cytokine regulation (Atsuta et al., 1997; Mullol 
et al., 1996), investigating the direct cytotoxic effects of environmental tobacco smoke 
on airway epithelial cells (Sun et al., 1995), chemokine expression in CF epithelia 
(Schwiebert et al., 1999) and assessment of cytotoxicity of occupational particles  
(Veranth et al., 2007). Also BEAS-2B have been employed understand the mechanisms 
of pneumococcal infection (Adamou et al., 1998) and to study the expression and 
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activity of drug metabolizing enzymes (Eaton et al., 1996; Proud et al., 1994). BEAS-2B 
cells have also been shown to retain electron microscopic features of epithelial cells (as 
shown by the presence of keratin during indirect immunofluorescence for cytokeratin) as 
well as being nontumorigenic following s.c. injection of the SV40 transformed cells into 
nude mice thereby making them a useful cell line for studying multistage bronchial 
epithelial carcinogenesis (Reddel et al., 1988). BEAS-2B have been used for all the 
above mentioned studies because they are a fairly easy epithelial cell line to maintain in 
culture while studying the effects of chemicals on them.  
 
7.2.2.3     IB3-1 cells 
IB3-1 cells are an immortalized cell line created in 1992 from a primary culture of 
bronchial epithelial cells isolated from a patient with cystic fibrosis. The cells were 
transformed with a hybrid virus, adeno-12-SV40, making them immortalised and suitable 
substrates for studies involving mutant CFTR (Zeitlin et al., 1991). IB3-1 cells retain 
characteristics of epithelial cells and the fact that they are deficient in the cyclic AMP-
mediated protein kinase A activation of chloride conductance which is a diagnostic 
feature of CF; (Flotte et al., 1993), makes them suitable for use as a CF model. 
Genotypically, the cell line is a compound heterozygote containing the delta F508 
mutation and the nonsense mutation, W1282X, with a premature termination signal 
(Schneider et al., 1999).  
 
7.2.2.4     C38 cells 
The C38 cells are essentially derived from the IB3-1 cell line, but have the additional 
transfection of wild-type CFTR in order to correct the CF phenotype (Anderson et al., 
2008). Inclusion of C38 cells aids to isolate airway epithelial cell responses that occur 
specifically due to ΔF508 and W1282X CFTR mutations, in other words, assessing our 
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formulations on both IB3-1 and C38 cells enables the identification of responses specific 
to defective CFTR in airway epithelium. 
  
By employing these four immortalised epithelial cells for our investigation, a basis for 
comparison of the responses between non-CF (CALU-3, BEAS-2B and C38) and CF 
(IB3-1) airway epithelial cells is established thereby eliminating bias which may have 
resulted if only one cell line had been exclusively employed. The IB3-1 cell line 
expressing the ΔF508 and W1282X mutant forms allows for simulation of a disease 
specific response (in this case cystic fibrosis lung model) thereby making it well suited 
for determining the effects of various antimicrobial agents in their eventual, intended 
target- the CF airway. Furthermore, by employing the use of immortalised cells, there 
was an added advantage of unlimited cell passages, making the 
assessment/investigation more cost-effective compared to using animals or even 
primary cells.  
 
7.2.3     In vitro methods to assess cytotoxicity of compounds in the 
airway 
In vitro cytotoxicity tests which employ relevant airway cells have proved most useful for 
determining the toxicity of compounds in the early developmental stages. Several 
indices have been suggested as possible indicators for inhaled therapy cytotoxicity 
including; cellular metabolic activity, assessment of cell membrane breakdown 
(measurement of endothelial leakage), estimation of cell numbers, cilliary beat 
frequency (supplies information on epithelial viability and function) and assessment of 
electrical resistance (measures the integrity of the epithelial layer). The first and most 
readily observed effect following exposure of cells to toxic compounds are morphological 
alterations of the cell layer which may be visualized by light microscopy (for gross 
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modifications) or transmission or scanning electron microscopy (for fine ultrastructural 
modifications). Other indices which are specific indicators of respiratory system toxicity 
are; changes in epithelial cell viability and changes in epithelial cell attachment 
 
In vitro cytotoxicity tests carried out in isolated cell models derived from human origin 
have shown to be useful in predicting human acute toxicity (Ekwall et al., 2000; 
Bondesson et al., 1989) and for predicting in vivo-equivalent and biologically relevant 
doses for a particular compound (Bérubé et al., 2010) In vitro test have provided 
meaningful information on parameters such as genotoxicity, induction of mutations and 
programmed cell death. The popularity of in vitro cytotoxicity assays has been widely 
driven by the need to evaluate the potential toxicity of large numbers of compounds 
making sure to limit animal experimentation whenever possible while using small 
quantities of a test compound. 
 
7.2.3.1     Techniques for assessing the cell viability of in vitro cell cultures 
Three basic principles generally govern in vitro cell viability measurements and they 
include; measurement of cellular metabolic activity, assessment of cell membrane 
breakdown and estimation of cell numbers 
 
1. Measurement of cellular metabolic activity: this principle assumes that a 
reduction in cellular metabolic activity signifies cellular damage, for example, the 
CellTiter-Blue® assay uses an optimized reagent containing resazurin, which is 
reduced to fluorescent resorufin by metabolically active cells. Resorufin 
production can be determined by the use of a fluorometer and gives an indication 
of cell viability, where low relative fluorescence units (indicative of low levels of 
resorufin) are considered to signify low cellular metabolic activity.  
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2. Assessment of cell membrane breakdown: the cell membrane is a functional 
barrier around the cell, it permits the exchange of materials into and out of the 
cells through specific transporters, receptors and secretory pathways, when 
damaged they become ‘leaky’ and this forms the basis of assessing cell viability. 
For example, in viable cells, the enzyme lactate dehydrogenase (LDH) is present 
in the cytosol and cannot be measured extracellularly.  Once cell damage 
occurs, e.g on exposure of cells to a damaging test compound, the presence of 
extracellular LDH indicates cellular toxicity. Other endpoint indicators of cell 
membrane damage measure the uptake of various dyes which is usually not able 
to penetrate intact cells.  
 
3. Estimation of cell numbers: this method is most often suited for adherent cell 
types such as epithelial cells. On exposure of these cell types to a damaging test 
compound, dead cells become detached from the cultureware. It is therefore 
possible to directly quantify the number of live cells by discarding the non-
adherent cells and counting the adherent cells or measuring the total protein (in 
adherent cells) or quantifying the DNA levels  (which is proportional to the 
number of remaining live cells). This method is usually not very accurate as a 
number of factors are responsible for epithelial cell detachment from the 
cultureware.  
 
Changes in cellular metabolism is the better predictor of early cell injury when compared 
to changes in cell membrane permeability or live cell number determinations. We chose 
to assess the cytotoxicity of the various antimicrobial agents on the epithelial cells by 
measuring their cellular metabolic activity.  
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7.2.3.2     Interleukin-8 (IL-8) assessment 
In vitro quantitative determinations of human IL-8 in an isolated cell culture model is a 
potentially useful tool for predicting in vivo inflammatory properties of new therapeutic 
agents. Interleukin-8, also known as neutrophil activating peptide 1 (NAP-1), granulocyte 
chemotactic protein 1(GCP-1), monocyte-derived neutrophil chemotactic factor 
(MONAP) and leukocyte adhesion inhibitor (LAI) (www.Genenames.Org) is a non 
glycosylated protein of 8 kDa. It is made up of 72 amino acids, belongs to the 
chemokine superfamily and specifically chemoattracts neutrophils (Baggiolini et al., 
1989; Zwahlen et al., 1993). Upon appropriate stimulation, IL-8 is produced by various 
cells including; monocytes, alveolar macrophages, endothelial cells, fibroblasts 
keratinocytes, hepatocytes chondrocytes, glioblatoma cells, mesothelial cells and 
epithelial cells (www.copewithcytokines.org). While fibroblast, epithelial cells and 
hepatocytes secrete IL-8 in response to IL-1-alpha, IL-1-beta, and Tissue Necrosis 
Factor- alpha (TNF-alpha) stimulation, monocytes, endothelial cells, epithelial cells and 
alveolar macrophages additionally express IL-8 when induced by bacterial 
lipopolysaccharide (Yoshimura et al., 1987; Strieter et al., 1988; Strieter et al., 1989; 
Kunkel et al., 1991). In the cystic fibrosis lung, enhanced macrophage production of 
proinflammatory cytokines including IL-1, IL-6, IL-8 TNF-alpha is produced in response 
to P. aeruginosa infection (Bonfield et al., 1995). This sustained production of cytokines 
and chemokines such as IL-8 in the CF airway has been implicated in the sustained 
neutrophil influx into the airways (Berger, 2002; Sagel et al., 2007) and consequently 
contributes to the vicious circle of mucus retention, infection and the inflammatory 
cascade observed in the airways of CF patients (Ratjen, 2009).   
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7.2.4     Submerged versus Air-liquid interface cell culture models 
Submerged cell cultures generally refer to in vitro cell culture models where cells are 
grown under submerged conditions in cultureware. Submerged cell culture techniques 
are most frequently used for expanding immortalised cell lines in cultureware flasks, 
maintaining excised tissues and also for investigating the toxicity of test agents (Zhu et 
al., 2010). Although many cells in the body do grow under submerged conditions, the 
cells in the airway are not submerged hence this method of cell culture does not 
recapitulate the features of respiratory epithelial cells in vivo. The airway epithelium 
differs greatly in morphology and distribution of differentiation markers compared to cells 
under submerged conditions (Auger et al., 2006).  The cells grown at air-liquid interface 
(ALI) more closely resemble in vivo cells (Auger et al., 2006). However, submerged cell 
cultures have been readily employed in in vitro screening assesments for the acute 
toxicity of chemical agents not just because they are relatively cheaper to setup and 
manage but also because they highly reproducible (Van De Sandt et al., 1999). 
However, their use is limited to toxicity testing of water-soluble test agents since the 
agents will be required to dissolve in the cell culture media in order to obtain accurate 
responses. On the other hand, although airway epithelial cell cultures grown at the ALI 
more closely resemble in vivo apical surfaces (especially due to the presence of cilia 
and mucus) compared to cells growing under submerged cell culture conditions, there 
are limited techniques which can be employed to analyse cells growing at ALI because 
disruptions to differentiated cell layers will possibly result in cell damage (Bielemeier, 
2012)   
 
7.2.5     Co-cultures of bacterial biofilms on human epithelial cells  
The design of in vitro cell models for screening compounds have generally relied on the 
application for which they are intended, consequently, a variety of cell models exist for 
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assessing test compounds. For compounds intended for antimicrobial applications it is 
pertinent that the cell model methods employed in their screening in vitro are robust and 
well suited for the application for which they are intended. Therefore, in order to better 
understand the in vitro activities of novel antimicrobials intended as anti-biofilm agents, 
in vitro testing methods should incorporate biofilms and human epithelial cells. To this 
end, Anderson et al., (2008) have reported the development of a static co-culture biofilm 
system in which P. aeruginosa biofilms were grown on human CF-derived lung epithelial 
cells in vitro. This model has so far been exploited to screen tobramycin’s anti-biofilm 
activity (Anderson et al., 2008), combinations of tobramycin with deferoxamine or 
deferasirox (Moreau-Marquis et al., 2008) and aztreonam alone and in combination with 
tobramycin (Yu et al., 2012). An immediate benefit of employing this co-culture model, 
especially in trying to simulate the CF lung in vitro is that it recapitulates several aspects 
of CF lung disease such as the commonly observed airway infections and in doing so 
provides a more disease-relevant model akin to what is observed in the CF lung. In 
order to assess the efficacy of the various formulations produced in this study, the 
method developed by Anderson et al., (2008) was adopted.  
 
7.3    Aims and Objectives 
This final chapter of work addresses the effects of the spray-dried formulations on 
human airway epithelial cells in vitro. Two markers will be examined; cellular viability 
(which gives an indication of the cytotoxic nature of the formulations and co-
formulations) and IL-8 secretion (which gives an indication of the pro-inflammatory 
effects of the compounds).  In addition, static co-culture of bacterial biofilms of P. 
aeruginosa will be grown on epithelial cells and our formulations added to these cell 
culture models to allow us to measure the antibacterial effects of these compounds on 
P. aeruginosa biofilms in situ in a relevant physiological system. 
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All compounds were to be tested on four different cell types in order to determine 
generalised cell responses rather than cell-type specific response. Thus, cultures of, 
CALU-3, BEAS-2B, IB3-1 and C38 are to be employed. The different formulations were 
administered at 10mg/ml concentration to the four cell types under submerged cell 
culture conditions for 24 hours, and CellTiter-Blue reagent used to assess metabolic 
activity. In addition, the supernatants collected from these experiments will be analysed 
for IL-8 in order to evaluate the pro-inflammatory potential of the compounds. In order to 
assess the effectiveness of formulations on bacterial biofilm growing in a relevant 
physiological environment, an overnight culture of P. aeruginosa was introduced onto 
the apical (uppermost) surface of the epithelial cultures and allowed to form a biofilm.  
After 24 hours of treating the static co-culture biofilm with the various formulations, the 
cells were lysed and the Internalised bacterial colonies (in the apical portion of the 
Transwell insert) enumerated. The overall objective of this study was to investigate 
possible cytotoxicity/pro-inflammatory potentail of the antimicrobial formulations, to 
assess their efficacy at reucing biofilm in situ and hence to evaluate the in vivo 
usefulness of employing our formulations as therapeutic agents for managing airway 
infections in people with cystic fibrosis. 
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7.4     Materials  
CellTiter-Blue reagent was from Promega (Hampshire, UK), human IL-8 enzyme 
linked immunosorbent assay (ELISA) development kit was from Peprotech EC Ltd 
(London, UK), Nunc Maxisorp 96 well plates, Tween 20, ITS supplement, BSA and 
Arginine were all from Sigma (Poole, UK), Dulbecco’s PBS, and all cell culture 
consumables and reagents were from PAA Laboratories Ltd (Somerset UK), for culture 
at ALI, Transwell cell culture inserts (polycarbonate emembrane, 0.4 m pore size) were 
from VWR 
 
7.5      Methods 
7.5.1      Cell culture 
Four human bronchial epithelial cell lines; BEAS-2B, IB3-1, C38 and CALU-3 were used 
in this study. For routine, submerged cell culture, cells were maintained in 75cm2 tissue 
culture flasks in full medium, this was a 1:1 mixture of Hams F12/DMEM with 10% (v/v) 
FCS, 2mM L-glutamine and 0.1 U/mL, penicillin and 0.1 mg/mL streptomycin.  Cells 
were passaged as described in section 2.2.20.2 when 80-90% confluent.  For co-culture 
experiments, cells were counted and seeded onto Transwell inserts as described in 
section 2.2.20.5 . 
 
7.5.2      Treating submerged cultures with formulations. 
All cell types were seeded at a density of 1 x 105 cells/ml in 0.5 mL full medium per well 
in 24-well plates and allowed to adhere overnight.  Cells were serum starved by 
overnight incubation with antibiotic-free ITS medium (Ham’s F 12/DMEM with ITS 
supplement and L-glutamine) before the formulations were added.  The various protein 
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formulations, with and without aminoglycosides, were diluted in antibiotic-free ITS 
medium to yield a final concentration of 10 mg/mL. 0.5 mL of the test solutions were 
added into the wells and the cells were then incubated for a further 24 hours. 
 
7.5.3      CellTiter-Blue (CTB) viability assay 
Following exposure of the submerged cells to the various agents for 24 hours, 0.1 mL of 
CTB was added to each well and cells were incubated at 37 °C for 3 hours. Upon 
completion of incubation, a 200 µL aliquot from each well was transferred into a black 96 
well plates and the fluorescence intensity measured using a standard multi-well 
fluorescence plate reader (Spectramax Gemini XS, Molecular Devices, Berkshire UK) 
with excitation and emission wavelengths of 560 and 590 nm, respectively. 
 
7.5.4      Quantitative measurement of IL-8 production by ELISA 
Culture supernatants from epithelial cells (CALU-3, BEAS-2B, IB3-1 and C38) exposed 
to the various protein-antibiotic formulations, were harvested and centrifuged to remove 
dead cells and cellular debris before the supernatant was taken for IL-8 measurement. 
IL-8 was measured using a commercially available ELISA kit (Human IL-8 ELISA 
Development kit, by PeproTech EC Ltd, (London, UK) according to the manufacturer’s 
instructions with some minor modifications outlined in section 2.2.20.7.2 
 
7.5.5      Static Co-culture Biofilm assay 
A model previously described by Anderson et al., (2008) was employed for this 
investigation with some modifications. Briefly, the four epithelial cell lines (CALU-3, 
BEAS-2B, IB3-1 and C38) were seeded at a density of 1×105 cells/ml on the apical 
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portion of a Transwell inserts, with 900 µL of epithelial cell growth medium in the basal 
portion of the insert. The transwells were incubated at 37 °C, 5 % CO2 for four days. 
On the fourth day, the epithelial growth medium on the apical portions of the Transwell® 
was removed and the epithelial cells are now able to differentiate at the air-liquid 
interface to form cilia and mucus (Matsui et al., 1998b). The epithelial cell growth 
medium in the basolateral compartment was replaced. Subsequently, all the liquid 
permeating to the apical portion of the inserts (apical liquid) were removed and the 
basolateral medium replaced every other 4 or 5 days until the cells had assumed the 
required tight junction resistance. This had been previously reported by Willetts (2012) 
and Bielemeier (2012) to be around 11 to 14 days post apical medium removal. 
 
With the epithelial cells growing at the ALI and following the formation of tight junctions, 
100 μL of P. aeruginosa was innoculated at a concentration of 3 x 107 CFU/mL onto the 
apical side of the Transwells and the plates incubated for 1 hr at 37 °C, 5 % CO2. After 1 
hr, unattached bacteria were gently removed by aspirating the supernatant on the apical 
side before replacing with 100 μL of antibiotic free and serum free DMEM/F12 airway 
epithelial medium containing 0.4 % arginine – to prolong the viability of airway cells 
incubated with P. aeruginosa under static conditions (Anderson et al., 2008), and the 
entire set-up incubated at 37 °C, 5 % CO2 for 2 hours. After 2 h, the arginine containing 
epithelial medium in the apical portion of the transwell were replaced with 100 μL of the 
various antibiotic agents diluted to 1mg/mL in antibiotic free and serum free DMEM/F12 
airway epithelial medium and incubated at 37 °C, 5 % CO2 for 24 hours. A control 
assembly was also setup which constituted the antibiotic free, serum free DMEM/F12 
airway epithelial medium on cells. 
 
Following 24 h treatment of the epithelial cells, the cells were washed three times with 
phosphate-buffered saline (PBS) to remove planktonic bacteria and then treated with 
Chapter seven: Characterisation of in vitro activity of co-formulations 
- 312 - 
 
100 μL of 0.1% Triton for 15 minutes to lyse the cell. The lysate was vortexed for 3 
minutes, serially diluted and plated onto Mueller-Hinton agar plates.  The plates were 
then stored at at 37 °C for 18 h, following which bacterial colonies were counted to 
determine the number of colony-forming units (CFU)/well which remained adherent to 
the cells  
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7.6      Results 
All the results have been summarised in tables 7.1 (cytotoxicity, pg 333 ), 7.2 (IL-8 
secretion, pg 334 ) and 7.3 (static co-culture biofilm assay, pg 336 ) 
 
7.6.1     Effect of exposure of CALU-3 cells to various antimicrobial 
agents on  
7.6.1.1     Cytotoxicity 
The cytotoxicity of the various antimicrobial agents towards CALU-3 cells in submerged 
cultures was evaluated using CTB. The protocol is based on the ability of viable cells to 
metabolise a highly purified resazurin into the fluorescent end product, resorufin.  
 
 
Figure 7 -1: Viability of CALU-3 cells in the presence of various formulations. Cells were seeded 
then grown in the presence of the indicated antimicrobial or in the case of the control, in medium 
alone. The presence of viable CALU-3 cell was determined using CTB assay and percent cell 
viability determined by converting the fluorescence read-out to percent assuming the 
fluorescence value of the control (i.e where no antimicrobial agent was included) to be 100% 
viable. 
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The data presented in figure 7 -1 indicate that, overall, exposure of CALU-3 cells to the 
various formulations did not cause the death of the epithelial cells rather incubation of 
CALU-3 cells with Lf resulted in the doubling of the fluorescent intensity from 5,387 FU 
for the control (where no antimicrobial was present) to 11,444 FU (i.e. a 112 % increase 
in cell viability when compared with the control). Incubation of CALU-3 cells with SDLf 
resulted in a fluorescent intensity of 6,887 FU (i.e. approximately 28 % increase in cell 
viability above the viability of cells in the control). Incubation of CALU-3 cells with aLf 
resulted in a fluorescent intensity of 18,555 FU representing approximately 244% 
increase in cell viability above the % cell viability of the cells in the control (where no 
antimicrobial was added). The fluorescence of the CALU-3 cells upon incubation with 
SDaLf, was 11,746 FU was obtained indicating that there was approximately 118 % 
increase in cell viability above the % cell viability of cells in the control. However, the 
observed increase % of viable cells was less than observed cell viability values obtained 
with aLf.  
 
Upon incubating CALU-3 cells with Tobi and SD Tobi, the fluorescence intensities were; 
5,536 and 6,586 FU representing 2 and 22 % increase above the % cell viability of the 
control while the fluorescence intensity was 5,325 FU when CALU-3 cells were 
incubated with SD Genta, representing a 1 % decrease in cell viability compared with 
the % cell viability of cells in the control.  
 
Incubation of submerged CALU-3 cells with SDLf + Tobi resulted in a fluorescence 
intensity of 17,774 FU which was approximately 230 % above the viability of the control, 
however, upon incubating CALU-3 cells with SDaLf + Tobi, a fluorescence intensity of 
6,544 FU was obtained this represented approximately 22 % increase in cell viability 
when compared with the control.  
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Upon incubating the submerged CALU-3 cells with SDLf + Genta, the fluorescence 
value obtained was approximately 9,916 FU representing an 84 % increase above the 
control. Finally, incubation of submerged CALU-3 cells with SDaLf + Genta resulted in a 
fluorescent intensity of approximately 5,728 FU following CTB assessment indicating a 6 
% increase compared with the the control.  
 
7.6.1.2     IL-8 secretion 
The secretion of IL-8 by CALU-3 cell on exposure to the different compounds for 24 h 
was investigated in order to determine if the various formulations had any pro-
inflammatory properties. 
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Figure 7 -2: Secretion of IL-8 from CALU-3 cells following 24 hours exposure to various 
antimicrobial formulations or in the case of the control, in the absence of antimicrobial agents. At 
the end of the incubation period, the IL-8 concentration in the supernatant was measured using 
ELISA. Data represent the mean of three individual measurements from the same experiment 
and are expressed as mean ±SD. Comparisons of the concentrations of IL-8 secreted by CALU-3 
cells upon exposures to the various antimicrobials were made by one-way analysis of variance 
(ANOVA) using graphpad prism 5 (GraphPad Software Inc., Version 5.0) followed by Dunnett 
post-test; ns indicates no significance compared to the control (no antimicrobial agent added), *** 
indicates p < 0.001 compared to the control, * indicates p < 0.05 compared to the control. 
 
The concentrations of IL-8 secreted by CALU-3 cells upon exposure to the various 
antimicrobial agents. Where no antimicrobial agent was present, it was found that 
CALU-3 cells secreted 125.5 ±22 pg/mL of IL-8. Upon incubating the cells with the 
various lactoferrin only formulations, a significant increase (p < 0.05) in IL-8 secretion 
compared to the control (figure 7 -2). In particular, when the CALU-3 cells were 
incubated with Lf, the cells secreted 342.5 ±19 pg/mL of IL-8 and upon incubation of 
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CALU-3 cells with SDLf, 583.8 ±91 pg/mL of IL-8 was secreted by the cells. On the other 
hand, incubation of CALU-3 cells with aLf resulted in the secretion of 285.9 ±118 pg/mL 
of IL-8 while incubation of CALU-3 cells with SDaLf resulted in the secretion of 256.5 
±84 pg/mL of IL-8.  
 
There was however, no effect of exposing the CALU-3 cells to the various 
aminoglycoside only formulations as 151.6 ±31, 167.4 ±31 and 236 ±30 pg/mL of IL-8 
was secreted by the cells in response to tobi, SD Tobi and SD Genta respectively. Upon 
exposing the CALU-3 cells to SDLf + Tobi, there was no significant difference in the 
amounts of IL-8 secreted compared with the control. Incubation of CALU-3 cells with 
SDaLf + Tobi led to the secretion of significant (p < 0.001) amounts (514.8 ±10 pg/mL) 
of IL-8 compared to the concentrations of IL-8 secreted constitutively in the control or 
upon exposure of CALU-3 cells to the SDLf + Tobi. Exposure of CALU-3 cells to SDLf + 
Genta elicited the secretion of 246.1 ±54 pg/mL of IL-8 while exposure of CALU-3 cell to 
SDaLf +Genta elicited the secretion of 129.8 ±26 pg/mL of IL-8, the amounts of IL-8 
produced by CALU-3 cells upon incubation with SDLf + Genta and SDaLf + Genta was 
not significantly different to the control (that is when no antimicrobial was present)  
 
7.6.1.3     P. aeruginosa biomass on CALU-3 cells cultured at ALI. 
Static co-cultures of P. aeruginosa biofilms on CALU-3 cells were developed and 
exposed to antimicrobial agents in order to determine the effectiveness of formulations 
on bacterial biofilm. The number of bacterial colonies which survived treatment was 
quantified using the spread plate method.  
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Figure 7 -3: P. aeruginosa biomass on CALU-3 epithelial cells following treatment with various 
antibiotics or combinations.  The control shows bacterial biomass on the cells in the absence of 
protein or antibiotics. Data are expressed as log of colony forming units per well, for single well 
analysis of each treatment. The concentration of the various protein-antibiotic used in these 
experiment was 10 mg/mL. The treatment was maintained for 24 hours before the remaining 
surface attached biofilms were dislodged by sonication and the number of cfu/well determined.  
Although the Lf preparations were not effective in reducing colony counts when applied in 
isolation, they appeared to enhance the activity of the antibiotics when used in combination. 
 
The control (i.e. when no antimicrobial agent was present) had the highest number of 
bacterial colonies at 1.24 x 109 cfu/well. Upon treating the static co-culture with Lf or 
SDLf, there was a 1 log reduction in the number of bacterial colonies to 9.2 x 108 and 
1.82 x 108 cfu/well for Lf and SDLf, respectively. When the static co-culture of biofilms 
and CALU-3 cells were treated with aLf and SDaLf, the number of residual bacterial 
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colonies was 6.4 x 106 and 2.1 x 106 cfu/well indicating that there was a 2 log reduction 
in bacterial colonies.  
Upon treating the static co-culture with aminoglycoside only antimicrobial agents, the 
number of cfu/well was decreased by approximately 5-log units compared with the 
control where there was no antimicrobial treatment; the residual bacterial colony was 3.8 
x 104, 6.6 x 104 and 2.7 x 104 cfu/well following treatment with Tobi, SD Tobi and SD 
Genta respectively.  
Treatment of the static co-culture of biofilms and CALU-3 cells with co-spray dried 
lactoferrin and aminoglycosides (tobramycin and gentamicin) resulted in approximately 
5-log reduction in the number of bacterial colonies compared with the control (where 
there was no treatment with antimicrobial agents). The residual number of bacterial 
colonies was 1.6 x 104, 9 x 103, 2.8 x 104 and 3.1 x 104 cfu/ well following treatment with 
SDLf + Tobi, SDaLf + Tobi, SDLf + Genta, SDaLf + Genta respectively.  
 
7.6.2     Effects of exposure of various antimicrobial agents to BEAS-
2B cells  
7.6.2.1     Cytotoxicity 
The cytotoxicity of the various antimicrobial agents on BEAS-2B cells in submerged 
cultures were evaluated. The fluorescence unit obtained by carrying out a CTB assay 
was converted to percent cell viability by assuming the fluorescence of the control (i.e 
where no antimicrobial agent was present) to be 100 %. 
BEAS-2B cells did not show any significant reduction in metabolic activity following 24 
hours incubation with the various agents. However, there were slight increases in the 
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number of viable BEAS-2B cells when they were incubated with the various 
antimicrobial agent compared with when no antimicrobial agent was included (control).  
 
Figure 7 -4: Percent cell viability of BEAS-2B cells in the presence of various antimicrobial 
formulations. Cells were seeded into 24 well plates then grown in submerged culture in the 
presence of the indicated formulation or in the case of the control, in cell culture medium alone. 
The cell viability was determined using CellTiter-Blue assay and the  percent cell viability 
determined by converting the fluorescence read-out to percent assuming the fluorescence value 
of the control (i.e where no antimicrobial agent was included) to represent 100% viability. The 
same plates were measured three times to ascertain a mean measurement of the readout.  
 
The fluorescence for the control was 16,368 FU, upon incubating BEAS-2B cells with Lf, 
a fluorescence of 18,702 FU was obtained indicating a 14 % increase when compared 
with the control. Incubation of BEAS-2B cells with SDLf resulted in a fluorescence of 
16,336 FU, indicating there was no change compared to the fluorescence of the control. 
Upon incubating the iron depleted aLf and SDaLf with BEAS2B, a fluorescence of 
18,318 and 17,175 FU was obtained indicating 11 and 4 % increase in viability 
compared to control.  
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Incubation of BEAS-2B cells with the aminoglycosides also showed increased 
fluorescence compared with the control. When BEAS-2B were incubated with Tobi, SD 
Tobi or SD Genta the fluorescence was 20,978, 22,376 and 17,721 FU, respectively.  
This represents an increase of 28, 36 and 8 % compared to the control.  
Incubating BEAS-2B cells with SDLf + Tobi and subsequently quantifying viable cells by 
the CTB assay showed that there was a 16 % increase in percent cell viability compared 
with the control. However, when BEAS-2B cells were incubated with SDaLf + Tobi, a 
fluorescence of 24,121 FU was obtained indicating approximately 47 % increase in 
percent cell viability compared with the control. Similarly, assessment of cell viability of 
BEAS-2B cells incubated with co-spray dried lactoferrin/ apo lactoferrin and gentamicin 
indicated a 47 and 52 % increase in percent viable cells when compared with the 
control. 
 
7.6.2.2     IL-8 secretion 
Upon exposing BEAS-2B cells to the various formulations, there was no significant 
difference in IL-8 production between the control and 10 of the different antimicrobial 
formulations (Lf, aLf, SDaLf, Tobi, SD Tobi, SD Genta, SDLf + tobi, SDaLf + tobi, SDLf + 
Genta and SDaLf + Genta). In contrast, exposure of BEAS-2B cells to SDLf resulted in a 
significant (p < 0.05) increase in IL-8 secretion compared with the constitutive 
concentration of IL-8 secreted by the control cells where no antimicrobial agent was 
added. 
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Figure 7 -5: IL-8 production by BEAS-2B cells following treatment with various formulations. The 
cells were seeded and grown in submerged culture for 24 h in the presence of the various 
protein-aminoglycoside combination at 10mg/ml or in the case of the control, with no 
antimicrobial additions. At the end of the incubation period, the IL-8 concentration in the 
supernatant was measured using ELISA. Data represents the mean of three individual 
measurements from the same experiment and are expressed as mean ±SD. Comparisons of IL-8 
secretion by the BEAS-2B were made by one-way analysis of variance (ANOVA) using graphpad 
prism 5 (GraphPad Software Inc., Version 5.0) followed by Dunnett post-test; ns indicates no 
significance compared to the control (no antimicrobial agent added) and *** indicates p < 0.001 
compared to the control. 
 
7.6.2.3     P. aeruginosa biomass on BEAS-2B cells cultured at ALI 
The surviving P. aeruginosa colonies on BEAS-2B cells following treatment with various 
antimicrobial agents were evaluated. The control (i.e. no antimicrobial agent added) had 
the highest number of bacterial cells (8.8 x 108 cfu/well). 
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Figure 7 -6: Effect of various antimicrobial formulations on P. aeruginosa biomass on BEAS-2B 
cells. Static co-cultures of biofilms of P. aeruginosa on BEAS-2B epithelial cells were treated for 
24 h with and without (control) the addition of the various antimicrobial preparations at a 
concentration of 10 mg/mL.  After 24 hours the surface attached biofilms were dislodged by 
sonication, and the number of CFU/well determined. The data shown are the mean values of 
triplicate colony counts from the same well expressed as log of colony forming units per well. 
 
Upon treatment of static co-cultures of P. aeruginosa biofilms on BEAS-2B cells with the 
lactoferrin only formulations, there was a 3-log reduction in colony forming units per well 
– i.e.  7.1 x 105, 9.9 x 105, 6.7 x 105 and 4.1 x 105 cfu/well for Lf, SDLf, aLf and SDaLf 
respectively – compared with 8.8 x 108 (the number of colonies in the control). Similarly, 
when the static co-culture of P. aeruginosa biofilms on BEAS-2B cells was treated with 
the aminoglycoside only antibiotics – Tobi, SD Genta and SD Genta – there was 
approximately 4-log reduction in colony forming units per well – i.e. 6.1 x 104, 1.2 x 105 
and 3.3 x 104 cfu/well respectively – compared with the colony forming units in the 
control. On treating the static co-culture of biofilms on BEAS-2B cells with combinations 
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of protein-aminoglycoside antimicrobials, there was an even further reduction in residual 
P. aeruginosa biomass on the BEAS-2B cells by -log reduction when compared with the 
number of colony forming unit in the control. 
 
7.6.3     Effects of incubating IB3-1 and C38 cells with various 
antimicrobial agents  
7.6.3.1     Cytotoxicity 
IB3-1 and C38 cell types are similar cell types except for the cystic fibrosis phenotype 
present in the IB3-1 cells which has been corrected by the stable transfection of wild 
type, functioning CFTR in C38. While IB3-1 cells are best suited for our investigational 
purposes, taken together, cellular responses obtained from both cell types can help 
determine in vitro cellular responses specific to a cystic fibrotic cell. 
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 IB3-1  C38 
A 
 
B 
 
Figure 7 -7: Percent cell viability of IB3-1 and C38 cells in the presence of various antimicrobial formulations. Cells were seeded then grown in the presence of 
the indicated compound or in the case of the control,no additions. (A) % cell viability of IB3-1 cells. (B) % cell viability of C38 cells. The cellular metabolic activity 
of IB3-1 and C38 epithelial cells were determined using cell titre blue (CTB) assay and the percent cell viability determined by converting the fluorescence read-
out to percent assuming the fluorescence value of the control (i.e where no antimicrobial agent was included) to represent 100. The same plates were measured 
three times to ascertain a mean measuremen of the readout. 
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On exposure of IB3-1 cells to the various formulations there was no reduction in 
metabolic activity (as determined by fluorescence) of the cells below the level observed 
in the control. Incubation of IB3-1 cell with the various lactoferrin only formulations – Lf, 
SDLf, aLf and SDaLf – produced fluorescence of 17,377, 18,048, 16,972 and 13,866 
FU which represents a 35, 40, 32 and 8 % increase in the cell viability of the IB3-1 cells 
respectively, when compared to the control (12,879 FU).  
Upon incubation of IB3-1 cells with the various aminoglycoside only formulations, a 
fluorescence of 13,501, 16,699 and 16,809 FU was obtained for Tobi, SD Tobi and SD 
Genta respectively following CTB assay and this represented a 4, 29 and 30 % 
increase in cell viability respectively above the % cell viability levels of the control.  
Incubation of submerged IB3-1 cells with various protein-antimicrobial combinations 
resulted in increased fluorescence following CTB assay, hence indicating increased % 
cell viability. The fluorescence values were 17,776, 18,016, 18,445 and 19,395 FU, 
representing 38, 40, 43 and 50 % increase in cell viability above the % cell viability 
levels of the control. 
 
Incubation of C38 cells with the various lactoferrin only formulations – Lf, SDLf, aLf and 
SDaLf – produced a fluorescence of 22,483, 22,713 and 20,231 FU which was about 
8, 7 and 17 % lower than the % cell viability of the control (24,299 FU) where no 
antimicrobial agent was added, however, incubation of the C38 cells with SDaLf 
produced a fluorescence of 26,013 FU (7 % increase in cell viability when compared 
with the control).  
Upon incubating the C38 cells with the various aminoglycoside only formulations, a 
fluorescence of 26,832, 26,525 and 28907 FU was obtained for Tobi, SD Tobi and SD 
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Genta respectively following CTB assay and this represented a 10, 9 and 18 % 
increase in cell viability respectively above the % cell viability levels of the control.  
Incubation of submerged C38 cells with various protein-antimicrobial combinations 
produced increased fluorescence an indication of increased % cell viability. The 
fluorescence values were 26938, 26417, 26365 and 26424 FU, representing 10, 8, 8 
and 8 % increase in cell viability above the % cell viability levels of the control. 
 
7.6.3.2     IL-8 secretion 
The secretion of IL-8 by both IB3-1 and C38 cells on exposure to the different 
compounds for 24 h was investigated to determine whether the exposure of the 
epithelial cells to the different antimicrobial agents may contribute to CF airway 
inflammation through increased expression of the neutrophil chemoattractant IL-8. This 
was determined by comparing the expression of IL-8 in the CF airway epithelial cell 
(IB3-1) with the expression of IL-8 in the non-CF airway epithelial cell (C38). 
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Figure 7 -8: IL-8 production by IB3-1 and C38 cells following treatment with formulations. Cells were seeded and grown in submerged culture for 24 h in the presence of the 
antimicrobial agents at a concentration of 10mg/ml or in the case of the control, with no antimicrobial additions. At the end of the incubation period, the IL-8 concentration in the 
supernatant was measured using ELISA. Data represents the mean of three individual IL-8 quantifications from the same experiment and are expressed as mean ±SD. (A) IL-8 
production by IB3-1 cells upon exposure of the IB3-1 cells to the antimicrobial formulations (B) IL-8 production by C38 cells upon exposure to antimicrobial agents. Comparisons of 
IL-8 secretion by the airway epithelial cells were made by one-way analysis of variance (ANOVA) using graphpad prism 5 (GraphPad Software Inc., Version 5.0) followed by 
Dunnett post-test; ns indicates no significance compared to the control (no antimicrobial agent added), ** indicates p < 0.01 compared to the control,  and * indicates p < 0.05 
compared to the control, and *** indicates p < 0.001 compared to the control. 
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The mean concentration of IL-8 which was produced by IB3-1 and C38 cells 
constitutively were neglible; 8 and 0 pg/mL repectively. However, upon exposure of 
submerged IB3-1 and C38 cells to the various lactoferrin formulations, there was 
increased production of IL-8 compared to the control (where no agent was added). The 
concentrations of IL-8 produced by incubating IB3-1 cells with Lf, SDLf, aLf and SDaLf 
were 99, 302, 139 and 146 pg/mL respectively. While the concentrations of IL-8 
produced by incubating C38 cells with Lf, SDLf, aLf and SDaLf were 97, 308, 111 and 
98 pg/mL respectively.  
Incubation of IB3-1 cells with the various aminoglycoside only formulations – Tobi, SD 
Tobi and SD Genta – elicited the production of 15.5 ±53, 3.8 ±8 and 2.8 ±6 pg/mL of 
IL-8 respectively, while incubation of C38 cells with the various aminoglycoside only 
formulations – Tobi, SD Tobi and SD Genta – elicited the production of 3.98 ±8, 20.0 
±29 and 35.3 ±30 pg/mL of IL-8 respectively.  
Upon exposure of IB3-1 cells to the various protein-aminoglycoside combinations – 
SDLf + Tobi,  SDaLf + Tobi, SDLf + Genta,  SDaLf + Genta – resulted  in the secretion 
of 171.1 ±54, 74.5 ±12, 279.2 ±24 and 85.3 ±6 pg/mL of IL-8 respectively (Figure 7 -
7A). Incubation of C38 cells with the the various protein-aminoglycoside combinations 
– SDLf + Tobi,  SDaLf + Tobi, SDLf + Genta,  SDaLf + Genta – resulted in the 
secretion of 100.3 ±14, 124.9 ±66, 302.6 ±59 and 73.8 ±15 pg/mL of IL-8 respectively. 
 
7.6.3.3     P. aeruginosa biomass on IB3-1 and C38 cells cultured at ALI  
Following treatment of co-cultures of biofilms on IB3-1 and C38 cells with the various 
antimicrobial agents, the surviving P. aeruginosa colonies on both cell types were 
enumerated. The controls (i.e. no antimicrobial agent added) had a colony forming unit 
per well of 3.9 x 109 and 5.8 109 cfu/mL for the IB3-1 and C38 cells respectively. Upon 
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treating the co-culture of biofilms on both IB3-1 and C38 cells with the different 
lactoferrin only formulations – Lf, SDLf, aLf and SDaLf – the residual bacterial biomass 
was reduced by between 2- and 3-log units compared with the number of colonies per 
well in the respective controls. However, upon treating co-culture of biofilms on both 
IB3-1 and C38 cells with aminoglycoside only formulations, there was approximately 5-
log reduction in number of colonies on the IB3-1 cells (4.2 x 104, 1.2 x 104, 2.2 x 104 
cfu/well for Tobi, SD Tobi, SD Genta) and between 3- and 5-log reduction in  number 
of colonies on the C38 (6.7 x105, 1.1 x 106 and 7.1 x 104 cfu/well for Tobi, SD Tobi, SD 
Genta). Treatment of co-culture of biofilms on IB3-1 and C38 cells with protein-
aminoglycoside combinations (SDLf + tobi, SDaLf + tobi, SDLf + Genta and SDaLf + 
Genta) resulted in the reduction of the cfu/well by between 5 and 6 log units compared 
with the cfu/well in the control.  
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Figure 7 -9: Effect of various antimicrobial formulations on P. aeruginosa biomass on IB3-1 (A) and C38 (B) epithelial cells. Static co-culture of P. aeruginosa 
biofilm and the epithelial cells were incubated for 24 h with and without addition of the various compounds at a concentration of 10 mg/mL. The treatment was 
maintained for 24 hours before the remaining surface attached biofilms were dislodge by sonication and the number of CFU/well determined. (A) bacterial colony 
forming unit on IB3-1 epithelial cell. (B) bacterial colony forming unit on C38 epithelial cell. The data shown are the mean values of triplicate colony counts from 
the same well expressed as log of colony forming units per well. 
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Table 7.1: Summary of the cell viability results from the four epithelial cell lines (CALU-3, BEAS-2B, IB3-1 and C38) upon exposure to the various 
antimicrobial agents. The effects of the individual agents on the cell viability of epithelial cells have been compared to the cell viability of the control (i.e. where 
no antimicrobial agent was present). 
Antimicrobial agents CALU-3 cells BEAS-2B cells IB3-1 cells C38 cells 
Lf  Increase Increase Increase Decrease 
SDLf  Increase No change Increase Decrease 
aLf  Increase Increase Increase Decrease 
SDaLf Increase No change No Change Increase 
Tobi No change Increase No Change Increase 
SD Tobi No change Increase Increase Increase 
SD Genta No change No Change Increase Increase 
SDLf + Tobi Increase Increase Increase Increase 
SDaLf + Tobi No Change Increase Increase Increase 
SDLf + Genta Increase Increase Increase Increase 
SDaLf + Genta No Change Increase Increase Increase 
Reference Figure 7 -1 (Pg 314) Figure 7 -4 (Pg 319) Figure 7 -7A (Pg 326) Figure 7 -7B (Pg 326) 
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Table 7.2: Summary of IL-8 release from the four epithelial cell lines (CALU-3, BEAS-2B, IB3-1 and C38) upon exposure to the various antimicrobial agents. 
The amounts of IL-8 secreted by the four epithelial cells upon exposure to the various antimicrobial agent have been compared to the concentrations of basal 
IL-8 in the control cells (i.e. where no antimicrobial agent was present). 
Antimicrobial 
agents 
CALU-3 cells BEAS-2B cells IB3-1 cells C38 cells 
Lf  +++ - ++ ++ 
SDLf  +++ +++ +++ +++ 
aLf  ++ - +++ + 
SDaLf - - +++ ++ 
Tobi - - - - 
SD Tobi - - - - 
SD Genta - - - - 
SDLf + Tobi - - +++ + 
SDaLf + Tobi +++ - - + 
SDLf + Genta - - +++ +++ 
SDaLf + Genta - - ++ - 
Reference Figure 7 -2 (Pg 317) Figure 7 -5 (Pg 323) Figure 7 -8A (Pg 329) Figure 7 -8B (Pg 329) 
Key: 
(+++) Significantly (p < 0.001) more IL-8 was secreted compared with the control  
(++) Significantly (p < 0.01) more IL-8 was secreted compared with the control  
(+) Significantly (p < 0.05) more IL-8 was secreted compared with the control  
(-) No significant difference in the amount of IL-8 secreted compared to the control   
- 3
3
3
 - 
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Table 7.3: Summary of residual P. aeruginosa colonies on the in vitro co-culture models following treatment of the co-culture models with the various 
antimicrobial agents. At the end of each drug treatment, the cells were washed three times with phosphate-buffered saline (PBS) to remove planktonic 
planktonic bacteria and then 0.1% Triton was added to lyse the epithelial cells and dissociate the biofilms. The lysate was vortexed for 3 mins and the number 
of colonies determined by the spread plate method. The residual colonies following treatment with the various antimicrobial agents have being compared to 
the colony forming units in the control cells at the end of the experiment. 
Antimicrobial agents CALU-3 cells BEAS-2B cells IB3-1 cells C38 cells 
Lf  1-Log reduction  3-Log reduction  1-Log reduction  2-Log reduction  
SDLf  1-Log reduction  3-Log reduction  2-Log reduction  3-Log reduction  
aLf  2-Log reduction  3-Log reduction  3-Log reduction  3-Log reduction  
SDaLf 2-Log reduction  3-Log reduction  3-Log reduction  3-Log reduction  
Tobi 5-Log reduction  4-Log reduction  4-Log reduction  5-Log reduction  
SD Tobi 5-Log reduction  3-Log reduction  3-Log reduction  5-Log reduction  
SD Genta 5-Log reduction  5-Log reduction  5-Log reduction  5-Log reduction  
SDLf + Tobi 5-Log reduction  5-Log reduction  5-Log reduction  6-Log reduction  
SDaLf + Tobi 5-Log reduction  5-Log reduction  5-Log reduction  6-Log reduction  
SDLf + Genta 5-Log reduction  5-Log reduction  5-Log reduction  5-Log reduction  
SDaLf + Genta 5-Log reduction  5-Log reduction  5-Log reduction  5-Log reduction  
- 3
3
4
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7.7     Discussion 
In this study, four airway epithelial cell lines (CALU-3, BEAS-2B, C38 and IB3-1) were 
used to evaluate the acute cytotoxicity properties of eleven formulations in terms of their 
cell viability and inflammatory response (in particular IL-8 secretion). For the 
assessment of cellular metabolic activities, the one-step CellTiter-Blue assay was 
employed to provide a general indication of cell viability of the the epithelial cells 
following exposures to the various antimicrobial formulations. The assay (which was an 
end point assay) involved incubating epithelial cells which had been previously exposed 
to the various formulations with highly purified resazurin (a fluorogenic redox indicator). 
Actively growing cells are able to convert resazurin (dark blue with little intrinsic 
fluorescence) to resorufin (a pink, highly fluorescent compound) (Promega Corporation, 
2009) thereby providing information on the metabolic (viability) apparatus of the cell.  
Even though CTB as a metabolic marker has been shown to correlate with number of 
viable cells under normal assay conditions, it does have limitations as it is unable to 
distinguish between cell proliferation and increased cellular ATP levels. However in this 
experiment, increased viability of the epithelial cells gave an indication of the metabolic 
status of mitochondrial enzymes in the various epithelial cells. Another interesting point 
to note at this juncture is that while this method was suitable for determining the cell 
viability of submerged cell culture it was unsuitable for determining the viability of the 
epithelial cells following co-culture with biofilms. This is because the assay is not specific 
for mammalian cells only and the results obtained reflect the metabolic activity of both 
actively growing bacterial and mammalian cells (Promega Corporation, 2009). 
Overall, the viability of the various epithelial cells were not affected by the different 
formulations indicating that they were not cytotoxic under the test conditions for period of 
time assessed (24 hrs). Generally, C38 cells were found to be the most metabolically 
active cells as in the absence of any added antimicrobial agent (i.e the control). The 
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ranking order of resazurin metabolism by the four epithelial cells were: C38 > BEAS-2B 
> IB3-1 > CALU-3.  
 
In order to investigate the possible secretion of inflammatory markers by the four airway 
epithelial cell lines upon exposure to the eleven antimicrobial agents, IL-8 secretion was 
chosen as the indicator to monitor since it had been previously shown to be secreted by 
the four epithelial cell lines in detectable quantities when stimulated (Bielemeier, 2012; 
Babu et al, 2004; Witschi and Mrsny, 1999). IL-8 is a well known acute inflammatory 
chemo-attracter for immune cells such as neutrophils and mast cells (Richman-Eisenstat 
et al., 1993), therefore induction of massive amounts of IL-8 secretion by the various 
antimicrobial formulations is an indication that in vivo application of the formulations 
would most likely result in acute inflammatory responses (Davies, 2002). In order to 
achieve a successful antimicrobial formulation that is best suited for P. aeruginosa 
eradication, there is a need to ensure that the antimicrobial therapy of choice does not 
antagonise the activities of other anti-inflammatory agents, like ibuprofen (Konstan et al., 
1991; Konstan et al., 1995) which may be co-administered during multiple drug therapy.  
Under basal, unstimulated conditions, the IL-8 concentrations secreted by the various 
cells were found to vary markedly amongst the four cell types. While BEAS-2B cells 
secreted the highest amount of IL-8 (374.2 ±28 pg/mL), corrected CF cells (C38) 
secreted the least amount of IL-8 (0 ±7 pg/mL). Our findings are consistent with a 
previously published report by Schwiebert and co-workers (1999) which showed that 
under basal conditions, there is increased IL-8 secretion in BEAS-2B cells compared to 
IB3-1 cells. Specifically, this study employed 6 epithelial cell lines (3 non-CF airway 
epithelial cell lines: BEAS-2B, 16HBE14o-, and A549; and 3 CF airway epithelial cell 
lines: IB3-1, CFBE41o-, and ΣCFTE29o-) and found that while BEAS-2B cells 
expressed > 20 ng/106 cells of IL-8 protein under basal conditions, the actual amount of 
IL-8 secreted by the IB3-1 cells were not detectable by the IL-8 specific ELISA method 
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which they employed in their investigation. However, our data also suggests that more 
IL-8 was secreted by the IB3-1 cells compared to the C38 cells and this may be related 
to previous reports by DiMango et al., (1998) and Tabary et al., (2006) who have also 
demonstrated that the very low levels of IL-8 secreted by C38 cells maybe as a result of 
minimal nuclear factor kappa B (NF-Κb) present in the C38 cells under unstimulated 
conditions. This suggestion has also been echoed in other published reports by Tabary 
et al., (1999), Tabary et al., (2001), Venkatakrishnan et al., (2000) and Weber et al., 
(2001).    
Upon exposure of CALU-3 cells to the 11 antimicrobial agents, there were 
inconsistencies in the in the levels of IL-8 expressed. While Lf, SDLf and SDLf + Tobi, 
elicited the secretion of significant (p < 0.001) amounts of IL-8 compared with the basal 
levels of IL-8 secreted in the control, exposure of CALU-3 cells to all the other eight 
antimicrobial agents produced no significant differences when compared to the levels of 
IL-8 expressed under basal conditions in the control (Figure 7 -2, Table 7.2) 
Upon exposing BEAS-2B cells to the eleven antimicrobial agents, only SDLf induced a 
significant increase (p < 0.001) in IL-8 protein expression, while all the other 
antimicrobial agents produced no significant change in IL-8 expression when compared 
to the basal IL-8 levels secreted by the control (Figure 7 -5, Table 7.2). IL-8 expression 
by both IB3-1 and C38 cells upon exposure to the different antimicrobial agents showed 
that while exposures of both cell types to the lactoferrin containing antimicrobials elicited 
significant (between p < 0.001 to p < 0.05) increases in IL-8 expression by the airway 
epithelial cells compared to the basal IL-8 levels secreted by the respective controls, 
there was no significant change in IL-8 levels expressed by both cell types (IB3-1 and 
C38 cells) upon exposure to the aminoglycoside only antimicrobials compared with 
basal IL-8 levels expressed by the respective controls (Figure 7 -7, Table 7.2).  Taken 
together, the data tells us more about the bovine lactoferrin which was used for these 
studies. Although the choice to use bovine lactoferrin for this pilot study was made 
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based on using the most economical purified lactoferrin we could obtain to prove our 
concept, the lactoferrin we obtained which was ~ 95% pure, may have contained other 
proinflammatory cytokines like interleukin 1 and 6, tumor necrosis factor and interferon 
gamma (Bocci et al., 1991; Stelwagen et al., 2009). Therefore, these cytokines may be 
responsible for the exaggerated IL-8 expression observed by the various airway 
epithelial cells which may also account for the protein bands seen on the silver stained 
SDS-PAGE gels (chapter 6, figure 5 -11b).  
To better understand the potential usefulness of the various formulations in preventing 
or disrupting established biofilms on the CF-derived airway cells, a static co-culture of P. 
aeruginosa biofilm on airway epithelial cells was employed. We found that the lactoferrin 
only formulations generally reduced the number P. aerugionsa colonies per well by 
between 1 and 3 log units when compared to the control (where no antimicrobial agent 
was applied to the co-culture of P. aeruginosa and the various epithelial cells). Also, the 
ability of the protein (Lf) to reduce bacterial growth was also found to be dependent its 
ferric ion (Fe3+) content as iron depletion seemed to be crucial in promoting a greater 
reduction in residual bacterial colonies. SD Tobi and SD Genta reduced the colony 
forming units by between 4- and 5-log units compared with the control, representing a 
further 1-log reduction when compared to the lactoferrin only formulations. This finding 
possibly contributes to previously published reports by Moreau-Marquis et al., (2009) 
which found that 1mg/mL tobramycin significantly (p < 0.05) reduced the biomass of 
estabalished biofilms.   
Upon treating the static co-culture models of P. aeruginosa and airway epithelial cells 
with co-spray dried lactoferrin-tobramycin formulations, the pattern of bacterial colony 
reduction was the same with the number of P. aeruginosa colonies reduced by between 
5 and 6 log units/well compared to the control. Our data suggests that the various 
combination therapies were no worse than the aminoglycoside only formulations in 
treating P. aeruginosa airway infections in both CF and non-CF cells with the SDLf + 
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Tobi and SDaLf + Tobi formulations performing slightly better on the C38 cells. This is 
significant because half the concentration of SD Tobi or SD Genta killed approximately 
the same number of bacterial colonies when combined with lactoferrin of apo lactoferrin. 
To the best of our knowledge, this is the first study reporting combinations of lactoferrin 
and aminoglycoside are effective in killing established P. aeruginosa biofilms growing on 
non-CF and CF airway epithelial cells. 
In summary, we studied some of the cellular effects of eleven antimicrobial formulations 
on four different airway epithelial cells (three non-CF and one CF airway epithelial cells) 
as well as on static co-culture systems of P. aeruginosa biofilms on the four airway 
epithelial cells and found that the various formulations were generally not toxic on the 
four airway epithelial cells used for the investigation, also, when 11 different 
antimicrobial agents were administered on static co-culture models of P. aeruginosa and 
epithelial cells, overall, it was found that combinations of lactoferrin and 
tobramycin/gentamicin were no worse than tobramycin alone at reducing biofilm mass 
growing on both non-CF and CF airway epithelial cells even though the formulations 
only contained 50% tobramycin/gentamicin. However, as this was the first study of its 
kind, further investigations are still needed to determine if there are other beneficial 
effects a combination therapy of lactoferrin and tobramycicn will contribute to, especially 
with regards to the management of airway infections.  
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8.1     Summary of the thesis 
Pulmonary delivery of peptides and protein drugs has come a long way since attempts 
were first made to deliver insulin via inhalation in the 1920s. Although important 
advances have been achieved so far, the production of efficacious peptides and protein 
formulations suitable for pulmonary administration has not been without challenge. 
Peptide and protein powders are finding increasing applications in dry powder drug 
delivery systems, however the methods available for preparing these peptide and 
protein powders are still limited due to the sensitive nature of peptides and proteins to 
the various processing environments. This is particularly evident when the dry powders 
are intended for lower airway delivery, since this requires that they possess a suitable 
aerodynamic particle size (usually < 5 µm), density, morphology and surface properties.  
These requirements present a challenge as the protein would be expected to undergo 
some amount of physical stress which may adversely impact the three dimensional 
structure of the proteins thereby resulting in negative outcomes in their functions 
following processing. However, to overcome some of these challenges, researchers 
carefully select suitable carriers (for example, liposomes, polymeric microspheres) and 
devices that are able to facilitate the delivery of the peptides and proteins to specific 
areas of the lungs. Consequently, pulmonary delivery of peptides and proteins is 
gradually emerging as a serious, non-invasive delivery option for protein administration.  
With the emergence of antibiotic resistant microorganisms, development of antimicrobial 
peptides and proteins appears an attractive alternative to antibiotics, however, 
pulmonary delivery of these antimicrobial therapies is yet to be achieved. This is a 
classic example of an area where the science of pulmonary delivery of peptides and 
proteins may find ready application since inhaled or nebulised antimicrobial peptides 
and proteins could potentially be employed to manage multi-drug resistant bacterial 
infections in the airway. A disease condition which would benefit immensely from 
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inhaled therapy is cystic fibrosis (CF).  This is a congenital, recessively inherited 
disorder affecting 1 in 2500 newborns of the Caucasian population, where the 
eradication of chronic respiratory infection resulting from abnormalities of fluid and 
electrolyte transport is rarely possible with the currently available antibiotics (Ratjen et 
al., 2010).  
It has been known for a while that the innate immune system, of which the antimicrobial 
peptides and proteins are  part, is responsible for keeping the airways free from 
infections (Ganz, 2003; Travis et al., 2001; Rogan et al., 2006). Currently, there is no 
established link between the defective chloride channel, the pathological changes in the 
airways and the persistent airways infections typical of CF and many theories have been 
proposed. Two major hypotheses have been advanced to explain the pathogenesis of 
airway infections in CF (i.e. the ‘low volume’ (Matsui et al., 1998b) and ‘high salt’ (Smith 
et al., 1996) hypotheses). Both of these theories hinge on inactivation of innate 
antimicrobial peptides. However, it appears that one of the most plausible explanations 
for the persistence of P. aeruginosa infections in the airway of people with CF, is the 
increased concentrations of Fe3+ in the airway surface liquid (Stites et al., 1998; Reid et 
al., 2007b).  Therefore, sequestering all the free iron may help decrease the incidence of 
P. aeruginosa in the CF airway. To this effect, various researchers have previously 
advanced the inclusion of an antimicrobial protein like lactoferrin which has iron 
chelation abilities as well as contributes to the enhancement of microbial susceptibility to 
various antibiotics  
The overall objective of the present body of work has been to show that it is possible to 
formulate antimicrobial proteins with particularly good inhalable properties either alone 
or in combination with aminoglycosides in order to maintain or improve upon the 
antimicrobial activity against planktonic and biofilm cultures of P. aeruginosa. By co-
formulating lactoferrin with antibiotics (chapter 6) it was found that it is possible to 
Chapter eight: General discussion 
 
- 343 - 
 
produce such an antimicrobial combination (fig 6 -4, pg 268, fig 6 -5, Pg 269). This is 
important because it suggests that; 1) it is possible to incorporate an antimicrobial 
protein like protein into currently relevant inhaled antimicrobial therapies, 2) 
combinations of antimicrobial proteins and antibiotics could help slow the rising 
instances of antimicrobial resistance, 3) such combinations may also offer the 
opportunity to decrease adverse effects arising from excessive dosing of currently 
prescribed antimicrobials. For the above reasons, co-spray dried lactoferrin-
tobramycin/gentamicin combination is novel and possesses several interesting 
properties that make it suitable as a drug candidate for treating P. aeruginosa infections 
in people with CF.   
Considering that aggressive antimicrobial therapy is the major reason for the dramatic 
increase in the life expectancy of people with CF over the last few decades, it is not 
surprising that the almost continuous, intensive antibiotic use, has resulted in the rising 
prevalence of multi-drug resistant bacterial.  In addition,  the lack of new anti-infective 
drugs coming on to clinical use means that all the previously perceived gains (mostly 
seen in the area of improvements to quality of life) are gradually being rolled back. For 
people with CF, for whom treatment of symptoms is the only strategy which could 
effectively manage their condition (since there is currently no cure), it has been 
suggested that to curtail the rising incidence of multi-drug resistant bacterial infection, it 
is pertinent that the currently available antimicrobial agents are effectively utilised and 
this includes employing combination therapies of antimicrobial proteins and antibiotics.  
Our results show that a combination therapy of an antimicrobial protein and an antibiotic 
can be formulated for delivery directly to the respiratory tract as dry powders.  This, 
thereby provides an effective strategy to reduce the prevalence of antibiotic-resistant P. 
aeruginosa strains in the airways. This is particularly an advantage since such 
combination therapies will utilize the sum of the individual components to inhibit the 
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development of resistant bacteria. For example, in the case in study, aminoglycosides, 
though highly potent against planktonic P.aeruginosa (Davis, 1987; Hancock, 1981), are 
poorly effective against slow growing bacterial cells seen when microbes reside within 
biofilms (Chernish and Aaron, 2003). Lactoferrin, though able to prevent biofilm 
formation by enhancing ‘twitching motility’  (Singh et al., 2002; Rogan et al., 2004), is not 
a very potent antimicrobial agent- requiring very high doses to effectively eliminate large 
populations of planktonic cells. For example, in the current study, 100 mg/L of lactoferrin 
was required to kill 1000 colonies of P. aeruginosa per hour compared to 2 mg/L of 
lactoferrin-tobramycin combination: fig 5 -2, pg 223 and 6 -3, pg 265). Therefore, making 
a novel formulation approach, exemplified by our formulations, is an attractive strategy 
to employ in developing inhaled antimicrobial agents which are effective against biofilm 
forming bacteria.  
 
8.2     Current treatment strategy for respiratory infections in 
people with CF 
Currently, the treatment strategy for respiratory infections in people with CF recognises 
that one antimicrobial agent may not be effective to completely eradicate the range of 
chronic infections. Hence, a combination of two or even three antimicrobial agent maybe 
used either together or successively during clinical management of airway infections 
(Ryan et al., 2011). In addition the treatment strategies also involves the use of both 
inhaled, nebulised and systemic antibiotics (also either alone or combination) (Ryan et 
al., 2011) but commonly treatments are nebulised and sytemic. For the control of P. 
aeruginosa specifically, the approved antibiotics are tobramycin and colistin with others 
(aztreonam; ciprofloxacin; amikacin; and combined fosfomycin-tobramycin) still under 
clinical evaluation (Ryan et al., 2011). While all these antibiotics have been shown to be 
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effective against planktonic bacteria, there is currently no antimicrobial agent indicated 
for the specific management of P. aeruginosa biofilm infections in the airways. We now 
know that P. aeruginosa has the ability to resist antibiotics either intrinsically, since they 
constitutively express β-lactamases and efflux pumps as well as by switching to a biofilm 
mode of growth where they are able to tolerate inflammatory response mechanisms and 
antimicrobial therapy, or following the acquisition of resistance genes (e.g. possession of 
genes for β-lactamases or enzymes that generally inactivate aminoglycosides) (Hoiby et 
al., 2005; Høiby and Pressler, 2006), so there is need to develop formulations which are 
able to overcome the bacterial resistance strategies. Investigators like MacLeod et al., 
(2009) have tried to solve this problem by developing novel 4:1 antimicrobial 
combinations of fosfomycin and tobramycin, and found that the combinations had a high 
activity both in vitro and in vivo against clinical isolates of E. coli, H. influenzae, S. 
aureus and Klebsiella spp. Similarly, Cai et al., (2009) investigated the effect of 
combinations of the aminoglycoside amikacin with fosfomycin or the aminoglycoside 
isepamicin with fosfomycin on a P. aeruginosa biofilm-infected rat model.  This study 
found that the combination not only showed a positive effect in vitro but also offered an 
improved therapeutic effect against the biofilm-infected rat model. Another group of 
investigators, Trapnell et al., (2012) have taken these findings a step further to clinically 
evaluate the safety and efficacy of a 4:1 (160/40 mg or 80/20 mg) fosfomycin-
tobramycin nebulised combination in 79 adults with CF.  The subjects all had chronic P. 
aeruginosa infections and FEV1 ≥25% but ≤75% and the trial found that the fosfomycin-
tobramycin combinations were well tolerated and substantially improved FEV1 %, 
although there was a lack of conclusive reduction of biofilm in the subjects. However if 
real advances are to be made there is a need to broaden the scope of research outwith 
combinations of antibiotics. There is a need to include antimicrobial agents to which 
microbes cannot develop resistance in these therapies. This is believed to be a strategy 
that may constitute significant advancement in combination antimicrobial research as 
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well as provide a more effective use of currently available antibiotics. To the best of our 
understanding, antimicrobial peptides and proteins make particularly attractive 
candidates for pharmaceutical development especially in combination with potent 
aminoglycosides.  
 
8.2.1     Use of antimicrobial peptides as therapeutic agents 
There are several characteristics of antimicrobial proteins and peptides that make them 
attractive candidates for therapeutic agents; one of the main ones of these has to be 
their ability to halt the rise in the incidence of multi-drug resistant “superbugs”.  In 
addition; 1) they are relatively fast acting, 2) they are microbicidal (rather than 
microbiostatic) and 3) despite their ancient lineage, they have remained effective 
defensive weapons with little observed resistance developed by different strains of 
bacteria.  This is a very essential property in the age of multi-resistant bacteria (Hancock 
and Patrzykat, 2002; Scott and Hancock, 2000). For these and several other reasons, 
the exciting idea of employing antimicrobial peptides as drugs has resonated a lot 
especially among biotechnology companies (Hancock, 2000).  
However, these widely held opinions on the use of antimicrobial peptides as potent 
therapeutic agents are not without controversy.  Indeed, one study by Andres et al., 
(2005) seems to suggest otherwise.  This study used time kill assays to show that 
human recombinant lactoferrin actually decreased the efficacy of tobramycin towards 
clinical isolates of P. aeruginosa.  The authors deduced that lactoferrin-induced cell 
depolarization maybe responsible for a slow-uptake of antibiotics such as tobramycin- 
thereby decreasing effectiveness. Their investigation employed the use of iron saturated 
lactoferrin (personal communication with with Randall Alfano Ph.D of InVitria, a division 
of Ventria bioscience) which is likely to reduce the the antimicrobial activity of lactoferrin 
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(Figure 5 -2, 5 -4, 5 -5, 6 -5 and 6 -6), an observation that has also been previously 
reported by Arnold et al., (1980). Also, the assessment method which was employed in 
their investigation involved the use of a high salt growth media (10 mM Tris-HCl buffer 
containing 100 mM NaCl) which would compromise the activity of Lactoferrin, since it 
has been shown that high salt inhibits the bactericidal activity of lactoferrin (Smith et al., 
1996; Viejo-Diaz et al., 2003; Viejo-Diaz et al., 2004). Therefore, it is possible that these 
observations, contradicting the current study, suggesting that Lactoferrin reduces 
tobramycin activity are actually a consequence of reduced lactoferrin activity because of 
the elevated sodium chloride levels in the culture medium and the saturation of the 
antimicrobial protein with ferric ion. 
Therefore, antimicrobial proteins and peptides remain an attractive propostion for 
inhalable therapies and still resonate among biotechnology companies (Hancock, 2000). 
This is even more evident as increasingly more protein biomolecules (with structural 
resemblance to naturally occurring antimicrobial peptides) are being discovered or 
employed as new and innovative alternatives to chemical antibiotics in the treatment of 
infections. 
 
8.3     Challenges of spray drying proteins 
For protein formulations that are insufficiently stable in aqueous solution, drying provides 
a suitable method for improving stability. There are numerous techniques that can be 
used to dry proteins (for example, freeze drying, spray drying, spray-freeze-drying and 
supercritical fluid drying). However, only spray drying offers an effective and efficient 
one-step method to produce dry powders with defined size, shape, surface property and 
density, all aerodynamic characteristics that cannot be readily achieved with other 
particle engineering processes (Shoyele and Cawthorne, 2006; Depreter et al., 2013). 
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Although this particle production technique is well suited for producing micronized solids 
in a controlled manner, it presents with other challenges when employed to formulate 
therapeutically active peptide and protein drugs since it also exerts a significant amount 
of stress that can destabilize these labile molecules. The thermal heat applied, pressure 
and mechanical stress the protein has to undergo, proteins adsorbing to the air-liquid 
interfaces during atomisation and dehydration stresses occurring during the drying 
process have all been shown to have the capacity to perturb and ultimately denature 
proteins (Maa and Prestrelski, 2000; Ameri and Maa, 2006). However, it was observed 
during process optimisation of this study, that a careful selection of operating 
parameters ensured the achievement of dry powders of suitable size distribution and 
substantial activity even without the inclusion of stabilizing excipients (table 3.4, pg152). 
It was also observed that spray drying proteins alone produced poor yields typically 
between 40 and 60 % even when the high performance cyclone was used (table 4.2, 
pg188). However, it was found that the yield was considerably improved by addition of 
either NaCMC (table 3.3, pg 150 and table 4.2, pg 188) or the aminoglycoside antibiotics 
(table 6.1, pg 262).  
In these studies, the spray drying parameters were initially optimised during the 
preliminary studies described in chapter 3.  Data obtained from that study indicated that 
it was possible to spray dry a protein and produce respirable, spherically shaped 
particles while maintaining the structural integrity of the protein.  These parameters were 
then applied to a clinically relevant antimicrobial protein- lactoferrin. The data presented 
in chapter 4 indicate that the optimised protocol produced inhalable particles (FPF6.4µm > 
50 %) that retained antimicrobial activity towards P. aeruginosa. The mass median 
aerodynamic diameter of the spray-dried lactoferrin particles was found to be lower than 
the starting material at between 4 and 6 µm (Fig 4 -10, pg 201), with this observation 
further validated by scanning electron micrographs which revealed that the spray drying 
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process produced spherically shaped particles closely resembling dehydrated 
blueberries (Fig. 4 -5, pg 194).  
As with most spray-dried proteins, X-ray powder diffraction analysis of the various dry 
powders suggest that all the spray-dried antimicrobial agents were amorphous in nature 
due to the presence of a broad halo and lack of resolved reflections. Although there 
might have been varying degrees of crystallinity, this line of investigation was not 
pursued further, because an absolute degree of crystallinity can only be made when 
reference materials of amorphous and crystalline materials are available and even then 
the ratio of the amorphous to crystalline protein would need to be established in a 
calibration plot which cannot effectively inform on the role of mixing the proteins with 
aminoglycoside. 
Interestingly, SDS-PAGE and western blot analysis of the various spray-dried lactoferrin 
preparations did not show any irregularities in terms of the molecular weight bands 
observed and also indicated that the spray-dried protein was still recognised by both the 
IG12 and 4C6 anti-bovine lactoferrin antibodies (Fig 5 -9, pg 237), a clear indication that 
the binding sites for these antibodies were not destroyed during spray drying.  
 
8.4     Penetration of antimicrobial agents through P. aeruginosa 
biofilms) 
Since microorganisms do not live as dispersed single cells, but rather as flocks or 
sludge or ‘biofilms’, many studies have tried to link the lack of antimicrobial penetration  
to the inherent antibiotic resistance of biofilms (Lewis, 2001; Mah and O'toole, 2001; 
Stewart, 1996; Xu et al., 2000). Based on this, it was essential to have a better 
understanding on how the various antimicrobial formulations prepared over the course 
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of this study may penetrate the biofilm matrix formed by P. aeruginosa. In chapter six, 
we found that combinations of lactoferrin and aminoglycoside significantly enhanced the 
penetration of aminoglycosides (between 40 and 70 %, table 6.3, pg 266) through P. 
aeruginosa biofilms compared to penetration of aminoglycoside alone. Our experimental 
observations were also further verified by confocal laser scanning microscopy, a non-
destructive visualization technique which was employed to gain an in-depth insight into 
the effect of the formulations on P. aeruginosa biofilms grown on coverslip glass. It was 
noticed that there was a mixture of live and dead cells in all the biofilms exposed to the 
various formulations, however, more dead cells were observed upon treating the 
biofilms with combinations of apo lactoferrin and tobramycin/gentamicin for 24 hours. 
Interestingly, we also observed a lower number of dead cells compared with live cells 
upon treating the biofilms with the aminoglycosides only antibiotics. This observation 
may help explain previous observations by Anwar et al., (1989) and Chuchalin et al., 
(2009) who suggested that complete elimination of P. aeruginosa from the airways is not 
achievable with inhaled tobramycin alone. 
 
8.5     In vitro administration of protein-aminoglycoside 
antimicrobial combinations 
Most importantly, we tested the various protein-aminoglycoside combinations on 
P.aeruginosa biofilms grown on both CF (IB3-1) and non CF (CALU-3, BEAS-2B and 
C38) airway epithelial cells to find out if formulations maintained their antimicrobial 
activities in vivo. To achieve this, we utilized a relevant co-culture model in which 
biofilms were grown on CF airway epithelial cells, a method which was previously used 
by Anderson et al., (2008) and Moreau-Marquis et al., (2009) to effectively model 
biofilms that form within CF airway. We found that on all four airway epithelial cells 
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employed for the study, the protein-aminoglycoside combinations caused a 5- log 
reduction in the number of colonies per well compared to lactoferrin only antimicrobials 
which still reduced the colony forming unit per well, but now by between 2- and 3- log 
units. The significance of this is that, if relatively low numbers of bacteria are present 
then using a spray-dried recombinant human lactoferrin or spray-dried recombinant apo 
lactoferrin alone is likely to be adequate if administered alone. Also as patients are 
routinely treated with other antibiotics, intermittent use of a recombinant dry powder 
inhaler could also significantly improve outcome of airway infections especially those 
caused by P. aeruginosa. Therefore, even though lactoferrin and apo lactoferrin failed to 
achieve the industry standard 3- log reductions at the end of the 24 hour treatment 
required for it to be designated as a bactericidal agent, it may still have many 
therapeutic uses. 
We estimate that 30 mg of the apo lactoferrin/aminoglycoside combination will be 
required to reduce the bacterial colony population in the conducting zone of the airways 
by greater than 99 %.  This calculation is based on the fact that the effective growth area 
of the transwell insert is 0.3 cm2; the total cross sectional area of the conducting zone of 
the respiratory tract is 180 cm2; and our results (table 7.3, pg 336) indicated that 0.1 mg 
of the combination effectively reduced the cfu/well by 5-log units. However, this may not 
be exact as it also depends upon the deposition profile of the formulation, the ability of 
formulation to synergise with resident antimicrobial peptides in the airways (Singh et al., 
2000), therefore, doses may need to be adjusted to reflect these significant variations. 
But overall, the significance of this is that the mass of tobramycin required will effectively 
be 73% less than the currently prescribed dose of tobramycin (4 x 28 mg capsules, 
twice daily), but will provide a comparable level of P. aeruginosa bacterial killing as 
tobramycin, this decrease in mass of tobramycin to be delivered should definitely 
translate to a decrease in incidences of adverse effects, improved patient compliance, 
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reduction in hospital visits (improvement in quality of life) and reduction in the use of 
intravenous antibiotic infusions. 
Cytotoxicity assessments of the various formulations on four relevant airway epithelial 
cells (CALU-3, BEAS-2B, IB3-1 and C38) which are representative of the bronchial 
epithelium where the formulations would impact upon inhalation, were promising and 
showed that the various compounds did not decrease the viability of the submerged 
cultured epithelial cells following 24 hours of exposure. Evaluation of cytokine secretion 
showed that exposure of IB3-1 and C38 airway epithelial cells to various lactoferrin 
containing combinations resulted in the secretion of significant amounts of the pro-
inflammatory cytokine, IL-8. This is a less than ideal situation to occur in the CF airways, 
however the data indicate that this response is not specific to CF as we see it in the 
corrected counterpart cells as well.  Therefore, we believe that the increased IL-8 
production might have resulted as a consequence of the non-human, non-purified 
source of lactoferrin used. We would hypothesise that using human recombinant 
lactoferrin would prevent this pro-inflammatory effect.  
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9.1     Concluding remarks 
The ubiquitous role of proteins in a plethora of biological processes makes them 
molecules with a high therapeutic potential. However, delivering them to active sites in 
the respiratory tract has remained a difficult challenge. This has principally been as a 
result of problems associated with their fabrication as micro-particulates that are suitable 
for lower airway deposition while simultaneously maintaining their stability and biological 
activity. This study, has sought to advance the specialist science of inhalation by 
investigating ways by which protein inactivation during spray drying can be substantially 
mitigated. Results from this study show that the extent of inactivation of the two proteins 
used in this study varied extensively depending on the spray drying parameters 
employed. In addition, it was also found that while the incorporation of suitable 
stabilization excipients like sodium carboxymethylcellulose (which helps to preserve the 
integrity of proteins) can help improve the activity of the model protein (alkaline 
phosphatase), it was however found to be detrimental to the antimicrobial activities of 
lactoferrin and apo lactoferrin.  
 
In vitro aerosolisation assessment results also showed that the aerodynamic deposition 
of the various powder formulations produced in this thesis, were appropriately suited for 
the delivery of substantial doses of the therapeutic proteins to the lower airways. The 
results imply that a dry powder inhalable formulation consisting of antimicrobial proteins 
could be used as an enhanced therapeutic alternative to the currently available 
antipseudomonal therapies.   
 
In the light of recent public health threats occasioned by the spread of antibiotic resistant 
microorganisms and the lack of new drugs in the drug delivery pipeline, some of the 
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strategies discussed in this thesis may readily find industrial or even commercial 
applications. However, even though much of the primary research is already being 
carried out, there is room for improvement as the strive to develop novel, effective and 
safe pulmonary delivered antimicrobial peptides and proteins that enable clinicians to 
remain ahead, especially in the fight against antibiotic resistant microorganisms residing 
in the respiratory tract. It is our believe that formulations prepared using the concepts 
presented in this thesis offer a paradigm shift in the way airway infections should be 
managed in the future, which until now have only involved antibiotic only preparations 
(either as a single therapy or a combination therapy). 
 
Reiterating two of the most important findings of this study; 
Although P. aeruginosa biofilms are highly resistant to antibiotics generally, lactoferrin or 
in particular apo lactoferrin in combination with tobramycin are able to significantly 
prevent P. aeruginosa biofilm formation in the first instance and to a certain degree their 
persistence once they have gained a foothold 
 
Spray dried lactoferrin, spray dried apo lactoferrin and co-spray dried combinations of 
lactoferrin/apo lactoferrin with aminoglycosides (tobramycin and gentamicin) remain 
active following processing. This is important because the spray drying technique can be 
used to produce antimicrobial particles containing proteins which can be effectively 
employed to target localized infections of the respiratory tract. 
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9.2     Recommendations and future work 
Although the results presented in this study have demonstrated the effectiveness of 
combinations of an antimicrobial proteins and aminoglycosides in preventing the 
formation of P. aeruginosa biofilms however, these studies could be further developed 
by a number of strategies: 
 
9.2.1     Elucidation of mechanism of action of the various 
antimicrobial agents 
Although during the course of the present study, efforts were made to better understand 
the mechanism by which the co-formulations exerted their superior antimicrobial 
activities on both planktonic and biofilms of P. aeruginosa, it would be insightful to 
analyse the chemistry of the various formulations in order gain a better information of 
how interactions at the functional group or molecular levels produce the observed 
enhancement of the antimicrobial activities of the various formulations. 
 
9.2.2     Evaluation of the various formulations on clinical isolates of 
P. aeruginosa 
Given that the various antimicrobial formulations produced in this research could be 
potentially useful in the treatment of airway infections especially those resulting from P. 
aeruginosa, a direct extension of this work should definitely involve investigations into 
the effectiveness of the various antimicrobial formulations on clinical isolates of P. 
aeruginosa, as well as, other relevant strains of microorganisms which are also 
deleterious to the airway mucosa or are more problematic to manage.  
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9.2.3     Combinatons of recombinant Lf, recombinant SLPI and 
recombinant lysozyme and relevant antibiotics 
In the normal airway, the relevant antimicrobial peptides involved in innate defences 
include; Lf, SLPI, Lysozyme. Various studies have shown that these antimicrobial 
peptides act in synergy to prevent bacterial infection, but in the CF airway, these 
antimicrobial peptides though produced are inactivated by high salt concentrations, 
perharps, delivering recombinant forms of these antimicrobial peptides (recombinant 
human lactoferrin, recombinant secretory leukocyte protease inhibitor, recombinant 
lysozyme) as dry powders in combinations with relevant antibiotics could potentially offer 
greater therapeutic benefits for the management of bronchitis, chronic obstructive 
pulmonary disorders and cystic fibrosis. It would also be interesting to determine if the 
penetration of the various combinations of recombinant antimicrobial proteins and 
relevant antibiotics through viscous mucus could be enhanced through co-
administeration with dornase alpha. 
 
9.2.4     Assessment of long-term stability of the various spray dried 
and co-spray dried formulations 
There is also much work to be done in the area of assessing the stability of the various 
formulations that were developed during the course of this research. This is necessary 
to enable the determination of the best storage conditions and suitable time periods 
within which the formulations should be used. Perhaps, the most direct extension of this 
work should entail carrying out this investigation 
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